0001437749-23-016374.txt : 20230602 0001437749-23-016374.hdr.sgml : 20230602 20230601164546 ACCESSION NUMBER: 0001437749-23-016374 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230601 DATE AS OF CHANGE: 20230601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO KEY INTERNATIONAL INC CENTRAL INDEX KEY: 0001019034 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 411761861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13463 FILM NUMBER: 23985352 BUSINESS ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING A, SUITE E CITY: WALL STATE: NJ ZIP: 07719 BUSINESS PHONE: 7323591100 MAIL ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING A, SUITE E CITY: WALL STATE: NJ ZIP: 07719 FORMER COMPANY: FORMER CONFORMED NAME: SAC TECHNOLOGIES INC DATE OF NAME CHANGE: 19961115 10-K 1 bkyi20221231_10k.htm FORM 10-K bkyi20221231_10k.htm
0001019034 false --12-31 2022 FY 3 0 0 0 0 2019 2020 2021 2022 0 0 0 0 0 0 0 10 0 0 0 0 3 0.0001 3 0 1 1 1 3 4 0.0001 0.0001 00010190342022-01-012022-12-31 thunderdome:item xbrli:shares 0001019034us-gaap:CommonStockMembersrt:ScenarioForecastMemberbkyi:StockIssuedInLieuOfBoardCommitteeFeesMembersrt:DirectorMember2023-05-112023-05-11 0001019034us-gaap:CommonStockMembersrt:ScenarioForecastMemberbkyi:StockIssuedInLieuOfBoardFeesMembersrt:DirectorMember2023-05-112023-05-11 0001019034us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMembersrt:ScenarioForecastMember2023-05-052023-05-05 0001019034us-gaap:CommonStockMembersrt:ScenarioForecastMemberbkyi:StockIssuedInLieuOfBoardCommitteeFeesMembersrt:DirectorMember2023-05-052023-05-05 utr:Y 0001019034us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2023-03-162023-03-16 0001019034us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberbkyi:StockIssuedInLieuOfBoardFeesMembersrt:DirectorMember2023-03-162023-03-16 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-12-31 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:WarrantMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2021-01-012021-12-31 0001019034us-gaap:EmployeeStockOptionMemberbkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember2022-01-012022-12-31 iso4217:USD 00010190342021-01-012021-12-31 00010190342020-12-31 0001019034srt:RestatementAdjustmentMember2020-12-31 0001019034srt:ScenarioPreviouslyReportedMember2020-12-31 00010190342021-12-31 0001019034srt:RestatementAdjustmentMember2021-12-31 0001019034srt:ScenarioPreviouslyReportedMember2021-12-31 xbrli:pure 0001019034srt:RestatementAdjustmentMember2021-01-012021-12-31 0001019034srt:ScenarioPreviouslyReportedMember2021-01-012021-12-31 00010190342022-12-31 0001019034us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2022-01-012022-12-31 0001019034us-gaap:StateAndLocalJurisdictionMemberus-gaap:InternalRevenueServiceIRSMember2022-12-31 0001019034us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2022-12-31 0001019034country:ES2021-01-012021-12-31 0001019034country:ES2022-01-012022-12-31 0001019034srt:AfricaMember2021-01-012021-12-31 0001019034srt:AfricaMember2022-01-012022-12-31 0001019034country:HK2021-01-012021-12-31 0001019034country:HK2022-01-012022-12-31 0001019034country:US2021-01-012021-12-31 0001019034country:US2022-01-012022-12-31 00010190342020-01-012020-12-31 0001019034bkyi:InTheMoneyOptionsMember2020-12-31 0001019034bkyi:InTheMoneyOptionsMember2022-12-31 0001019034bkyi:InTheMoneyOptionsMember2021-12-31 iso4217:USDxbrli:shares 0001019034bkyi:ExercisePriceRange3Member2022-12-31 0001019034bkyi:ExercisePriceRange3Member2022-01-012022-12-31 0001019034bkyi:ExercisePriceRange2Member2022-12-31 0001019034bkyi:ExercisePriceRange2Member2022-01-012022-12-31 0001019034bkyi:ExercisePriceRange1Member2022-12-31 0001019034bkyi:ExercisePriceRange1Member2022-01-012022-12-31 0001019034bkyi:NonPlanMember2022-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2022-12-31 0001019034bkyi:NonPlanMember2022-01-012022-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2022-01-012022-12-31 0001019034bkyi:NonPlanMember2021-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2021-12-31 0001019034bkyi:NonPlanMember2021-01-012021-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2021-01-012021-12-31 0001019034bkyi:NonPlanMember2020-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2020-12-31 0001019034bkyi:The2015EquityIncentivePlanMembersrt:MaximumMember2022-01-012022-12-31 0001019034bkyi:The2015EquityIncentivePlanMembersrt:MinimumMember2022-01-012022-12-31 0001019034bkyi:The2015EquityIncentivePlanMember2016-01-27 0001019034bkyi:PrefundedWarrantsMember2022-01-012022-12-31 0001019034bkyi:PublicOfferingWarrantsMember2021-01-012021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2022-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-31 0001019034bkyi:ReferralFeeWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-12-31 0001019034us-gaap:CommonStockMembersrt:DirectorMember2021-01-012021-12-31 0001019034us-gaap:CommonStockMembersrt:DirectorMember2022-01-012022-12-31 0001019034us-gaap:RestrictedStockMember2021-01-012021-12-31 0001019034us-gaap:RestrictedStockMember2022-01-012022-12-31 0001019034bkyi:SwivelSecureEuropeMember2021-01-012021-12-31 0001019034bkyi:SwivelSecureEuropeMember2022-01-012022-12-31 0001019034bkyi:EmployeeStockPurchasePlanMember2021-01-012021-12-31 0001019034bkyi:EmployeeStockPurchasePlanMember2022-01-012022-12-31 0001019034bkyi:EmployeeStockPurchasePlanMember2022-03-082022-03-08 0001019034bkyi:EmployeeStockPurchasePlanMember2022-12-31 0001019034bkyi:SwivelSecureEuropeMember2022-12-31 0001019034bkyi:SwivelSecureEuropeMember2022-03-082022-03-08 0001019034bkyi:SwivelSecureEuropeMember2022-03-08 0001019034bkyi:TheNoteMember2022-12-31 0001019034bkyi:TheNoteMembersrt:MaximumMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-22 0001019034bkyi:TheNoteMembersrt:MaximumMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-222022-12-22 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-222022-12-22 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMember2022-12-22 0001019034bkyi:WarrantsIssuedInConnectionWithNoteMember2022-12-22 0001019034bkyi:WarrantsIssuedInConnectionWithNoteMember2022-12-222022-12-22 0001019034bkyi:TheNoteMemberbkyi:SeniorSecuredPromissoryNoteMembersrt:ScenarioForecastMember2023-06-23 0001019034bkyi:ResearchDevelopmentAndEngineeringExpenseMember2021-01-012021-12-31 0001019034bkyi:ResearchDevelopmentAndEngineeringExpenseMember2022-01-012022-12-31 0001019034us-gaap:PatentsMember2021-12-31 0001019034us-gaap:PatentsMember2022-12-31 0001019034us-gaap:CustomerRelationshipsMember2021-12-31 0001019034us-gaap:CustomerRelationshipsMember2022-12-31 0001019034bkyi:ProprietarySoftwareMember2021-12-31 0001019034bkyi:ProprietarySoftwareMember2022-12-31 0001019034us-gaap:TradeNamesMember2021-12-31 0001019034us-gaap:TradeNamesMember2022-12-31 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0001019034us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-31 0001019034us-gaap:LeaseholdImprovementsMember2021-12-31 0001019034us-gaap:LeaseholdImprovementsMember2022-12-31 0001019034us-gaap:SoftwareDevelopmentMember2021-12-31 0001019034us-gaap:SoftwareDevelopmentMember2022-12-31 0001019034us-gaap:FurnitureAndFixturesMember2021-12-31 0001019034us-gaap:FurnitureAndFixturesMember2022-12-31 0001019034us-gaap:EquipmentMember2021-12-31 0001019034us-gaap:EquipmentMember2022-12-31 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2020-09-30 0001019034us-gaap:ForeignCorporateDebtSecuritiesMember2020-06-30 iso4217:HKD 0001019034bkyi:The2015SoftwareLicenseMember2021-01-012021-12-31 0001019034bkyi:The2015SoftwareLicenseMember2022-01-012022-12-31 0001019034bkyi:The2015SoftwareLicenseMember2021-12-31 0001019034bkyi:The2015SoftwareLicenseMember2022-12-31 0001019034bkyi:SoftwareLicenseRightsMember2015-12-31 0001019034bkyi:SoftwareLicenseRightsMember2015-12-312015-12-31 0001019034country:NG2022-12-31 0001019034srt:ScenarioForecastMember2024-02-062024-02-06 00010190342022-07-062022-07-06 00010190342022-02-252022-02-25 00010190342020-07-012020-09-30 00010190342020-09-30 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:ThreeCustomersMember2021-01-012021-12-31 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-01-012022-12-31 0001019034us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2021-01-012021-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberbkyi:OneCustomerMember2022-01-012022-12-31 0001019034us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0001019034bkyi:SwivelSecureEuropeMember2022-03-082022-12-31 0001019034bkyi:SwivelSecureEuropeMemberus-gaap:CustomerRelationshipsMember2022-03-082022-03-08 0001019034bkyi:GovernmentLoanMemberbkyi:BbvaBankMembersrt:ScenarioForecastMember2022-05-222026-04-30 0001019034bkyi:GovernmentLoanMemberbkyi:BbvaBankMembersrt:ScenarioForecastMember2026-04-30 0001019034bkyi:SwivelSecureEuropeMemberbkyi:RestrictedMember2022-01-012022-12-31 0001019034srt:AsiaMember2021-01-012021-12-31 0001019034us-gaap:EMEAMember2021-01-012021-12-31 0001019034srt:NorthAmericaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:AsiaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:AfricaMember2021-01-012021-12-31 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034bkyi:HardwareMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:AsiaMember2021-01-012021-12-31 0001019034bkyi:HardwareMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:AfricaMember2021-01-012021-12-31 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:AsiaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMemberus-gaap:EMEAMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:AfricaMember2021-01-012021-12-31 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2021-01-012021-12-31 0001019034srt:AsiaMember2022-01-012022-12-31 0001019034us-gaap:EMEAMember2022-01-012022-12-31 0001019034srt:NorthAmericaMember2022-01-012022-12-31 0001019034us-gaap:ServiceMember2022-01-012022-12-31 0001019034us-gaap:ServiceMembersrt:AsiaMember2022-01-012022-12-31 0001019034us-gaap:ServiceMemberus-gaap:EMEAMember2022-01-012022-12-31 0001019034us-gaap:ServiceMembersrt:AfricaMember2022-01-012022-12-31 0001019034us-gaap:ServiceMembersrt:NorthAmericaMember2022-01-012022-12-31 0001019034bkyi:HardwareMember2022-01-012022-12-31 0001019034bkyi:HardwareMembersrt:AsiaMember2022-01-012022-12-31 0001019034bkyi:HardwareMemberus-gaap:EMEAMember2022-01-012022-12-31 0001019034bkyi:HardwareMembersrt:AfricaMember2022-01-012022-12-31 0001019034bkyi:HardwareMembersrt:NorthAmericaMember2022-01-012022-12-31 0001019034us-gaap:LicenseMember2022-01-012022-12-31 0001019034us-gaap:LicenseMembersrt:AsiaMember2022-01-012022-12-31 0001019034us-gaap:LicenseMemberus-gaap:EMEAMember2022-01-012022-12-31 0001019034us-gaap:LicenseMembersrt:AfricaMember2022-01-012022-12-31 0001019034us-gaap:LicenseMembersrt:NorthAmericaMember2022-01-012022-12-31 0001019034us-gaap:ConvertibleDebtMember2022-12-31 0001019034us-gaap:ConvertibleDebtMember2022-01-012022-12-31 0001019034us-gaap:ConvertibleDebtMember2021-12-31 0001019034bkyi:MeasurementInputLikelihoodOfDefaultMember2022-12-22 0001019034us-gaap:MeasurementInputDiscountRateMember2022-12-22 0001019034bkyi:PrincipalUponDefaultMember2022-12-22 0001019034us-gaap:MeasurementInputDefaultRateMember2022-12-22 0001019034srt:MaximumMember2022-12-22 0001019034srt:MinimumMember2022-12-22 00010190342022-12-22 0001019034us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleDebtMember2022-12-31 0001019034us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2022-12-31 0001019034us-gaap:FairValueInputsLevel1Memberus-gaap:ConvertibleDebtMember2022-12-31 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-31 0001019034us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-31 0001019034srt:MinimumMember2022-01-012022-12-31 0001019034us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-12-31 0001019034us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-12-31 0001019034us-gaap:EquipmentMembersrt:MaximumMember2022-12-31 0001019034us-gaap:EquipmentMembersrt:MinimumMember2022-12-31 0001019034us-gaap:RetainedEarningsMember2022-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001019034us-gaap:CommonStockMember2022-12-31 0001019034us-gaap:RetainedEarningsMember2022-01-012022-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0001019034us-gaap:CommonStockMember2022-01-012022-12-31 0001019034us-gaap:RetainedEarningsMember2021-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001019034us-gaap:CommonStockMember2021-12-31 0001019034us-gaap:RetainedEarningsMember2021-01-012021-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0001019034us-gaap:CommonStockMember2021-01-012021-12-31 0001019034us-gaap:RetainedEarningsMember2020-12-31 0001019034us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0001019034us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001019034us-gaap:CommonStockMember2020-12-31 00010190342023-05-30 00010190342022-06-30 0001019034us-gaap:NotesReceivableMember2022-01-012022-12-31
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM ___ TO ___

 

COMMISSION FILE NUMBER: 1-13463

 

BIO-KEY INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

41-1741861

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification Number)

 

3349 HIGHWAY 138, BUILDING A, SUITE E, WALL, NJ 07719

(Address of principal executive offices) (Zip Code)

(732) 359-1100

Registrant’s telephone number, including area code.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

  

BKYI

  

Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes  ☐    No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  ☐    No  ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☐      No  ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒   No  ☐

 

 
 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐

  

Accelerated filer   ☐
     

Non-accelerated filer    ☒

  

Smaller reporting company   ☒
     
   

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).  ☐ 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒

 

As of June 30, 2022 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s common stock held by non-affiliates was $13,509,134 based upon the closing price for shares of the registrant’s post-split common stock of $1.77 as reported by the Nasdaq Stock Market on that date.

 

As of May 30, 2023, the registrant had 9,234,833 shares of common stock outstanding.

 

 
 

 

 

TABLE OF CONTENTS

 

 

PART I

 1
     

Item 1.

Business

1

Item 1A

Risk Factors

9
Item 1B Unresolved Staff Comments 17

Item 2

Properties

17

Item 3

Legal Proceedings

17

Item 4

Mine Safety Disclosures

17
     
 

PART II

 18
     

Item 5

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

18

Item 6

Reserved

18

Item 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 7A

Quantitative And Qualitative Disclosures About Market Risk

24

Item 8

Financial Statements and Supplementary Data

24

Item 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

24

Item 9A

Controls and Procedures

25

Item 9B

Other Information

25

Item 9C

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

25
     
 

PART III

 26
     

Item 10

Directors, Executive Officers and Corporate Governance

26

Item 11

Executive Compensation

29

Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

33

Item 13

Certain Relationships and Related Transactions, and Director Independence

35

Item 14

Principal Accountant Fees and Services

35
     
 

PART IV

 36
     

Item 15

Exhibits and Financial Statement Schedules

36

Item 16

Form 10-K Summary

37
 

Signatures

69

 

 
 

 

 

PRIVATE SECURITIES LITIGATION REFORM ACT

 

All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; delays in the development of products, statements of assumption underlying any of the foregoing, and numerous other matters of national, regional and global scale, including those set forth under the caption “Risk Factors” in Item 1A of this Annual Report and other filings with the Securities and Exchange Commission (“SEC”). These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 
 
 

PART I

 

ITEM 1. BUSINESS

 

Solely for convenience, trademarks and tradenames referred to in this Annual Report on Form 10-K appear (after the first usage) without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

 

Overview

 

BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity and access management (IAM) platform provider enabling secure work-from-anywhere for enterprise, education, and government customers using secure multi-factor authentication (MFA).  Our vision is to enable any organization to secure streamlined and passwordless workforce, customer, citizen and student access to any online service, workstation, or mobile application, without a requirement to use tokens or phones for roving users and shared workstations.  Our products include PortalGuard® and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, WEB-key® biometric civil and large-scale ID infrastructure, MobileAuth® mobile phone authentication application for iOS and Android, and high-quality, low-cost accessory fingerprint scanner and FIDO-compliant hardware to provide a full and complete solution for identity-innovating customers.

 

BIO-key PortalGuard empowers organizations to maximize the power of cloud, mobile and web technologies by securing users’ identities and connecting them with the applications they rely on, while keeping cyber-intruders and unauthorized delegates (proxy users) out. Competing MFA solutions require a phone or token for every user authentication use case, but this is expensive and ineffective for workforce users who cannot use a phone in their workplace, or who rove among workstations or share kiosks for access to information systems. BIO-key’s exclusive Identity-Bound Biometrics (IBB) authentication methods address this by making biometric identification based available at any end point device, making the user their own credential, not their phone or a token.

 

Our customers trust BIO-key® to secure access to a variety of cloud, mobile and web applications, on-premise and cloud-based hypervisor servers from all of their devices. Employees and contractors sign into BIO-key PortalGuard to seamlessly and securely access the applications needed to do their work, and customers sign into BIO-key PortalGuard to access online services.  Organizations use PortalGuard to securely collaborate and communicate with their partners and to provide their customers with flexible, resilient user experiences online and while using mobile devices.  PortalGuard can operate standalone as a comprehensive MFA, Single Sign On, and Self-Service Password Reset solution, directly authenticating for Windows sign in and application access, or as an upgraded MFA user experience within an enterprise IAM framework such as Microsoft, Okta, Ping or ForgeRock.

 

BIO-key’s WEB-key is a scalable biometric service management platform, incorporating key functions for regulatory compliance, enrollment, authentication or identification, and integrity in a multi-tenant private or public cloud delivery platform.  Government agencies use BIO-key for their large-scale civil ID projects, because WEB-key underpins a biometric identity ecosystem, is cloud-ready, and provides a scalable, high-integrity trust platform which can be operated anywhere and supports over 30 fingerprint scanners interchangeably.

 

We also deliver biometric software integration application programming interfaces, or APIs, allowing software developers to leverage our platform to securely and efficiently embed biometric multi-factor authentication, or MFA, into their own products.  This allows software developers to focus on their core functionality while BIO-key ensures users enter the application without requiring them to carry their phone or any token.

 

Even the most security-focused organizations are suffering breaches as a result of human error or improper conduct. As enterprises scale the number of software as a service, or SaaS applications, and multi-cloud services they rely on and the interconnections between them increase, assured identity has emerged as a critical component of an organization’s security framework, directly affecting each triad of cybersecurity – confidentiality, integrity, and availability.  As access perimeters dissolve, organizations must evolve from network-based security models to Zero Trust and Continuous Authentication and Risk Trust Assessment (CARTA) security models, focusing on adaptive and context-aware controls.  True server-secured biometric verification removes the human nature vulnerability at the root of many security compromises creating a more reliable means to manage user access and protect digital assets against rogue users willing to hand over their credentials to a proxy.  Our global identity as a service, or IDaaS, hosting capability allows our customers to simplify and efficiently scale their security infrastructures across internal IT systems and external customer facing applications without installation overhead, security or uptime management efforts.

 

1
 

 

We designed BIO-key PortalGuard IDaaS and WEB-key to provide organizations an integrated approach to managing and securing all of their identities using the technologies they already use while providing capacity for future needs through the strategic use of biometrics to limit vulnerability and contain authentication costs.  Our platform allows users to authenticate their customers, employees, contractors, and partners. It enables any user to connect to any device, cloud or application, all with a simple, customizable, intuitive and consumer-friendly user experience.  We utilize server-secured Identity-Bound Biometrics to support roving users without requiring them to carry their phone or a token. As of December 31, 2022, more than 600 customers across multiple industries use BIO-key to secure and manage access for users around the world.

 

Development of Business

 

BIO-key was founded in 1993 to develop and market advanced fingerprint biometric technology and related security software solutions. First incorporated as BBG Engineering, the company was renamed SAC Technologies in 1994 and renamed BIO-key International, Inc. in 2002. Our principal executive office is located at 3349 Highway 138, Building A, Suite E, Wall, New Jersey 07719.   

 

BIO-key was a pioneer in developing automated finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, credit card, passports, driver’s licenses, or other form of possession or knowledge-based credentialing. Our advanced technology and is used to improve both the accuracy and speed of fingerprint biometrics in some of the largest biometric systems in the world.

 

On June 30, 2020, we enhanced our product offering by acquiring PistolStar, Inc. (“PistolStar”).  PistolStar provides enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally.  PistolStar develops and markets our PortalGuard line of software and services.  

 

On March 8, 2022, we expanded our sales and support operation into Europe, Africa and the Middle East (“EMEA”) by acquiring Swivel Secure Europe, SA. Swivel Secure Europe is a Madrid, Spain based provider of IAM solutions serving over 300 customers through a network of dozens of channel partners throughout EMEA. Swivel Secure Europe is the exclusive distributer of AuthControl® Sentry, AuthControl Enterprise and AuthControl MSP product line in Europe, Middle East, and Africa, excluding the United Kingdom. Swivel Secure maintains a direct sales force with offices in Madrid, Spain and Lisbon, Portugal.

 

Our Products

 

BIO-key PortalGuard and PortalGuard IDaaS

 

BIO-key PortalGuard is an independent, customer-controlled and neutral-by-design cloud-based identity platform that allows our customers to integrate with any cloud or on-premise SaaS application, service or cloud host, as well as Windows device authentication through a single secure, reliable and scalable IAM platform.  It provides identical capabilities in both a SaaS (PortalGuard IDaaS) or on-premise (PortalGuard) delivery model. PortalGuard integrates BIO-key’s Identity Bound Biometric (IBB) authentication as what-you-are authentication options that are not tied to a device or “what you have” authentication, allowing our customers to positively identify who is accessing their systems, not the device they might have handed off to another user.   Our three-way IAM neutrality consists of:

 

 

●

seventeen MFA authentication factor choices, including our server-secured IBB via fingerprint scanners, or using a palm scan, facial selfie, or voice biometric via our MobileAuth app on a mobile phone;
 

●

open user directory choices including on premise, hybrid or full-Azure Active Directory, LDAP, IBM Domino, or custom SQL user directory; and  
 

●

multiple single sign on, or SSO, federation options, including SAML, Open ID Connect (OIDC), OAUTH, CAS and WS-Fed.

 

These capabilities allow our customers to combine and authenticate legacy and future technologies and to securely connect users to the technology that they choose. We design transparent compatibility of the BIO-key PortalGuard IDaaS with on-premise infrastructures and public and hybrid clouds.

 

Our customers use the BIO-key PortalGuard IDaaS to secure their workforces and student populations and make their partner networks more collaborative. PortalGuard IDaaS provides more and secure experiences for their customers and end users, which enables our customers to future-proof their environments. PortalGuard IDaaS can be used as the central system for an organization’s connectivity, access, authentication and identity lifecycle management needs across all of its users, technology and applications. We enable our customers to easily deploy, manage and secure applications and devices, and offer provisioning services using open source tools.

 

Developers can leverage an extensive suite of API and modular SDK tools to build custom cloud, mobile and web application enrollment and authentication experiences that leverage BIO-key PortalGuard and WEB-key as the underlying identity management platform. Once deployed, PortalGuard allows administrators to enforce contextual access management decisions based on conditions such as user identity, device, geolocation, application destination identity, IP range, and time of day.

 

2
 

 

Our customers use BIO-key to (i) manage and secure work-related IT access of their employees, contractors and supply chain partners, which we call workforce identity; and (ii) manage and secure the identities of users of their web properties, which we call customer identity.

 

BIO-key PortalGuard and PortalGuard IDaaS for Workforce Identity.  PortalGuard streamlines the way an organization’s employees, contractors and supply chain partners connect to its applications and data from any device, while increasing user efficiency, preventing unauthorized delegation, credential sharing, and keeping digital environments secure through our MFA capabilities. We enable organizations to provide their workforces with immediate and secure access to every application from any device they use, without maintaining multiple credentials.  Our multi-directory support interfaces with the directories in place at an organization, while allowing SQL-based custom directories where none presently exist.  BIO-key PortalGuard Desktop allows customers to extend the BIO-key PortalGuard IDaaS to their existing on-premises and remote workstation Windows sign in.  

 

BIO-key PortalGuard and PortalGuard IDaaS for Customer Identity.  BIO-key PortalGuard allows organizations to secure access to their online properties, while upgrading their customers’ user experience by delivering self-enrollment and management for customer-facing cloud, mobile or web applications. We enable an organization’s product team to layer BIO-key’s MFA, SSO and self-service password reset, or SSPR, functionality into their cloud, web and mobile applications through federation standards or using our APIs.  Our customers are able to centrally manage policies, audit and log access across their properties, leading to more seamless customer experiences.

 

BIO-key VST and WEB-key; Products; Civil and Large-Scale ID Infrastructure

 

We have developed what we believe is the most discriminating and effective commercially available finger-based biometric technology. This technology is embedded in our PortalGuard product for enterprise security, providing customers with a unique capability to authenticate users without a phone or token, where appropriate, such as manufacturing, retail, call centers, and health care workers.  Other markets for scalable biometric engines include government markets, large scale identity projects such as voter’s registration, driver’s license, national ID programs, and SIM card registration.

 

We also offer a full line of easy to use finger scanners for both enterprise and consumer markets.  Our PIV Pro, SidePass®, EcoID II® and SideSwipes® finger readers can be used on any laptop, tablet or other device which contains a USB A or C port.  We market and sell these fingerprint scanners through distributors and directly to end users via Amazon.

 

AuthControl Sentry; AuthControl Enterprise; AuthControl MSP

 

Swivel Secure is the exclusive distributer of AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland.  These solutions include a patented one-time-code extraction technology, helping enterprises manage the increasing data security risks posed by cloud services and bring your own device policies.

 

Fingerprint Readers

 

Our series of compact fingerprint readers, we from both commercial companies use SidePass®, SideSwipe® or EcoID II® to replace their Windows passwords and enable Windows Hello for Business without replacing or upgrading laptops or tablets.

 

Identity and Access Management, User Multi-Factor Authentication, Single Sign On, Privilege Entitlement and Access Control

 

Our products simplify the authentication process for enterprise users and consumers, while raising security levels. This allows our customers to meet new, stronger authentication requirements and security best practices across many industries, while delivering a superior end-user experience. Customers use our products to reduce risk of theft, fraud, loss, account takeover attacks, and unauthorized account sharing by limiting access to valuable assets, privileges, data, services, networks and places to only authorized individuals. Our products provide stronger identity binding and a superior user experience versus traditional credentialing systems, which utilize a physical or knowledge-based electronic credential to authenticate the holder but fail to authenticate the actual user in addition to the token. Both commercial enterprises and the public sector have seen a shift in the requirement for stronger authentication, and the FBI, NIST and industry thought leaders such as SalesForce and Microsoft have encouraged entities to enhance their security posture by implementing stronger 2-factor authentication (2FA) or MFA. We believe the market for advanced user MFA, including fingerprint biometrics, extends to nearly every industry segment and the market opportunity for our products is massive, global and growing. 

 

Our Markets

 

Historically, our largest market has been identity and access management for highly regulated industries like government and healthcare. However, we are witnessing a change in the landscape as organizations within all industries and of all sizes are embracing biometric technology and MFA as a security and workflow solution. Millions of users have been successfully using biometrics in phones from Apple and Samsung and they welcome the same user experience to access applications without passwords or tokens.

 

Our acquisition of PistolStar added a large customer base in the state and local government and higher education (SLED) vertical. Colleges and universities throughout the United States use our PortalGuard MFA and SSO platform. As governments, colleges and universities continue to operate in remote environments, we have seen additional demand for our solutions.

 

3
 

 

We believe there is potential for significant market growth in the following key areas:

 

 

●

Enterprise MFA for access to computer networks, and applications.
   

 
 

●

Large scale identification projects, especially in Africa and the surrounding regions.
   

 
 

●

Government funded initiatives, including the state board of elections.
   

 
 

●

International law enforcement use case applications as prospects see us as a global leader in the biometric technology space as witnessed by our agreement with the Israeli Defense Force, and the Singapore and Dubai Police departments.
   

 
 

●

Consumer mobile credentialing, including mobile payments, credit and payment card programs, data and application access, and commercial loyalty programs. 
   

 
 

●

Demand for BIO-key hardware products from Windows Hello for Business users and Fortune 2000 companies.
   

 
 

●

Government services and highly regulated industries including, Medicare, Medicaid, Social Security, drivers' licenses, campus and school ID, passports/visas.
   

 
 

●

Remote authentication challenges, including those created by the remote work shift resulting from the pandemic.

 

 

Business Model

 

Our business model is focused on the following key areas:

 

Market

Drivers

Enterprise needs are not being met by mainstream MFA’s phone app or token approach. Supply chain breaches, ransomware attacks, and administrative access compromises highlight the shortcomings of mainstream MFA and security approaches, which leave far too much responsibility on end-users to comply with cyber-hygiene policies. BIO-key’s biometric authentication process prevents human error and human nature from undermining secure authentication, while making the end user’s access easier than ever. The current climate of broad enterprise adoption of MFA to replace passwords presents opportunities for us to leverage our unique differentiators and exploit the gaps in existing IAM technology approaches. One of those gaps is the challenge of authenticating users that “rove” among workstations. A second gap is preventing unauthorized account sharing and delegation.

 

OEM

Customers

We continue to prioritize securing agreements with OEM customers. The history of success supporting NCR, McKesson, Omnicell, and LexisNexis provides an established footprint that we intend to build upon. As OEM customers embed our solutions within their products, the customer benefits from the enhanced security and workflow, and frees them from investing in R&D to manage an IAM infrastructure of their own. OEM customers’ ordering patterns are more predictable and OEM customers generally require lower service and support resourcing.

 

Highly

Regulated

Industries

Government ID projects and healthcare organizations, including hospitals, clinics, and small private practices present a strong opportunity for us. Additionally, the financial services industry, including banks and credit unions has grown substantially.

 

Partner

Model

In 2022, we continued to grow our Channel Alliance Partner program (CAP) focused on partnering with select value added resellers, integrators, and distributors. We partner with leading application, managed service and infrastructure vendors, such as Intelisys, Insight, NGEN, Amazon Web Services, Pathify (formerly UCROO Campus), Software House International (SHI), Virtual Graffiti, Atlassian, and ProCirrus. 

 

Microsoft

Partnership

We are a Microsoft Partner and our line of compact fingerprint scanners has been tested and qualified by Microsoft to support Windows Hello and Windows Hello for Business. 

 

4
 

 

Hardware

Hardware products generated 9% of our revenue in 2022. EcoID II® has emerged as our most popular scanner for enterprise deployments. For customers that require the highest level of security, PIV-Pro is a FIPS compliant fingerprint scanner, suitable for highly regulated industries and organizations that want a best-in-class solution.

 

We have grown our business through a combination of organic growth and the strategic acquisitions of PistolStar and Swivel Secure Europe. We expect to continue to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations. Please see the section captioned “RISK FACTORS” for additional information regarding acquisition risks.

 

Marketing and Distribution

 

We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners. Through our Channel Alliance Program, we have partnered with more than 40 resellers, system integrators and other distribution partners.  We are committed to continue to aggressively grow this program in 2023.

 

We partner with leading application, managed service and infrastructure vendors, such as Intelisyss, Insight, NGEN, Amazon Web Services, Pathify (formerly UCROO Campus), Software House International (SHI), Virtual Graffiti, Atlassian, and ProCirrus.

 

We offer our software under a SaaS term license and generate annual recurring revenue (ARR) primarily by selling multi-year subscriptions to our software. We employ a customer success team, focused on customer satisfaction and early remediation. 

 

Intellectual Property Rights

 

We develop and own significant intellectual property and believe that our intellectual property is fundamental to our biometric and IAM product operation: We own patented technologies and trade secrets developed or acquired by us.

 

Patents

 

On December 26, 2006, we were issued US patent No. 7,155,040 covering our unique image processing technology, which is critical for enhancing information used in the extraction of biometric minutiae. The issued patent protects a critical part of an innovative four-phase image enhancement process developed by us. With the payment of all maintenance fees, this patent will expire on January 29, 2025.

 

On April 15, 2008, we were issued US patent No. 7,359,553 covering our image enhancement and data extraction core algorithm components. The solution protected under this patent provides the capability to quickly and accurately transform a fingerprint image into a computer image that can be analyzed to determine the critical data elements. With the payment of all maintenance fees, this patent will expire on January 3, 2025.

 

5
 

 

On November 18, 2008, we were issued US patent No. 7,454,624 for our “Match Template Protection within a Biometric Security System” method. The solution protected under this patent limits the scope of enrollment templates usage and also eliminates the need for revocation or encryption processes, which can be expensive and time consuming. With the payment of all maintenance fees, this patent will expire on May 17, 2025.

 

On March 10, 2009, we were issued US patent No. 7,502,938 for our “Trusted Biometric Device” which covers a simple, yet secure method of protecting a user’s biometric information. It covers the transmission of information from the point the information is collected at the biometric reader until the data reaches the computer or device that is authenticating the user’s identity. With the payment of all maintenance fees, this patent will expire on October 25, 2025.

 

On November 8, 2011, we were issued US Patent No. 8,055,027 for our “Generation of Directional Information in the Context of Image Processing” method for image enhancement and processing. With the payment of all maintenance fees, this patent will expire on October 10, 2027.

 

On June 5, 2012, PistolStar was issued US Patent No. 8,196,193 for “Method For Retrofitting Password Enabled Computer Software with a Redirectional User Authentication Method”, where a device, method, and system may be used to integrate and control authentication and passwords among various applications and platforms. With the payment of all maintenance fees, this patent will expire on November 1, 2030. 

 

On July 3, 2012, we were issued US Patent No. 8,214,652 for our “Biometric Identification Network Security”, an expanded method of network and related network authentication security systems utilizing hardware-based support for encryption and key management for authentication purposes. With the payment of all maintenance fees, this patent will expire on April 24, 2024.

 

On March 12, 2013, PistolStar was issued US Patent No. 8,397,077 for “Client Side Authentication Redirection”, where user specific attributes may be accessed and used to produce a generated password, using an algorithm and the user attributes. With the payment of all maintenance fees, this patent will expire on August 7, 2030.

 

On May 3, 2017, we were issued US Patent No. 9,646,146 for our “Utilization of Biometric Data”, a method enables existing small area sensors to capture substantially more fingerprint surface area, leading to a higher degree of accuracy when performing a match. With the payment of all maintenance fees, this patent will expire on March 6, 2035.   

 

On June 19, 2018, we were issued U.S. Patent No. 10,002,244 for our “Utilization of Biometric Data” to allow continuous, passive user authentication on a mobile device. With the payment of all maintenance fees, this patent will expire on March 6, 2035.

 

On July 27, 2018, we were issued U.S. Patent No. 10,025,831 for “Adaptive Short Lists and Acceleration of Biometric Database Search”, a method to quickly and iteratively search a database of biometric data. With the payment of all maintenance fees, this patent will expire on August 10, 2036.

 

On September 3, 2019, we were issued U.S. Patent No. 10,400,481 for “Fingerprint Lock”, a lock design method of the shackle and spring integration to electronics. With the payment of all maintenance fees, this patent will expire on June 27, 2037.

 

On September 10, 2019, we were issued U.S Patent No. 10,410,040 for “Fingerprint Lock Control method and Fingerprint Lock System”, a lock design method of the control process of scanning, and server communications for user profile management. With the payment of all maintenance fees, this patent will expire on July 26, 2037.

 

On April 20, 2021, we were issued U.S. Patent No. 10,984,085 for “Biometric Recognition for Uncontrolled Acquisition Environments”, expected to be deployed in mobile devices, the patent provides a method of continuous capture of the users biometric data before the need of the authentication or enrollment, as well as during an active session with a user, to assure the user has not changed. With the payment of all maintenance fees, this patent will expire on March 13, 2039.

 

We have also been granted parallel patents to the US Patent portfolio to certain of our patents in many foreign countries offering protection of our intellectual property rights around the world.

 

Trademarks

 

We have registered our trademarks “BIO-key”, “True User Identification”, “Intelligent Image Indexing”, “WEB-key”, “SideSwipe”, “SidePass”, “EcoID”, “PistolStar®”, “PortalGuard”, “MobileAuth”, “PASSIVEKEY®” and “PISTOLSTAR®”. with the U.S. Patent & Trademark Office, as well as many foreign countries, protecting the names of our companies and our key technology offerings.

 

6
 

 

We also own the following unregistered trademarks: “PortalGuard Nebula™”, “Password Power™” and “Scooch™”.

 

Copyrights and trade secrets

 

We take measures to ensure copyright and license protection for our software releases prior to distribution. When possible, the software is licensed in an attempt to ensure that only licensed and activated software functions to its full potential. We also take measures to protect the confidentiality of our trade secrets.

 

Research and Development

 

Our PortalGuard IAM product line is mature, with hundreds of active customers, and we are adding additional factors and capabilities to the product, as well as enhancing the self-management for the functionally equivalent PortalGuard IDaaS offering. A significant new authentication factor set will come via our MobileAuth application for users to experience multiple biometric secure authentication via their mobile phone devices. Our VST and WEB-key biometric platforms are mature, stable, and widely-deployed. We concentrate our research and development efforts on enhancing the functionality, reliability and integration of our current products as well as acquiring and developing new and innovative products and solutions for providing broader access to the BIO-key user experience. 

 

Although we believe that our identification technology is one of the most advanced and discriminating fingerprint technologies available today, the markets in which we compete are characterized by rapid technological change and evolving standards and use-cases. In order to maintain our position in the market, we will need to continue to upgrade and refine our existing technologies as new standards become relevant to our customers and markets.

 

During the years ended December 31, 2022 and 2021, we incurred expenses of $3,252,236 and $2,355,056, respectively, for research and development.

 

In future periods our R&D efforts will remain focused on updating and advancing our core software products including PortalGuard and PortalGuard IDaaS, MobileAuth, WEB-key and VST. These products are critical to support the anticipated growth in enterprise IAM.

 

Competition

 

The IAM, MFA and SSO market is characterized by multiple solution providers of solutions in either standalone or IAM suite delivery models. We believe that our unique differentiator in this market is the incorporation of an unparalleled server-secured biometric authentication capability among our 17 authentication factors. There are numerous companies involved in the development, manufacturing and marketing of fingerprint biometrics products to commercial, government, law enforcement and prison markets. These companies include, but are not limited to, IDEMIA, Thales, NEC, Neurotechnology, and Innovatrics.

 

The majority of sales for automated fingerprint identification products in the market to date have been deployed for government agencies, healthcare facilities, and law enforcement applications. The consumer and commercial markets represent areas of growth potential for biometrics, led by the use of mobile devices.

 

The epidemic of security and data breaches reported over the past few years is one of the driving factors for identifying new methods of protecting valuable data. After attempting to create a more sophisticated password, or more efficient token or PIN, it has become apparent that each of these methods are easily compromised, and the downside risks are significant.

 

We have also seen FIDO-compliant keys enter the market, led by Yubico’s YubiKey, a hardware token device that acts as a credential for access.  FIDO officially recommends enterprises purchase two or more keys for every user, to prevent lockout in the event of a lost or misplaced FIDO token.  These hardware tokens alone do not meet the needs of large organizations for which key sharing and lost keys are concerns, establishing the opportunity for our Identity Bound Biometric differentiation. Where FIDO is needed, we offer a line of equivalent function and quality, but lower-cost FIDO 2.0 keys.

 

With respect to competing biometrics technologies, each has its strengths and weaknesses and none has emerged as a market leader:

 

 

●

Fingerprint identification is generally viewed as very accurate, inexpensive and non-intrusive and is the dominant biometric in use today and will be for the foreseeable future;

 

 

●

Palm Vein scanning is expensive, technique-sensitive, and offers mobility challenges;

 

7
 

 

 

●

Iris scanning is viewed as accurate, but the hardware is significantly more expensive; and

 

 

●

Facial recognition can have privacy concerns with work-from-home use, and is typically highly dependent on ambient lighting conditions, angle of view, and other factors.

 

Government Regulations

 

Various state, federal and EU privacy laws govern the collection, storage, use and any sale of biometric-related data.  To the extent that BIO-key’s IDaaS offerings include the collection and storage of customer users’ personal or biometric data, we operate as a processor of such data.  Our WEB-key platform includes compliance features to ensure automated compliance with these laws including collection of informed written consent during enrollment workflows and robust auditing to control and report on the retention of biometric data and removal requests.  Additionally, our customers have access to these tools to maintain their own compliance, including deletion of user data when business relationships terminate.

 

We believe in biometric privacy rights, and that both users and their organizations benefit from a responsibly operated biometric identity infrastructure.  We actively participate in industry privacy workgroups as recognized biometric subject matter experts in order to influence and keep abreast of any proposed changes to these regulations. Beyond these regulations, we are not currently subject to direct regulation by any government agency, other than regulations generally applicable to businesses or related to specific project requirements. In the event of any international sales, we would be subject to various domestic and foreign laws regulating such exports and export activities.

 

Environmental Regulations

 

As of the date of this report, we have not incurred any material expenses relating to our compliance with federal, state, or local environmental laws and do not expect to incur any material expenses in the foreseeable future.

 

Seasonality

 

Generally, our revenues do not exhibit a seasonal pattern, however, revenue is affected by customer budgeting, government fiscal year planning, and capital budgets.

 

Human Capital Resources

 

As of the date of this report, we employed fifty-two individuals consisting of fifty-one individuals on a full-time basis as follows: (i) twenty in engineering, customer support, and research and development; (ii) nine in finance and administration; and (iii) twenty-two in sales and marketing. We also have two part time employees, one who provides engineering services, and one who provides administrative services, and two factory contractors in China. None of our employees are represented by a labor union and we believe that our relationship with our employees is good.

 

8
 

 

ITEM 1A. RISK FACTORS

 

Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements appearing just before the section captioned “BUSINESS” in Item 1 above.

 

BUSINESS AND FINANCIAL RISKS

 

Based on our lack of sufficient revenue and recurring losses from operations, our independent registered public accounting firm has included an explanatory paragraph in their opinion as to the substantial doubt about our ability to continue as a going concern.

 

Due to, among other factors, our history of losses and insufficient revenue, our independent registered public accounting firm has included an explanatory paragraph in their opinion for the year ended December 31, 2022 as to the substantial doubt about our ability to continue as a going concern. Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States, which contemplate that we will continue to operate as a going concern. Our financial statements do not contain any adjustments that might result if we are unable to continue as a going concern.

 

We have historically not generated significant revenue and have sustained substantial operating losses.

 

In order to increase revenue, we have developed a direct sales force and anticipate the need to retain additional sales, marketing and technical support personnel and may need to incur substantial expenses. We cannot assure you that we will be able to secure these necessary resources, that a significant market for our technologies will develop, or that we will be able to achieve our targeted revenue. If we are unable to achieve revenue or raise capital sufficient to cover our ongoing operating expenses, we will be required to scale back operations, including marketing and research initiatives, or in the extreme case, discontinue operations.

 

We may need to obtain additional financing to execute our business plan over the long-term, which may not be available. If we are unable to raise additional capital or generate significant revenue, we may not be able to continue operations.

 

We have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $798,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During 2022, we generated approximately $7.0 million of revenue, which is below our average monthly requirements. If we are unable to generate sufficient revenue to cover operating expenses and fund our business plan, we will need to obtain additional third-party financing. We may, therefore, need to obtain additional financing through the issuance of debt or equity securities. We cannot assure you that we will be able to secure any such additional financing on terms acceptable to us or at all. If we cannot obtain such financing, we will not be able to execute our business plan, will be required to reduce operating expenses, and in the extreme case, discontinue operations. 

 

Our $2.2 million principal amount secured note matures on December 22, 2023 and we may not have sufficient cash flow from our business or the ability to raise sufficient funds to repay this note when due which may expose us to the risk of default which would materially and adversely affect our financial condition.

 

On December 22, 2022, we issued a $2.2 million secured promissory note (the “Note”) to an investor which is due six months following the date of issuance, subject to one six-month extension by us. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six increasing to 12% per annum if we extend the term of the Note for an additional six months. The Note is secured by a lien on substantially all of our assets and properties.  In addition to current interest payment obligations, the Note contains various covenants.  Upon the occurrence of any event of default (as defined in the Note), whether for payment or covenant breach, and expiration of any applicable cure periods, all amounts due under the Note will immediately become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock at a conversion price equal to the 10 day volume weighted average sales price of our stock.  Although the aggregate number of shares of common stock issuable upon conversion of the Note is capped at 985,576 shares, any such conversion could cause substantial dilution to existing stockholders and cause the price of our stock to drop.   In April of 2023, we were in default under the Note due to our failure to timely file this annual report and timely file a registration statement covering the public resale of the shares issued to the holder of the Note in connection with the financing.  We have obtained a waiver and, therefore, as of the date of this report we are not in default. 

 

We plan to satisfy our obligations under the Note through a combination of cash from operations, liquidation of existing inventory, and proceeds from the issuance of additional debt or equity securities.  Such payments will reduce the funds available to us for working capital, capital expenditures and other corporate purposes which may in turn limit our ability to implement our business strategy, heighten our vulnerability to downturns in our business, the industry, or in the general economy, and prevent us from taking advantage of business opportunities as they arise.   While we believe that our plans to repay and or refinance this indebtedness are reasonable, as of the date of this report, we can provide no assurances that we will have cash resources from operations or be able to obtain the necessary financing on attractive terms or at all to repay the Note in full.  Any plans to refinance are subject to the conditions in the capital and credit markets, which have been volatile due to, among other things, increases in interest rates.  As a result, we may be forced to obtain capital on terms that are unattractive or that are dilutive to our stockholders and may need to pursue other alternatives to satisfy our obligation under the Note if we are unable to access the capital markets.

 

Our biometric technology has yet to gain widespread market acceptance and we do not know how large of a market will develop for our technology.

 

Biometric technology has received only limited market acceptance, particularly in the private sector. Our technology represents a novel security solution and we have not yet generated significant sales. Although recent security concerns relating to identification of individuals and appearance of biometric readers on popular consumer products, including the Apple iPhone, have increased interest in biometrics generally, it remains an undeveloped, evolving market. Biometric based solutions compete with more traditional security methods including keys, cards, personal identification numbers and security personnel. Acceptance of biometrics as an alternative to such traditional methods depends upon a number of factors including:

 

 

●

national or international events which may affect the need for or interest in biometric solutions;

 

 

●

the performance and reliability of biometric solutions;

 

 

●

marketing efforts and publicity regarding these solutions;

 

 

●

public perception regarding privacy concerns;

 

 

●

costs involved in adopting and integrating biometric solutions;

 

 

●

proposed or enacted legislation related to privacy of information; and

 

 

●

competition from non-biometric technologies that provide more affordable, but less robust, authentication (such as tokens and smart cards).

 

For these reasons, we are uncertain whether our biometric technology will gain widespread acceptance in any commercial markets or that demand will be sufficient to create a market large enough to produce significant revenue or earnings. Our future success depends, in part, upon business customers adopting biometrics generally, and our solution specifically.

 

Biometric technology is a new approach to Internet security, which must be accepted in order for our WEB-key solution to generate significant revenue.

 

Our WEB-key authentication initiative represents a new approach to Internet security, which has been adopted on a limited basis by companies that distribute goods, content or software applications over the Internet. The implementation of our WEB-key solution requires the distribution and use of a finger scanning device and integration of database and server side software. Although we believe our solutions provide a higher level of security for information transmitted over the Internet than existing traditional methods, unless business and consumer markets embrace the use of a scanning device and believe the benefits of increased accuracy outweigh implementation costs, our solution will not gain market acceptance.

 

9
 

 

The market for our solutions is still developing and if the biometrics industry adopts standards or a platform different from our standards or platform, our competitive position would be negatively affected.

 

The market for identity solutions is still developing. The evolution of this market may result in the development of different technologies and industry standards that are not compatible with our current solutions, products or technologies. Several organizations set standards for biometrics to be used in identification and documentation. Although we believe that our biometric technologies comply with existing standards, these standards may change and any standards adopted could prove disadvantageous to or incompatible with our business model and current or future solutions, products and services.

 

Our software products may contain defects which will make it more difficult for us to establish and maintain customers.

 

Although we have completed the development of our core biometric technology, it has only been used by a limited number of business customers. Despite extensive testing during development, our software may contain undetected design faults and software errors, or “bugs” that are discovered only after it has been installed and used by a greater number of customers. Any such defect or error in new or existing software or applications could cause delays in delivering our technology or require design modifications. These could adversely affect our competitive position and cause us to lose potential customers or opportunities. Since our technologies are intended to be utilized to secure physical and electronic access, the effect of any such bugs or delays will likely have a detrimental impact on us. In addition, given that biometric technology generally, and our biometric technology specifically, has yet to gain widespread acceptance in the market, any delays would likely have a more detrimental impact on our business than if we were a more established company.  

 

In order to generate revenue from our biometric products, we are dependent upon independent original equipment manufacturers, system integrators and application developers, which we do not control. As a result, it may be more difficult to generate sales.

 

We market our technology through licensing arrangements with:

 

 

●

original equipment manufacturers (OEMs), system integrators and application developers which develop and market products and applications which can then be sold to end users; and

 

 

●

companies which distribute goods, services or software applications over the Internet.

 

As a technology licensing company, our success will depend upon the ability of these manufacturers and developers to effectively integrate our technology into products and services which they market and sell. We have no control over these licensees and cannot assure you that they have the financial, marketing or technical resources to successfully develop and distribute products or applications acceptable to end users or generate any meaningful revenue for us. These third parties may also offer the products of our competitors to end users. While we have commenced a significant sales and marketing effort, we have only begun to develop a significant distribution channel and may not have the resources or ability to sustain these efforts or generate any meaningful sales.

 

We face intense competition and may not have the financial and human resources necessary to keep up with rapid technological changes, which may result in our technology becoming obsolete.

 

The Internet, facility access control, and information security markets are subject to rapid technological change and intense competition. We compete with both established biometric companies and a significant number of startup enterprises as well as providers of more traditional methods of access control. Most of our competitors have substantially greater financial and marketing resources than we do and may independently develop superior technologies, which may result in our technology becoming less competitive or obsolete. We may not be able to keep pace with this change. If we are unable to develop new applications or enhance our existing technology in a timely manner in response to technological changes, we will be unable to compete in our chosen markets. In addition, if one or more other biometric technologies such as voice, face, iris, hand geometry or blood vessel recognition are widely adopted, it would significantly reduce the potential market for our fingerprint identification technology. 

 

We recognized revenues from Africa and the European Union in 2021 and 2022 and expect continued revenues from these regions in future periods. Our financial performance will be subject to risks associated with changes in the value of the U.S. dollar versus local currencies.

 

Owing to the international scope of our operations, including our recent acquisition of Swivel Secure Europe, SA, we are exposed to foreign exchange risk. Our primary exposure to movements in foreign currency exchange rates relates to non-U.S. dollar-denominated sales and operating expenses worldwide. Weakening of foreign currencies relative to the U.S. dollar will adversely affect the U.S. dollar value of our foreign currency-denominated sales and earnings, if any, and could lead to us raising international pricing, potentially reducing the demand for our products. In addition, margins on sales of our products in foreign countries and on sales of products that include components obtained from foreign suppliers could be materially adversely affected by foreign currency exchange rate fluctuations. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.

 

10
 

 

Although we have made significant sales of our products throughout Asia and Africa in prior years, we have not been able to consistently enforce our contract rights and collect all receivables which has resulted in material write-offs.

 

Our ability to enforce our international contracts is contingent on our relationships with foreign resellers, and their financial viability. Although we are making efforts to better enforce our contract rights, there can be no assurance that we will be able to fully collect all receivables originating in Asia and Africa or that will not have to write-off future receivables which may be material in amount.  Any such write-offs have in the past and will negatively impact our financial position and results of operation.

 

We depend on key employees and members of our management team, including our Chairman of the Board and Chief Executive Officer, Chief Financial Officer, and our Chief Legal Officer, in order to achieve our goals. We cannot assure you that we will be able to retain or attract such persons.

 

Our employment contracts with Michael W. DePasquale, our Chairman of the Board and Chief Executive Officer, Cecilia C. Welch, our Chief Financial Officer, and James D. Sullivan, our Chief Legal Officer, expire annually, and renew automatically for successive one-year periods unless notice of non-renewal is provided by the Company. Although the contracts do not prevent them from resigning, they do contain confidentiality and non-compete clauses, which are intended to prevent them from working for a competitor within one year after leaving our Company. Our success depends on our ability to attract, train and retain employees with expertise in developing, marketing and selling software solutions. In order to successfully market our technology, we will need to retain additional engineering, technical support and marketing personnel. The market for such persons remains highly competitive and our limited financial resources will make it more difficult for us to recruit and retain qualified persons.

 

We cannot assure you that the intellectual property protection for our core technology provides a sustainable competitive advantage or barrier to entry against our competitors.

 

Our success and ability to compete is dependent in part upon proprietary rights to our technology. We rely primarily on a combination of patent, copyright and trademark laws, trade secrets and technical measures to protect our propriety rights. We have filed a patent application relating to both the optic technology and biometrics solution components of our technology wherein several claims have been allowed. The U.S. Patent and Trademark Office has issued us a series of patents for our Vector Segment fingerprint technology (VST), and our other core biometric analysis and identification technologies. However, we cannot assure you that we will be able to adequately protect our technology or other intellectual property from misappropriation in the U.S. and abroad. Any patent issued to us could be challenged, invalidated or circumvented or rights granted thereunder may not provide a competitive advantage to us. Furthermore, patent applications that we file may not result in issuance of a patent or, if a patent is issued, the patent may not be issued in a form that is advantageous to us. Despite our efforts to protect our intellectual property rights, others may independently develop similar products, duplicate our products or design around our patents and other rights. In addition, it is difficult to monitor compliance with, and enforce, our intellectual property rights on a worldwide basis in a cost-effective manner. In jurisdictions where foreign laws provide less intellectual property protection than afforded in the U.S. and abroad, our technology or other intellectual property may be compromised, and our business would be materially adversely affected. If any of our proprietary rights are misappropriated or we are forced to defend our intellectual property rights, we will have to incur substantial costs. Such litigation could result in substantial costs and diversion of our resources, including diverting the time and effort of our senior management, and could disrupt our business, as well as have a material adverse effect on our business, prospects, financial condition and results of operations. We can provide no assurance that we will have the financial resources to oppose any actual or threatened infringement by any third party. Furthermore, any patent or copyrights that we may be granted may be held by a court to infringe on the intellectual property rights of others and subject us to the payment of damage awards. 

 

We may be subject to claims with respect to the infringement of intellectual property rights of others, which could result in substantial costs and diversion of our financial and management resources.

 

Third parties may claim that we are infringing on their intellectual property rights. We may violate the rights of others without our knowledge. We may expose ourselves to additional liability if we agree to indemnify our customers against third party infringement claims. While we know of no basis for any claims of this type, the existence of and ownership of intellectual property can be difficult to verify, and we have not made an exhaustive search of all patent filings. Additionally, most patent applications are kept confidential for twelve to eighteen months, or longer, and we would not be aware of potentially conflicting claims that they make. We may become subject to legal proceedings and claims from time to time relating to the intellectual property of others in the ordinary course of our business. If we are found to have violated the intellectual property rights of others, we may be enjoined from using such intellectual property, and we may incur licensing fees or be forced to develop alternative technology or obtain other licenses. In addition, we may incur substantial expenses in defending against these third party infringement claims and be diverted from devoting time to our business and operational issues, regardless of the merits of any such claim.

 

11
 

 

In addition, in the event that we recruit employees from other technology companies, including certain potential competitors, and these employees are engaged in the development of portions of products which are similar to the development in which they were involved at their former employers, we may become subject to claims that such employees have improperly used or disclosed trade secrets or other proprietary information. If any such claims were to arise in the future, litigation or other dispute resolution procedures might be necessary to retain our ability to offer our current and future services, which could result in substantial costs and diversion of our financial and management resources. Successful infringement or licensing claims against us may result in substantial monetary damages, which may materially disrupt the conduct of our business and have a material adverse effect on our reputation, business, financial condition and results of operations. Even if intellectual property claims brought against us are without merit, they could result in costly and time consuming litigation, and may divert our management and key personnel from operating our business.

 

If we are unable to effectively protect our intellectual property rights on a worldwide basis, we may not be successful in the international expansion of our business.

 

Access to worldwide markets depends in part on the strength of our intellectual property portfolio. There can be no assurance that, as our business expands into new areas, we will be able to independently develop the technology, software or know-how necessary to conduct our business or that we can do so without infringing the intellectual property rights of others. To the extent that we have to rely on licensed technology from others, there can be no assurance that we will be able to obtain licenses at all or on terms we consider reasonable. The lack of a necessary license could expose us to claims for damages and/or injunction from third parties, as well as claims for indemnification by our customers in instances where we have a contractual or other legal obligation to indemnify them against damages resulting from infringement claims. With regard to our own intellectual property, we actively enforce and protect our rights. However, there can be no assurance that our efforts will be adequate to prevent the misappropriation or improper use of our protected technology in international markets.

 

We may not achieve profitability if we are unable to maintain, improve our offerings.

 

We believe that our future business prospects depend in part on our ability to maintain and improve our current services and to develop new ones on a timely basis. Our services will have to achieve market acceptance, maintain technological competitiveness, and meet an expanding range of customer requirements. As a result of the complexities inherent in our service offerings, major new wireless data services and service enhancements require long development and testing periods. We may experience difficulties that could delay or prevent the successful development, introduction or marketing of new services and service enhancements. Additionally, our new services and service enhancements may not achieve market acceptance. If we cannot effectively develop and improve services, we may not be able to recover our fixed costs or otherwise become profitable.

 

If we fail to adequately manage our resources, it could have a severe negative impact on our financial results or stock price.

 

We could be subject to fluctuations in technology spending by existing and potential customers. Accordingly, we will have to actively manage expenses in a rapidly changing economic environment. This could require reducing costs during economic downturns and selectively growing in periods of economic expansion. If we do not properly manage our resources in response to these conditions, our results of operations could be negatively impacted.

 

We are subject to risks and uncertainties associated with the continued growth of our international operations, which may harm our business.

 

We have international operations and recently expanded our international operations when we acquired Swivel Secure Europe SA, and plan to continue expanding abroad. Accordingly, our business is subject to risks and uncertainties associated with doing business outside of the United States and could be adversely affected by a variety of factors, including:

 

 

●

multiple, conflicting and changing laws and regulations such as privacy, security, and data use regulations, tax laws, export and import restrictions, economic and trade sanctions and embargoes, employment laws, anticorruption laws, regulatory requirements, reimbursement or payer regimes and other governmental approvals, permits and licenses;
 

●

failure by us, our collaborators or our distributors to obtain regulatory clearance, authorization or approval for the use of our product candidates in various countries;
 

●

additional potentially relevant third-party patent rights;
 

●

complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;
 

●

difficulties in staffing and managing foreign operations;
 

●

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our product candidates and exposure to foreign currency exchange rate fluctuations;
 

●

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;
 

●

regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act (FCPA), its books and records provisions, or its anti-bribery provisions, or laws similar to the FCPA in other jurisdictions in which we may now or in the future operate; and
 

●

anti-bribery requirements of several Member States in the European Union and other countries that may change and require disclosure of information to which U.S. legal privilege may not extend.

 

Any of these factors could significantly harm our business, operating results, financial condition or prospects.

 

12
 

 

Our business could be negatively impacted by security threats, including cybersecurity threats, ransomware, and other disruptions.

 

Our customers use our solutions to access their business systems and store data related to their employees, contractors, partners and customers.  Our systems’ integrity is essential to their use of our platform, which stores, transmits and processes customers’ proprietary information and users’ personal data. If the confidentiality, integrity or availability of our customers’ data or systems is disrupted, we could incur significant liability to our customers and to individuals or businesses whose information was being stored by our customers, and our platform may be perceived as less desirable, which could negatively affect our business and damage our reputation. We, our third-party service providers, and our customers may be unable to anticipate these techniques or to implement adequate preventive measures. Further, because we do not control our third-party service providers, or the processing of data by our third-party service providers, we cannot ensure the integrity or security of measures they take to protect customer information and prevent data loss beyond evaluating and relying on their representations as to their security methods and posture.  Although we utilize various procedures and controls to monitor these threats and mitigate our exposure to such threats, there can be no assurance that these procedures and controls will be sufficient in preventing security threats from materializing. If any of these events were to materialize, they could lead to losses of sensitive information, critical infrastructure, personnel or capabilities, essential to our operations and could have a material adverse effect on our reputation, financial position, results of operations, or cash flows. As a technology company, we face various security threats, including cybersecurity threats to gain unauthorized access to sensitive information. on an ongoing basis.

 

In addition to threats from traditional computer “hackers,” malicious code (such as malware, viruses, worms and ransomware), employee or contractor theft or misuse, password spraying, phishing and denial-of-service attacks, we and our third-party service providers now also face threats from sophisticated nation-state and nation-state-supported actors who engage in attacks (including advanced persistent threat intrusions) that add to the risks to our systems (including those hosted on AWS’ systems), internal networks, our customers’ systems and the information that they store and process.  Cybersecurity attacks in particular are evolving, we expect that they will continue, and we expect the scope and sophistication of these efforts may increase in future periods. As a result, we and our third-party service providers may be unable to anticipate these techniques or implement adequate preventative measures quickly enough to prevent either an electronic intrusion into our systems or services or a compromise of customer data, employee data or other protected information. 

 

Although we have implemented systems and procedures that are designed to protect customer, employee, vendor and Company information, prevent data loss and other security breaches, and otherwise identify, assess, and analyze cybersecurity risks, these measures may not function as expected or may not be sufficient to protect our internal networks and platform against certain attacks. Development and maintenance of these systems is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures increase and become more sophisticated. We face an evolving threat landscape in which cybercriminals, among others, employ a complex array of techniques designed to access personal data and other information, including, for example, the use of fraudulent or stolen access credentials, malware, ransomware, phishing, denial of service and other types of attacks. While, to the best of our knowledge, we have not experienced any material misappropriation, loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a security breach or cyberattack that could materially increase financial risk to the Company or our customers, such a security breach or cyberattack could adversely affect our business and operations, including by damaging our reputation and our relationships with our customers, employees and investors, exposing us to litigation, fines, penalties or remediation costs.

 

We maintain cybersecurity insurance, but our insurance may be insufficient to cover all liabilities incurred in any such incident, and any incident may result in loss of, or increased costs of, that cybersecurity insurance. Any breach, or any perceived breach, of our systems, our customers’ systems, or other systems or networks secured by our products, without regard to whether any breach is due to a vulnerability in our platform, may also undermine confidence in our platform or the identity as a service industry and could result in damage to our reputation and brand, negative publicity, loss of partners, customers and sales, increased costs to correct any problem, costly litigation and other liabilities. In addition, a breach of the security measures of one of our partners could result in the disclosure of confidential information or other data that may provide additional avenues of attack, and if a high profile security breach occurs with respect to a comparable cloud technology provider, our customers and potential customers may lose trust in the security of the cloud business model generally, which could adversely impact our ability to retain existing customers or attract new ones. Any of these negative outcomes could adversely impact market acceptance of our products and could harm our business, results of operations, and financial condition.

 

Our failure to comply with applicable privacy, data protection and information security laws or related contractual obligations could subject us to significant liability and negatively impact our financial position and results of operation.

 

There are numerous laws and regulations in various jurisdictions regarding privacy, data protection, information security, and the storing, sharing, use, processing, transfer, disclosure and protection of personal data. In light of the increasing pace of new technology development, including with respect to biometric data, the scope of these data protection and privacy-related laws and regulations are expanding, subject to differing interpretations, and may be inconsistent among jurisdictions, or conflict with other rules that we are subject to. These evolving laws and regulations may result in increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. We are also subject to the terms of our privacy policies and contractual obligations to third parties related to privacy, data protection and information security.

 

Any failure or perceived failure by us to comply with our privacy policies, our privacy-related obligations to customers or other third parties, or applicable laws or regulations relating to privacy, data protection, or information security may result in governmental investigations or enforcement actions, litigation, claims or public statements against us by consumer advocacy groups or others, and could result in significant liability or cause our customers to lose trust in us, which could cause them to cease or reduce use of our products and services and otherwise have an adverse effect on our reputation and business. Any similar failure or perceived failure by users of our products or services may also have an adverse effect on our reputation and business. In addition, legal, regulatory, contractual and other obligations as well as public concerns relating to privacy, data protection or information security could restrict our ability to store and process data as part of our solutions or otherwise impact our ability to provide our solutions in certain jurisdictions and may result in the loss of business opportunities from customers operating in, or seeking to expand into, those jurisdictions. Additionally, in 2022, the SEC proposed new rules related to cybersecurity risk management, which may further increase our regulatory burden and the cost of compliance in such events.

 

13
 

 

Our failure to maintain appropriate environmental, social, and governance ("ESG") practices and disclosures could result in reputational harm, a loss of customer and investor confidence, and adverse business and financial results.

 

There is an increasing focus from certain investors, employees, customers and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance matters (“ESG”). Some investors may use these non-financial performance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to corporate responsibility are inadequate. The growing investor demand for measurement of non-financial performance is addressed by third-party providers of sustainability assessment and ratings on companies. The criteria by which our corporate responsibility practices are assessed may change due to the constant evolution of the sustainability landscape, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies and/or actions with respect to corporate social responsibility are inadequate. We may face reputational damage in the event that we do not meet the ESG standards set by various constituencies.

 

Furthermore, if our competitors’ corporate social responsibility performance is perceived to be better than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors, employees and other stakeholders or our initiatives are not executed as planned, our reputation and business, operating results and financial condition could be adversely impacted.

 

New climate disclosure rules, if adopted by the SEC, may increase our costs and litigation risks, which could materially and adversely affect our future results of operations and financial condition.

 

During 2022, the SEC proposed new climate disclosure rules, which, if adopted, would require new climate-related disclosure in SEC filings, including certain climate-related metrics and greenhouse gas emissions data, information about climate-related targets and goals, transition plans, if any, and extensive attestation requirements. In addition to requiring public companies to quantify and disclose direct emissions data, the new rules also would require disclosure of climate impact arising from the operations and uses by the company’s business partners and contractors and end-users of the company’s products and/or services. We are currently assessing the impact of the new rules, if adopted as proposed, but at this time, we cannot predict the costs of implementation or any potential adverse impacts resulting from the new rules if adopted. However, we may incur increased costs relating to the assessment and disclosure of climate-related risks and increased litigation risks related to disclosures made pursuant to the new rules, either of which could materially and adversely affect our future results of operations and financial condition.

 

The war in Ukraine and the international community’s response have created substantial political and economic disruption, uncertainty, and risk.

 

Russia’s military intervention in Ukraine in late February 2022, Ukraine’s widespread resistance, and the NATO led and United States coordinated economic, financial, communications, and other sanctions imposed by other countries have created significant political and economic world uncertainty. There is significant risk of expanded military confrontation between Russia and other countries.  It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the U.S. and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response. At a minimum, the continuing conflict is likely to cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy, which could materially adversely affect our financial condition or results of operations.  Current and likely additional international sanctions against Russia may contribute to higher costs, particularly for petroleum-based products.  These and related actions, responses, and consequences that cannot now be predicted or controlled may contribute to world-wide economic reversals.

 

There is a scarcity of and competition for acquisition opportunities.

 

There are a limited number of operating companies available for acquisition that we deem to be desirable targets. In addition, there is a very high level of competition among companies seeking to acquire these operating companies. Many established and well-financed entities are active in acquiring interests in companies that we may find to be desirable acquisition candidates. Many of these entities have significantly greater financial resources, technical expertise and managerial capabilities than us. Consequently, we will be at a competitive disadvantage in negotiating and executing possible acquisitions of these businesses. Even if we are able to successfully compete with these entities, this competition may affect the terms of completed transactions and, as a result, we may pay more or receive less favorable terms than we expected for potential acquisitions. We may not be able to identify operating companies that complement our strategy, and even if we identify a company that complements our strategy, we may be unable to complete an acquisition of such a company for many reasons, including:

 

●

failure to agree on the terms necessary for a transaction, such as the purchase price;

 

●

incompatibility between our operational strategies or management philosophies with those of the potential acquiree;

 

●

competition from other acquirers of operating companies;

 

●

lack of sufficient capital to acquire a profitable distribution company; and

 

●

unwillingness of a potential acquiree to work with our management.

 

14
 

 

Risks related to acquisition financing.

 

We have a limited amount of financial resources and our ability to make additional acquisitions without securing additional financing from outside sources is limited. In order to continue to pursue our acquisition strategy, we may be required to obtain additional financing. We may obtain such financing through a combination of traditional debt financing or the placement of debt and equity securities. We may finance some portion of our future acquisitions by either issuing equity or by using shares of our common stock for all or a portion of the purchase price for such businesses. In the event that our common stock does not attain or maintain a sufficient market value, or potential acquisition candidates are otherwise unwilling to accept our common stock as part of the purchase price for the sale of their businesses, we may be required to use more of our cash resources, if available, in order to maintain our acquisition program. If we do not have sufficient cash resources, we will not be able to complete acquisitions and our growth could be limited unless we are able to obtain additional capital through debt or equity financings.

 

We may experience difficulties in integrating the operations, personnel and assets of any business we acquire which may disrupt our business, dilute stockholder value, and adversely affect our operating results.

 

A component of our business plan is to acquire businesses and assets in the biometric and identity access management industry. There can be no assurance that we will be able to identify, acquire or profitably manage businesses or successfully integrate acquired businesses into the Company without substantial costs, delays or other operational or financial problems. Such acquisitions also involve numerous operational risks, including:

 

●

difficulties in integrating operations, technologies, services and personnel;

 

●

the diversion of financial and management resources from existing operations;

 

●

the risk of entering new markets;

 

●

difficulties in retaining the existing customers;

 

●

the potential loss of existing or acquired strategic operating partners following an acquisition;

 

●

the potential loss of key employees following an acquisition and the associated risk of competitive efforts from departures;

 

●

assumed or unforeseen liabilities that arise in connection with the acquired business

 

●

possible legal disputes with the acquired company following an acquisition; and

 

●

the inability to generate sufficient revenue to offset acquisition or investment costs.

 

As a result, if we fail to properly evaluate and execute any acquisitions or investments, our business and prospects may be seriously harmed.

 

To the extent we make any material acquisitions, our earnings may adversely affected by non-cash charges relating to the amortization of intangible assets.

 

Under applicable accounting standards, purchasers are required to allocate the total consideration paid in a business combination to the identified acquired assets and liabilities based on their fair values at the time of acquisition. The excess of the consideration paid to acquire a business over the fair value of the identifiable tangible assets acquired must be allocated among identifiable intangible assets including goodwill. The amount allocated to goodwill is not subject to amortization. However, it is tested at least annually for impairment. The amount allocated to identifiable intangible assets, such as customer relationships and the like, is amortized over the life of these intangible assets. We expect that this will subject us to periodic charges against our earnings to the extent of the amortization incurred for that period. Because our business strategy focuses, in part, on growth through acquisitions, our future earnings may be subject to greater non-cash amortization charges than a company whose earnings are derived solely from organic growth. As a result, we may experience an increase in non-cash charges related to the amortization of intangible assets acquired in our acquisitions. Our financial statements will show that our intangible assets are diminishing in value, even if the acquired businesses are increasing (or not diminishing) in value.

 

RISKS RELATED TO OUR COMMON STOCK

 

We have issued a substantial number of options and warrants exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.

 

As of the date of this report, approximately 5,075,000 shares of our common stock were reserved for issuance upon exercise or conversion of outstanding stock options and warrants. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders. 

 

Upon an event of default under our $2.2 million principal amount secured note, all amounts then due under the note plus all resulting default sums will be convertible into up to 985,576 shares of our common at conversion price equal to the 10-day volume weighted average closing price of our stock.  Any such conversion could cause substantial dilution to our existing stockholders and cause the price of our stock to decline. 

 

Upon the occurrence of any event of default (as defined) under our $2.2 million principal amount secured note, whether for payment or covenant breach, and expiration of any applicable cure periods, all amounts then due under the note, will immediately become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30% to approximately $2.86 million, and the holder of the note will have the right to convert all amounts then due under the Note into shares of common stock conversion price equal to the 10-day volume weighted average sales price of our common stock on the date of conversion.  Although the aggregate number of shares of common stock issuable upon conversion of the Note is capped at 985,576 shares, any conversion of the note could cause substantial dilution to our existing stockholders and cause the price of our stock to decline.   During April 2023, we were in default under the Note due to our failure to timely file this annual report and timely file a registration statement covering the public resale of the shares issued to the holder of the Note in connection with the financing.  We have obtained a waiver and, therefore, as of the date of this report we are not in default.

 

15
 

 

An active trading market for our common stock may not be sustained.

 

Although our common stock is listed on the Nasdaq Capital Market, an active trading market for our shares may not be developed and if developed, sustained. If an active market for our common stock is not developed or sustained, it may be difficult for you to sell your shares without depressing the market price for the shares or sell your shares at all. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. 

 

If we fail to comply with the continued minimum closing bid requirements, the requirement to timely file all required periodic financial reports with the Securities and Exchange Commission, or other Nasdaq requirements for continued listing, our Common Stock may be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.

 

Our common stock is listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share and minimum stockholders’ agreement.  On January 12, 2023, we received a letter from the NASDAQ advising us that we have failed to satisfy the $1.00 minimum bid requirement due to the fact that the closing bid price for our Common Stock for thirty consecutive days was less than $1.00.  We have 180 calendar days, or until July 11, 2023, to regain compliance.  If we are unable to regain compliance during this period, we may be eligible for an additional 180 calendar day period to satisfy the minimum bid requirement. In addition, on April 18, 2023, we received notice from Nasdaq advising that we were not in compliance with Nasdaq’s continuing listing rule which requires us to timely file all required periodic financial reports with the Securities and Exchange Commission due to our failure to timely file this Annual Report on Form 10-K.  We have 60 calendar days to submit a plan to regain compliance. If the plan is accepted, we may be eligible for an additional 180 calendar days from the filing’s due date, or until October 16, 2023, to regain compliance.

 

We may need to raise additional funds in the future through issuances of securities and such additional funding may be dilutive to stockholders or impose operational restrictions.

 

We may need to raise additional capital in the future to help fund our operations through sales of shares of our common stock or securities convertible into shares of our common stock, as well as issuances of debt. Such additional financing may be dilutive to our stockholders, and debt financing, if available, and may involve restrictive covenants which may limit our operating flexibility. If additional capital is raised through the issuance of shares of our common stock or securities convertible into shares of our common stock, the percentage ownership of existing stockholders will be reduced. These stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.

 

Because we do not expect to pay dividends for the foreseeable future, investors seeking cash dividends should not purchase our shares of common stock.

 

We have never declared or paid any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. Payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. Accordingly, investors seeking cash dividends should not purchase shares of our common stock. 

 

Provisions of our certificate of incorporation, bylaws and Delaware law may make a contested takeover of our Company more difficult.

 

Certain provisions of our certificate of incorporation, bylaws and the General Corporation Law of the State of Delaware (“DGCL”) could deter a change in our management or render more difficult an attempt to obtain control of us, even if such a proposal is favored by a majority of our stockholders. For example, we are subject to the provisions of the DGCL that prohibit a public Delaware corporation from engaging in a broad range of business combinations with a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting shares (an “interested stockholder”) for three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Our certificate of incorporation also includes undesignated preferred stock, which may enable our board of directors to discourage an attempt to obtain control of us by means of a tender offer, proxy contest, merger or otherwise. Finally, our bylaws include an advance notice procedure for stockholders to nominate directors or submit proposals at a stockholders meeting. Delaware law and our charter may, therefore, inhibit a takeover. 

 

The trading price of our common stock may be volatile.

 

The trading price of our shares has from time to time fluctuated widely and in the future may be subject to similar fluctuations. The trading price may be affected by a number of factors including the risk factors set forth in this Annual Report on Form 10-K as well as our operating results, financial condition, announcements of innovations or new products by us or our competitors, general conditions in the biometrics and access control industries, and other events or factors. We cannot assure you that any of the broker-dealers that currently make a market in our common stock will continue to serve as market makers or have the financial capability to stabilize or support our common stock. A reduction in the number of market makers or the financial capability of any of these market makers could also result in a decrease in the trading volume of and price of our shares. In recent years broad stock market indices, in general, and the securities of technology companies, in particular, have experienced substantial price fluctuations. Such broad market fluctuations may adversely affect the future-trading price of our common stock.  

 

16
 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2. PROPERTY

 

We do not own any real estate. We conduct operations from leased premises in Eagan, Minnesota (5,544 square feet), Bedford, New Hampshire (3,364 square feet), and Wall, New Jersey (4,517 square feet). Internationally, we conduct operations from leased premises in Tsuen Wan, Hong Kong (1,098 square feet), in Jiangmen, China (3,267 square feet) and in Madrid, Spain (1,504 square feet). Our Eagan, Minnesota and Bedford, New Hampshire offices provide research and development, and customer support, for BIO-key software and PistolStar software, respectively. Our Wall, New Jersey location serves as our corporate headquarters. Our Hong Kong location is a small warehouse for finished goods as well as administrative and sales support. Our Jiangmen, China facility provides our hardware research and development, contract manufacturing and warehousing of raw materials, work-in-process, and finished goods. Our Madrid, Spain office serves as our sales organization for Europe, the Middle East, and parts Africa.

 

ITEM 3. LEGAL PROCEEDINGS

 

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of this report, we are not a party to any pending lawsuit.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

17
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock currently trades on the Nasdaq Capital Market under the symbol “BKYI”.

 

Holders

 

As of May 18, 2023, the number of stockholders of record of our common stock was 131.

 

Dividends

 

We have not paid any cash dividends on our common stock to-date and have no intention of paying any cash dividends on our common stock in the foreseeable future. The terms of our secured promissory note issued in December 2022 prohibits us from paying or declaring any dividends or without the consent of the lender. The declaration and payment of dividends on our common stock is also subject to the discretion of our Board of Directors and certain limitations imposed under the Delaware General Corporation Law. The timing, amount, and form of dividends, if any, will depend on, among other things, our results of operations, financial condition, cash requirements and other factors deemed relevant by our Board of Directors.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

For information on securities authorized for issuance under the Company’s equity compensation plans, see “Item 12 - Security Ownership of Certain Beneficial Owners and Related Stockholder Matters.”

 

Unregistered Sales of Equity Securities

 

There were no unregistered sales of the Company’s equity securities during 2022 that were not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.

 

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6. RESERVED

 

Not Applicable.

 

18
 

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations, and other parts of this Report contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this Report are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in the section captioned “RISK FACTORS” in Item 1A and elsewhere in this Report.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help you understand our Company. This discussion is provided as a supplement to and should be read in conjunction with our consolidated financial statements for the years ended December 31, 2022 and 2021 and the accompanying notes included elsewhere in this Report.

 

Overview

 

We are a leading identity access management (IAM) platform provider for the enterprise and large-scale customer and civil ID solutions.  Built to leverage BIO-key’s world-class biometric core platform among 17 strong authentication factors, BIO-key PortalGuard and hosted PortalGuard IDaaS are platforms that enable our customers to securely and easily assure that only the right people can access the right systems.  PortalGuard goes beyond traditional multifactor authentication (MFA) solutions by addressing functional gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens, eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification. 

 

Our customers use BIO-key every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. Employees, contractors, students and faculty sign in through PortalGuard to seamlessly and securely access the applications they need to do their important work, without relying on personal phone use or per-user tokens. Organizations use our platform to securely collaborate with their supply chain and partners, and to provide their customers with flexible, resilient user experiences online or in-person.

 

Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. One large bank has enrolled and identifies over 21.7 million of their customers using BIO-key fingerprint biometrics in branches on a daily basis. 

 

PortalGuard and hosted PortalGuard IDaaS are platforms that enable our customers to securely and easily assure that only the right people can access the right systems by utilizing our world-class biometric core platform among 17 other authentication factors.  PortalGuard goes beyond traditional multi-factor authentication, or MFA, solutions by addressing sizeable gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens, eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification.

 

PortalGuard and IBB deliver unique value to enterprises who find that mainstream MFA solutions do not adequately address their workforce use cases.  PortalGuard operates as a single MFA user experience, providing a rich set of authentication choices to meet every use case.  We sell our branded biometric and FIDO authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. We do not mandate the use of BIO-key hardware with our software and services. Our NIST-certified fingerprint biometric platform is unique in that it supports interoperable mixing and matching combinations of different manufactures’ fingerprint scanners in a deployment, so that the right scanner can be selected for the right use case, without mandating the user of a particular scanner.

 

Security-conscious software developers leverage our platform APIs and federation interfaces to securely and efficiently embed biometric and MFA identity capabilities into their software.   Our approach to IDaaS allows our customers to efficiently scale their security and identity infrastructures to protect both internal cloud workforce- and external customer-facing applications.

 

In 2022, we expanded our product offerings and customer base when we acquired Swivel Secure, a Madrid, Spain based provider of IAM solutions.  Swivel Secure is the exclusive distributer of AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland.  These solutions include a patented one-time-code extraction technology, helping enterprises manage the increasing data security risks posed by cloud services and bring your own device policies.

 

We operate a SaaS business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year. 

 

19
 

 

Strategic Outlook

 

We plan to have a more significant role in the IAM market which continues to expand. We plan to offer customers a suite of authentication options that complement our biometric solutions. The more well-rounded offerings of authentication options will allow customers to customize their approach to authentication all under one umbrella.

 

We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare.  We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 10 users will accelerate the demand for our computer network log-on solutions and fingerprint readers.  Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base. 

 

Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than one hundred and fifty participants and continues to generate incremental revenues. 

 

A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations. 

 

Recent Developments

 

As discussed under “Item 1A. Risk Factors” given the uncertainty of the duration and severity of a possible economic recession and the conflict between Ukraine and Russia and their effects on our business operations, sales cycles, personnel, and the geographic markets in which we operate, and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature, the related financial impact cannot be reasonably estimated at this time.

 

The current trend of continued remote work environments increases the risk of unauthorized users, phishing attacks, and hackers who are eager to take advantage of the challenges of securing remote workers. We believe that biometrics should continue to play a key role in remote user authentication.

 

RESULTS OF OPERATIONS

 

Consolidated Results of Operations

 

Two Year % trend

 

   

Years ended

December 31,

  
   

2022

    

2021

  

Revenues

                

Services

     26

%

     25

%

License fees

     65

%

     50

%

Hardware

     9

%

     25

%
      100

%

     100

%

Costs and other expenses

                

Cost of services

     10

%

     13

%

Cost of license fees

     13

%

     4

%

Cost of hardware

     12

%

     16

%
      35

%

     33

%

Gross Profit

     65

%

     67

%
                 

Operating expenses

                

Selling, general and administrative

     133

%

     118

%

Research, development and engineering

     46

%

     46

%
Reversal of earnout payable-Swivel acquisition     -7 %        

Impairment of goodwill

     34

%

     -  

Total operating expenses

     206

%

     164

%

Operating loss

     -141

%

     -97

%
                 

Other income (expense)

                

Total other income (expense)

     -29

%

     -2

%
                 
Loss before provision for income tax benefit     -170 %     -99 %
                 
Provision for income tax benefit     -       -  
                 

Net loss

     -170

%

     -99

%

 

20
 

 

Revenues and Costs and other expenses

 

                   

2022-2021

  
   

2022

    

2021

    

$ Chg

    

% Chg

  
                                 

Revenues

                                

Services

   $ 1,789,720     $ 1,273,354     $ 516,366       41

%

License fees

     4,584,052       2,555,809       2,028,243       79

%

Hardware

     646,486       1,285,326       (638,840 )     -50

%

Total Revenue

   $ 7,020,258     $ 5,114,489     $ 1,905,769       37

%
                                 

Costs and other expenses

                                

Services

   $ 722,152     $ 686,175     $

35,977

       5

%

License fees

     906,417       183,199      

723,218

       395

%

Hardware

     811,001       803,555       7,446       1

%

Total Costs and other expenses

   $ 2,439,570     $ 1,672,929     $ 766,641       46

%

 

Revenues

 

Revenue increased $1,905,769 or 37% to $7,020,258 in 2022 as compared to $5,114,489 in 2021 due to the factors stated below. 

 

For the years ended December 31, 2022, and 2021, service revenues included approximately $1,243,000 and $1,100,000, respectively, of recurring maintenance and support revenue, and approximately $546,000 and $173,000, respectively, of non-recurring custom services revenue.  Recurring service revenue increased 13% from 2021 to 2022 due largely to the increased maintenance related to increased license revenue. Non-recurring custom services increased 216% due to increased new customer installations, Swivel service fees, and conversion to the cloud platform. Although inflation has negatively impacted many industries, we have continued to see our pipeline increase for the cybersecurity protection software and services that we offer. As our customer base continues to grow, we expect the service revenue to increase in future periods.

 

For the years ended December 31, 2022 and 2021, license revenue increased $2,028,243 or 79% to $4,584,052, due primarily to new customer orders, revenues from Swivel Secure for approximately $1.9 million, and existing recurring revenue contracts. We expect the recurring revenue to continue to grow in 2023.

 

Hardware sales decreased by $638,840, or 50%, to $646,486 in 2022 from $1,285,326 in 2021. The decrease was attributable largely to Q1 2021 sales in Nigeria to an international government agency, which did not recur in 2022 due to delayed roll out of the government project.

 

Costs of goods sold

 

For the year ended December 31, 2022, cost of services increased approximately 5% to $722,152, due to the increased costs to support for the PortalGuard deployments.

 

License fees for the year ended December 31, 2022 increased $732,218, or approximately 395%, to $906,417 related to increased license revenue and license fees payable for third-party software distributed by Swivel Secure.

 

Hardware costs for the year ended December 31, 2022 increased $7,446, or approximately 1%, to $811,001. The increase was associated with the decreased hardware sales and hardware mix described above, offset by the $400,000 reserve on inventory due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product.

 

21
 

 

Selling, general and administrative

 

            2022 - 2021  

2022

    

2021

    

$ Chg

    

% Chg

 
                     
$ 9,364,887     $ 6,028,360     $ 3,336,527       55 %

 

Selling, general and administrative costs for year ended December 31, 2022 were $9,364,887 representing a 55% increase from 2021. The increase included higher sales and marketing expenses incurred by Swivel Secure which we acquired in 2022, increased legal, professional, and other fees and expenses incurred in connection with the acquisition of Swivel Secure and the AJB Capital loan, bad debt expense related to a reserve on a note receivable, and an increase in the allowance for doubtful accounts of $360,000.

 

Research, development and engineering

 

            2022 - 2021  

2022

    

2021

    

$ Chg

    

% Chg

 
                     
$ 3,252,236     $ 2,355,056     $ 897,180       38

%

 

For the year ended December 31, 2022, research, development and engineering costs were $3,252,236 representing a 38% increase over 2021. Included in the increase were personnel costs associated with retaining outside services related to the development of our MobileAuth application, and wages and benefits for new engineering employees.

 

Reversal of earnout payable – Swivel acquisition

 

               

2022 - 2021

  

2022

    

2021

    

$ Chg

    

% Chg

 
                             
$ (500,000

)

   $ -     $ (500,000

)

     100

%

 

For the year ended December 31, 2022, we recognized income on the elimination of the earnout payable on the acquisition of Swivel Secure as the certain requirements for the payout were not achieved.

 

Impairment of goodwill

 

               

2022 - 2021

  

2022

    

2021

    

$ Chg

    

% Chg

 
                             
$ 2,387,193     $ -     $ 2, 387,193       100

%

 

For the year ended December 31, 2022, we recognized an impairment of our goodwill balances due to the decrease in market value of our common stock compared to the carrying value of our net assets.

 

Other income (expense)

 

                    2022-2021  
    2022     2021     $ Chg     % Chg  
                                 

Interest income

   $ 233     $ 4,075     $ (3,842

)

     -94 %

Foreign currency loss

     -       (50,000

)

     50,000       100 %

Investment-debt security reserve

     (452,821

)

     (60,000

)

     (392,821

)

     -655 %

Loan transaction costs

     (1,147,456

)

     -       (1,147,456

)

     -100 %

Change in fair value of convertible note

     (396,203

)

     -       (396,203

)

     -100 %

Interest expense

     (10,462

)

     (18,000 )     7,538

 

     42 %
    $ (2,006,709

)

   $ (123,925

)

   $ (1,882,784

)

     -1519 %

 

 

The amounts for other income (expense) for the year ended December 31, 2022 consisted of interest income of $233, a write-off of the investment-debt security as the Company received the proceeds and the bond issuer defaulted on repayment, loan transactions costs expensed for the convertible note payable as the Company elected to value the convertible note payable under the fair value option, the change in the fair value of the convertible note payable, and interest expense of $10,462 on the convertible note payable and the government loan through the BBVA bank. The amounts for the year ended December 31, 2021, related to a loss on a reserve on the investment in the debt security due to a delay in receiving the funds, interest expense from the amortization of debt discounts, and a foreign currency adjustment to an accounts receivable invoice, offset by interest income.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Operating activities overview

 

Net cash used for operations during the year ended December 31, 2022 was $6,229,034. Items of note included:

 

 

●

 Net positive cash flows related to non-cash expenses of approximately $5,980,000.
 

●

 Net negative cash flows related to changes in accounts receivable, prepayments, accruals, lease liabilities, and deferred revenue in the aggregate amount of approximately $299,000 and our net loss for the period.

 

Investing activities overview

 

Net cash used in investing activities during the year December 21, 2022 was $696,618. This consisted of approximately $82,000 of capital expenditures, $9,000 of receipts from a note receivable and $624,000 (net of cash acquired and currency adjustment) to fund the cash portion of the purchase price for Swivel Secure.

 

22
 

 

Financing activities overview

 

Net cash from financing activities was $1,903,240 during the year ended December 31, 2022 consisting of proceeds of $2,002,000 from the issuance of a convertible note, costs paid to acquire the convertible note of $155,140 and proceeds of $56,380 from sales of common stock under the employee stock purchase plan.

 

Sources of Liquidity

 

Since our inception, our capital needs have been principally met through proceeds from the sale of equity and debt securities. We expect capital expenditures to be less than $100,000 during the next twelve months.

 

The following sets forth our primary sources of capital during the previous two years:

 

In December 2022, we entered into and closed a securities purchase agreement (the “Purchase Agreement”) with AJB Capital Investments, LLC under which we issued a $2,200,000 principal amount senior secured promissory note (the “Note”). The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

 

In March 2022, in connection with the acquisition of Swivel Secure, we assumed a €500,000 government loan that was issued through BBVA Bank during the COVID-19 pandemic.  The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through maturity in April 2026. Upon closing of the acquisition, Swivel Secure had cash equal to the outstanding balance.

 

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2023 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.   

 

Liquidity Outlook

 

At December 31, 2022, our total cash and cash equivalents were approximately $2,600,000, as compared to $7,800,000 at December 31, 2021.  At December 31, 2022, we had working capital of approximately $3,529,000. 

 

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $798,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During 2022, we generated approximately $7,020,000 of revenue, which did not generate enough cash to fully fund our average monthly cash requirements. We expect that Swivel Secure Europe will continue to generate positive cash flow in 2023. We also have approximately $3.8 million of inventory purchased for projects in Nigeria. We are  looking into other markets and opportunities to sell or return the product to generate additional cash.

 

If we are unable to generate sufficient revenue to fund current operations and execute our business plan, we may need to obtain additional third-party financing. Our secured note is due on June 22, 2023 which we expect to extend for an additional six months. Unless we generate sufficient positive cash flow from operations or liquidation of existing inventory, we expect that we will need to obtain additional financing during the next twelve months to be used in part to repay our outstanding secured note.

 

Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.

 

23
 

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ significantly from these estimates under different assumptions or conditions. There have been no material changes to these estimates for the periods presented in this Annual Report on Form 10-K.

 

We believe that of our significant accounting policies, which are described in Note A of the notes to our consolidated financial statements included in this Annual Report on Form 10-K, the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of operations, as listed below:

 

1. Business Combinations  We allocate the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Acquired customer relationships, proprietary software, and trade names are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. We include the results of operations of the business that we have acquired in our consolidated results prospectively from the date of acquisition.

 

2. Impairment of Goodwill   Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit based on the Company’s market capitalization and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The effect of any impairment would be reflected in operating income in the consolidated statement of operations. The annual goodwill impairment test is performed as of December 31st of each year.

 

3. Income Taxes  We account for income taxes under the asset and liability method, based on the income tax laws and rates in the jurisdictions in which operations are conducted and income is earned. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using expected rates in effect for the tax year in which the differences are expected to reverse. Developing the provision for income taxes requires significant judgment including the determination of deferred tax assets and liabilities and, if necessary, any valuation allowances that may be required for deferred tax assets. The Company has recorded a valuation allowance in the current and prior years to reduce net deferred tax assets to zero. If we were to subsequently determine that we would be able to realize deferred tax assets in the future in excess of its net recorded amount, an adjustment to deferred tax assets would increase net income for the period in which such determination was made. We will continue to assess the adequacy of the valuation allowance on a quarterly basis. Our judgments and tax strategies are subject to audit by various taxing authorities.

 

4. Fair Value of Convertible Note Payable  We elected the fair value option to account for the convertible note payable. The fair value option provides an election that allows a company to irrevocably elect to record certain financial assets and liabilities at fair value on an instrument-by-instrument basis at initial recognition. We elected the fair value option to better depict the ultimate liability associated with the note, including all features and embedded derivatives. The note accounted for under the fair value option election represents the debt host financial instrument containing certain embedded features that would otherwise be required to be bifurcated from the debt host and recognized as separate derivative liabilities subject to initial and subsequent periodic fair value measurement in accordance with U.S. GAAP. When the fair value option election is applied to financial liabilities, bifurcation of embedded derivatives is not required, and the financial liability in totality is recorded at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each balance sheet date thereafter. We estimated the fair value of the note using a probability-weighted discounted cash flow model with significant assumptions including the present value discount rate and the likelihood of default.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not Applicable.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See financial statements appearing at pages 37-64 of this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

24
 

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were not effective over the income tax provision in our financial statements.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f) and 15d-15(f). Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, the risk. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

Under the supervision and with the participation of our management, including our CEO and CFO, we have conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022, based upon the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management has concluded that our internal control over financial reporting was not effective as of December 31, 2022 as a result of certain material weaknesses discovered during the course of their review.

 

In particular, in connection with the audit of our financial statements as of and for the year ended December 31, 2022, our management identified a material weakness relating to the effectiveness of management’s review and controls over the income tax provision in our financial footnotes, such that management’s review procedures were not operating at a level of precision to prevent or detect a potential material misstatement in our consolidated financial statements. We have also identified a lack of control over our foreign subsidiaries with respect to the filing of required tax returns on a timely basis.

 

We are currently assessing the actions that need to be taken to remedy each of the material weaknesses identified above which will include promptly establishing written controls and operating procedures to address these issues.

 

Each of the material weaknesses noted will only be deemed to have been remediated after the new controls and procedures have been in place for a sufficient period and management has concluded through appropriate testing that the controls are operating effectively. However, we cannot assure you that these or other measures will fully remediate the material weaknesses in a timely manner.

 

As we are a smaller reporting company, this annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

 

Changes in Internal Control Over Financial Reporting

 

No change in our internal control over financial reporting occurred during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not Applicable.

 

25
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following sets forth certain information about each director and executive officer of the Company.

 

NAME

  

AGE

  

POSITIONS HELD

Michael W. DePasquale

    

68

  

Chairman of the Board of Directors and Chief Executive Officer

Thomas E. Bush, III (a)* (c)

    

70

  

Director

Robert J. Michel (a) (b)*

    

66

  

Director

Wong Kwok Fong (Kelvin)

    

59

  

Director and Vice-Chairman of the Board of Directors

Emmanuel Alia (Manny) (b) (c)

    

58

  

Director

Cecilia C. Welch

    

63

  

Chief Financial Officer

Mira K. LaCous

    

62

  

Chief Technology Officer

James D. Sullivan

    

55

  

Vice President of Strategy and Compliance, Chief Legal Officer

 

 

(a)

Compensation Committee Member

 

 

(b)

Audit Committee Member

 

 

(c)

Nominating Committee Member

 

 

(d)

Mr. Gilley resigned from the Board of Directors effective February 9, 2023

 

 

*

Indicates chair of committee

 

Set forth below is a brief description of the background and business experience of our directors and executive officers for the past five years. 

 

Directors

 

Michael W. DePasquale has served as our Chief Executive Officer and a Director since January 3, 2003, and Chairman of the Board since January 29, 2014. He served as Co-Chief Executive Officer of the Company from July 2005 to August 2006. Mr. DePasquale brings more than 30 years of executive management, sales and marketing experience to the Company. Mr. DePasquale has held executive management positions with McGraw-Hill, Digital Equipment Corporation, and other companies in the software and professional services industries. Mr. DePasquale earned a Bachelor of Science degree from the New Jersey Institute of Technology. He serves as the Vice Chairman on the Board of Directors of the International Biometrics and Identification Industry Association. We believe Mr. DePasquale’s qualifications to sit on the board of directors include his extensive executive management experience in the technology sector and biometric industry expertise which strengthen the board’s collective qualifications, skills and experience.   

 

Thomas E. Bush, III has served as a Director of the Company since January 29, 2014. Since 2009, Mr. Bush has provided business consulting services through his firm, Tom Bush Consulting. Prior to that, Mr. Bush served with the Federal Bureau of Investigation for over 33 years. Mr. Bush joined the FBI in September 1975, ultimately becoming the Director of the CJIS division, with over 2,500 employees and a budget of approximately one billion dollars.  During this time, Mr. Bush provided critical services in support of the criminal justice community, including two significant IT projects, Next Generation Identification and N-Dex, which were awarded by CJIS during his tenure at the FBI. Mr. Bush has received many awards during his career, most notably a Presidential Rank Award for Meritorious Service in 2007. We believe Mr. Bush’s qualifications to sit on the board of directors include his extensive experience in law enforcement, security matters, and the use of biometric technologies in the government sector, which provide the board with a unique perspective on security and public sector matters. 

 

26
 

 

Robert J. Michel has served as a Director of the Company since April 10, 2017. He has over 30 years of accounting and financial management experience. Since September, 2018, he has served as the Chief Financial Officer of Daxor Corporation (Nasdaq: DXR), a medical device manufacturing company specializing in blood volume analysis. Prior to Daxor, from November, 2017 until September 2018, Mr. Michel served as the CFO of Roadway Moving, Inc., a transportation, moving and storage company located in New York City.  Mr. Michel spent 15 years at Asta Funding, Inc. (Nasdaq: ASFI), a diversified financial services company, including serving as its Chief Financial Officer from 2009 until 2017 where he was responsible for all financial matters and SEC reporting. Mr. Michel is a certified public accountant, earned an MBA in Taxation from St. John’s University, and a BS in Business Administration from Villanova University. We believe Mr. Michel’s qualifications to sit on the board of directors include his substantial experience in accounting and financial management for public companies which provide the board with a deep knowledge of financial and SEC reporting and strengthen the board’s collective qualifications, skills, and experience.

 

Wong Kwok Fong (Kelvin) has served as a Director of the Company since December 4, 2015, as Managing Director of our Hong Kong Subsidiary since August 2016, and as Vice-Chairman of the Board of Directors since March 2019. He is the co-founder of China Goldjoy Group (previously World Wide Touch Technology Holdings Limited), a company listed on The Stock Exchange of Hong Kong. From 1997 until August, 2015, Mr. Wong served as the Chairman of China Goldjoy Group and served as its Chief Technology Officer through October 2016. During this time, Kelvin played a significant role in the substantial growth of the business. Kelvin brings over 25 years of senior management experience in manufacturing, supply chain, and marketing functions in the electronics and technology industries, including establishing manufacturing plants in Hong Kong and China, and building an extensive network in the electronics and technology industries. We believe Kelvin’s qualifications to sit on the board of directors include his substantial experience in the technology industry, including biometrics and payment systems, and serving the Asian markets, which broaden and strengthen the board’s collective qualifications, skills, and experience.

 

Emmanuel Alia (Manny) was appointed Director of the Company on April 3, 2020. Since 2018, Mr. Alia has been providing management consulting services as an advisor to businesses seeking market entry strategies to emerging markets such as Africa and the Caribbean. From 2011 to 2018, Mr. Alia served as an Executive Director at the Corporate and Investment division of JPMorgan, and as a Senior Vice-President at CHASE Bank’s Consumer and Community Banking specializing in the financial and banking services industry and opportunities in Africa. During Mr. Alia’s tenure with JPMorgan, he served as head of WholeSale Operations in the Receivables Operations of the Global banking operations in the US and Canada, head of Retail Banking in the Greater Detroit area, and head of branches in the New York and New Jersey areas. For two years Mr. Alia was co-chair of the Black Organizational Leadership Development, an employee networking group in JPMorgan that works with firm’s leadership to strengthen the firm’s message, strategies and community outreach globally. Mr. Alia received a Bachelor of Arts in Accounting from SouthEastern University and a Master’s of Business Administration (MBA) from Cornell University. We believe Mr. Alia’s qualifications to sit on the board of directors include his extensive industry experience and connection and networking abilities in the African communities and markets which further broaden and strengthen the board’s collective qualifications, skills, and experience.

 

Executive Officers

 

Cecilia C. Welch has served as the Chief Financial Officer of the Company since December 21, 2009. Ms. Welch joined the Company in 2007 as Corporate Controller. Prior to joining the Company, Ms. Welch has held senior financial management positions in various industries, including software and manufacturing.  Ms. Welch has a Bachelor’s degree in Accounting from Franklin Pierce University.

 

Mira K. LaCous has served as Chief Technology Officer of the Company since March 13, 2014, as Senior Vice President of Technology & Development since 2012, and as our Vice President of Technology and Development since 2000. Ms. LaCous has over 39 years of product/project management, solution architecture, software development, team leadership and customer relations experience, with a background that includes successfully bringing numerous innovative products and technologies to market, including automated voice response systems, automated building control systems, software piracy protection, internet training materials and testing, WYSIWYG page layout and design software, image scanning / recognition software and systems, biometric security systems and algorithms, automated national ID systems using biometrics, and mobile applications with secure frameworks. Ms. LaCous has been a speaker at multiple events/conferences and has worked with teams around the globe bringing biometric technology deployments to life.  Ms. LaCous is the author of eight (8) US patented technologies, multiple international patents and lead the engineering team in developing other patents and inventive technologies. Ms. LaCous earned a Bachelor’s in Computer Science, with mathematics and physics from North Dakota State University.

 

27
 

 

James D. Sullivan has served as BIO-key’s Senior Vice President of Strategy and Compliance and BIO-key’s Chief Legal Officer since February 2020, as Senior Vice President of Strategy and Business Development from April 2012 through December 2018, and the dual role as Senior Vice President of Global Sales from August 2015 through December of 2016. Mr. Sullivan is a recognized expert in privacy, cybersecurity, and biometric authentication for workforce and consumer applications. During his twenty years with the Company, Mr. Sullivan has directly worked with dozens of the Company’s customers, including AT&T, Israel Defense Forces, LexisNexis, NCR and Omnicell, as well as large-scale biometric-centered identity management projects that interface daily with millions of corporate and consumer users. Mr. Sullivan earned a Juris Doctor with Honors from Georgia State University College of Law, is a member of the Georgia Bar, and enrolled to practice before the IRS. Mr. Sullivan has an undergraduate degree in Computer Science from Brown University and has over 26 years of experience in IT projects and implementation, including directly working with security and identity management solutions at the Company, Computer Associates, Platinum Technology, and Memco Software.

 

Committees of the Board of Directors

 

Audit Committee

 

Our audit committee was comprised of Robert J. Michel (Chair), Pieter Knook, and Emmanuel Alia until May 13, 2023, when Pieter Knook resigned from the Board of Directors. Robert J. Michel and Emmanuel Alia both meet the independence standards for purposes of serving on an audit committee established by NASDAQ and under the Exchange Act. Our audit committee (i) assists the board of directors in its oversight of the integrity of our financial statements, compliance with legal and regulatory requirements, and corporate policies and controls, (ii) has the sole authority to retain and terminate our independent registered public accounting firm, approve all auditing services and related fees and the terms thereof, and pre-approve any non-audit services to be rendered by our independent registered public accounting firm, and (iii) is responsible for confirming the independence and objectivity of our independent registered public accounting firm. Our independent registered public accounting firm has unrestricted access to our audit committee. Our board of directors has determined that Robert J. Michel qualifies as an “audit committee financial expert,” as such term is defined in Item 407 of Regulation S-K.

 

Our audit committee operates under a written charter that is reviewed annually. The charter is available on our website at www.bio-key.com.

 

Compensation Committee

 

Our compensation committee is comprised of Thomas Bush, III (Chair) and Robert Michel, both of whom meet the independence standards established by NASDAQ and under the Exchange Act. The compensation committee’s duties include overseeing our overall compensation philosophy, policies and programs. This includes reviewing and analyzing the design and function of our various compensation components, establishing salaries, incentives and other forms of compensation for officers and non-employee directors, and administering our equity incentive plan. In fulfilling its responsibilities, the compensation committee has the authority to delegate any or all of its responsibilities to a subcommittee of the compensation committee.

 

Our compensation committee operates under a written charter that is reviewed annually. The charter is available on our website at www.bio-key.com.

 

Code of Ethics

 

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Our Code of Ethics is designed to deter wrongdoing and promote: (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in our other public communications; (iii) compliance with applicable governmental laws, rules, and regulations; (iv) the prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and (v) accountability for adherence to the code.  We intend to disclose amendments or waivers of the Code of Ethics on our website within four business days.  Any person may obtain a copy of our Code of Ethics free of charge by sending a written request for such to the attention of the Chief Financial Officer of the Company, 3349 Highway 138, Building A Suite E, Wall, NJ 07719.  

 

28
 

 

Term of Office

 

Our directors are elected at the annual meeting of stockholders and hold office until the annual meeting of the stockholders next succeeding his or her election, or until his or her prior death, resignation or removal in accordance with our bylaws. Our officers are appointed by the Board and hold office until the annual meeting of the Board next succeeding his or her election, and until his or her successor shall have been duly elected and qualified, subject to earlier termination by his or her death, resignation or removal.

 

Delinquent Section 16(a) Reports

 

Reports of all transactions in our common stock by officers, directors and ten percent (10%) stockholders are required to be filed with the SEC pursuant to Section 16(a) of the Exchange Act. Based solely on our review of copies of the reports received, or representations of such reporting persons, we believe that during the year ended December 31, 2022, all Section 16(a) filing requirements applicable to our officers, directors and ten percent (10%) stockholders were satisfied in a timely fashion, except for four late Form 4 filings including one late Form 4 filing by Mr. Michel for payment for a BOD committee meeting, and one each for Mr. Sullivan, Mr. DePasquale and Ms. LaCous reporting shares acquired under the BIO-key International, Inc. 2021 Employee Stock Purchase Plan.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The following table sets forth a summary of the compensation paid to or accrued by our chief executive officer and the two most highly compensated executive officers other than our chief executive officer, for the fiscal years ended December 31, 2022 and 2021:

 

SUMMARY COMPENSATION TABLE

Name and Principal

Position

 

Year

  

Salary

($)

    

Stock

Awards

($) (1)

   

All Other

Compensation

($) (2)

    

Total

($)

  
                                   

Michael W. DePasquale

2022

    

295,833

      

75,250

      

997

      

372,080

  

Chief Executive Officer

2021

    

275,000

      

-

      

1,944

      

276,944

  
                                   

Mira K. LaCous

2022

    

223,000

      

16,125

      

1,301

      

240,426

  

Chief Technology Officer

2021

    

216,333

      

-

      

3,092

      

219,425

  
                                   

James D. Sullivan

2022

    

233,333

      

64,500

      

134,157

(3)

    

431,990

  

Chief Legal Officer

2021

    

225,000

      

-

      

10,241

(4)

    

235,241

  

 

(1)

The aggregate grant date fair value of the restricted shares is calculated by the multiplying the quantity of shares issued by the closing trading price of the shares on the date of issuance calculated under FASB ASC 718.

(2)

Consists of life insurance premiums paid by the Company except as otherwise noted.

(3)

Consists of $132,826 of sales commissions and $1,331 of life insurance premiums paid by the Company.
(4)

Consists of $8,987 of sales commissions and $1,254 of life insurance premiums paid by the Company.

 

Narrative Disclosure to Summary Compensation Table

 

Compensation for our executives is comprised of three main components: base salary, annual performance-based cash bonus, and long-term equity awards. We do not target a specific weighting of these three components or use a prescribed formula to establish pay levels. Rather, the board of directors and compensation committee considers changes in the business, external market factors and our financial position each year when determining pay levels and allocating between long-term and current compensation for the named executive officers.

 

Cash compensation is comprised of base salary and an annual performance-based cash bonus opportunity. The compensation committee generally seeks to set a named executive officer’s targeted total cash compensation opportunity within a range that is the average of the applicable peer company and/or general industry compensation survey data, adjusted as appropriate for individual performance and internal pay equity and labor market conditions.

 

In setting cash compensation levels, we favor a balance in which base salaries are generally targeted at slightly below the peer average and a bonus opportunity that is targeted at slightly above the average. The base salary of our CEO has not been increased since 2018. Effective January 1, 2021, we increased the base salary of Mr. Sullivan to $225,000 to compensate for the fact that in connection with his promotion to Chief Legal Officer, he would be limited to sales commissions on only three of his existing long term accounts.  Effective January 1, 2022, we increased the base compensation of Mr. Sullivan and Ms. LaCous.

 

Performance-based bonuses have historically been based upon the achievement of certain revenue milestones established by the compensation committee. The committee believes that this higher emphasis on performance-based cash bonuses places an appropriate linkage between a named executive officer’s pay, his or her individual performance, and the achievement of specific business goals by placing a higher proportion of annual cash compensation at risk, thereby aligning executive opportunity with the interests of stockholders.

 

29
 

 

We also include an equity component as part of our compensation package because we believe that equity-based compensation aligns the long-term interests of our named executive officers with those of stockholders. We did not issue any stock options or restricted stock awards to our named executive officers during 2021.  In 2022, we issued restricted stock awards to each of our named executive officers in  recognition of the revenue growth of the Company in 2021 and successful integration of Portal Guard.

 

These cash and equity compensation components of pay are supplemented by various benefit plans that provide health, life, accident, disability and severance benefits, most of which are the same as the benefits provided to all of our US based employees.

 

Employment Agreements

 

On March 26, 2010, we entered into an employment agreement, effective as of March 25, 2010, with Michael W. DePasquale to serve as our Chief Executive Officer until March 24, 2011. The agreement automatically renews for subsequent one-year terms, unless the employment relationship is terminated by either party, or modified in accordance with the terms and conditions of the agreement. Since 2018, Mr. DePasquale’s annual base salary has been $275,000, subject to adjustment by the compensation committee. In addition to the base salary, a “Performance Bonus” may be awarded to Mr. DePasquale on the basis of the Company achieving certain corporate and strategic performance goals, as determined by the compensation committee in its sole discretion. The employment agreement contains standard and customary confidentiality, non-solicitation and “work made for hire” provisions as well as a covenant not to compete which prohibits Mr. DePasquale from doing business with any current or prospective customer of the Company or engaging in a business competitive with that of the Company during the term of his employment and for the one-year period thereafter. This agreement also contains a number of termination and change in control provisions as described under the captions “Termination Arrangements” and “Change in Control Arrangements” below.

 

On April 5, 2017, we entered into an employment agreement with James Sullivan. The agreement automatically renews for subsequent one-year terms, unless terminated by the Company upon at least two months prior written notice which is treated as termination without cause. Since 2021, Mr. Sullivan’s annual base salary has been $225,000, subject to adjustment by the compensation committee. The agreement contains standard and customary confidentiality, technical invention provisions as well as non-competition and non-solicitation covenants which prohibit Mr. Sullivan from doing business with any current or prospective customer of the Company or engaging in any business competitive with that of the Company during the term or his employment and for the one-year period thereafter. The agreement also contains a number of termination provisions as described under the caption “Termination Agreements” below.

 

On November 20, 2001, we entered into an employment agreement with Mira LaCous. The agreement automatically renews for subsequent one-year terms, unless terminated by the Company upon at least one-month prior written notice which is treated as termination without cause and provides for a discretionary bonus which shall not exceed 50% of base salary. The agreement contains standard and customary confidentiality, technical invention provisions as well as non-competition and non-solicitation covenants which prohibit Ms. LaCous from doing business with any current or prospective customer of the Company or engaging in any business competitive with that of the Company during the term or her employment and for the one-year period thereafter. The agreement also contains a number of termination provisions as described under the caption “Termination Agreements” below.

 

Stock Option Grants and Restricted Stock Awards

 

In the event of any change in the outstanding shares of our common stock by reason of a stock dividend, stock split, combination of shares, recapitalization, merger, consolidation, transfer of assets, reorganization, conversion or what the board deems to be similar circumstances, the number and kind of shares subject to outstanding options and restricted stock awards, and the exercise price of such options shall be appropriately adjusted. Restricted Furthermore, option agreements and restricted stock award agreements contain change of control provisions as described under the caption “Change in Control Provisions” below. 

 

30
 

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

 

The following table sets forth for each named executive officer, information regarding outstanding equity awards as at December 31, 2022.

 

   

Option Awards

  

Stock Awards

  

Name

  

Number of

securities

underlying

unexercised

options

exercisable

(#)

    

Option

exercise

price

($)

  

Option

expiration

date

  

Number of

shares or

units

of stock that

have not

vested

(#)

    

Market value

of

shares of

units of

stock that

have not

vested

($)(1)

  
                                   

Michael W. DePasquale

     31,250       21.20  

3/16/2024

     36,375       21,461  
      4,167       15.68  

3/23/2025

                
      4,167       9.44  

3/21/2026

                
                                   

Mira K. LaCous

     12,500       21.20  

3/16/2024

     8,875       5,236  
      1,563       15.68  

3/23/2025

                
      1,563       9.44  

3/21/2026

                
                                   

James D. Sullivan

     12,500       21.20  

3/16/2024

     31,375       18,511  
      3,125       15.68  

3/23/2025

                
      3,125       9.44  

3/21/2026

                

 

 

(1)

Calculated based on the closing market price of the Company’s common stock on December 31, 2022 of $0.59 per share.

 

Narrative Disclosure to Outstanding Equity Awards at Fiscal Year End Table

 

The following are the material terms of each agreement, contract, plan or arrangement that provide for payments to one or more of our named executive officers at, following or pursuant to their resignation, retirement or termination, or in connection with a change in control of the Company.

 

Termination Arrangements

 

We may terminate our employment agreement with Mr. DePasquale at any time with or without cause. In the event of termination by us without cause, we will continue to pay Mr. DePasquale his then current base salary for the greater of nine months from the date of such termination or the number of months remaining until the end of the term of the agreement.

 

We may terminate our employment agreement with Mr. Sullivan at any time with or without cause. In the event of termination by us without cause, we will continue to pay Mr. Sullivan his then current base salary, plus earned commissions, for the greater of six months from the date of such termination or the number of months remaining until the end of the term of the agreement.

 

We may terminate our employment agreement with Ms. LaCous at any time with or without cause. In the event of termination by us without cause, we will continue to pay Ms. LaCous her then current base salary for nine months from the date of such termination.

 

Change in Control Provisions

 

Our 2015 Equity Incentive Plan (the “Plan”) provides for the acceleration of vesting of unvested options and termination of any restriction or forfeiture provisions applicable to restricted stock awards upon a “Change in Control” of the Company. A Change in Control is defined in the Plans to include (i) a sale or transfer of substantially all of the Company’s assets; (ii) the dissolution or liquidation of the Company; (iii) a merger or consolidation to which the Company is a party and after which the prior stockholders of the Company hold less than 50% of the combined voting power of the surviving corporation’s outstanding securities; (iv) the incumbent directors cease to constitute at least a majority of the Board of Directors; or (v) a change in control of the Company which would otherwise be reportable under Section 13 or 15(d) of the Exchange Act. In the event of a “Change In Control” the Plan provides for the immediate vesting of all options issued thereunder and termination of all forfeiture provisions applicable to restricted stock award issued thereunder. Options issued to executive officers outside of the Plans contain change in control provisions substantially similar to those contained in the Plans.

 

Our employment agreement with Mr. DePasquale contains a change in control provision that is triggered if Mr. DePasquale is not offered continued employment with us or any successor, or within five years following such Change of Control, we or any successor terminate Mr. DePasquale’s employment without cause. If this occurs, then we will pay Mr. DePasquale his base salary and benefits earned but unpaid through the date of termination, and any prorated bonus earned during the then current bonus year, plus two times his then current base salary.

 

31
 

 

DIRECTOR COMPENSATION

 

The following table sets forth for each director, information regarding their compensation for the year ended December 31, 2022:

 

Name (1)

  

Stock Awards

($) (2)

    

Total

($)

  

Thomas E. Bush, III (3)

    

14,007

      

14,007

  

Thomas Gilley (3)(4)

    

14,007

      

14,007

  

Pieter Knook (3)(5)

    

16,008

      

16,008

  

Robert J. Michel (3)

    

16,008

      

16,008

  

Emmanuel Alia (6)

    

16,008

      

16,008

  

 

 

(1)

Mr. DePasquale and Kelvin Wong have been omitted from the above table because they do not receive any additional compensation for serving on our Board of Directors.
 

(2)

The aggregate fair value of the common stock issued was calculated based on the closing price of our common stock on the date of issuance in accordance with FASB ASC 718.
 

(3)

At December 31, 2022, Messrs. Bush, Gilley, Knook and Michel each held options to purchase 2,064 shares of common stock and each held 5,000 shares restricted common stock.
 

(4)

Mr. Gilley resigned from the Board of Directors on February 9, 2023.
  (5) Mr. Knook resigned from the Board of Directors effective May 13, 2023.
  (6) At December 31, 2022, Mr. Alia held options to purchase 313 shares of common stock and held 5,000 shares restricted common stock.

 

Narrative Disclosure to Director Compensation Table

 

During 2022, we had a policy to pay each non-employee director $3,000 per board meeting, $1,000 per telephonic board meeting, and $1,000 per board committee meeting attended. Fees for attendance at regular quarterly board meetings held during the first three quarters of each fiscal year are paid through the issuance of common stock and payments for the last meeting of the year are paid in cash or, at the option of the director, in shares of common stock. All of our directors elected to receive payment in common stock for the last board meeting in 2022. All directors will be indemnified by us for actions associated with being a director to the fullest extent permitted under Delaware law. We reimburse each of our non-employee directors for their reasonable expenses incurred in connection with attending meetings of the board of directors and related committees. 

 

32
 

 

ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth, as of May 30, 2023 information with respect to the securities holdings of all persons that we, pursuant to filings with the SEC and our stock transfer records, have reason to believe may be deemed the beneficial owner of more than 5% of our common stock. The following table also sets forth, as of such date, the beneficial ownership of our common stock by all of our current executive officers and directors, both individually and as a group.

 

The beneficial owners and amount of securities beneficially owned have been determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as awarded, and, in accordance therewith, include all shares of our common stock that may be acquired by such beneficial owners within 60 days of May 30, 2023 upon the exercise or conversion of any options, warrants or other convertible securities. This table has been prepared based on 9,234,833 shares of common stock outstanding on May 30, 2023.

 

Name and Address of Beneficial Owner (1)

  

Amount and Nature

of Beneficial

Ownership

    

Percentage

of

Class

  
                 

Directors and Executive Officers

                
                 

Michael W. DePasquale

     128,227 (2)     1.4

%

Cecilia C. Welch

     69,375 (3)     *  

Mira K. LaCous

     40,001 (4)     *  

James D. Sullivan

     110,500 (5)     1.2

%

Robert J. Michel

     32,760 (6)     *  

Thomas E. Bush, III

     29,869 (7)     *  

Emmanuel Alia

     27,360 (8)     *  

Wong Kwok Fong (Kelvin)

     589,464 (9)     6.4

%

All officers and directors as a group (eight (8) persons)

     1,047,472       11.3

%
                 

Beneficial Owners

                
                 

Lind Global Micro Fund, LP

     833,125 (10)     9.0

%

AJB Capital Investments LLC

     900,000 (11)     9.7

%

 

 

*

Less than 1%
 

(1)

Unless otherwise indicated, the address of each person listed below is c/o BIO-key International, Inc., 3349 Highway 138, Building A, Suite E, Wall, NJ 07719.
 

(2)

Includes 39,584 shares issuable on exercise of options and 39,125 shares of restricted stock of which 24,709 remain subject to vesting.
 

(3)

Includes 22,500 of shares issuable upon exercise of options and 34,125 shares of restricted stock of which 21.375 remain subject to vesting.
 

(4)

Includes 15,626 of shares issuable upon exercise of options and 11,625 shares of restricted stock of which 6,375 remain subject to vesting.
 

(5)

Includes 18,750 of shares issuable on exercise of options and 34,125 shares of restricted stock of which 21,375 remain subject to vesting.
 

(6)

Includes 1,960 of shares issuable on exercise of options and 5,000 shares of restricted stock of which 3,334 remain subject to vesting. Does not include 104 shares issuable upon exercise of options subject to vesting.
 

(7)

Includes 1,960 of shares issuable on exercise of options and 5,000 shares of restricted stock of which 3,334 remain subject to vesting. Does not include 104 shares issuable upon exercise of options subject to vesting.
 

(8)

Includes 209 of shares issuable on exercise of options and 5,000 shares of restricted stock of which 3,334 remain subject to vesting. Does not include 104 shares issuable upon exercise of options subject to vesting.
 

(9)

Includes 27,084 of shares issuable on exercise of options and 9,125 shares of restricted stock of which 4,709 remain subject to vesting. The address of Kelvin is Flat C, 27/F, Block 5, Grand Pacific Views, Siu Lam, Hong Kong N7.
 

(10)

Consists of shares issuable upon exercise of warrants. The address of Lind Global Capital Micro Fund, LP is 444 Madison Ave, Floor 41, New York, NY 10022
 

(11)

Includes 200,000 shares issuable upon exercise of warrants.  The address of AJB Capital Investments LLC is 4700 Sheridan Street, Suite J, Hollywood, FL 33021.

 

33
 

 

EQUITY COMPENSATION PLAN INFORMATION

 

The following table sets forth, as of December 31, 2022, information with respect to securities authorized for issuance under equity compensation plans.

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan, which was amended on June 13, 2019 by vote of stockholders, and amended and restated by vote of stockholders on June 18, 2021 (as amended and restated, the “2015 Plan”). The 2015 Plan reserves 789,000 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. Options are issued at exercise prices which may not be below 100-110% of fair market value and have terms not to exceed ten years. Options issued under the 2015 Plan vest pursuant to the terms of stock option agreements with the recipients. In the event of a change in control, certain stock awards issued under this plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

In addition to options issued under the 2015 Plan, we have issued options to purchase common stock to employees, officers, directors and consultants outside of the plan. The terms of these outstanding options are substantially similar to the provisions of the 2015 Plan and options issued thereunder.  In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (“ESPP”). Under the terms of this plan, 789,000 shares of common stock are reserved for issuance and sale to employees and officers of the Company at a purchase price equal to 85% of the lower of the closing price of our common stock as reported on the Nasdaq Capital Market on the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares of common stock funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031.

 

Plan Category

  

Number of

securities to be

issued

upon exercise

of outstanding

options,

warrants and

rights

(a)

    

Weighted-

average

exercise price

of outstanding

options,

warrants and

rights

(b)

    

Number

of securities

remaining

available for

future issuance

under equity

compensation

plans

(excluding

securities

reflected in

column (a))

(c)

  

Equity compensation plans approved by security holders

    

90,808

(1)(2) 

    

10.79

      

989,032

(3) 

Equity compensation plans not approved by security holders

    

112,188

    

$

21.18

      

—

  

Total

    

202,996

(1)(2) 

  

$

16.53

      

989,032

(3) 

 

(1)

Consists of shares of common stock issuable upon the exercise of options outstanding as of December 31, 2022 under the 2015 Plan.

 

(2)

Excludes employee stock purchase rights accruing under the ESPP.

 

(3)

Amount includes 280,065 shares of common stock available as of December 31, 2022 for future issuance under the 2015 Plan and 708,967 shares of common stock available as of December 31, 2022 for future issuance under the ESPP.

 

34
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Standstill Agreement with Principal Stockholder

 

Pursuant to separate securities purchase agreements dated October 29, 2015 and November 11, 2015 with Wong Kwok Fong (Kelvin), we issued and sold shares of series A-1 stock to Kelvin which were subsequently converted into shares of our common stock. The forgoing agreements contain a standstill provision (the “Standstill”) which prohibits Kelvin either alone or together with any other person, from acquiring additional shares of our common stock or any of our assets, soliciting proxies, or seeking representation on our board of directors. Kelvin is the Co-Chairman of the board of directors and an executive officer.

 

Director Independence

 

As required under the NASDAQ Marketplace Rules, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Our board considered certain relationships between our directors and us when determining each director’s status as an “independent director” under Rule 5605(a)(2) of the NASDAQ Marketplace Rules. Based upon such definition and SEC regulations, we have determined that Robert Michel, Emmanuel Alia, and Thomas Bush, III, are “independent” under NASDAQ standards. 

 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The following table shows fees for professional services and quarterly audit fees billed to us by Marcum LLC for the audit of our annual consolidated financial statements for the year ended December 31, 2022, and reviews of our second and third quarters 2022 and Rotenberg Meril Solomon Bertiger & Guttilla, P.C. (“RMSBG”), prior to RMSBG’s merger with Marcum, for the audit of our annual consolidated financial statements for the year ended December 31, 2021 and for the first quarter 2022:

 

   

2022

    

2021

  
                 

Audit Fees

   $ 133,000     $ 123,900  

Audit-Related Fees

     27,913       9,795  

Tax Fees

     17,000       17,000  
                 

Total Fees

   $ 177,913     $ 150,695  

 

Audit Fees consist of fees billed for professional services rendered for the audit of our financial statements and review of the interim financial statements included in quarterly reports and services that are normally provided by our auditors in connection with statutory and regulatory filings or engagements.

 

Audit-Related Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and which are not reported under audit fees. These fees relate primarily to services provided in connection with registration of securities and review of documents filed with the SEC.

 

Tax Fees consist of fees billed for professional services for tax compliance assistance rendered during the fiscal year.

 

35
 

 

Audit Committee Pre-Approval Procedures

 

The audit committee approves the engagement of our independent auditors to render audit and non-audit services before they are engaged. All of the fees for 2022 and 2021 shown above were pre-approved by the audit committee.

 

The audit committee pre-approves all audit and other permitted non-audit services provided by our independent auditors. Pre-approval is generally provided for up to one year, is detailed as to the particular category of services and is subject to a monetary limit. Our independent auditors and senior management periodically report to the audit committee the extent of services provided by the independent auditors in accordance with the pre-approval, and the fees for the services performed to date. The audit committee may also pre-approve particular services on a case-by-case basis.

 

Our audit committee will not approve engagements of our independent registered public accounting firm to perform non-audit services for us if doing so will cause our independent registered public accounting firm to cease to be independent within the meaning of applicable SEC rules. In addition, our audit committee considers, among other things, whether our independent registered public accounting firm is able to provide the required services in a more or less effective and efficient manner than other available service providers.

 

PART IV

 

ITEM 15. – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)       The following documents are filed as part of this Report. Portions of Item 15 are submitted as separate sections of this Report:

 

   

(1)  Financial statements filed as part of this Report:
   

 
   

Report of Independent Registered Public Accounting Firm (Marcum LLP, Saddle Brook, NJ, PCAOB ID:688

 

Report of Independent Registered Public Accounting Firm (Rotenberg Meril Solomon Bertiger & Guttilla, P.C., Saddle Brook, NJ, PCAOB ID:361)
   

 
   

Consolidated Balance Sheets as of December 31, 2022 and 2021
   

 
   

Consolidated Statements of Operations—Years ended December 31, 2022 and 2021
   

 
   

Consolidated Statements of Stockholders’ Equity—Years ended December 31, 2022 and 2021
   

 
   

Consolidated Statements of Cash Flows—Years ended December 31, 2022 and 2021
   

 
   

Notes to Consolidated Financial Statements—December 31, 2022 and 2021

 

(b)       The exhibits listed in the Exhibits Index immediately preceding such exhibits are filed as part of this Report

 

36
 

 

 

ITEM 16. – FORM 10-K SUMMARY

 

None.

 

FINANCIAL STATEMENTS

 

The following financial statements of BIO-key International, Inc. are included herein at the indicated page numbers:
 

Report of Independent Registered Public Accounting Firm (Marcum LLC., Saddle Brook, NJ, PCAOB ID:688)

38
Report of Independent Registered Public Accounting Firm (Rotenberg Meril Solomon Bertiger & Guttilla, P.C., Saddle Brook, NJ, PCAOB ID:361) 39

Consolidated Balance Sheets as of December 31, 2022 and 2021

40
Consolidated Statements of Operations and Comprehensive Loss—Years ended December 31, 2022 and 2021

41

Consolidated Statements of Stockholders’ Equity —Years ended December 31, 2022 and 2021

42

Consolidated Statements of Cash Flows—Years ended December 31, 2022 and 2021

43
Supplementary Disclosures of Cash Flow Information—Years ended December 31, 2022 and 2021

44

Notes to the Consolidated Financial Statements—December 31, 2022 and 2021

45

 

37
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors of

BIO-key International, Inc. Wall, NJ

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of BIO-key International, Inc. and Subsidiaries (the “Company”) as of December 31, 2022, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

 

Revision to Correct Previously Issued Financial Statements

As discussed in Note S to the financial statements, the 2021 financial statements have been revised to correct certain previously issued disclosures related to the reconciliation of the Company’s income tax rate for the year ended December 31, 2021 and the components of the Company’s deferred tax assets and liabilities and valuation allowance as of December 31, 2021 and 2020. The financial statements of the Company for the year ended December 31, 2021, before the effects of the adjustments to correct the errors discussed in Note S to the financial statements, were audited by other auditors whose report, dated March 31, 2022, expressed an unqualified opinion on those statements. We have also audited the adjustments described in Note S that were applied to revise the 2021 financial statements to correct the errors. In our opinion, such adjustments are appropriate and have been properly applied. Except for the corrections to revise the tax footnote we were not engaged to audit, review, or apply any procedures to the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year then ended, other than stated above and, accordingly, we do not express an opinion or any other form of assurance on the 2021 financial statements taken as a whole.

 

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As disclosed in Note A of the financial statements, the Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations, all of which raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans regarding these matters are disclosed in Note A. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. We determined that there are no critical audit matters.

 

/s/ Marcum LLP

 

Marcum LLP

 

We have served as the Company’s auditor since 2010 (such date takes into account the acquisition of Rotenberg Meril Solomon Bertiger & Guttilla, P.C., by Marcum LLP effective February 1, 2022).

Saddle Brook, New Jersey

June 1, 2023

 

38
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors of
BIO-key International, Inc.
Wall, NJ

 

Opinion on the Financial Statements

We have audited, before the effects of the adjustment for the correction of the errors described in Note S, the accompanying consolidated balance sheets of BIO-key International, Inc. and Subsidiaries (the “Company”) as of December 31, 2021, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

We were not engaged to audit, review, or apply any procedures to the adjustments for the correction of the errors described in Note S, and accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by Marcum LLP.

 

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

 

ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

 

We have served as the Company's auditors from 2010 to 2022.

 

Saddle Brook, New Jersey
March 31, 2022 

 

39
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS

 

   

December 31,

  
   

2022

    

2021

  
ASSETS                

Cash and cash equivalents

   $ 2,635,522     $ 7,754,046  

Accounts receivable, net

     1,522,784       970,626  

Due from factor

     49,500       49,500  

Note receivable, net of allowance

     -       82,000  
Inventory, net of reserve     4,434,369       4,940,660  

Prepaid expenses and other

     342,706       216,041  

Total current assets

     8,984,881       14,012,873  

Resalable software license rights

     -       48,752  

Investment – debt security, net

     -       452,821  

Equipment and leasehold improvements, net

     107,413       69,168  

Capitalized contract costs, net

     283,069       249,012  

Deposits and other assets

     8,712       8,712  

Note receivable, net of allowance

     -       113,000  

Operating lease right-of-use assets

     197,355       254,100  

Intangible assets, net

     1,762,825       1,298,077  

Goodwill

     -       1,262,526  

Total non-current assets

     2,359,374       3,756,168  

TOTAL ASSETS

   $ 11,344,255     $ 17,769,041  
                 
LIABILITIES                

Accounts payable

   $ 1,108,279     $ 427,772  

Accrued liabilities

     1,009,123       828,997  

Convertible note payable

     2,596,203       -  

Government loan – BBVA Bank, current portion

     120,000       -  

Deferred revenue - current

     462,418       565,355  

Operating lease liabilities, current portion

     159,665       177,188  

Total current liabilities

     5,455,688       1,999,312  

Deferred revenue, net of current portion

     52,134       67,300  
Deferred tax liability     170,281       -  

Government loan – BBVA Bank, net of current portion

     326,767       -  

Operating lease liabilities, net of current portion

     37,829       86,974  

Total non-current liabilities

     587,011       154,274  

TOTAL LIABILITIES

     6,042,699       2,153,586  
                 
Commitments (Note O)            
                 
STOCKHOLDERS’ EQUITY                

Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,190,504 and 7,853,759 of $.0001 par value at December 31, 2022 and December 31, 2021, respectively

     919       786  

Additional paid-in capital

     122,028,612       120,190,139  

Accumulated other comprehensive loss

     (242,602

)

     -  

Accumulated deficit

     (116,485,373 )     (104,575,470

)

TOTAL STOCKHOLDERS’ EQUITY

    5,301,556       15,615,455  

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

   $ 11,344,255     $ 17,769,041  

 

The accompanying notes are an integral part of these statements.

 

40
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 
Revenues                

Services

   $ 1,789,720     $ 1,273,354  

License fees

     4,584,052       2,555,809  

Hardware

     646,486       1,285,326  

Total revenues

     7,020,258       5,114,489  
                 
Costs and other expenses                

Cost of services

     722,152       686,175  

Cost of license fees

     906,417       183,199  

Cost of hardware

     811,001       803,555  

Total costs and other expenses

     2,439,570       1,672,929  

Gross Profit

     4,580,688       3,441,560  
                 
Operating expenses                

Selling, general and administrative

     9,364,887       6,028,360  

Research, development and engineering

     3,252,236       2,355,056  
Reversal of earnout payable – Swivel acquisition     (500,000 )     -  

Impairment of goodwill

     2,387,193       -  

Total operating expenses

     14,504,316       8,383,416  

Operating loss

    (9,923,628

)

     (4,941,856

)
                 
Other income (expense)                

Interest income

     233       4,075  

Loss on foreign currency transactions

     -       (50,000

)

Investment-debt security reserve

     (452,821 )     (60,000

)
Loan transaction costs     (1,147,456 )     -  
Change in fair value of convertible note     (396,203 )     -  

Interest expense

     (10,462 )     (18,000 )

Total other income (expense)

     (2,006,709 )     (123,925

)
                 
Loss before provision for income tax benefit     (11,930,337 )     -  
                 
Provision for income tax benefit     20,434       -  
                 

Net loss

   $ (11,909,903 )     (5,065,781

)
                 
Comprehensive loss:                

Net loss

   $ (11,909,903 )   $ (5,065,781

)

Other comprehensive loss- Foreign translation adjustment

     (242,602 )     -  
Comprehensive loss   $ (12,152,505

)

   $ (5,065,781

)
                 

Basic and Diluted Loss per Common Share

   $ (1.47

)

   $ (0.65

)
                 
Weighted Average Shares Outstanding:                

Basic and Diluted

     8,100,785       7,791,741  

 

The accompanying notes are an integral part of these statements.

 

41
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

   

Common Stock

    

Additional

Paid-in

     Accumulated
Other
Comprehensive 		    Accumulated          
   

Shares

    

Amount

    

Capital

     Income (Loss)    

Deficit

     Total  

Balance as of December 31, 2020

     7,814,572     $ 782     $ 119,844,026     $ -     $ (99,509,689

)

   $ 20,335,119  

Issuance of common stock for directors’ fees

     7,828       1       25,535       -       -       25,536  

Issuance of restricted common stock to employees

     13,125       1       (1 )     -       -       -  

Forfeiture of restricted stock

     (1,250 )     -       -       -       -       -  

Legal fees

     -       -       (5,228 )     -       -       (5,228

)

Issuance of common stock for Employee stock purchase plan

     19,484       2       36,628       -       -       36,630  

Share based compensation for employee stock purchase plan

     -       -       10,680       -       -       10,680  

Share-based compensation

     -       -       278,499       -       -       278,499  

Net loss

     -       -       -       -       (5,065,781 )     (5,065,781

)

Balance as of December 31, 2021

     7,853,759     $ 786     $ 120,190,139     $ -     $ (104,575,470

)

   $ 15,615,455  

Issuance of common stock for directors’ fees

     39,636       4       76,039       -       -       76,043  

Issuance of restricted common stock to employees

     278,000       27       (27 )     -       -       -  

Forfeiture of restricted stock

     (10,500 )     (1 )     -       -       -       (1

)

Issuance of common stock pursuant to Swivel purchase agreement

     269,060       27       599,977       -       -       600,004  

Issuance of common stock for note issuance fees

     700,000       70       699,930       -       -       700,000  

Issuance of warrant in conjunction with note payable

     -       -       94,316       -               94,316  

Issuance of common stock for employee stock purchase plan

     60,549       6       56,374       -       -       56,380  

Share based compensation for employee stock purchase plan

     -       -       18,787       -       -       18,787  

Foreign currency translation adjustment

     -       -               (242,602 )     -       (242,602

)
Share-based compensation     -       -       293,077       -       -       293,077  

Net loss

     -       -       -       -       (11,909,903

)

     (11,909,903

)

Balance as of December 31, 2022

     9,190,504     $ 919     $ 122,028,612     $ (242,602 )   $ (116,485,373

)

   $ 5,301,556  

 

The accompanying notes are an integral part of these statements.

 

42
 

 

 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 
CASH FLOW FROM OPERATING ACTIVITIES:                

Net loss

   $ (11,909,903

)

   $ (5,065,781

)
Adjustments to reconcile net loss to cash used for operating activities:                

Depreciation

     43,794       54,649  
Impairment of goodwill     2,387,193       -  
Reversal of earnout payable – Swivel acquisition     (500,000 )     -  

Amortization of intangible assets and write-off

     298,113       216,069  

Amortization of resalable software license rights

     48,752       10,130  
Loan transaction costs     1,147,456       -  

Loss on foreign currency

     -       50,000  

Reserve for investment security

     452,821       60,000  
Reserve for inventory     400,000       -  

Reserve for note receivable

     186,000       100,000  

Allowance for doubtful account

     360,000       200,000  

Amortization of debt discount

     -       18,000  

Amortization of capitalized contract costs

     106,624       110,681  

Share based and warrant compensation for employees and consultants

     311,864       289,179  

Stock based fees to directors

     76,043       25,536  
Bad debt expense     130,111       -  
Change in fair value of convertible note     396,203       -  
Deferred income tax benefit     (20,434 )     -  

Amortization of operating lease right-of-use assets

     155,353       233,225  
Change in operating assets and liabilities:                

Accounts receivable

     (339,383

)

     (672,577

)

Due from factor

     -       10,953  

Capitalized contract costs

     (140,681

)

     (194,378

)

Inventory

     106,291       (4,609,713

)

Prepaid expenses and other

     (46,655

)

     (14,534

)

Accounts payable

     239,144       183,614  

Accrued liabilities

     167,614       320,510  

Deferred revenue

     (120,078

)

     (69,681

)

Operating lease liabilities

     (165,276

)

     (234,310

)

Net cash used for operating activities

     (6,229,034

)

     (8,978,428

)
CASH FLOWS FROM INVESTING ACTIVITIES:                

Purchase of Swivel Secure, net of cash acquired of $729,905

     (623,578 )     -  
Receipt of cash from note receivable     9,000       -  
Capital expenditures     (82,040 )     (42,024 )

Net cash used for investing activities

     (696,618

)

     (42,024

)
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from issuance of convertible notes     2,002,000       -  
Costs incurred for issuance of convertible note     (155,140 )     -  

Proceeds from Employee Stock Purchase Plan

     56,380       36,630  

Repayment of note payable - PistolStar

     -       (250,000

)

Legal fees

     -       (5,228

)

Net cash (used in) provided by financing activities

     1,903,240       (218,598

)
Effect of exchange rate changes     (96,112 )     -  

NET DECREASE IN CASH AND CASH EQUIVALENTS

     (5,118,524

)

     (9,239,050

)

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

     7,754,046       16,993,096  

CASH AND CASH EQUIVALENTS, END OF YEAR

   $ 2,635,522     $ 7,754,046  

 

The accompanying notes are an integral part of these statements.

 

43
 

 

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 
Cash paid during the year for:                
Taxes   $ 25,682     $ -  

Interest

   $ 10,462     $ -  
                 
Noncash investing and financing activities:                
                 

Accounts receivable acquired from Swivel Secure

   $ 702,886     $ -  

Equipment acquired from Swivel Secure

   $ 65,640     $ -  

Other assets acquired from Swivel Secure

   $ 20,708     $ -  

Intangible assets acquired from Swivel Secure

   $ 762,860     $ -  

Goodwill resulting from the acquisition from Swivel Secure

   $ 1,258,087     $ -  

Accounts payable and accrued expenses acquired from Swivel Secure

   $ 431,884     $ -  

Government loan acquired from Swivel Secure

   $ 544,000     $ -  
Deferred tax liability from the acquisition of Swivel Secure   $ 190,715     $ -  

Common stock issued for acquisition of Swivel Secure

   $ 600,004     $ -  
Common stock issued for acquisition of note payable   $ 700,000     $ -  
Issuance of warrant for acquisition of note payable   $ 94,316     $ -  
Operating lease right-of-use asset and liability for new lease   $ 105,893     $ -  

 

The accompanying notes are an integral part of these statements.

 

44
 

 

BIO-key International, Inc. and Subsidiaries

NOTES TO THE FINANCIAL STATEMENTS

December 31, 2022 and 2021

 

 

 

NOTE A —THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

 

Going Concern and Basis of Presentation

 

The Company has historically financed our operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered our expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and therefore is looking into other markets and opportunities to sell or return the product to generate additional cash.

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

Foreign Currency

 

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.

 

The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss.

 

 

Summary of Significant Accounting Policies

 

A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:

 

1. Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation.

 

45
 

 

2. Use of Estimates

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to accounts receivable, inventory, intangible assets and goodwill, fair value of convertible note payable, and income taxes.

 

3. Revenue Recognition

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:

 

 

●

Identify the contract with a customer

 

 

●

Identify the performance obligations in the contract

 

 

●

Determine the transaction price

 

 

●

Allocate the transaction price to performance obligations in the contract

 

 

●

Recognize revenue when or as the Company satisfies a performance obligation

 

All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consists of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the term of the contract begins. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

46
 

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

Deferred Revenue

Deferred revenue includes customer advances and amounts that have been paid by customers for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2022 and 2021, amounts in deferred revenue were approximately $515,000 and $633,000, respectively.

 

4. Business Combinations

 

In accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

 

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

 

5. Goodwill and acquired intangible assets

 

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31st of each year. Refer Note K for more information regarding the impairment of goodwill in 2022.

 

Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

 

6. Cash Equivalents

 

Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2022 and 2021, cash equivalents consisted of a money market account.

 

47
 

 

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2022 and 2021 consisted of the following:

 

   

December 31,

  
   

2022

    

2021

  
                 

Accounts receivable

   $ 2,096,569     $ 1,234,411  
Loss on foreign currency     -       (50,000

)

Allowance for doubtful accounts

     (573,785

)

     (213,785

)

Accounts receivable, net of allowances for doubtful accounts

   $ 1,522,784     $ 970,626  

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense.

 

The allowance for doubtful accounts for the years ended December 31, 2022 and 2021 is as follows:

 

   

Balance at

Beginning of Year

    

Charged to Costs and Expenses

    

Deductions from Reserves

    

Balance at End of Year

  
                                 

Year ended December 31, 2022 Allowance for Doubtful Accounts

   $ 213,785     $ 360,000     $ -     $ 573,785  

Year ended December 31, 2021 Allowance for Doubtful Accounts

   $ 1,733,785     $ 200,000     $ (1,720,000 )   $ 213,785  

 

8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and Amortization

 

Equipment and leasehold improvements are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.

 

The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:

 

 

Years

  

Equipment and leasehold improvements

          

Equipment

   3

-

 5  

Furniture and fixtures

   3

-

 5  

Software

     3    

Leasehold improvements

 

life or lease term

  

 

Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships. Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.

 

9. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. There were no impairments in 2022 and 2021.

 

10. Advertising Expense

 

The Company expenses the costs of advertising as incurred. Advertising expenses for 2022 and 2021 were approximately $842,000 and $527,000, respectively.

 

11. Research and Development Expenditures

 

Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred.

 

48
 

 

12. Earnings Per Share of Common Stock (“EPS”)

 

The Company’s EPS is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.

 

13. Accounting for Stock-Based Compensation

 

The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over a three year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of certain assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.

 

The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:

 

   

Year ended

December 31,

  
   

2022

    

2021

  
                 

Selling, general and administrative

   $ 310,017     $ 269,368  

Research, development and engineering

     77,890       45,347  
    $ 387,907     $ 314,715  

 

49
 

 

14. Income Taxes

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.

 

The Company accounts for uncertain tax provisions in accordance with ASC 740. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

15. Leases

 

In accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases.

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.

 

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

 

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

 

16. The Fair Value Measurement Option

 

The Company has elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the convertible promissory note was recorded at fair value upon issuance and will subsequently be remeasured at each reporting date until settled or converted. The Company recognized the note initially at fair value, which exceeded the proceeds received resulting in a day one loss that has been recognized in net loss. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations.

 

17. Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

 

The following table summarizes our financial instruments measured at fair value at December 31, 2022:

 

    Total     Level 1     Level 2     Level 3  
                                 
Convertible note at fair value   $ 2,596,203     $ -     $ -     $ 2,596,203  

 

The Company issued a convertible note to which included an original issue discount, conversion features and a detachable warrant, as further discussed in Note M. The detachable warrant represents a freestanding, separable equity-linked financial instrument recorded at fair value. The fair value of the detachable warrant was calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt which was determined based on significant unobservable inputs including the likelihood of default, the estimated date at which the default could take place, and the present value discount rate, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The fair value option requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as change in fair value of convertible note in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible note were expensed and not deferred.

 

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at December 22, 2022:

1. Face amount - $2,200,000

2. Nominal interest rate – 10% - 12%

3. Default interest rate – 18%

4. Increase in principal upon a default – 30%

5. Present value discount rate – 15.18%

6. Likelihood of default – estimated to be 50% at the extended maturity date

 

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the year ended December 31, 2022:

 

Beginning balance   $ -  
Purchases and issuances     2,200,000  
Day one loss on value of hybrid instrument     396,203  
Ending balance   $ 2,596,203  

 

18. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016- 13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct writedown of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for the Company for annual periods, including interim periods within those annual periods, beginning on January 1, 2023. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 

 

NOTE B—REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Disaggregation of Revenue

 

The following table summarizes revenue from contracts with customers for the years ended December 31, 2022 and 2021:

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2022

  
                                         

License fees

   $ 1,856,814     $ 517,161     $ 2,124,088     $ 85,989     $ 4,584,052  

Hardware

     422,275       25,833       19,914       178,464       646,486  

Services

     1,270,067       83,306       436,293       54       1,789,720  

Total Revenues

   $ 3,549,156     $ 626,300     $ 2,580,295     $ 264,507     $ 7,020,258  

 

50
 

 
   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  

 

* EMESA – Europe, Middle East, South America

 

Revenue recognized during the year ended December 31, 2022 from amounts included in deferred revenue at the beginning of the year was approximately $489,000. Revenue recognized during the year ended December 31, 2021 from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Total deferred revenue (contract liability) was approximately $515,000 and $633,000 at December 31, 2022 and 2021, respectively.

 

Transaction Price Allocated to the Remaining Performance Obligations

 

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

 

 

●

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

 

Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from one to five years.

 

 

 

NOTE C—SWIVEL SECURE EUROPE, SA ACQUISITION

 

On March 8, 2022, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure based in Madrid, Spain, pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of $500,000. The earn-out was payable based on Swivel Secure generating $3,000,000 of revenue and $1,000,000 of operating profit during an earn-out period commencing on the closing date and ending on January 31, 2023, which was not attained. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement. The shares of Company common stock were priced at $2.23, the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market.

 

The business combination has been accounted for as an acquisition and, in accordance with ASC 805. The Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the purchase price allocation, with no earnout payment:

 

Purchase consideration:        

Total cash paid, including working capital adjustment

   $ 1,273,483  
Earnout payable     500,000  

Common stock issued

     600,004  

Total purchase price consideration

   $ 2,373,487  
         
Fair value of assets acquired and liabilities assumed:        

Cash and cash equivalents

   $ 729,905  

Accounts receivable

     702,886  

Equipment acquired

     65,640  

Other assets

     20,708  

Intangible assets

     762,860  

Goodwill

     1,258,087  

Total estimated assets acquired

     3,540,086  
         

Accounts payable and accrued expenses

     431,884  

Government loan

     544,000  
Deferred tax liability     190,715  

Total liabilities assumed

     1,166,599  

Total estimated fair value of assets acquired and liabilities assumed

   $ 2,373,487  

 

51
 

 

The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce. Refer to Note K for more information regarding the impairment of goodwill.

 

The significant intangible asset identified in the purchase price allocation discussed above was Customer Relationships. To value the Customer Relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value.

 

The government loan was issued through BBVA Bank during the COVID-19 pandemic. The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through April 2026. The installment payments have been paid monthly as per the schedule, as of the date of this report.

 

The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:

 

   

Amount

    

Estimated useful

life

(in years)

  

Customer relationships

   $ 762,860       7  

Total identifiable intangible assets

   $ 762,860          

 

As discussed above, the earnout payable was not achieved. As such, the Company reversed the earnout payable of $500,000 and recognized the income on the reversal of the earnout payable.

 

For the period from March 8, 2022 to December 31, 2022, revenue from Swivel Secure amounted to $2,351,975 and net loss amounted to $720,691.

 
 

NOTE D—FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.

 

52
 

 
 

NOTE E—CONCENTRATION OF RISK

 

Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.

 

The Company maintains its cash and cash equivalents with various financial institutions, which, at times may exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $2,000,000 and $7,057,000 at December 31, 2022 and 2021, respectively. The Company has not incurred any losses on these accounts.

 

The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.

 

For the year ended December 31, 2022 no customer accounted for 10% of total revenue. For the year ended December 2021, one customer accounted for 13% of total revenue.

 

At December 31, 2022, one customer accounted for 35% of the total accounts receivable. At December 31, 2021, three customers accounted for 87% of total accounts receivable.

 

 

 

 

NOTE F—NOTE RECEIVABLE

 

During the third quarter of 2020, the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note did not bear any interest if paid within the nine (9) monthly installments beginning December 31, 2020. The note bore a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $186,000 of the note as an allowance. On February 17, 2022, the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on or before December 6, 2023. On May 5, 2022, the Company amended the note to modify the payment terms to eight biweekly installments of $1,000 beginning February 25, 2022, nineteen consecutive monthly installments of $15,000 beginning on July 6, 2022, and $2,000 on or before February 6, 2024. Currently, the payments are several months behind schedule. Due to the delay in payments, the Company has increased the allowance for the remainder of the balance owed under the note. We are continuing to pursue payment and expect that we will start to receive funds in the second quarter of 2023. A member of our board of directors served as Chief Executive Officer of TTI until August 12, 2020.

 

   

December 31,

    

December 31,

  
   

2022

    

2021

  
                 

Note receivable

   $ 195,000     $ 295,000  

Repayment of note

     (9,000 )     -  

Allowance for doubtful account

     (186,000 )     (100,000

)

Note receivable, net of allowance

     -       195,000  
Current portion, net of allowance   $ -     $ 82,000  
Noncurrent portion, net of allowance   $ -     $ 113,000  

 

 

 

NOTE G—INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product.

 

Inventory is comprised of the following as of December 31:

 

   

2022

    

2021

  
                 

Finished goods

   $ 4,764,643     $ 4,798,203  

Fabricated assemblies

     69,726       142,457  
Reserve on finished goods     (400,000 )     -  

Total inventory

   $ 4,434,369     $ 4,940,660  

 

53
 

 
 

NOTE H—RESALABLE SOFTWARE LICENSES RIGHTS

 

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company was amortizing the total cost at the greater of the actual unit cost per license sold or straight-line amortization over 10 years. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $141,190 has been charged to cost of sales. Since we have not received any sales for the license within the last two years, we accelerated the amortization for the balance of the license in 2022, leaving a carrying balance of $0 and $48,752 as of December 31, 2022 and 2021, respectively. A total of $48,752 and $10,130 was charged to cost of sales during the years ended December 31, 2022 and 2021, respectively.

 

 

 

NOTE I—INVESTMENT IN DEBT SECURITY

 

The Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in September 2020 bearing interest at 5% per annum. The Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date.  The investment was originally recorded at amortized cost and was scheduled to mature in June 2021. The Company never received the proceeds and accrued interest from the investment and as such, wrote off the investment during 2022 as the bond issuer defaulted on repayment, and the Company had no recourse.

 

 

 

NOTE J—EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Equipment and leasehold improvements consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Equipment

   $ 825,058     $ 831,784  

Furniture and fixtures

     225,978       164,079  

Software

     49,143       32,045  

Leasehold improvements

     34,903       25,135  
      1,135,082       1,053,043  
                 
                 

Less accumulated depreciation and amortization

     (1,027,669

)

     (983,875

)
                 

Total

   $ 107,413     $ 69,168  

 

Depreciation was $43,794 and $54,649 for 2022 and 2021, respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.

 

 

NOTE K—INTANGIBLE ASSETS AND GOODWILL

 

Intangible assets consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Trade name

   $ 130,000     $ 130,000  

Proprietary software

     420,000       420,000  

Customer relationships

     1,692,860       930,000  

Patents and patents pending

     365,080       365,080  
      2,607,940       1,845,080  
                 
                 

Less accumulated amortization

     (845,115

)

     (547,003 )
                 

Total

   $ 1,762,825     $ 1,298,077  

 

54
 

 

Aggregate amortization expense for 2022 and 2021 was approximately $298,000 and $216,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next five years and thereafter approximates the following:

 

Years ending December 31

        

2023

   $ 320,000  

2024

     320,000  

2025

     280,000  

2026

     230,000  

2027

     220,000  

Thereafter

     392,825  

Total

   $ 1,762,825  

 

Goodwill

 

The Company conducted its annual impairment analysis of its goodwill balances as at December 31, 2022. The Company noted the noted the cyclical downturn in technology stock values over the 2022 period, since our previous annual impairment assessment.

 

The analysis showed the carrying value of the Company’s reporting segment was in excess of the Company’s market valuation as at December 31, 2022 based on a fair valuation measure as the quoted market price for the Company’s publicly traded stock as of that date.

 

Accordingly, the Company concluded the amounts in goodwill had been fully impaired and accordingly wrote-off the entire balance in full as at December 31, 2022.

 

 

 

NOTE L—ACCRUED LIABILITIES

 

Accrued liabilities consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Compensation

   $ 377,958     $ 254,433  

Compensated absences

     378,874       293,297  

Accrued legal and accounting fees

     110,008       95,738  
Franchise taxes     7,000       40,000  
Employee expenses reimbursement     114,209       76,000  

Sales tax payable

     17,594       18,548  

Other

     3,480       50,981  
                 

Total

   $ 1,009,123     $ 828,997  

 

 

 

NOTE M—CONVERTIBLE NOTE PAYABLE

 

Securities Purchase Agreement dated December 22, 2022

 

On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) which issued a $2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $2,002,000 was funded, with the proceeds to be used for general working capital.

 

55
 

 

The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension by the Company. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

 

In connection with the issuance of the Note, the Company issued to the investor 700,000 shares of Common Stock (the “Commitment Shares”) valued at $1.00 per share and a warrant (the “Warrant”) to purchase 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $3.00 per share, exercisable commencing on the date of issuance with a term of five years. The warrant was valued at $94,316 (see Note P. #3). In the event the Note is paid in full within six months after the date of issuance, the Company will exercise its right to repurchase 350,000 of the Commitment Shares for aggregate payment to the Investor of $1.00.

 

Upon issuance, the Note is not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.

 

The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at 1,684,576 which is 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).

 

During April 2023, we were in default under the Note due to our failure to timely file this annual report and timely file a registration statement covering the public resale of the shares issued to the holder of the Note in connection with the financing. We have obtained a waiver and, therefore, as of the date of this report we are not in default.

 

As of December 31, 2022, the Note with principal balance of $2,200,000, at fair value, was recorded at $2,596,203.

 

56
 

 
 

NOTE N—LEASES

 

The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
Lease cost                

Operating lease cost

   $ 254,649     $ 255,892  

Total lease cost

   $ 254,649     $ 255,892  
                 
Balance sheet information          

Operating right-of-use assets

   $ 197,355     $ 254,100  
                 

Operating lease liabilities, current portion

   $ 159,665     $ 177,188  

Operating lease liabilities, non-current portion

     37,829       86,974  

Total operating lease liabilities

   $ 197,494     $ 264,162  
                 

Weighted average remaining lease term (in years) – operating leases

     0.96       1.45  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 259,558     $ 256,977  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2022:                
                 

2023

   $ 164,596          

2024

     38,808          

Total future lease payments

   $ 203,404          

Less: imputed interest

     (5,910

)

        

Total

   $ 197,494          

 

 

57
 

 

 

NOTE O—COMMITMENTS AND CONTINGENCIES

 

Distribution Agreement

 

Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:

 

 

1.

The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.

 

 

2.

SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.

 

 

3.

Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.

 

The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.

 

 

Litigation

 

From time to time, the Company may be involved in litigation relating to claims arising out of its operations in the normal course of business. As of December 31, 2022, the Company was not a party to any pending lawsuits.

 

 

NOTE P— EQUITY

 

1. Preferred Stock

 

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.

 

2. Common Stock

 

Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.

 

Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (“ESPP”). Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031.

 

Issuances of Common Stock

 

On December 22, 2022, the Company issued the Commitment Shares. See Note M - Convertible Note Payable for more information.

 

On March 8, 2022, the Company issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $600,004, priced at $2.23, based on the contractual 20-day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. During 2022 and 2021, 60,549, and 19,484 shares respectively were issued under the ESPP to employees, which resulted in a $18,787, and $10,680 non-cash compensation expense respectively for the Company.

 

58
 

 

Issuances of Restricted Stock

 

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

 

The Company issued 278,000 shares of restricted common stock to certain employees of the Company and 10,500 of shares of restricted common stock were forfeited during fiscal year 2022. The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year 2021. These shares vest in equal annual installments over a three-year period from the date of grant.

 

Restricted stock compensation for the years ended December 31, 2022 and 2021 was $218,552 and $71,819, respectively.

 

Issuances to Directors, Executive Officers & Consultants

 

During the 2022 and 2021 years, the Company issued 39,636 and 7,828 shares of common stock respectively to its directors in lieu of payment of board fees, valued at $76,043 and $25,536 respectively.

 

3. Warrants

 

There were no warrants issued during 2021.

 

Warrants Issued with Convertible Note:

 

See Note M - Convertible Note Payable for the warrant issued with a convertible note in 2022.

 

Valuation Assumptions for Warrants:

 

The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of the warrant issued in 2022 was estimated with the following assumptions:

 

   

Years ended

December 31,

  
   

2022

    

2021

  

Weighted average risk-free interest rate

     3.70

%

     -

%

Weighted average exercise price

   $ 3.00     $ -  

Weighted average exercise period

     5       -  

Weighted average Volatility of stock price

     108.60

%

     -

%

 

The volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.

 

A summary of warrant activity is as follows:

 

   

Total

Warrants

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life

(in years)

    

Aggregate

intrinsic

value

  
                                 

Outstanding, as of December 31, 2020

     4,689,387     $ 6.04       4.48       —  

Granted

     —       —                  

Exercised

     —       —                  

Forfeited

     —       —                  

Expired

     —       —                  

Outstanding, as of December 31, 2021

     4,689,387       6.04       3.48       —  

Granted

     200,000       3.00                  

Exercised

     —      

—

                  

Forfeited

     —       —                  

Expired

     (17,362 )    

28.80

                  

Outstanding, as of December 31, 2022

     4,872,025     $ 5.83       2.59       —  

 

59
 

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were no in-the-money warrants exercisable as of December 31, 2022, 2021 and 2020.

 

 

 

NOTE Q—STOCK OPTIONS

 

2015 Stock Option Plan

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. The term of stock options granted under the 2015 Plan, may not exceed ten years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

Non-Plan Stock Options

 

Periodically, the Company has granted options outside of the 2015 Plan to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

Stock Option Activity

 

Information summarizing option activity is as follows:

 

   

Number of Options

    

Weighted

average

    

Weighted

average

remaining

    

Aggregate

  
   

2015

Plan

    

Non

Plan

    

Total

    

exercise

price

    

life

(in years)

    

intrinsic

value

  
                                                 

Outstanding, as of December 31, 2020

     94,183       133,091       227,274     $ 17.61       3.87     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     (3,291 )    

—

       (3,291 )    

3.87

                  

Expired

     (84

)

     (11,438

)

     (11,522

)

     39.13                  

Outstanding, as of December 31, 2021

     90,808       121,653       212,461     $ 16.65       3.03     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     —       —      

—

       —                  

Expired

     —       (9,465

)

     (9,465

)

     17.28                  

Outstanding, as of December 31, 2022

     90,808       112,188       202,996     $ 16.63       2.14     $ 0  

Vested or expected to vest at December 31, 2022

                     201,271     $ 16.72       2.12     $ 0  

Exercisable at December 31, 2022

                     194,561     $ 17.12       2.03     $ 0  

 

60
 

 

The options outstanding and exercisable at December 31, 2022 were in the following exercise price ranges:

 

           

Options Outstanding

    

Options Exercisable

  

Range of exercise prices

    

Number of

shares

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life (in years)

    

Number

exercisable

    

Weighted

average

exercise

price

  
$ 4.08 - 5.84       25,565     $ 5.20       4.63       17,130     $ 5.20  
$ 5.85 - 28.00       177,431       18.27       1.81       177,431       18.27  
$ 4.08 - 28.00       202,996                       194,561          

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of December 31, 2022, 2021 and 2020.

 

The weighted average fair value of options granted during the years ended December 31, 2022 and 2021 was $0 as no options were granted in either year. The total intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2022 and 2021 was $100,668 and $252,874, respectively.

 

As of December 31, 2022, future forfeiture adjusted compensation cost related to nonvested stock options is $17,630 and will be recognized over an estimated weighted average period of 0.64 years.

 

 

 

NOTE R—INCOME TAXES

 

The components of net loss consist of the following:

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

United States

   $ (10,416,593 )   $ (4,507,071 )

Hong Kong

     (458,839 )     (439,814 )

Nigeria

     (143,499 )     (118,896 )

Spain

     (890,972 )     -  

Total

   $ (11,909,903 )   $ (5,065,781 )

 

There was no provision for current federal, foreign or state taxes for both of the years ended December 31, 2022 and 2021 as a result of taxable losses incurred in these jurisdictions. The provision for income tax benefits consist of the following (in thousands):

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

Current – federal, states, and foreign

   $ -     $ -  

Deferred- Federal

     1,175,000       128,000  

Deferred - States

     122,000       47,000  

Deferred - Foreign

     (20,000

)

     -  

Total

     1,277.000       175,000  

Change in valuation allowance

     (1,297,000

)

     (175,000

)
                 

Provision for income tax benefits

   $ (20,434

)

   $ —  

 

Significant components of deferred tax assets and liabilities are as follows at December 31, 2022 and 2021 (in thousands):

 

   

December 31,

2022

    

December 31,

2021

As Revised

  
                 

Accrued compensation

   $ 113,000     $ 110,000  

Allowance for doubtful accounts

     169,000       70,000  
Research and development expenses     633,000       -  
Capital loss carry forward     114,000       -  

Stock-based compensation

     456,000       486,000  

Equipment and leasehold improvements

     (19,000

)

     1,000  

Intangible assets - US

     341,000       61,000  
Intangible assets - Foreign     (170,000 )     -  
Inventory reserve     89,000       -  
Interest expense     44,000       -  
Operating lease liabilities     44,000       59,000  
Reserve on debt security     -       13,000  
Operating lease right-of-use assets     (44,000 )     (57,000 )

Net operating loss and research and credit carryforwards

     15,248,000       15,148,000  

Valuation allowance

     (17,188,000

)

     (15,891,000

)
                 
Net deferred tax liability   $ (170,000 )   $ —  

 

During the year ended December 31, 2022, the Company determined that certain attributes of deferred tax assets and liabilities were incorrect for December 31, 2021 and 2020. See Note S for further information.

 

The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. With a full valuation allowance, any change in the deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. At December 31, 2022 and 2021, the Company provided a valuation allowance on its net deferred tax assets of $17,188,000 and $15,891,000, respectively.

 

61
 

 

As of December 31, 2022, the Company has U.S. federal net operating loss carryforwards of approximately $61.3 million. Approximately $43.1 million are subject to expiration between 2023 and 2037, and $18.2 million net operating loss carryforwards have no expiration date. These net operating loss carryforwards could be subject to the limitations under Section 382 of the Internal Revenue Code due to changes in the equity ownership of the Company. In addition, the Company has net operating loss carry forwards from various states of approximately $6.87 million which expire from 2026 through 2042.

 

A reconciliation of the effective income tax rate on operations reflected in the statements of operations to the US federal statutory income tax rate is presented below.

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

As Revised

  
                 

Federal statutory income tax rate

     21.0

%

     21.0

%

State taxes, net of federal benefit

     0.9       1.1  

Permanent differences

     (4.7

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     (5.7

)

     (13.8

)

Expiration and forfeiture of stock options

     (0.3

)

     (1.5

)

Other

     (0.5 )     (2.4

)

Valuation allowance

     (10.9

)

     (3.4

)
                 

Effective tax rate

     (0.2

)%

     —

%

 

The Company has not been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2019 through 2022 remain open to examination by the IRS and state jurisdictions.

 

Our subsidiary in Nigeria has not filed its required returns since inception. Management believes that when the returns are filed, no taxes will be owed due to the losses incurred during those periods. We are also not subject to minimum tax during the first four years of operations. As a result, management could not calculate the amount of net operating loss carryforwards that are available to offset future taxable income.

 

Our subsidiary in Hong Kong has not filed its required returns in several years. Management believes that when the returns are filed, no taxes will be owed due to losses incurred during those periods. As a result, management could not calculate the amount of net operating loss carryforwards are available to offset future taxable income.

 

The Company believes it is not subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended December 31, 2022 and 2021.

 

In August 2022, the Inflation Reduction Act of 2022 was signed into law which includes a stock buyback excise tax of 1% on share repurchases, which will apply to net stock buybacks after December 31, 2022. We do not expect this to have a material impact if and when share repurchases occur.

 
 

NOTE S—REVISION OF PREVIOUSLY ISSUED CONSOLDATED FINANCIAL STATEMENTS

 

Due to errors discovered in the Company’s 2020 and 2021 tax provisions, the Company revised certain previously issued disclosures related to the components of its deferred tax assets and liabilities and valuation allowance as of December 31, 2021 and 2020. Additionally, the Company has revised the reconciliation of its income tax rate computed using the federal statutory rate for the year ended December 31, 2021. The errors related primarily to the calculation of available net operating loss carryforwards and to stock based compensation. Since the Company provided a full valuation allowance on its net deferred tax assets, there was no impact to the Consolidated Balance Sheet as of December 31, 2021 and the consolidated statements of operations, stockholders’ equity and cash flows as of and for the year ended December 31, 2021.

 

62
 

 

The Company further reviewed its disclosure of the rate reconciliation and deferred tax calculation along with the valuation allowance of its net deferred tax assets. Other items that were corrected in the disclosure included allowance for doubtful accounts, equipment and leasehold improvements and operating lease liability along with the associated operating lease ROU assets.

 

The below table summarizes the revisions to the reconciliation of our income tax rate computed using the federal statutory rate to our actual income tax rate for the year ended December 31, 2021:

 

   

December 31,

  
   

2021

As Reported

     Adjustments    

2021

As Revised

  
                         

U.S. statutory income tax rate

     21.0

%

     - %     21.0 %

State taxes, net of federal benefit

     -       1.1       1.1  

Permanent differences

     -       (1.0

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     -       (13.8

)

     (13.8

)

Expiration and forfeiture of stock options

     -       (1.5

)

     (1.5

)

Other

     -       (2.4

)

     (2.4

)
Valuation allowance     -       (3.4 )     (3.4 )

Effect of net operating loss

     (21.0 )%     21.0       -  

Total

     -

%

     -

%

     -

%

 

The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2021 (in thousands):

 

   

December 31,

  
   

2021

As Reported

    

Adjustments

    

2021

As Revised

  
                         

Accrued compensation

   $ 135,000     $ (25,000 )   $ 110,000  

Allowance for doubtful accounts

     75,000       (5,000

)

     70,000  

Stock based compensation

     1,149,000       (663,000

)

     486,000  

Equipment and leasehold improvements

     (10,000

)

     11,000       1,000  

Intangible assets

     75,000       (14,000 )     61,000  

Operating lease liability

     -       59,000       59,000  

Reserve on debt security

     -       13,000       13,000  

Operating lease right-of -use assets

     -       (57,000

)

     (57,000 )

Net operating loss and research credit carryforwards

     14,467,000       681,000       15,148,000  

Valuation allowance

     (15,891,000

)

     -       (15,891,000

)

Net deferred tax assets

   $ -     $ -     $ -  

 

The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2020 (in thousands):

 

   

December 31,

  
   

2020

As Reported

    

Adjustments

    

2020

As Revised

  
                         
Accrued compensation   $ 81,000     $ (15,000 )   $ 66,000  

Allowance for doubtful accounts

     474,000       (471,000

)

     3,000  

Stock based compensation

     1,073,000       (511,000

)

     562,000  

Equipment and leasehold improvements

     (14,000

)

     19,000       5,000  

Intangible assets

     65,000       (12,000 )     53,000  

Operating lease liability

     -       111,000       111,000  
Operating lease right-of -use assets     -       (109,000

)

     (109,000 )

Net operating loss and research credit carryforwards

     13,337,000       1,688,000       15,025,000  

Valuation allowance

     (15,016,000

)

     (700,000

)

     (15,716,000

)

Net deferred tax assets

   $ -     $ -     $ -  

 
63
 

 
 

NOTE T—PROFIT SHARING PLAN

 

The Company has established a savings plan under section 401(k) of the Internal Revenue Code. All employees of the Company, after completing one day of service, are eligible to enroll in the 401(k) plan. Participating employees may elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is not required to match employee contributions but may do so at its discretion. The Company made no matching contributions during the years ended December 31, 2022 and 2021.

 

 

NOTE U—EARNINGS PER SHARE (EPS)

 

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 

Stock options

     202,996       212,461  

Warrants

     4,872,025       4,689,387  

Total

     5,075,021       4,901,848  

 

 

 

NOTE V—SUBSEQUENT EVENTS

 

On March 16, 2023, the Company issued 15,388 shares of common stock to its directors in payment of board fees.

 

On March 16, 2023, the Company issued an aggregate of 40,000 shares of restricted common stock to new employees which vest in equal annual installments over a three-year period from the date of grant.

 

On May 5, 2023, the Company issued 2,858 shares of common stock to its directors in payment of board committee fees.

 

On May 5, 2023, the Company received 14,375 shares of restricted common stock from employees who left the Company before the vesting period was completed.

 

On May 11, 2023, the Company issued 17,392 shares of common stock to its directors in payment of board fees.

 

On May 11, 2023, the Company issued 2,900 shares of common stock to its directors in payment of board committee fees.

 

64
 

 
 

EXHIBIT INDEX

 

Exhibit

  

Exhibit 

No.

    
     

2.1

  

Stock Purchase Agreement by and among the Company, Thomas J. Hoey, and PistolStar, Inc. dated June 6, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020)
     

2.2

  

Stock Purchase Agreement by and among the Company, Alex Rocha and Swivel Secure Europe, SA dated February 2, 2022 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on February 3, 2022)
     

2.3

  

Amendment No. 1 to Stock Purchase Agreement by and among the Company, Alex Rocha and Swivel Secure Europe, SA dated March 4, 2022 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on March 9, 2022)
     

3.1

  

Certificate of Incorporation of BIO-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on January 5, 2005)
     

3.2

  

Bylaws (incorporated by reference to Exhibit 3.3 to the current report on Form 8-K, filed with the SEC on January 5, 2005)
     

3.3

  

Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Appendix A to the definitive proxy statement, filed with the SEC on January 18, 2006)
     

3.4

  

Certificate of Amendment of Certificate of Incorporation of Bio-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed with the SEC on March 31, 2015)
     

3.5

  

Certificate of Elimination of BIO-key International, Inc. filed October 6, 2015 (incorporated by reference to Exhibit 3.5 to the registration statement on Form S-1 File No. 333-208747 filed with the SEC on December 23, 2015)
     

3.6

  

Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on November 2, 2015)
     

3.7

  

Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the quarterly report on Form 10-Q, filed with the SEC on November 16, 2015)
     

3.8

  

Certificate of Amendment of Certificate of Incorporation of Bio-key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on December 28, 2016)
     

3.9

  

Certificate of Amendment of Certificate of Incorporation of Bio-Key International, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the SEC on November 19, 2020)
     

4.1

  

Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the registration statement on Form SB-2, File No. 333-16451)

     

4.2

  

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registration Statement on Form S-1/A, filed with the SEC on July 17, 2020)
     

4.3

  

Form of Warrant (incorporated by reference to Exhibit 4.3 to Amendment No. 1 to the Registration Statement on Form S-1/A, filed with the SEC on July 17, 2020)
     

4.4

  

Form of Warrant Agency Agreement (incorporated by reference to Exhibit 4.4 to Amendment No. 2 to the Registration Statement on Form S-1/A, filed with the SEC on July 20, 2020)
     

4.5

  

BIO-key International, Inc. Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the annual report on From 10-K filed with the SEC on April 1, 2022
     

10.1

  

Employment Agreement by and between BIO-key International, Inc. and Mira LaCous dated November 20, 2001 (incorporated by reference to Exhibit 10.39 to the current report on Form 8-K, filed with the SEC on January 22, 2002)***

 

65
 

 

10.2

  

BIO-key International, Inc. 2004 Stock Incentive Plan (incorporated by reference to Exhibit 10.48 to amendment no. 1 the registrant’s registration statement on Form SB-2, File No. 33-120104, filed with the SEC on December 14, 2004)***
     

10.3

  

Employment Agreement, effective March 25, 2010, by and between the Company and Michael W. DePasquale (incorporated by reference to Exhibit 10.93 to the annual report on Form 10-K, filed with the SEC on March 26, 2010)***
     

10.4

  

Employment Agreement by and between BIO-key International, Inc. and Cecilia Welch dated May 15, 2013 (incorporated by reference to Exhibit 10.42 to the annual report on Form 10-K, filed with the SEC on March 31, 2014)***
     

10.5

  

Employment Agreement by and between BIO-key International, Inc. and James Sullivan dated April 5, 2017 (incorporated by reference to Exhibit 10.42 to the annual report on Form 10-K, filed with the SEC on March 29, 2021)***

 

10.6

  

First Amendment to Lease Agreement by and between BIO-key International, Inc. and BRE/DP MN LLC dated September 12, 2013 (incorporated by reference to Exhibit 10.44 to the annual report on Form 10-K, filed with the SEC on March 31, 2014)
     

10.7

  

BIO-key International, Inc. 2015 Equity Incentive Plan (incorporated by reference to Appendix B to the definitive proxy statement filed with the SEC on December 15, 2015)***
     

10.8

  

Software License Purchase Agreement Dated November 11, 2015 by and among BIO-key Hong Kong Limited, Shining Union Limited, WWTT Technology China, Golden Vast Macao Commercial Offshore Limited, Giant Leap International Limited (incorporated by reference to Exhibit 10.36 to the registration statement on Form S-1 File No. 333-208747 filed with the SEC on December 23, 2015)**
     

10.9

  

Form Non-Plan Option Agreement between the Company and certain of its directors, officers, employees and contractors (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q filed with the SEC on May 15, 2017)***
     

10.10

  

Securities Purchase Agreement dated May 23, 2018 by and between the Registrant and Giant Leap International Limited (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on May 30, 2018)
     

10.11

  

Securities Purchase Agreement dated May 23, 2018 by and between the Registrant and Micron Technology Development Limited (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on May 30, 2018)
     

10.12

  

Securities Purchase Agreement dated May 31, 2018 by and between the Registrant and Wong Kwok Fong (Kelvin) (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on June 4, 2018)
     

10.13

  

Underwriting Agreement dated August 22, 2018 by and between the Registrant and Maxim Group LLP (incorporated by reference to Exhibit 1.1 to the current report on Form 8-K, filed with the SEC on August 27, 2018)
     

10.14

  

Form of Common Stock Purchase Warrant dated August 24, 2018 (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the SEC on August 27, 2018)
     

10.15

  

GLP 2nd Amendment to Lease dated July 27, 2018 (incorporated by reference to Exhibit 10.26 to the annual report on Form 10-K, filed with the SEC on April 1, 2019)
     

10.16

  

Marlen 4th Amendment to Lease dated June 2, 2018 (incorporated by reference to Exhibit 10.27 to the annual report on Form 10-K, filed with the SEC on April 1, 2019)

 

66
 

 

10.17

  

Common Stock Purchase Warrant dated July 10, 2019 (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on August 14, 2019)

 

10.18

  

Sales Incentive Agreement with Technology Transfer Institute dated March 25, 2020. (incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.19

  

Form of Technology Transfer Institute Warrant. (incorporated by reference to Exhibit 10.2 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.20

  

Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 issued by the Company to Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.21

  

Amendment to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated April 12, 2020. (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.22

  

Securities Purchase Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.5 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.23

  

$2,415,000 Senior Secured Convertible Promissory Note dated May 6, 2020. (incorporated by reference to Exhibit 10.6 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.24

  

Common Stock Purchase Warrant dated May 6, 2020. (incorporated by reference to Exhibit 10.7 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.25

  

Amended and Restated Security Agreement dated May 6, 2020 by and between the Company and Lind Global Macro Fund, LP. (incorporated by reference to Exhibit 10.8 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.26

  

Amendment No. 2 to Amended and Restated Senior Secured Convertible Promissory Note, due April 13, 2020 by and between the Company and Lind Global Macro Fund, LP dated May 13, 2020. (incorporated by reference to Exhibit 10.9 to the quarterly report on Form 10-Q, filed with the SEC on June 8, 2020)
     

10.27

  

Securities Purchase Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.28

  

$1,811,250 Senior Secured Convertible Promissory Note dated June 29, 2020. (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.29

  

Common Stock Purchase Warrant dated June 29, 2020. (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.30

  

Second Amended and Restated Security Agreement dated June 29, 2020 by and between the Company and Lind Global Macro Fund, LP (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the SEC on July 1, 2020)
     

10.31

  

$500,000 Promissory note, dated June 30, 2020 (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on July 7, 2020)
     

10.32

  

Form of Restricted Stock Award Agreement under the BIO-key International, Inc. Amended & Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on August 28, 2020)***

 

67
 

 

10.33

  

BIO-key International, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the definitive proxy statement filed with the SEC on May 4, 2021)
     

10.34

  

BIO-key International, Inc. Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Appendix B to the definitive proxy statement filed with the SEC on May 4, 2021)
     
10.35   Management Services Agreement dated March 8, 2022 by and among Swivel Aman-FZCO, Swivel Secure Europe, SA, and Alex Rocha (incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q filed with the SEC on May 23, 2022)
     
10.36   Option Agreement dated March 8, 2022 by and between the Company and Alex Rocha (incorporated by reference to Exhibit 10.2 to the quarterly report on Form 10-Q filed with the SEC on May 23, 2022)
     
10.37   Distribution Agreement dated October 23, 2020 by and between Swivel Secure Europe, SA and Swivel Secure Limited (incorporated by reference to Exhibit 10.3 to the quarterly report on Form 10-Q filed with the SEC on May 23, 2022) +
     
10.38   Deed of Variation dated January 26, 2022 by and between Swivel Secure Europe, SA and Swivel Secure Limited (incorporated by reference to Exhibit 10.4 to the quarterly report on Form 10-Q filed with the SEC on May 23, 2022) +
     
10.39   Securities Purchase Agreement dated December 22, 2022 by and between the Company and AJB Capital Investments, LLC (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed with the SEC on December 23, 2022)
     
10.40   $2,200,000 Senior Secured Promissory Note, dated December 22, 2022 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K filed with the SEC on December 23, 2022)
     
10.41   Common Stock Purchase Warrant, dated December 22, 2022 (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K filed with the SEC on December 23, 2022)
     
10.42   Security Agreement dated December 22, 2022 by and between the Company and AJB Capital Investments, LLC (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K filed with the SEC on December 23, 2022)
     

21.1*

  

List of subsidiaries of BIO-key International, Inc.
     

23.1*

  

Consent of Marcum LLP
     
23.2*   Consent of Rotenberg Meril Solomon Bertiger & Guttilla, P.C.
     

31.1*

  

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

  

Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

  

Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

  

Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101.INS*

Inline XBRL Instance
   

101.SCH*

Inline XBRL Taxonomy Extension Schema
   

101.CAL*

Inline XBRL Taxonomy Extension Calculation
   

101.DEF*

Inline XBRL Taxonomy Extension Definition
   

101.LAB*

Inline XBRL Taxonomy Extension Labels
   

101.PRE*

Inline XBRL Taxonomy Extension Presentation
   

104

Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

*  filed herewith

 

** Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted sections have been filed separately with the Securities and Exchange Commission.

 

*** Management compensatory plan.

 

+ Certain portions of this exhibit (indicated by “[***]”) have been omitted as the Company has determined that such portions are (a) not material and (b) would likely cause competitive harm to the Company if publicly disclosed.

 

68
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-KEY INTERNATIONAL, INC.
     
Date: June 1, 2023

By:

/s/  MICHAEL W. DEPASQUALE
   

Michael W. DePasquale
   

CHIEF EXECUTIVE OFFICER

(Principal Executive Officer)

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities on the dates indicated.

 

 

Signature

  

Title

  

Date
         

/s/  MICHAEL W.

DEPASQUALE

  

Chairman of the Board of Directors, Chief Executive Officer and Director

(Principal Executive Officer)

   June 1, 2023

Michael W. DePasquale

        
         

/s/  CECILIA WELCH

  

Chief Financial Officer (Principal Financial and Accounting Officer)

   June 1, 2023

Cecilia Welch

        
         

/s/ROBERT J. MICHEL

  

Director

   June 1, 2023

Robert J. Michel

        
         

/s/  WONG KWOK FONG

  

Director

   June 1, 2023

Wong Kwok Fong

        
         
/s/  Thomas Bush III   Director   June 1, 2023
Thomas Bush III        
         

/s/  MANNY ALIA

  

Director

   June 1, 2023

Manny Alia

        

 

69
 EX-21.1 2 ex_493138.htm EXHIBIT 21.1 ex_493138.htm

 

Exhibit 21.1

Subsidiaries

 

Name

State/Country of Incorporation

 

BIO-key Hong Kong Limited

Hong Kong
   

Public Safety Group, Inc. 

Delaware
   

PistolStar, Inc.

New Hampshire
   

BIOKEY AFRICA LIMITED

Nigeria
   

Swivel Secure Europe, SA

Spain
   

Swivel Secure, Unipessoal LDA.

Portugal
   
BIO-key Europe SL Spain

 

 
 EX-23.1 3 ex_493139.htm EXHIBIT 23.1 ex_493139.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference into the registration statements of BIO-key International, Inc. on Form S-8 (file nos. 333- 233737, 333-212066, 333-257520 and 333-257754), Form S-1 (file no. 333-239782), and Form S-3 (file nos. 333-233713, 333-225934 and 333-257875) of our report dated June 1, 2023 relating to the financial statements which appear in this Form 10-K as of December 31, 2022 and for the year then ended, which report is included in this Annual Report on Form 10-K of the Company for the year ended December 31, 2022.

 

Our report on the consolidated financial statements contain an explanatory paragraph regarding adjustments described in Note S to the consolidated financial statements that were applied to restate the 2021 financial statements to correct errors. We were not engaged to audit, review, or apply any procedures to the 2021 financial statements of the Company other than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the 2021 financial statements taken as a whole.

 

/s/ Marcum LLP

 

Marcum LLP

Saddle Brook, New Jersey 

June 1, 2023

 

 

 
 EX-23.2 4 ex_523736.htm EXHIBIT 23.2 HTML Editor

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference into the registration statements of BIO-key International, Inc. on Form S-8 (file nos. 333- 233737, 333-212066, 333-257520 and 333-257754), Form S-1 (file no. 333-239782), and Form S-3 (file nos. 333-233713, 333-225934 and 333-257875) of our report dated March 31, 2022 relating to the financial statements which appear in this Form 10-K for the year ended December 31, 2022.

 

Our report on the 2021 consolidated financial statements indicates that we were not engaged to audit, review, or apply any procedures to the adjustments for the correction of the errors described in Note S to the financial statements, and accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by Marcum LLP.

 

/s/ Rotenberg Meril Solomon Bertiger & Guttilla, P.C.

 

ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.

Saddle Brook, New Jersey

June 1, 2023

 
 EX-31.1 5 ex_493140.htm EXHIBIT 31.1 ex_493140.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Michael W. DePasquale, certify that: 

 

1. I have reviewed this annual report on Form 10-K of BIO-key International, Inc. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Dated: June 1, 2023

  
   
 

/s/ Michael W. DePasquale
 

Michael W. DePasquale
 

Chief Executive Officer

 

 

 
 EX-31.2 6 ex_493141.htm EXHIBIT 31.2 ex_493141.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Cecilia C. Welch, certify that: 

 

1. I have reviewed this annual report on Form 10-K of BIO-key International, Inc. (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

 

Dated: June 1, 2023

  
   
 

/s/ CECILIA C. WELCH
 

Cecilia C. Welch
 

Chief Financial Officer

 

 

 
 EX-32.1 7 ex_493142.htm EXHIBIT 32.1 ex_493142.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of BIO-key International, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. DePasquale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

BIO-KEY INTERNATIONAL, INC.
   
   
 

By:

/s/ Michael W. DePasquale
   

Michael W. DePasquale
   

Chief Executive Officer
   
 

Dated: June 1, 2023

 

 
 EX-32.2 8 ex_493143.htm EXHIBIT 32.2 ex_493143.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of BIO-key International, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecilia Welch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that to my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

BIO-KEY INTERNATIONAL, INC.
   
   
 

By:

/s/ CECILIA C. WELCH
   

Cecilia C. Welch
   

Chief Financial Officer
   
 

Dated: June 1, 2023

 

 
 EX-101.SCH 9 bkyi-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note B - Revenue From Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note D - Fair Values of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note E - Concentration of Risk link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note F - Note Receivable link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note G - Inventory link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note H - Resalable Software Licenses Rights link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note I - Investment in Debt Security link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note J - Equipment and Leasehold Improvements link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note K - Intangible Assets and Goodwill link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note L - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note M - Convertible Note Payable link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note N - Leases link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note O - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note P - Equity link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note Q - Stock Options link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note R - Income Taxes link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note T - Profit Sharing Plan link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note U - Earnings Per Share (EPS) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note V - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note F - Note Receivable (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note G - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note J - Equipment and Leasehold Improvements (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note K - Intangible Assets and Goodwill (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note L - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note N - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note P - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note Q - Stock Options (Tables) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note R - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements (Tables) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note U - Earnings Per Share (EPS) (Tables) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note E - Concentration of Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note F - Note Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note F - Note Receivable - Summary of Note Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note G - Inventory (Details Textual) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note G - Inventory - Components of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note H - Resalable Software Licenses Rights (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note I - Investment in Debt Security (Details Textual) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note J - Equipment and Leasehold Improvements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note K - Intangible Assets and Goodwill (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note K - Intangible Assets and Goodwill - Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note M - Convertible Note Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note N - Leases - Operating Lease Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note P - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note P - Equity - Valuation Assumptions for Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note P - Equity - Summary of Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note Q - Stock Options (Details Textual) link:calculationLink link:definitionLink link:presentationLink 074 - Disclosure - Note Q - Stock Options - Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 075 - Disclosure - Note Q - Stock Options - Options Outstanding and Exercisable (Details) link:calculationLink link:definitionLink link:presentationLink 076 - Disclosure - Note R - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 077 - Disclosure - Note R - Income Taxes - Net Income Loss (Details) link:calculationLink link:definitionLink link:presentationLink 078 - Disclosure - Note R - Income Taxes - Components of Income Tax Expense (Details) link:calculationLink link:definitionLink link:presentationLink 079 - Disclosure - Note R - Income Taxes - Components of Deferred Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 080 - Disclosure - Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 081 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details) link:calculationLink link:definitionLink link:presentationLink 082 - Disclosure - Note T - Profit Sharing Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 083 - Disclosure - Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) link:calculationLink link:definitionLink link:presentationLink 084 - Disclosure - Note V - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 10 bkyi-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 bkyi-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Note To Financial Statement Details Textual Significant Accounting Policies Note A - The Company and Summary of Significant Accounting Policies Note B - Revenue From Contracts With Customers Note C - Swivel Secure Europe, SA Acquisition Note F - Note Receivable Note G - Inventory Note J - Equipment and Leasehold Improvements Note K - Intangible Assets and Goodwill Accounts receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Note L - Accrued Liabilities Income Tax Disclosure [Text Block] Note N - Leases Note P - Equity Cash and cash equivalents us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Note Q - Stock Options Note R - Income Taxes us-gaap_LiabilitiesCurrent Total current liabilities Note S - Revision of Previously Issued Consolidated Financial Statements Note U - Earnings Per Share (EPS) bkyi_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) bkyi_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration Amount of operating loss carryforward not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Common stock issued us-gaap_ProceedsFromCollectionOfNotesReceivable Repayment of note Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Total purchase price consideration Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details) Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Intangible Assets, Amount Estimated useful life (Year) Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details) Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details) Note F - Note Receivable - Summary of Note Receivable (Details) Note G - Inventory - Components of Inventory (Details) Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) bkyi_SoftwareLicenseRights Software License Rights Represents the amount of current and noncurrent software license rights as of the balance sheet date. Debt Security, Corporate, Non-US [Member] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) Note K - Intangible Assets and Goodwill - Amortization Expense (Details) Other comprehensive loss- Foreign translation adjustment us-gaap_BusinessAcquisitionSharePrice Business Acquisition, Share Price Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Note N - Leases - Operating Lease Balance Sheet Information (Details) Note P - Equity - Valuation Assumptions for Warrants (Details) Note P - Equity - Summary of Warrant Activity (Details) Note Q - Stock Options - Option Activity (Details) Note Q - Stock Options - Options Outstanding and Exercisable (Details) Note R - Income Taxes - Net Income Loss (Details) Note R - Income Taxes - Components of Income Tax Expense (Details) Note R - Income Taxes - Components of Deferred Taxes (Details) Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details) Vested or expected to vest, weighted average remaining life (Year) Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) Government loan – BBVA Bank, current portion Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs Vested or expected to vest (in shares) Vested or expected to vest, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Vested or expected to vest, aggregate intrinsic value Exercisable, weighted average exercise price (in dollars per share) Exercisable, weighted average remaining life (Year) us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Exercisable, aggregate intrinsic value us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Outstanding, weighted average remaining life (Year) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding, aggregate intrinsic value Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Error Correction [Text Block] Forfeited, weighted average exercise price (in dollars per share) Deferred revenue - current Expired, weighted average exercise price (in dollars per share) Financial Instrument [Axis] Sales tax payable Goodwill and Intangible Assets Disclosure [Text Block] The Note [Member] Information pertaining to The Note. Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued liabilities Total Lessee, Operating Leases [Text Block] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired (in shares) Other Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Compensation us-gaap_PolicyTextBlockAbstract Accounting Policies bkyi_ConcentrationRiskNumberOfMajorCustomers Concentration Risk, Number of Major Customers Represents the number of external customers that accounts for 10 percent or more of an entity's revenues or accounts receivable. Trade Names [Member] Accrued legal and accounting fees Exercise Price Range 1 [Member] The first exercise price range. Exercise Price Range 2 [Member] The second exercise price range. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Capital expenditures us-gaap_PaymentsToAcquireSoftware Payments to Acquire Software Noncash investing and financing activities: Weighted Average Shares Outstanding: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Grantee Status [Domain] Taxes Grantee Status [Axis] LIABILITIES Cash paid for: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Operating lease liabilities us-gaap_Assets TOTAL ASSETS Patents [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Commitments Disclosure [Text Block] Customer Relationships [Member] Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock Issued in Lieu of Board Fees [Member] Related to stock issued in lieu of board fees. Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Equity Interest Type [Axis] Equity Interest Issued or Issuable, Type [Domain] Award Type [Domain] Business Description and Accounting Policies [Text Block] Net loss Net loss Net loss Net loss Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Less accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Total Intangible assets, net Gross carrying amount Restricted Stock [Member] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Goodwill resulting from the acquisition from Swivel Secure Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation and amortization Equipment and leasehold improvements, net Total Goodwill Goodwill Property, plant, and equipment, gross Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Compensated absences bkyi_WarrantsOutstandingExercisePrice Outstanding, weighted average exercise price, warrants (in dollars per share) Outstanding, weighted average exercise price, warrants (in dollars per share) Warrants outstanding exercise price. Outstanding, weighted average remaining contractual life, warrants (Year) bkyi_WarrantsOutstandingWeightedAverageRemainingLife Warrants outstanding weighted average remaining life. Note receivable Non Plan [Member] Non plan member. Pre-Funded Warrants [Member] Represents the pre-funded warrants. CASH FLOWS FROM INVESTING ACTIVITIES: Permanent differences bkyi_EffectiveIncomeTaxReconciliationPermanentDifferences Effective income tax reconciliation permanent differences. Stock based fees to directors The costs and payments related to stock-based fees to directors and consultants. Earnings Per Share [Text Block] Convertible Debt [Member] Useful Lives of Property Plan and Equipment [Table Text Block] Tabular disclosure of the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). Provision for income tax benefit Provision for income tax benefits us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Equipment acquired from Swivel Secure Represents the amount of equipment acquired. Intangible assets acquired from Swivel Secure Represents intangible assets acquired. Short-Term Debt, Type [Axis] bkyi_BusinessCombinationIndemnificationAssetsSharesAsOfAcquisitionDate Business Combination, Indemnification Assets, Shares as of Acquisition Date The number of shares held for indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination. Short-Term Debt, Type [Domain] bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees Legal fees Represents the amount of decrease to additional paid in capital during the period resulting from legal fees. Accounts receivable acquired from Swivel Secure Represents the amount of accounts receivable acquired. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable bkyi_RightToRepurchaseSharesIfDebtInstrumentPaidInFullWithinSixMonths Right to Repurchase Shares if Debt Instrument Paid in Full Within Six Months The number of shares that can be repurchased if the debt instrument is paid in full within six months. bkyi_DebtInstrumentDefaultPercentageIncreaseInPrincipal Debt Instrument, Default, Percentage Increase In Principal Percentage increase in principal outstanding in the event of default on the debt instrument. Senior Secured Promissory Note [Member] Represents the senior secured promissory note. us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount SPAIN Cash and cash equivalents Share-based compensation expense Share-Based Payment Arrangement, Expense us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Day one loss on value of hybrid instrument us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Debt Instrument, Convertible, Number of Equity Instruments Amendment Flag Comprehensive loss: HONG KONG us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss dei_CityAreaCode City Area Code Use of Estimates, Policy [Policy Text Block] Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block] The tabular disclosure of costs, assets, and liabilities subject to operating lease by lessee. New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Forfeiture of restricted stock us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal us-gaap_SharesOutstanding Balance (in shares) Balance as of December 31, 2021 (in shares) Common stock, shares outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_NotesReceivableNet Note receivable, net of allowance Total lease cost Stock Issued in Lieu of Board Committee Fees [Member] refers to stock issued in lieu of board committee fees. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other Convertible note at fair value Debt Instrument, Fair Value Disclosure Weighted average discount rate – operating leases Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Amortization of resalable software license rights The amount of amortization charged against earnings during the period for software license rights. Swivel Secure Europe [Member] Information regarding the business acquisition of Swivel Secure Europe. dei_DocumentPeriodEndDate Document Period End Date Operating lease right-of-use asset and liability for new lease Weighted average remaining lease term (in years) – operating leases (Year) dei_EntityFileNumber Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type Research, Development, and Engineering Expense [Member] Primary financial statement caption in which the reported facts about research, development and engineering expense have been included. Entity Small Business dei_EntityShellCompany Entity Shell Company Document Information [Line Items] Document Information [Table] Service [Member] Software License Rights [Member] The software license rights, generally of limited duration, for internal use. us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Beginning balance Ending balance dei_EntityPublicFloat Entity Public Float Referral Fee Warrants [Member] Related to referral fee warrants. Entity Filer Category Purchases and issuances Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] bkyi_TotalWarrantsExercised Exercised, warrants (in shares) The number of warrants exercised during period. dei_EntityVoluntaryFilers Entity Voluntary Filers Granted, warrants (in shares) The amount of warrants granted during the period. dei_EntityWellKnownSeasonedIssuer Entity Well-known Seasoned Issuer bkyi_TotalWarrantsExpired Expired, warrants (in shares) Number of warrants expired during period. bkyi_TotalWarrantsForfeited Forfeited, warrants (in shares) Number of warrants forfeited during period. Granted, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of warrants granted during period. Forfeited, weighted average exercise price, warrants (in dollars per share) Forfeited, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of the warrants forfeited. us-gaap_IncreaseDecreaseInOtherReceivables Due from factor Expired, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of the warrants expired during period. Exercised, weighted average exercise price, warrants (in dollars per share) Weighted average exercise price of the warrants exercised in the period. Impairment of goodwill Issuance of warrant in conjunction with note payable Amortization of capitalized contract costs Share-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage In The Money Options [Member] Represents in-the-money options exercisable. Entity Tax Identification Number Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction dei_EntityRegistrantName Entity Registrant Name Share based compensation for employee stock purchase plan Entity [Domain] us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Customer Concentration Risk [Member] Legal Entity [Axis] Exercise Price Range 3 [Member] The third exercise price range. dei_EntityAddressAddressLine1 Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] bkyi_PaymentsForLegalFees Legal fees The amount of cash outflow for legal fees. Amortization of intangible assets and write-off Amortization of Intangible Assets us-gaap_FinancingReceivableAllowanceForCreditLosses Allowance for doubtful account NIGERIA dei_EntityAddressCityOrTown Entity Address, City or Town dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] us-gaap_AdvertisingExpense Advertising Expense Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventory Trading Symbol Concentration Risk Benchmark [Axis] Employee Stock Purchase Plan [Member] Information regarding employee stock purchase plan. Concentration Risk Benchmark [Domain] Issuance of common stock pursuant to Swivel purchase agreement (in shares) bkyi_BusinessCombinationContingentConsiderationEarnoutPayableRevenueToTriggerPayment Business Combination, Contingent Consideration Earnout Payable, Revenue to Trigger Payment The amount of revenue required to trigger earnout payable payment under contingent consideration. bkyi_BusinessCombinationContingentConsiderationEarnoutPayableOperatingProfitToTriggerPayment Business Combination, Contingent Consideration Earnout Payable, Operating Profit to Trigger Payment The amount of operating profit to trigger payment of earnout payable under contingent consideration. Issuance of common stock for Employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans dei_LocalPhoneNumber Local Phone Number Accounts payable and accrued expenses acquired from Swivel Secure Amount of accounts payable and accrued expenses, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition. Issuance of common stock pursuant to Swivel purchase agreement Stock Issued During Period, Value, Acquisitions us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common stock for Employee stock purchase plan Government loan bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebt Amount of debt assumed at the acquisition date. us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Forfeiture of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited bkyi_NotesReceivablePeriodicPayment Notes Receivable, Periodic Payment The amount of periodic payment of notes receivable. Issuance of restricted common stock to employees (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures bkyi_BusinessCombinationBasePurchasePrice Business Combination, Base Purchase Price The amount of base purchase price under business combination. Resalable software license rights Carrying amounts as of the balance sheet date of software license rights classified as non-current. Issuance of restricted common stock to employees Expiration of net operating loss and research credit carryforwards bkyi_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAndResearchCreditCarryforwardsPercent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating loss and research credit carryforwards. us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Issuance of common stock for directors’ fees (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Selling, general and administrative us-gaap_SellingGeneralAndAdministrativeExpense Accounts Receivable, Credit Loss Expense (Reversal) Issuance of common stock for directors’ fees Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Granted (in shares) Weighted average risk-free interest rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited (in shares) Line of Credit Facility, Lender [Domain] Issuance of common stock for note issuance fees (in shares) Lender Name [Axis] Fabricated assemblies us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY us-gaap_CashUninsuredAmount Cash, Uninsured Amount Finished goods Issuance of common stock for note issuance fees UNITED STATES Accumulated deficit Research, development and engineering us-gaap_AssetsNoncurrent Total non-current assets Accumulated other comprehensive loss Operating lease liability bkyi_DeferredTaxAssetsOperatingLeaseLiabilities Operating lease liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities. Measurement Input, Discount Rate [Member] bkyi_DeferredTaxAssetsResarchAndDevelopmentExpenses Research and development expenses Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses. Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense Measurement Input, Default Rate [Member] Measurement Input, Price Volatility [Member] Change in operating assets and liabilities: Three Customers [Member] Information pertaining to three customers. One Customer [Member] Information pertaining to one customer. Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities, net of current portion Operating lease liabilities, non-current portion Inventory Disclosure [Text Block] Subsequent Event [Member] Measurement Input, Expected Term [Member] Schedule of Inventory, Current [Table Text Block] Total us-gaap_OperatingLeaseLiability Total operating lease liabilities Operating lease liabilities, current portion Operating lease liabilities, current portion Measurement Input, Exercise Price [Member] Subsequent Event Type [Axis] us-gaap_DebtInstrumentMeasurementInput Debt Instrument, Measurement Input Subsequent Event Type [Domain] bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate Investment in Held-to-maturity Debt Securities, Interest Rate Represents the interest rate of an investment in held-to-maturity debt securities. Retirement Benefits [Text Block] Deposits and other assets Subsequent Events [Text Block] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total future lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Deferred income tax benefit Measurement Input Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Thereafter Measurement Input Type [Domain] Fair Value Measurement, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2024 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2025 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2026 Lessee, Operating Lease, Liability, to be Paid, Year One us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2023 bkyi_DebtInstrumentInterestRateDefault Debt Instrument, Interest Rate, Default Percentage of interest rate in the event of default on the debt instrument. Warrants Issued in Connection With Note [Member] Represents warrants issued in connection with note. Share-Based Payment Arrangement, Employee [Member] bkyi_DebtInstrumentConvertiblePercentageOfOutstandingStock Debt Instrument, Convertible, Percentage of Outstanding Stock Percentage of of outstanding stock for shares issued upon conversion of debt instrument. Capitalized contract costs, net Common stock issued for acquisition of note payable Amount of stock issued with note payable. Foreign Currency Transactions and Translations Policy [Policy Text Block] bkyi_StockIssuedDuringPeriodSharesCommitmentFee Stock Issued During Period, Shares, Commitment Fee The number fo shares issued during the period for commitment fee. Lessee, Leases [Policy Text Block] Valuation allowance bkyi_EffectiveIncomeTaxRateReconciliationEffectOfNetOperatingLossPercent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to effect of net operating loss. Business Combinations Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life Earnings Per Share, Policy [Policy Text Block] Note receivable, net of allowance Noncurrent portion, net of allowance Operating expenses Amortization of debt discount Income Tax, Policy [Policy Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] Research and Development Expense, Policy [Policy Text Block] Investment – debt security, net us-gaap_Depreciation Depreciation Proprietary Software [Member] Represents information pertaining to proprietary software. us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share Africa [Member] us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Advertising Cost [Policy Text Block] Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,190,504 and 7,853,759 of $.0001 par value at December 31, 2022 and December 31, 2021, respectively Other assets acquired from Swivel Secure Adjustments to reconcile net loss to cash used for operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Asia [Member] Revenue from Contract with Customer [Policy Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Previously Reported [Member] us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance Valuation allowance us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowances Deferred Tax Assets, Valuation Allowance Revision of Prior Period, Adjustment [Member] Statistical Measurement [Domain] Cash paid for amounts included in the measurement of operating lease liabilities Maximum [Member] Minimum [Member] us-gaap_OtherAssetsCurrent Due from factor Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Net deferred tax asset us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax liability North America [Member] Interest Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Geographical [Axis] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Geographical [Domain] Property, Plant and Equipment [Table Text Block] us-gaap_PreferredStockSharesAuthorized Preferred Stock, Shares Authorized Inventory, net of reserve Total inventory us-gaap_PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share EMEA [Member] us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Services us-gaap_InventoryValuationReserves Inventory Valuation Reserves Reserve on debt security us-gaap_DeferredTaxAssetsInvestments Reserve on debt security Fair Value, Inputs, Level 3 [Member] Loss on foreign currency transactions Loss on foreign currency Fair Value Hierarchy and NAV [Domain] Customer [Axis] us-gaap_DeferredTaxAssetsInventory Inventory reserve Fair Value, Inputs, Level 1 [Member] Customer [Domain] Intangible assets Intangible assets Fair Value, Inputs, Level 2 [Member] Equipment and leashold improvements us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment Equipment and leasehold improvements Fair Value Hierarchy and NAV [Axis] us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue Property, Plant, and Equipment, useful life (Year) Exercise Price Greater Than Average Market Price Of Common Shares [Member] Exercise price greater than average market price of common shares member. CASH FLOW FROM OPERATING ACTIVITIES: Allowance for doubtful accounts Allowance for doubtful accounts us-gaap_NotesAndLoansReceivableNetCurrent Note receivable, net of allowance bkyi_InvestmentIncomeDebtSecurityReserveExpense Investment-debt security reserve Amount of expenses related to debt security reserve. us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] us-gaap_AccountsReceivableGrossCurrent Accounts receivable us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, net of allowances for doubtful accounts Accounts receivable, net Furniture and Fixtures [Member] Accrued Compensation Accrued compensation Additional paid-in capital Stock based compensation Stock-based compensation Revenues us-gaap_HeldToMaturitySecuritiesCurrent Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current bkyi_ReserveForInvestmentSecurity Reserve for investment security Amount of reserve for investment security. AOCI Attributable to Parent [Member] bkyi_ReserveForNoteReceivable Reserve for note receivable Amount of reserve for note receivable. STOCKHOLDERS’ EQUITY Capital loss carry forward Common stock issued for acquisition of Swivel Secure Represents stock issued related to noncash or part noncash acquisition. Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] us-gaap_NonoperatingIncomeExpense Total other income (expense) bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost Percentage of Support and Maintenance Revenue to License Cost The percentage of support and maintenance revenue for SaaS license to total license cost. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Net operating loss and research credit carryforwards Net operating loss and credit carryforwards Accounts payable and accrued expenses bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued liabilities, assumed at the acquisition date. Government loan acquired from Swivel Secure Represents government loan acquired. Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR CASH AND CASH EQUIVALENTS, END OF YEAR ASSETS License [Member] Interest income Effect of exchange rate changes us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET DECREASE IN CASH AND CASH EQUIVALENTS us-gaap_Liabilities TOTAL LIABILITIES us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities Commitments and Contingencies Director [Member] Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss Other income (expense) us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used for operating activities us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized Prepaid expenses and other us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used for investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liability Share based and warrant compensation for employees and consultants Amount of noncash expense for share-based payment arrangement, excluding directors fees. us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Intangible assets - Foreign bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits Cumulative Amount of Amortization Expense, Net of Credits Represents cumulative amount of amortization expense net of credit expense. us-gaap_GrossProfit Gross Profit us-gaap_CostOfGoodsAndServicesSold Cost of services Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Deferred tax liability Derivatives, Policy [Policy Text Block] us-gaap_InventoryWriteDown Reserve for inventory us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Operationg Lease right-of -use assets us-gaap_DeferredTaxLiabilitiesLeasingArrangements Operating lease right-of-use assets us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Equipment and leashold improvements us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Equipment and leasehold improvements Notes Receivable [Text Block] The entire disclosure for notes receivable. Costs and other expenses Scenario [Domain] Forecast [Member] Retained Earnings [Member] The 2015 Software License [Member] Represents information about the 2015 Software License. Title of Individual [Domain] Title of Individual [Axis] Deferred - States Scenario [Axis] Deferred - Foreign Additional Paid-in Capital [Member] Common Stock [Member] Deferred- Federal Equity Components [Axis] Equity Component [Domain] Current – federal, states, and foreign Public Offering Warrants [Member] Information related to the public offering warrants. us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Schedule of Warrants Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants. us-gaap_ClassOfWarrantOrRightOutstanding Outstanding, warrants (in shares) Outstanding, warrants (in shares) Amortization of note discount Amount of noncash expenses to amortize note discount. us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before provision for income tax benefit Government Loan [Member] Represents information related to government loan. bkyi_InventoryFinishedGoodsReserves Reserve on finished goods Carrying amount of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. BBVA Bank [Member] Represents information related to BBVA bank. bkyi_IncreaseDecreaseInCapitalizedContractCosts Capitalized contract costs The amount of increase (decrease) in capitalized contract costs. Hardware [Member] Represents information pertaining to hardware. bkyi_WarrantsIssuedWithLoan Issuance of warrant in conjunction with note payable The fair value of warrants issued with loan in noncash financing activities. dei_IcfrAuditorAttestationFlag ICFR Auditor Attestation Flag us-gaap_PaymentsOfDebtIssuanceCosts Costs incurred for issuance of convertible note Allowance for doubtful accounts, charged to costs and expenses bkyi_AllowanceForDoubtfulAccounts Allowance for doubtful account Amount of allowance for credit loss on accounts receivable. State and Local Jurisdiction [Member] Proceeds from Employee Stock Purchase Plan Represents proceeds from employee stock purchase plan. Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Equipment [Member] Revenue from Contract with Customer [Text Block] Document Annual Report bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal Total estimated assets acquired Amount of assets including goodwill acquired at the acquisition date. Principal Upon Default [Member] Represents increase in principal upon a default. Change in fair value of convertible note Change in fair value of convertible note Represents fair value adjustment of convertible note. Cash and Cash Equivalents, Policy [Policy Text Block] bkyi_LoanTransactionCosts Loan transaction costs Represents transaction costs for loan. Measurement Input, Likelihood of Default [Member] Represents likelihood of default for measurement input. Franchise taxes Represents current portion of accrued franchise taxes. Deferred tax liability from the acquisition of Swivel Secure Represents noncash or part noncash acquisition for deferred tax liability. Software Development [Member] Receivable [Policy Text Block] Employee expenses reimbursement Represents accrued employee expenses reimbursement, current. Entity Incorporation, State or Country Code Accounting Policies [Abstract] us-gaap_OpenTaxYear Open Tax Year Document Transition Report dei_DocumentFinStmtErrorCorrectionFlag Document Financial Statement Error Correction [Flag] Basis of Accounting, Policy [Policy Text Block] Concentration Risk Disclosure [Text Block] Convertible note payable, net of debt discount Selling, General and Administrative Expenses [Member] dei_EntityInteractiveDataCurrent Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Bad debt expense Receivable Type [Axis] Receivable [Domain] Proceeds from issuance of convertible notes, net of OID Notes Receivable [Member] Research and Development Expense [Member] Income Statement Location [Axis] Income Statement Location [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Auditor Name Auditor Firm ID Auditor Location bkyi_BusinessCombinationReversalOfEarnoutPayable Reversal of earnout payable – Swivel acquisition Amount of earnout payable reversal incurred as part of a business combination. us-gaap_RepaymentsOfNotesPayable Repayment of note payable - PistolStar us-gaap_SharePrice Share Price Restricted [Member] Represents restricted classification. Antidilutive securities (in shares) Earnout payable Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination, fair value. us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Statement [Table] Statement of Financial Position [Abstract] Basic and Diluted (in shares) Expiration and forfeiture of stock options us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Accounts Payable and Accrued Liabilities Disclosure [Text Block] Other us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective tax rate Basic and Diluted Loss per Common Share (in dollars per share) Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Valuation allowance Valuation allowance Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Schedule of Accrued Liabilities [Table Text Block] us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate Receivable with Imputed Interest, Effective Yield (Interest Rate) Net Income (Loss) by Geographic Areas [Table Text Block] Tabular disclosure of net income (loss) by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. bkyi_IncomeTaxExpenseBenefitGross Total Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations before valuation allowance. bkyi_IncomeTaxExpenseBenefitValuationAllowance Change in valuation allowance Amount of valuation allowance for income tax expense (benefit). Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] State taxes, net of federal benefit us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes us-gaap_LiabilitiesNoncurrent Total non-current liabilities CASH FLOWS FROM FINANCING ACTIVITIES: U.S. statutory income tax rate Federal statutory income tax rate The 2015 Equity Incentive Plan [Member] Refers to information regarding the 2015 Equity Incentive plan. bkyi_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period The class of warrant or right issued during the period. Research, Development, and Computer Software Disclosure [Text Block] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Total estimated fair value of assets acquired and liabilities assumed Deferred revenue, net of current portion us-gaap_StockholdersEquity TOTAL STOCKHOLDERS’ EQUITY Balance Balance as of December 31, 2021 Amortization of operating lease right-of-use assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Total liabilities assumed Total cash paid, including working capital adjustment us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Class of Stock [Axis] Government loan – BBVA Bank, net of current portion Receipt of cash from note receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred tax liability us-gaap_PaymentsToAcquireBusinessesGross Purchase of Swivel Secure, net of cash acquired of $729,905 Payments to Acquire Businesses, Gross Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average remaining remaining life (Year) Interest expense Options exercisable (in shares) Range of exercise prices, upper range (in dollars per share) Options outstanding (in shares) Exercise Price Range [Axis] Equipment acquired us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment Exercise Price Range [Domain] Other assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Range of exercise prices, lower range (in dollars per share) EX-101.PRE 12 bkyi-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 13 bkyi-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
May 30, 2023
Jun. 30, 2022
Document Information [Line Items]        
Document Type 10-K      
Document Annual Report true      
Document Period End Date Dec. 31, 2022      
Document Transition Report false      
Entity File Number 1-13463      
Entity Registrant Name BIO-KEY INTERNATIONAL, INC.      
Entity Incorporation, State or Country Code DE      
Entity Tax Identification Number 41-1741861      
Entity Address, Address Line One 3349 HIGHWAY 138, BUILDING A, SUITE E      
Entity Address, City or Town WALL      
Entity Address, State or Province NJ      
Entity Address, Postal Zip Code 07719      
City Area Code 732      
Local Phone Number 359-1100      
Title of 12(b) Security Common Stock, $0.0001 par value per share      
Trading Symbol BKYI      
Security Exchange Name NASDAQ      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status No      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Entity Shell Company false      
Entity Public Float       $ 13,509,134
Entity Common Stock, Shares Outstanding (in shares)     9,234,833  
Auditor Name Marcum LLC. Rotenberg Meril Solomon Bertiger & Guttilla, P.C.    
Auditor Location Saddle Brook, NJ Saddle Brook, NJ    
Auditor Firm ID 688 361    
Entity Central Index Key 0001019034      
Current Fiscal Year End Date --12-31      
Document Fiscal Year Focus 2022      
Document Fiscal Period Focus FY      
Amendment Flag false      
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
ASSETS    
Cash and cash equivalents $ 2,635,522 $ 7,754,046
Accounts receivable, net 1,522,784 970,626
Due from factor 49,500 49,500
Note receivable, net of allowance 0 82,000
Inventory, net of reserve 4,434,369 4,940,660
Prepaid expenses and other 342,706 216,041
Total current assets 8,984,881 14,012,873
Resalable software license rights 0 48,752
Investment – debt security, net 0 452,821
Equipment and leasehold improvements, net 107,413 69,168
Capitalized contract costs, net 283,069 249,012
Deposits and other assets 8,712 8,712
Note receivable, net of allowance 0 113,000
Operating lease right-of-use assets 197,355 254,100
Intangible assets, net 1,762,825 1,298,077
Goodwill 0 1,262,526
Total non-current assets 2,359,374 3,756,168
TOTAL ASSETS 11,344,255 17,769,041
LIABILITIES    
Accounts payable 1,108,279 427,772
Accrued liabilities 1,009,123 828,997
Convertible note payable, net of debt discount 2,596,203 0
Government loan – BBVA Bank, current portion 120,000 0
Deferred revenue - current 462,418 565,355
Operating lease liabilities, current portion 159,665 177,188
Total current liabilities 5,455,688 1,999,312
Deferred revenue, net of current portion 52,134 67,300
Deferred tax liability 170,281 0
Government loan – BBVA Bank, net of current portion 326,767 0
Operating lease liabilities, net of current portion 37,829 86,974
Total non-current liabilities 587,011 154,274
TOTAL LIABILITIES 6,042,699 2,153,586
Commitments and Contingencies  
STOCKHOLDERS’ EQUITY    
Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,190,504 and 7,853,759 of $.0001 par value at December 31, 2022 and December 31, 2021, respectively 919 786
Additional paid-in capital 122,028,612 120,190,139
Accumulated other comprehensive loss (242,602) 0
Accumulated deficit (116,485,373) (104,575,470)
TOTAL STOCKHOLDERS’ EQUITY 5,301,556 15,615,455
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 11,344,255 $ 17,769,041
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Common stock, shares authorized (in shares) 170,000,000 170,000,000
Common stock, shares issued (in shares) 9,190,504 7,853,759
Common stock, shares outstanding (in shares) 9,190,504 7,853,759
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues    
Services $ 7,020,258 $ 5,114,489
Costs and other expenses    
Cost of services 2,439,570 1,672,929
Gross Profit 4,580,688 3,441,560
Operating expenses    
Selling, general and administrative 9,364,887 6,028,360
Research, development and engineering 3,252,236 2,355,056
Reversal of earnout payable – Swivel acquisition (500,000) 0
Impairment of goodwill 2,387,193 0
Total operating expenses 14,504,316 8,383,416
Operating loss (9,923,628) (4,941,856)
Other income (expense)    
Interest income 233 4,075
Loss on foreign currency transactions 0 (50,000)
Investment-debt security reserve (452,821) (60,000)
Loan transaction costs (1,147,456) 0
Change in fair value of convertible note (396,203) 0
Interest expense (10,462) (18,000)
Total other income (expense) (2,006,709) (123,925)
Loss before provision for income tax benefit (11,930,337) 0
Provision for income tax benefit 20,434 0
Net loss (11,909,903) (5,065,781)
Comprehensive loss:    
Net loss (11,909,903) (5,065,781)
Other comprehensive loss- Foreign translation adjustment (242,602) 0
Comprehensive loss $ (12,152,505) $ (5,065,781)
Basic and Diluted Loss per Common Share (in dollars per share) $ (1.47) $ (0.65)
Weighted Average Shares Outstanding:    
Basic and Diluted (in shares) 8,100,785 7,791,741
Service [Member]    
Revenues    
Services $ 1,789,720 $ 1,273,354
Costs and other expenses    
Cost of services 722,152 686,175
License [Member]    
Revenues    
Services 4,584,052 2,555,809
Costs and other expenses    
Cost of services 906,417 183,199
Hardware [Member]    
Revenues    
Services 646,486 1,285,326
Costs and other expenses    
Cost of services $ 811,001 $ 803,555
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2020 7,814,572        
Balance at Dec. 31, 2020 $ 782 $ 119,844,026 $ 0 $ (99,509,689) $ 20,335,119
Issuance of common stock for directors’ fees (in shares) 7,828        
Issuance of common stock for directors’ fees $ 1 25,535 0 0 25,536
Issuance of restricted common stock to employees (in shares) 13,125        
Issuance of restricted common stock to employees $ 1 (1) 0 0 0
Forfeiture of restricted stock (in shares) (1,250)        
Forfeiture of restricted stock $ 0 0 0 0 0
Legal fees $ 0 (5,228) 0 0 (5,228)
Issuance of common stock for Employee stock purchase plan (in shares) 19,484        
Issuance of common stock for Employee stock purchase plan $ 2 36,628 0 0 36,630
Share based compensation for employee stock purchase plan 0 10,680 0 0 10,680
Share-based compensation 0 278,499 0 0 278,499
Net loss $ 0 0 0 (5,065,781) (5,065,781)
Other comprehensive loss- Foreign translation adjustment         0
Balance as of December 31, 2021 (in shares) at Dec. 31, 2021 7,853,759        
Balance as of December 31, 2021 at Dec. 31, 2021 $ 786 120,190,139 0 (104,575,470) 15,615,455
Issuance of common stock for directors’ fees (in shares) 39,636        
Issuance of common stock for directors’ fees $ 4 76,039 0 0 76,043
Issuance of restricted common stock to employees (in shares) 278,000        
Issuance of restricted common stock to employees $ 27 (27) 0 0 0
Forfeiture of restricted stock (in shares) (10,500)        
Forfeiture of restricted stock $ (1) 0 0 0 (1)
Issuance of common stock for Employee stock purchase plan (in shares) 60,549        
Issuance of common stock for Employee stock purchase plan $ 6 56,374 0 0 56,380
Share based compensation for employee stock purchase plan 0 18,787 0 0 18,787
Share-based compensation 0 293,077 0 0 293,077
Net loss $ 0 0 0 (11,909,903) (11,909,903)
Issuance of common stock pursuant to Swivel purchase agreement (in shares) 269,060        
Issuance of common stock pursuant to Swivel purchase agreement $ 27 599,977 0 0 600,004
Issuance of common stock for note issuance fees (in shares) 700,000        
Issuance of common stock for note issuance fees $ 70 699,930 0 0 700,000
Issuance of warrant in conjunction with note payable 0 94,316 0   94,316
Other comprehensive loss- Foreign translation adjustment $ 0   (242,602) 0 (242,602)
Balance as of December 31, 2021 (in shares) at Dec. 31, 2022 9,190,504        
Balance as of December 31, 2021 at Dec. 31, 2022 $ 919 $ 122,028,612 $ (242,602) $ (116,485,373) $ 5,301,556
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOW FROM OPERATING ACTIVITIES:    
Net loss $ (11,909,903) $ (5,065,781)
Adjustments to reconcile net loss to cash used for operating activities:    
Depreciation 43,794 54,649
Impairment of goodwill 2,387,193 0
Reversal of earnout payable – Swivel acquisition (500,000) 0
Amortization of intangible assets and write-off 298,113 216,069
Amortization of resalable software license rights 48,752 10,130
Amortization of note discount 1,147,456 0
Loss on foreign currency 0 50,000
Reserve for investment security 452,821 60,000
Reserve for inventory 400,000 0
Reserve for note receivable 186,000 100,000
Allowance for doubtful account 360,000 200,000
Amortization of debt discount 0 18,000
Amortization of capitalized contract costs 106,624 110,681
Share based and warrant compensation for employees and consultants 311,864 289,179
Stock based fees to directors 76,043 25,536
Bad debt expense 130,111 0
Change in fair value of convertible note 396,203 (0)
Deferred income tax benefit (20,434) 0
Amortization of operating lease right-of-use assets 155,353 233,225
Change in operating assets and liabilities:    
Accounts receivable (339,383) (672,577)
Due from factor 0 10,953
Capitalized contract costs (140,681) (194,378)
Inventory 106,291 (4,609,713)
Prepaid expenses and other (46,655) (14,534)
Accounts payable 239,144 183,614
Accrued liabilities 167,614 320,510
Deferred revenue (120,078) (69,681)
Operating lease liabilities (165,276) (234,310)
Net cash used for operating activities (6,229,034) (8,978,428)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of Swivel Secure, net of cash acquired of $729,905 (623,578) 0
Receipt of cash from note receivable 9,000 0
Capital expenditures 82,040 42,024
Net cash used for investing activities (696,618) (42,024)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of convertible notes, net of OID 2,002,000 0
Costs incurred for issuance of convertible note (155,140) 0
Proceeds from Employee Stock Purchase Plan 56,380 36,630
Repayment of note payable - PistolStar 0 (250,000)
Legal fees 0 (5,228)
Net cash (used in) provided by financing activities 1,903,240 (218,598)
Effect of exchange rate changes (96,112) 0
NET DECREASE IN CASH AND CASH EQUIVALENTS (5,118,524) (9,239,050)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 7,754,046 16,993,096
CASH AND CASH EQUIVALENTS, END OF YEAR 2,635,522 7,754,046
Cash paid for:    
Taxes 25,682 0
Interest 10,462 0
Noncash investing and financing activities:    
Accounts receivable acquired from Swivel Secure 702,886 0
Equipment acquired from Swivel Secure 65,640 0
Other assets acquired from Swivel Secure 20,708 0
Intangible assets acquired from Swivel Secure 762,860 0
Goodwill resulting from the acquisition from Swivel Secure 1,258,087 0
Accounts payable and accrued expenses acquired from Swivel Secure 431,884 0
Government loan acquired from Swivel Secure 544,000 0
Deferred tax liability from the acquisition of Swivel Secure 190,715 0
Common stock issued for acquisition of Swivel Secure 600,004 0
Common stock issued for acquisition of note payable 700,000 0
Issuance of warrant in conjunction with note payable 94,316 0
Operating lease right-of-use asset and liability for new lease $ 105,893 $ 0
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Parentheticals)
 12 Months Ended
Dec. 31, 2022
USD ($)
Receipt of cash from note receivable $ 9,000
Swivel Secure Europe [Member]  
Receipt of cash from note receivable $ 729,905
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

NOTE A —THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

 

Going Concern and Basis of Presentation

 

The Company has historically financed our operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered our expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and therefore is looking into other markets and opportunities to sell or return the product to generate additional cash.

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

Foreign Currency

 

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.

 

The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss.

 

 

Summary of Significant Accounting Policies

 

A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:

 

1. Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation.

 

2. Use of Estimates

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to accounts receivable, inventory, intangible assets and goodwill, fair value of convertible note payable, and income taxes.

 

3. Revenue Recognition

 

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:

 

 

●

Identify the contract with a customer

 

 

●

Identify the performance obligations in the contract

 

 

●

Determine the transaction price

 

 

●

Allocate the transaction price to performance obligations in the contract

 

 

●

Recognize revenue when or as the Company satisfies a performance obligation

 

All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.

 

Software licenses

Software license revenue consists of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.

 

Hardware

Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.

 

Support and Maintenance

Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the term of the contract begins. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.

 

Professional Services

Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.

 

Contracts with Multiple Performance Obligations

Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.

 

The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.

 

Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.

 

Costs to Obtain and Fulfill a Contract

Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

 

Deferred Revenue

Deferred revenue includes customer advances and amounts that have been paid by customers for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2022 and 2021, amounts in deferred revenue were approximately $515,000 and $633,000, respectively.

 

4. Business Combinations

 

In accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.

 

The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.

 

5. Goodwill and acquired intangible assets

 

Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31st of each year. Refer Note K for more information regarding the impairment of goodwill in 2022.

 

Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.

 

6. Cash Equivalents

 

Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2022 and 2021, cash equivalents consisted of a money market account.

 

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2022 and 2021 consisted of the following:

 

   

December 31,

  
   

2022

    

2021

  
                 

Accounts receivable

   $ 2,096,569     $ 1,234,411  
Loss on foreign currency     -       (50,000

)

Allowance for doubtful accounts

     (573,785

)

     (213,785

)

Accounts receivable, net of allowances for doubtful accounts

   $ 1,522,784     $ 970,626  

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense.

 

The allowance for doubtful accounts for the years ended December 31, 2022 and 2021 is as follows:

 

   

Balance at

Beginning of Year

    

Charged to Costs and Expenses

    

Deductions from Reserves

    

Balance at End of Year

  
                                 

Year ended December 31, 2022 Allowance for Doubtful Accounts

   $ 213,785     $ 360,000     $ -     $ 573,785  

Year ended December 31, 2021 Allowance for Doubtful Accounts

   $ 1,733,785     $ 200,000     $ (1,720,000 )   $ 213,785  

 

8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and Amortization

 

Equipment and leasehold improvements are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.

 

The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:

 

 

Years

  

Equipment and leasehold improvements

          

Equipment

   3

-

 5  

Furniture and fixtures

   3

-

 5  

Software

     3    

Leasehold improvements

 

life or lease term

  

 

Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships. Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.

 

9. Impairment or Disposal of Long Lived Assets, including Intangible Assets

 

The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. There were no impairments in 2022 and 2021.

 

10. Advertising Expense

 

The Company expenses the costs of advertising as incurred. Advertising expenses for 2022 and 2021 were approximately $842,000 and $527,000, respectively.

 

11. Research and Development Expenditures

 

Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred.

 

12. Earnings Per Share of Common Stock (“EPS”)

 

The Company’s EPS is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.

 

13. Accounting for Stock-Based Compensation

 

The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over a three year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of certain assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.

 

The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:

 

   

Year ended

December 31,

  
   

2022

    

2021

  
                 

Selling, general and administrative

   $ 310,017     $ 269,368  

Research, development and engineering

     77,890       45,347  
    $ 387,907     $ 314,715  

 

14. Income Taxes

 

The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.

 

The Company accounts for uncertain tax provisions in accordance with ASC 740. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

15. Leases

 

In accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases.

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.

 

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.

 

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.

 

16. The Fair Value Measurement Option

 

The Company has elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the convertible promissory note was recorded at fair value upon issuance and will subsequently be remeasured at each reporting date until settled or converted. The Company recognized the note initially at fair value, which exceeded the proceeds received resulting in a day one loss that has been recognized in net loss. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations.

 

17. Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

 

The following table summarizes our financial instruments measured at fair value at December 31, 2022:

 

    Total     Level 1     Level 2     Level 3  
                                 
Convertible note at fair value   $ 2,596,203     $ -     $ -     $ 2,596,203  

 

The Company issued a convertible note to which included an original issue discount, conversion features and a detachable warrant, as further discussed in Note M. The detachable warrant represents a freestanding, separable equity-linked financial instrument recorded at fair value. The fair value of the detachable warrant was calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt which was determined based on significant unobservable inputs including the likelihood of default, the estimated date at which the default could take place, and the present value discount rate, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The fair value option requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as change in fair value of convertible note in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible note were expensed and not deferred.

 

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at December 22, 2022:

1. Face amount - $2,200,000

2. Nominal interest rate – 10% - 12%

3. Default interest rate – 18%

4. Increase in principal upon a default – 30%

5. Present value discount rate – 15.18%

6. Likelihood of default – estimated to be 50% at the extended maturity date

 

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the year ended December 31, 2022:

 

Beginning balance   $ -  
Purchases and issuances     2,200,000  
Day one loss on value of hybrid instrument     396,203  
Ending balance   $ 2,596,203  

 

18. Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016- 13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct writedown of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for the Company for annual periods, including interim periods within those annual periods, beginning on January 1, 2023. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Revenue From Contracts With Customers
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

NOTE B—REVENUE FROM CONTRACTS WITH CUSTOMERS

 

Disaggregation of Revenue

 

The following table summarizes revenue from contracts with customers for the years ended December 31, 2022 and 2021:

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2022

  
                                         

License fees

   $ 1,856,814     $ 517,161     $ 2,124,088     $ 85,989     $ 4,584,052  

Hardware

     422,275       25,833       19,914       178,464       646,486  

Services

     1,270,067       83,306       436,293       54       1,789,720  

Total Revenues

   $ 3,549,156     $ 626,300     $ 2,580,295     $ 264,507     $ 7,020,258  

 

   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  

 

* EMESA – Europe, Middle East, South America

 

Revenue recognized during the year ended December 31, 2022 from amounts included in deferred revenue at the beginning of the year was approximately $489,000. Revenue recognized during the year ended December 31, 2021 from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Total deferred revenue (contract liability) was approximately $515,000 and $633,000 at December 31, 2022 and 2021, respectively.

 

Transaction Price Allocated to the Remaining Performance Obligations

 

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:

 

 

●

The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.

 

Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from one to five years.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Swivel Secure Europe, SA Acquisition
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

NOTE C—SWIVEL SECURE EUROPE, SA ACQUISITION

 

On March 8, 2022, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure based in Madrid, Spain, pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of $500,000. The earn-out was payable based on Swivel Secure generating $3,000,000 of revenue and $1,000,000 of operating profit during an earn-out period commencing on the closing date and ending on January 31, 2023, which was not attained. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement. The shares of Company common stock were priced at $2.23, the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market.

 

The business combination has been accounted for as an acquisition and, in accordance with ASC 805. The Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the purchase price allocation, with no earnout payment:

 

Purchase consideration:        

Total cash paid, including working capital adjustment

   $ 1,273,483  
Earnout payable     500,000  

Common stock issued

     600,004  

Total purchase price consideration

   $ 2,373,487  
         
Fair value of assets acquired and liabilities assumed:        

Cash and cash equivalents

   $ 729,905  

Accounts receivable

     702,886  

Equipment acquired

     65,640  

Other assets

     20,708  

Intangible assets

     762,860  

Goodwill

     1,258,087  

Total estimated assets acquired

     3,540,086  
         

Accounts payable and accrued expenses

     431,884  

Government loan

     544,000  
Deferred tax liability     190,715  

Total liabilities assumed

     1,166,599  

Total estimated fair value of assets acquired and liabilities assumed

   $ 2,373,487  

 

The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce. Refer to Note K for more information regarding the impairment of goodwill.

 

The significant intangible asset identified in the purchase price allocation discussed above was Customer Relationships. To value the Customer Relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value.

 

The government loan was issued through BBVA Bank during the COVID-19 pandemic. The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through April 2026. The installment payments have been paid monthly as per the schedule, as of the date of this report.

 

The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:

 

   

Amount

    

Estimated useful

life

(in years)

  

Customer relationships

   $ 762,860       7  

Total identifiable intangible assets

   $ 762,860          

 

As discussed above, the earnout payable was not achieved. As such, the Company reversed the earnout payable of $500,000 and recognized the income on the reversal of the earnout payable.

 

For the period from March 8, 2022 to December 31, 2022, revenue from Swivel Secure amounted to $2,351,975 and net loss amounted to $720,691.

 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Note D - Fair Values of Financial Instruments
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

NOTE D—FAIR VALUES OF FINANCIAL INSTRUMENTS

 

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Concentration of Risk
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]

NOTE E—CONCENTRATION OF RISK

 

Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.

 

The Company maintains its cash and cash equivalents with various financial institutions, which, at times may exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $2,000,000 and $7,057,000 at December 31, 2022 and 2021, respectively. The Company has not incurred any losses on these accounts.

 

The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.

 

For the year ended December 31, 2022 no customer accounted for 10% of total revenue. For the year ended December 2021, one customer accounted for 13% of total revenue.

 

At December 31, 2022, one customer accounted for 35% of the total accounts receivable. At December 31, 2021, three customers accounted for 87% of total accounts receivable.

 

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Note Receivable
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Notes Receivable [Text Block]

NOTE F—NOTE RECEIVABLE

 

During the third quarter of 2020, the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note did not bear any interest if paid within the nine (9) monthly installments beginning December 31, 2020. The note bore a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $186,000 of the note as an allowance. On February 17, 2022, the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on or before December 6, 2023. On May 5, 2022, the Company amended the note to modify the payment terms to eight biweekly installments of $1,000 beginning February 25, 2022, nineteen consecutive monthly installments of $15,000 beginning on July 6, 2022, and $2,000 on or before February 6, 2024. Currently, the payments are several months behind schedule. Due to the delay in payments, the Company has increased the allowance for the remainder of the balance owed under the note. We are continuing to pursue payment and expect that we will start to receive funds in the second quarter of 2023. A member of our board of directors served as Chief Executive Officer of TTI until August 12, 2020.

 

   

December 31,

    

December 31,

  
   

2022

    

2021

  
                 

Note receivable

   $ 195,000     $ 295,000  

Repayment of note

     (9,000 )     -  

Allowance for doubtful account

     (186,000 )     (100,000

)

Note receivable, net of allowance

     -       195,000  
Current portion, net of allowance   $ -     $ 82,000  
Noncurrent portion, net of allowance   $ -     $ 113,000  

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Inventory
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE G—INVENTORY

 

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product.

 

Inventory is comprised of the following as of December 31:

 

   

2022

    

2021

  
                 

Finished goods

   $ 4,764,643     $ 4,798,203  

Fabricated assemblies

     69,726       142,457  
Reserve on finished goods     (400,000 )     -  

Total inventory

   $ 4,434,369     $ 4,940,660  

 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Note H - Resalable Software Licenses Rights
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Research, Development, and Computer Software Disclosure [Text Block]

NOTE H—RESALABLE SOFTWARE LICENSES RIGHTS

 

On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company was amortizing the total cost at the greater of the actual unit cost per license sold or straight-line amortization over 10 years. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $141,190 has been charged to cost of sales. Since we have not received any sales for the license within the last two years, we accelerated the amortization for the balance of the license in 2022, leaving a carrying balance of $0 and $48,752 as of December 31, 2022 and 2021, respectively. A total of $48,752 and $10,130 was charged to cost of sales during the years ended December 31, 2022 and 2021, respectively.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Note I - Investment in Debt Security
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE I—INVESTMENT IN DEBT SECURITY

 

The Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in September 2020 bearing interest at 5% per annum. The Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date.  The investment was originally recorded at amortized cost and was scheduled to mature in June 2021. The Company never received the proceeds and accrued interest from the investment and as such, wrote off the investment during 2022 as the bond issuer defaulted on repayment, and the Company had no recourse.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Equipment and Leasehold Improvements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

NOTE J—EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Equipment and leasehold improvements consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Equipment

   $ 825,058     $ 831,784  

Furniture and fixtures

     225,978       164,079  

Software

     49,143       32,045  

Leasehold improvements

     34,903       25,135  
      1,135,082       1,053,043  
                 
                 

Less accumulated depreciation and amortization

     (1,027,669

)

     (983,875

)
                 

Total

   $ 107,413     $ 69,168  

 

Depreciation was $43,794 and $54,649 for 2022 and 2021, respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Note K - Intangible Assets and Goodwill
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

NOTE K—INTANGIBLE ASSETS AND GOODWILL

 

Intangible assets consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Trade name

   $ 130,000     $ 130,000  

Proprietary software

     420,000       420,000  

Customer relationships

     1,692,860       930,000  

Patents and patents pending

     365,080       365,080  
      2,607,940       1,845,080  
                 
                 

Less accumulated amortization

     (845,115

)

     (547,003 )
                 

Total

   $ 1,762,825     $ 1,298,077  

 

Aggregate amortization expense for 2022 and 2021 was approximately $298,000 and $216,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next five years and thereafter approximates the following:

 

Years ending December 31

        

2023

   $ 320,000  

2024

     320,000  

2025

     280,000  

2026

     230,000  

2027

     220,000  

Thereafter

     392,825  

Total

   $ 1,762,825  

 

Goodwill

 

The Company conducted its annual impairment analysis of its goodwill balances as at December 31, 2022. The Company noted the noted the cyclical downturn in technology stock values over the 2022 period, since our previous annual impairment assessment.

 

The analysis showed the carrying value of the Company’s reporting segment was in excess of the Company’s market valuation as at December 31, 2022 based on a fair valuation measure as the quoted market price for the Company’s publicly traded stock as of that date.

 

Accordingly, the Company concluded the amounts in goodwill had been fully impaired and accordingly wrote-off the entire balance in full as at December 31, 2022.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Note L - Accrued Liabilities
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

NOTE L—ACCRUED LIABILITIES

 

Accrued liabilities consisted of the following as of December 31:

 

   

2022

    

2021

  
                 

Compensation

   $ 377,958     $ 254,433  

Compensated absences

     378,874       293,297  

Accrued legal and accounting fees

     110,008       95,738  
Franchise taxes     7,000       40,000  
Employee expenses reimbursement     114,209       76,000  

Sales tax payable

     17,594       18,548  

Other

     3,480       50,981  
                 

Total

   $ 1,009,123     $ 828,997  

 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Note M - Convertible Note Payable
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Debt Disclosure [Text Block]

NOTE M—CONVERTIBLE NOTE PAYABLE

 

Securities Purchase Agreement dated December 22, 2022

 

On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) which issued a $2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $2,002,000 was funded, with the proceeds to be used for general working capital.

 

The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension by the Company. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

 

In connection with the issuance of the Note, the Company issued to the investor 700,000 shares of Common Stock (the “Commitment Shares”) valued at $1.00 per share and a warrant (the “Warrant”) to purchase 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $3.00 per share, exercisable commencing on the date of issuance with a term of five years. The warrant was valued at $94,316 (see Note P. #3). In the event the Note is paid in full within six months after the date of issuance, the Company will exercise its right to repurchase 350,000 of the Commitment Shares for aggregate payment to the Investor of $1.00.

 

Upon issuance, the Note is not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.

 

The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at 1,684,576 which is 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).

 

During April 2023, we were in default under the Note due to our failure to timely file this annual report and timely file a registration statement covering the public resale of the shares issued to the holder of the Note in connection with the financing. We have obtained a waiver and, therefore, as of the date of this report we are not in default.

 

As of December 31, 2022, the Note with principal balance of $2,200,000, at fair value, was recorded at $2,596,203.

 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Note N - Leases
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

NOTE N—LEASES

 

The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
Lease cost                

Operating lease cost

   $ 254,649     $ 255,892  

Total lease cost

   $ 254,649     $ 255,892  
                 
Balance sheet information          

Operating right-of-use assets

   $ 197,355     $ 254,100  
                 

Operating lease liabilities, current portion

   $ 159,665     $ 177,188  

Operating lease liabilities, non-current portion

     37,829       86,974  

Total operating lease liabilities

   $ 197,494     $ 264,162  
                 

Weighted average remaining lease term (in years) – operating leases

     0.96       1.45  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 259,558     $ 256,977  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2022:                
                 

2023

   $ 164,596          

2024

     38,808          

Total future lease payments

   $ 203,404          

Less: imputed interest

     (5,910

)

        

Total

   $ 197,494          

 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Note O - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments Disclosure [Text Block]

NOTE O—COMMITMENTS AND CONTINGENCIES

 

Distribution Agreement

 

Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:

 

 

1.

The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.

 

 

2.

SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.

 

 

3.

Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.

 

The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.

 

 

Litigation

 

From time to time, the Company may be involved in litigation relating to claims arising out of its operations in the normal course of business. As of December 31, 2022, the Company was not a party to any pending lawsuits.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Note P - Equity
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Equity [Text Block]

NOTE P— EQUITY

 

1. Preferred Stock

 

Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $.0001 par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.

 

2. Common Stock

 

Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.

 

Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (“ESPP”). Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031.

 

Issuances of Common Stock

 

On December 22, 2022, the Company issued the Commitment Shares. See Note M - Convertible Note Payable for more information.

 

On March 8, 2022, the Company issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $600,004, priced at $2.23, based on the contractual 20-day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market

 

On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. During 2022 and 2021, 60,549, and 19,484 shares respectively were issued under the ESPP to employees, which resulted in a $18,787, and $10,680 non-cash compensation expense respectively for the Company.

 

Issuances of Restricted Stock

 

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

 

The Company issued 278,000 shares of restricted common stock to certain employees of the Company and 10,500 of shares of restricted common stock were forfeited during fiscal year 2022. The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year 2021. These shares vest in equal annual installments over a three-year period from the date of grant.

 

Restricted stock compensation for the years ended December 31, 2022 and 2021 was $218,552 and $71,819, respectively.

 

Issuances to Directors, Executive Officers & Consultants

 

During the 2022 and 2021 years, the Company issued 39,636 and 7,828 shares of common stock respectively to its directors in lieu of payment of board fees, valued at $76,043 and $25,536 respectively.

 

3. Warrants

 

There were no warrants issued during 2021.

 

Warrants Issued with Convertible Note:

 

See Note M - Convertible Note Payable for the warrant issued with a convertible note in 2022.

 

Valuation Assumptions for Warrants:

 

The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of the warrant issued in 2022 was estimated with the following assumptions:

 

   

Years ended

December 31,

  
   

2022

    

2021

  

Weighted average risk-free interest rate

     3.70

%

     -

%

Weighted average exercise price

   $ 3.00     $ -  

Weighted average exercise period

     5       -  

Weighted average Volatility of stock price

     108.60

%

     -

%

 

The volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.

 

A summary of warrant activity is as follows:

 

   

Total

Warrants

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life

(in years)

    

Aggregate

intrinsic

value

  
                                 

Outstanding, as of December 31, 2020

     4,689,387     $ 6.04       4.48       —  

Granted

     —       —                  

Exercised

     —       —                  

Forfeited

     —       —                  

Expired

     —       —                  

Outstanding, as of December 31, 2021

     4,689,387       6.04       3.48       —  

Granted

     200,000       3.00                  

Exercised

     —      

—

                  

Forfeited

     —       —                  

Expired

     (17,362 )    

28.80

                  

Outstanding, as of December 31, 2022

     4,872,025     $ 5.83       2.59       —  

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were no in-the-money warrants exercisable as of December 31, 2022, 2021 and 2020.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Note Q - Stock Options
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

NOTE Q—STOCK OPTIONS

 

2015 Stock Option Plan

 

On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. The term of stock options granted under the 2015 Plan, may not exceed ten years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.

 

Non-Plan Stock Options

 

Periodically, the Company has granted options outside of the 2015 Plan to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.

 

Stock Option Activity

 

Information summarizing option activity is as follows:

 

   

Number of Options

    

Weighted

average

    

Weighted

average

remaining

    

Aggregate

  
   

2015

Plan

    

Non

Plan

    

Total

    

exercise

price

    

life

(in years)

    

intrinsic

value

  
                                                 

Outstanding, as of December 31, 2020

     94,183       133,091       227,274     $ 17.61       3.87     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     (3,291 )    

—

       (3,291 )    

3.87

                  

Expired

     (84

)

     (11,438

)

     (11,522

)

     39.13                  

Outstanding, as of December 31, 2021

     90,808       121,653       212,461     $ 16.65       3.03     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     —       —      

—

       —                  

Expired

     —       (9,465

)

     (9,465

)

     17.28                  

Outstanding, as of December 31, 2022

     90,808       112,188       202,996     $ 16.63       2.14     $ 0  

Vested or expected to vest at December 31, 2022

                     201,271     $ 16.72       2.12     $ 0  

Exercisable at December 31, 2022

                     194,561     $ 17.12       2.03     $ 0  

 

The options outstanding and exercisable at December 31, 2022 were in the following exercise price ranges:

 

           

Options Outstanding

    

Options Exercisable

  

Range of exercise prices

    

Number of

shares

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life (in years)

    

Number

exercisable

    

Weighted

average

exercise

price

  
$ 4.08 - 5.84       25,565     $ 5.20       4.63       17,130     $ 5.20  
$ 5.85 - 28.00       177,431       18.27       1.81       177,431       18.27  
$ 4.08 - 28.00       202,996                       194,561          

 

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of December 31, 2022, 2021 and 2020.

 

The weighted average fair value of options granted during the years ended December 31, 2022 and 2021 was $0 as no options were granted in either year. The total intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2022 and 2021 was $100,668 and $252,874, respectively.

 

As of December 31, 2022, future forfeiture adjusted compensation cost related to nonvested stock options is $17,630 and will be recognized over an estimated weighted average period of 0.64 years.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE R—INCOME TAXES

 

The components of net loss consist of the following:

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

United States

   $ (10,416,593 )   $ (4,507,071 )

Hong Kong

     (458,839 )     (439,814 )

Nigeria

     (143,499 )     (118,896 )

Spain

     (890,972 )     -  

Total

   $ (11,909,903 )   $ (5,065,781 )

 

There was no provision for current federal, foreign or state taxes for both of the years ended December 31, 2022 and 2021 as a result of taxable losses incurred in these jurisdictions. The provision for income tax benefits consist of the following (in thousands):

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

Current – federal, states, and foreign

   $ -     $ -  

Deferred- Federal

     1,175,000       128,000  

Deferred - States

     122,000       47,000  

Deferred - Foreign

     (20,000

)

     -  

Total

     1,277.000       175,000  

Change in valuation allowance

     (1,297,000

)

     (175,000

)
                 

Provision for income tax benefits

   $ (20,434

)

   $ —  

 

Significant components of deferred tax assets and liabilities are as follows at December 31, 2022 and 2021 (in thousands):

 

   

December 31,

2022

    

December 31,

2021

As Revised

  
                 

Accrued compensation

   $ 113,000     $ 110,000  

Allowance for doubtful accounts

     169,000       70,000  
Research and development expenses     633,000       -  
Capital loss carry forward     114,000       -  

Stock-based compensation

     456,000       486,000  

Equipment and leasehold improvements

     (19,000

)

     1,000  

Intangible assets - US

     341,000       61,000  
Intangible assets - Foreign     (170,000 )     -  
Inventory reserve     89,000       -  
Interest expense     44,000       -  
Operating lease liabilities     44,000       59,000  
Reserve on debt security     -       13,000  
Operating lease right-of-use assets     (44,000 )     (57,000 )

Net operating loss and research and credit carryforwards

     15,248,000       15,148,000  

Valuation allowance

     (17,188,000

)

     (15,891,000

)
                 
Net deferred tax liability   $ (170,000 )   $ —  

 

During the year ended December 31, 2022, the Company determined that certain attributes of deferred tax assets and liabilities were incorrect for December 31, 2021 and 2020. See Note S for further information.

 

The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. With a full valuation allowance, any change in the deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. At December 31, 2022 and 2021, the Company provided a valuation allowance on its net deferred tax assets of $17,188,000 and $15,891,000, respectively.

 

 

As of December 31, 2022, the Company has U.S. federal net operating loss carryforwards of approximately $61.3 million. Approximately $43.1 million are subject to expiration between 2023 and 2037, and $18.2 million net operating loss carryforwards have no expiration date. These net operating loss carryforwards could be subject to the limitations under Section 382 of the Internal Revenue Code due to changes in the equity ownership of the Company. In addition, the Company has net operating loss carry forwards from various states of approximately $6.87 million which expire from 2026 through 2042.

 

A reconciliation of the effective income tax rate on operations reflected in the statements of operations to the US federal statutory income tax rate is presented below.

 

   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

As Revised

  
                 

Federal statutory income tax rate

     21.0

%

     21.0

%

State taxes, net of federal benefit

     0.9       1.1  

Permanent differences

     (4.7

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     (5.7

)

     (13.8

)

Expiration and forfeiture of stock options

     (0.3

)

     (1.5

)

Other

     (0.5 )     (2.4

)

Valuation allowance

     (10.9

)

     (3.4

)
                 

Effective tax rate

     (0.2

)%

     —

%

 

The Company has not been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from 2019 through 2022 remain open to examination by the IRS and state jurisdictions.

 

Our subsidiary in Nigeria has not filed its required returns since inception. Management believes that when the returns are filed, no taxes will be owed due to the losses incurred during those periods. We are also not subject to minimum tax during the first four years of operations. As a result, management could not calculate the amount of net operating loss carryforwards that are available to offset future taxable income.

 

Our subsidiary in Hong Kong has not filed its required returns in several years. Management believes that when the returns are filed, no taxes will be owed due to losses incurred during those periods. As a result, management could not calculate the amount of net operating loss carryforwards are available to offset future taxable income.

 

The Company believes it is not subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended December 31, 2022 and 2021.

 

In August 2022, the Inflation Reduction Act of 2022 was signed into law which includes a stock buyback excise tax of 1% on share repurchases, which will apply to net stock buybacks after December 31, 2022. We do not expect this to have a material impact if and when share repurchases occur.

 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Note S - Revision of Previously Issued Consolidated Financial Statements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Error Correction [Text Block]

NOTE S—REVISION OF PREVIOUSLY ISSUED CONSOLDATED FINANCIAL STATEMENTS

 

Due to errors discovered in the Company’s 2020 and 2021 tax provisions, the Company revised certain previously issued disclosures related to the components of its deferred tax assets and liabilities and valuation allowance as of December 31, 2021 and 2020. Additionally, the Company has revised the reconciliation of its income tax rate computed using the federal statutory rate for the year ended December 31, 2021. The errors related primarily to the calculation of available net operating loss carryforwards and to stock based compensation. Since the Company provided a full valuation allowance on its net deferred tax assets, there was no impact to the Consolidated Balance Sheet as of December 31, 2021 and the consolidated statements of operations, stockholders’ equity and cash flows as of and for the year ended December 31, 2021.

 

 

The Company further reviewed its disclosure of the rate reconciliation and deferred tax calculation along with the valuation allowance of its net deferred tax assets. Other items that were corrected in the disclosure included allowance for doubtful accounts, equipment and leasehold improvements and operating lease liability along with the associated operating lease ROU assets.

 

The below table summarizes the revisions to the reconciliation of our income tax rate computed using the federal statutory rate to our actual income tax rate for the year ended December 31, 2021:

 

   

December 31,

  
   

2021

As Reported

     Adjustments    

2021

As Revised

  
                         

U.S. statutory income tax rate

     21.0

%

     - %     21.0 %

State taxes, net of federal benefit

     -       1.1       1.1  

Permanent differences

     -       (1.0

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     -       (13.8

)

     (13.8

)

Expiration and forfeiture of stock options

     -       (1.5

)

     (1.5

)

Other

     -       (2.4

)

     (2.4

)
Valuation allowance     -       (3.4 )     (3.4 )

Effect of net operating loss

     (21.0 )%     21.0       -  

Total

     -

%

     -

%

     -

%

 

The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2021 (in thousands):

 

   

December 31,

  
   

2021

As Reported

    

Adjustments

    

2021

As Revised

  
                         

Accrued compensation

   $ 135,000     $ (25,000 )   $ 110,000  

Allowance for doubtful accounts

     75,000       (5,000

)

     70,000  

Stock based compensation

     1,149,000       (663,000

)

     486,000  

Equipment and leasehold improvements

     (10,000

)

     11,000       1,000  

Intangible assets

     75,000       (14,000 )     61,000  

Operating lease liability

     -       59,000       59,000  

Reserve on debt security

     -       13,000       13,000  

Operating lease right-of -use assets

     -       (57,000

)

     (57,000 )

Net operating loss and research credit carryforwards

     14,467,000       681,000       15,148,000  

Valuation allowance

     (15,891,000

)

     -       (15,891,000

)

Net deferred tax assets

   $ -     $ -     $ -  

 

The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2020 (in thousands):

 

   

December 31,

  
   

2020

As Reported

    

Adjustments

    

2020

As Revised

  
                         
Accrued compensation   $ 81,000     $ (15,000 )   $ 66,000  

Allowance for doubtful accounts

     474,000       (471,000

)

     3,000  

Stock based compensation

     1,073,000       (511,000

)

     562,000  

Equipment and leasehold improvements

     (14,000

)

     19,000       5,000  

Intangible assets

     65,000       (12,000 )     53,000  

Operating lease liability

     -       111,000       111,000  
Operating lease right-of -use assets     -       (109,000

)

     (109,000 )

Net operating loss and research credit carryforwards

     13,337,000       1,688,000       15,025,000  

Valuation allowance

     (15,016,000

)

     (700,000

)

     (15,716,000

)

Net deferred tax assets

   $ -     $ -     $ -  

 

 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Note T - Profit Sharing Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Retirement Benefits [Text Block]

NOTE T—PROFIT SHARING PLAN

 

The Company has established a savings plan under section 401(k) of the Internal Revenue Code. All employees of the Company, after completing one day of service, are eligible to enroll in the 401(k) plan. Participating employees may elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is not required to match employee contributions but may do so at its discretion. The Company made no matching contributions during the years ended December 31, 2022 and 2021.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Note U - Earnings Per Share (EPS)
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

NOTE U—EARNINGS PER SHARE (EPS)

 

Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 

Stock options

     202,996       212,461  

Warrants

     4,872,025       4,689,387  

Total

     5,075,021       4,901,848  

 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Note V - Subsequent Events
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

NOTE V—SUBSEQUENT EVENTS

 

On March 16, 2023, the Company issued 15,388 shares of common stock to its directors in payment of board fees.

 

On March 16, 2023, the Company issued an aggregate of 40,000 shares of restricted common stock to new employees which vest in equal annual installments over a three-year period from the date of grant.

 

On May 5, 2023, the Company issued 2,858 shares of common stock to its directors in payment of board committee fees.

 

On May 5, 2023, the Company received 14,375 shares of restricted common stock from employees who left the Company before the vesting period was completed.

 

On May 11, 2023, the Company issued 17,392 shares of common stock to its directors in payment of board fees.

 

On May 11, 2023, the Company issued 2,900 shares of common stock to its directors in payment of board committee fees.

 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block] Going Concern and Basis of PresentationThe Company has historically financed our operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered our expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and therefore is looking into other markets and opportunities to sell or return the product to generate additional cash.The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.
Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign CurrencyThe Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss.
Consolidation, Policy [Policy Text Block] 1. Principles of ConsolidationThe accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block] 2. Use of Estimates
Revenue from Contract with Customer [Policy Text Block] 3. Revenue RecognitionIn accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:
 

●

Identify the contract with a customer
 

●

Identify the performance obligations in the contract
 

●

Determine the transaction price
 

●

Allocate the transaction price to performance obligations in the contract
 

●

Recognize revenue when or as the Company satisfies a performance obligation
All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.Software licensesSoftware license revenue consists of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.HardwareHardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.Support and MaintenanceSupport and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the term of the contract begins. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.Professional ServicesProfessional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.Contracts with Multiple Performance ObligationsSome contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.Costs to Obtain and Fulfill a ContractCosts to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be four years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.Deferred RevenueDeferred revenue includes customer advances and amounts that have been paid by customers for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2022 and 2021, amounts in deferred revenue were approximately $515,000 and $633,000, respectively.
Business Combinations Policy [Policy Text Block] 4. Business CombinationsIn accordance with ASC 805, Business Combinations (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.
Goodwill and Intangible Assets, Policy [Policy Text Block] 5. Goodwill and acquired intangible assetsGoodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31st of each year. Refer Note K for more information regarding the impairment of goodwill in 2022.Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.
Cash and Cash Equivalents, Policy [Policy Text Block] 6. Cash EquivalentsCash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2022 and 2021, cash equivalents consisted of a money market account.
Receivable [Policy Text Block]

7. Accounts Receivable

 

Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.

 

Accounts receivable at December 31, 2022 and 2021 consisted of the following:

 

   

December 31,

  
   

2022

    

2021

  
                 

Accounts receivable

   $ 2,096,569     $ 1,234,411  
Loss on foreign currency     -       (50,000

)

Allowance for doubtful accounts

     (573,785

)

     (213,785

)

Accounts receivable, net of allowances for doubtful accounts

   $ 1,522,784     $ 970,626  

 

Bad debt expenses (if any) are recorded in selling, general, and administrative expense.

 

The allowance for doubtful accounts for the years ended December 31, 2022 and 2021 is as follows:

 

   

Balance at

Beginning of Year

    

Charged to Costs and Expenses

    

Deductions from Reserves

    

Balance at End of Year

  
                                 

Year ended December 31, 2022 Allowance for Doubtful Accounts

   $ 213,785     $ 360,000     $ -     $ 573,785  

Year ended December 31, 2021 Allowance for Doubtful Accounts

   $ 1,733,785     $ 200,000     $ (1,720,000 )   $ 213,785  
Property, Plant and Equipment, Policy [Policy Text Block] 8. Equipment and Leasehold Improvements, Intangible Assets and Depreciation and AmortizationEquipment and leasehold improvements are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:
 

Years

  

Equipment and leasehold improvements

          

Equipment

   3

-

 5  

Furniture and fixtures

   3

-

 5  

Software

     3    

Leasehold improvements

 

life or lease term

  
Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships. Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] 9. Impairment or Disposal of Long Lived Assets, including Intangible AssetsThe Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. There were no impairments in 2022 and 2021.
Advertising Cost [Policy Text Block] 10. Advertising Expense The Company expenses the costs of advertising as incurred. Advertising expenses for 2022 and 2021 were approximately $842,000 and $527,000, respectively.
Research and Development Expense, Policy [Policy Text Block] 11. Research and Development ExpendituresResearch and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred.
Earnings Per Share, Policy [Policy Text Block] 12. Earnings Per Share of Common Stock (“EPS”)The Company’s EPS is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.
Share-Based Payment Arrangement [Policy Text Block] 13. Accounting for Stock-Based Compensation The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over a three year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of certain assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:
   

Year ended

December 31,

  
   

2022

    

2021

  
                 

Selling, general and administrative

   $ 310,017     $ 269,368  

Research, development and engineering

     77,890       45,347  
    $ 387,907     $ 314,715  
Income Tax, Policy [Policy Text Block] 14. Income TaxesThe provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.The Company accounts for uncertain tax provisions in accordance with ASC 740. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Lessee, Leases [Policy Text Block] 15. LeasesIn accordance with ASC 842, Leases (ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases.At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.
Derivatives, Policy [Policy Text Block]

16. The Fair Value Measurement Option

 

The Company has elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the convertible promissory note was recorded at fair value upon issuance and will subsequently be remeasured at each reporting date until settled or converted. The Company recognized the note initially at fair value, which exceeded the proceeds received resulting in a day one loss that has been recognized in net loss. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations.
Fair Value Measurement, Policy [Policy Text Block]

 

17. Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

 

The following table summarizes our financial instruments measured at fair value at December 31, 2022:

 

    Total     Level 1     Level 2     Level 3  
                                 
Convertible note at fair value   $ 2,596,203     $ -     $ -     $ 2,596,203  

 

The Company issued a convertible note to which included an original issue discount, conversion features and a detachable warrant, as further discussed in Note M. The detachable warrant represents a freestanding, separable equity-linked financial instrument recorded at fair value. The fair value of the detachable warrant was calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt which was determined based on significant unobservable inputs including the likelihood of default, the estimated date at which the default could take place, and the present value discount rate, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The fair value option requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as change in fair value of convertible note in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible note were expensed and not deferred.

 

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at December 22, 2022:

1. Face amount - $2,200,000

2. Nominal interest rate – 10% - 12%

3. Default interest rate – 18%

4. Increase in principal upon a default – 30%

5. Present value discount rate – 15.18%

6. Likelihood of default – estimated to be 50% at the extended maturity date

 

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the year ended December 31, 2022:

 

Beginning balance   $ -  
Purchases and issuances     2,200,000  
Day one loss on value of hybrid instrument     396,203  
Ending balance   $ 2,596,203  
New Accounting Pronouncements, Policy [Policy Text Block] 18. Recent Accounting PronouncementsIn June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016- 13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct writedown of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for the Company for annual periods, including interim periods within those annual periods, beginning on January 1, 2023. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
   

December 31,

  
   

2022

    

2021

  
                 

Accounts receivable

   $ 2,096,569     $ 1,234,411  
Loss on foreign currency     -       (50,000

)

Allowance for doubtful accounts

     (573,785

)

     (213,785

)

Accounts receivable, net of allowances for doubtful accounts

   $ 1,522,784     $ 970,626  
   

Balance at

Beginning of Year

    

Charged to Costs and Expenses

    

Deductions from Reserves

    

Balance at End of Year

  
                                 

Year ended December 31, 2022 Allowance for Doubtful Accounts

   $ 213,785     $ 360,000     $ -     $ 573,785  

Year ended December 31, 2021 Allowance for Doubtful Accounts

   $ 1,733,785     $ 200,000     $ (1,720,000 )   $ 213,785  
Useful Lives of Property Plan and Equipment [Table Text Block]
 

Years

  

Equipment and leasehold improvements

          

Equipment

   3

-

 5  

Furniture and fixtures

   3

-

 5  

Software

     3    

Leasehold improvements

 

life or lease term

  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   

Year ended

December 31,

  
   

2022

    

2021

  
                 

Selling, general and administrative

   $ 310,017     $ 269,368  

Research, development and engineering

     77,890       45,347  
    $ 387,907     $ 314,715  
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]
    Total     Level 1     Level 2     Level 3  
                                 
Convertible note at fair value   $ 2,596,203     $ -     $ -     $ 2,596,203  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Beginning balance   $ -  
Purchases and issuances     2,200,000  
Day one loss on value of hybrid instrument     396,203  
Ending balance   $ 2,596,203  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Revenue From Contracts With Customers (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2022

  
                                         

License fees

   $ 1,856,814     $ 517,161     $ 2,124,088     $ 85,989     $ 4,584,052  

Hardware

     422,275       25,833       19,914       178,464       646,486  

Services

     1,270,067       83,306       436,293       54       1,789,720  

Total Revenues

   $ 3,549,156     $ 626,300     $ 2,580,295     $ 264,507     $ 7,020,258  
   

North

America

    

Africa

    

EMESA*

    

Asia

    

December

31,

2021

  
                                         

License fees

   $ 1,854,088     $ 521,751     $ 105,314     $ 74,656     $ 2,555,809  

Hardware

     278,655       698,264       265,996       42,411       1,285,326  

Services

     1,162,526       42,000       54,918       13,910       1,273,354  

Total Revenues

   $ 3,295,269     $ 1,262,015     $ 426,228     $ 130,977     $ 5,114,489  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Swivel Secure Europe, SA Acquisition (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Purchase consideration:        

Total cash paid, including working capital adjustment

   $ 1,273,483  
Earnout payable     500,000  

Common stock issued

     600,004  

Total purchase price consideration

   $ 2,373,487  
         
Fair value of assets acquired and liabilities assumed:        

Cash and cash equivalents

   $ 729,905  

Accounts receivable

     702,886  

Equipment acquired

     65,640  

Other assets

     20,708  

Intangible assets

     762,860  

Goodwill

     1,258,087  

Total estimated assets acquired

     3,540,086  
         

Accounts payable and accrued expenses

     431,884  

Government loan

     544,000  
Deferred tax liability     190,715  

Total liabilities assumed

     1,166,599  

Total estimated fair value of assets acquired and liabilities assumed

   $ 2,373,487  
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
   

Amount

    

Estimated useful

life

(in years)

  

Customer relationships

   $ 762,860       7  

Total identifiable intangible assets

   $ 762,860          
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Note Receivable (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
   

December 31,

  
   

2022

    

2021

  
                 

Accounts receivable

   $ 2,096,569     $ 1,234,411  
Loss on foreign currency     -       (50,000

)

Allowance for doubtful accounts

     (573,785

)

     (213,785

)

Accounts receivable, net of allowances for doubtful accounts

   $ 1,522,784     $ 970,626  
   

Balance at

Beginning of Year

    

Charged to Costs and Expenses

    

Deductions from Reserves

    

Balance at End of Year

  
                                 

Year ended December 31, 2022 Allowance for Doubtful Accounts

   $ 213,785     $ 360,000     $ -     $ 573,785  

Year ended December 31, 2021 Allowance for Doubtful Accounts

   $ 1,733,785     $ 200,000     $ (1,720,000 )   $ 213,785  
Notes Receivable [Member]  
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
   

December 31,

    

December 31,

  
   

2022

    

2021

  
                 

Note receivable

   $ 195,000     $ 295,000  

Repayment of note

     (9,000 )     -  

Allowance for doubtful account

     (186,000 )     (100,000

)

Note receivable, net of allowance

     -       195,000  
Current portion, net of allowance   $ -     $ 82,000  
Noncurrent portion, net of allowance   $ -     $ 113,000  
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Inventory (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

2022

    

2021

  
                 

Finished goods

   $ 4,764,643     $ 4,798,203  

Fabricated assemblies

     69,726       142,457  
Reserve on finished goods     (400,000 )     -  

Total inventory

   $ 4,434,369     $ 4,940,660  
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Equipment and Leasehold Improvements (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

2022

    

2021

  
                 

Equipment

   $ 825,058     $ 831,784  

Furniture and fixtures

     225,978       164,079  

Software

     49,143       32,045  

Leasehold improvements

     34,903       25,135  
      1,135,082       1,053,043  
                 
                 

Less accumulated depreciation and amortization

     (1,027,669

)

     (983,875

)
                 

Total

   $ 107,413     $ 69,168  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Note K - Intangible Assets and Goodwill (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

2022

    

2021

  
                 

Trade name

   $ 130,000     $ 130,000  

Proprietary software

     420,000       420,000  

Customer relationships

     1,692,860       930,000  

Patents and patents pending

     365,080       365,080  
      2,607,940       1,845,080  
                 
                 

Less accumulated amortization

     (845,115

)

     (547,003 )
                 

Total

   $ 1,762,825     $ 1,298,077  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Years ending December 31

        

2023

   $ 320,000  

2024

     320,000  

2025

     280,000  

2026

     230,000  

2027

     220,000  

Thereafter

     392,825  

Total

   $ 1,762,825  
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Note L - Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

2022

    

2021

  
                 

Compensation

   $ 377,958     $ 254,433  

Compensated absences

     378,874       293,297  

Accrued legal and accounting fees

     110,008       95,738  
Franchise taxes     7,000       40,000  
Employee expenses reimbursement     114,209       76,000  

Sales tax payable

     17,594       18,548  

Other

     3,480       50,981  
                 

Total

   $ 1,009,123     $ 828,997  
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Note N - Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block]
   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
Lease cost                

Operating lease cost

   $ 254,649     $ 255,892  

Total lease cost

   $ 254,649     $ 255,892  
                 
Balance sheet information          

Operating right-of-use assets

   $ 197,355     $ 254,100  
                 

Operating lease liabilities, current portion

   $ 159,665     $ 177,188  

Operating lease liabilities, non-current portion

     37,829       86,974  

Total operating lease liabilities

   $ 197,494     $ 264,162  
                 

Weighted average remaining lease term (in years) – operating leases

     0.96       1.45  

Weighted average discount rate – operating leases

     5.50

%

     5.50

%
                 
Supplemental cash flow information related to leases were as follows:                
                 

Cash paid for amounts included in the measurement of operating lease liabilities

   $ 259,558     $ 256,977  
                 
Maturities of operating lease liabilities were as follows as of December 31, 2022:                
                 

2023

   $ 164,596          

2024

     38,808          

Total future lease payments

   $ 203,404          

Less: imputed interest

     (5,910

)

        

Total

   $ 197,494          
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Note P - Equity (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Warrants Valuation Assumptions [Table Text Block]
   

Years ended

December 31,

  
   

2022

    

2021

  

Weighted average risk-free interest rate

     3.70

%

     -

%

Weighted average exercise price

   $ 3.00     $ -  

Weighted average exercise period

     5       -  

Weighted average Volatility of stock price

     108.60

%

     -

%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
   

Total

Warrants

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life

(in years)

    

Aggregate

intrinsic

value

  
                                 

Outstanding, as of December 31, 2020

     4,689,387     $ 6.04       4.48       —  

Granted

     —       —                  

Exercised

     —       —                  

Forfeited

     —       —                  

Expired

     —       —                  

Outstanding, as of December 31, 2021

     4,689,387       6.04       3.48       —  

Granted

     200,000       3.00                  

Exercised

     —      

—

                  

Forfeited

     —       —                  

Expired

     (17,362 )    

28.80

                  

Outstanding, as of December 31, 2022

     4,872,025     $ 5.83       2.59       —  
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Note Q - Stock Options (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
   

Number of Options

    

Weighted

average

    

Weighted

average

remaining

    

Aggregate

  
   

2015

Plan

    

Non

Plan

    

Total

    

exercise

price

    

life

(in years)

    

intrinsic

value

  
                                                 

Outstanding, as of December 31, 2020

     94,183       133,091       227,274     $ 17.61       3.87     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     (3,291 )    

—

       (3,291 )    

3.87

                  

Expired

     (84

)

     (11,438

)

     (11,522

)

     39.13                  

Outstanding, as of December 31, 2021

     90,808       121,653       212,461     $ 16.65       3.03     $ 0  

Granted

     —       —       —       —                  

Exercised

     —       —       —       —                  

Forfeited

     —       —      

—

       —                  

Expired

     —       (9,465

)

     (9,465

)

     17.28                  

Outstanding, as of December 31, 2022

     90,808       112,188       202,996     $ 16.63       2.14     $ 0  

Vested or expected to vest at December 31, 2022

                     201,271     $ 16.72       2.12     $ 0  

Exercisable at December 31, 2022

                     194,561     $ 17.12       2.03     $ 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]
           

Options Outstanding

    

Options Exercisable

  

Range of exercise prices

    

Number of

shares

    

Weighted

average

exercise

price

    

Weighted

average

remaining

life (in years)

    

Number

exercisable

    

Weighted

average

exercise

price

  
$ 4.08 - 5.84       25,565     $ 5.20       4.63       17,130     $ 5.20  
$ 5.85 - 28.00       177,431       18.27       1.81       177,431       18.27  
$ 4.08 - 28.00       202,996                       194,561          
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Net Income (Loss) by Geographic Areas [Table Text Block]
   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

United States

   $ (10,416,593 )   $ (4,507,071 )

Hong Kong

     (458,839 )     (439,814 )

Nigeria

     (143,499 )     (118,896 )

Spain

     (890,972 )     -  

Total

   $ (11,909,903 )   $ (5,065,781 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

  
                 

Current – federal, states, and foreign

   $ -     $ -  

Deferred- Federal

     1,175,000       128,000  

Deferred - States

     122,000       47,000  

Deferred - Foreign

     (20,000

)

     -  

Total

     1,277.000       175,000  

Change in valuation allowance

     (1,297,000

)

     (175,000

)
                 

Provision for income tax benefits

   $ (20,434

)

   $ —  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

December 31,

2022

    

December 31,

2021

As Revised

  
                 

Accrued compensation

   $ 113,000     $ 110,000  

Allowance for doubtful accounts

     169,000       70,000  
Research and development expenses     633,000       -  
Capital loss carry forward     114,000       -  

Stock-based compensation

     456,000       486,000  

Equipment and leasehold improvements

     (19,000

)

     1,000  

Intangible assets - US

     341,000       61,000  
Intangible assets - Foreign     (170,000 )     -  
Inventory reserve     89,000       -  
Interest expense     44,000       -  
Operating lease liabilities     44,000       59,000  
Reserve on debt security     -       13,000  
Operating lease right-of-use assets     (44,000 )     (57,000 )

Net operating loss and research and credit carryforwards

     15,248,000       15,148,000  

Valuation allowance

     (17,188,000

)

     (15,891,000

)
                 
Net deferred tax liability   $ (170,000 )   $ —  

 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   

Year ended

December 31,

2022

    

Year ended

December 31,

2021

As Revised

  
                 

Federal statutory income tax rate

     21.0

%

     21.0

%

State taxes, net of federal benefit

     0.9       1.1  

Permanent differences

     (4.7

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     (5.7

)

     (13.8

)

Expiration and forfeiture of stock options

     (0.3

)

     (1.5

)

Other

     (0.5 )     (2.4

)

Valuation allowance

     (10.9

)

     (3.4

)
                 

Effective tax rate

     (0.2

)%

     —

%

 
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Note S - Revision of Previously Issued Consolidated Financial Statements (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
   

December 31,

  
   

2021

As Reported

     Adjustments    

2021

As Revised

  
                         

U.S. statutory income tax rate

     21.0

%

     - %     21.0 %

State taxes, net of federal benefit

     -       1.1       1.1  

Permanent differences

     -       (1.0

)

     (1.0

)

Expiration of net operating loss and research credit carryforwards

     -       (13.8

)

     (13.8

)

Expiration and forfeiture of stock options

     -       (1.5

)

     (1.5

)

Other

     -       (2.4

)

     (2.4

)
Valuation allowance     -       (3.4 )     (3.4 )

Effect of net operating loss

     (21.0 )%     21.0       -  

Total

     -

%

     -

%

     -

%
   

December 31,

  
   

2021

As Reported

    

Adjustments

    

2021

As Revised

  
                         

Accrued compensation

   $ 135,000     $ (25,000 )   $ 110,000  

Allowance for doubtful accounts

     75,000       (5,000

)

     70,000  

Stock based compensation

     1,149,000       (663,000

)

     486,000  

Equipment and leasehold improvements

     (10,000

)

     11,000       1,000  

Intangible assets

     75,000       (14,000 )     61,000  

Operating lease liability

     -       59,000       59,000  

Reserve on debt security

     -       13,000       13,000  

Operating lease right-of -use assets

     -       (57,000

)

     (57,000 )

Net operating loss and research credit carryforwards

     14,467,000       681,000       15,148,000  

Valuation allowance

     (15,891,000

)

     -       (15,891,000

)

Net deferred tax assets

   $ -     $ -     $ -  
   

December 31,

  
   

2020

As Reported

    

Adjustments

    

2020

As Revised

  
                         
Accrued compensation   $ 81,000     $ (15,000 )   $ 66,000  

Allowance for doubtful accounts

     474,000       (471,000

)

     3,000  

Stock based compensation

     1,073,000       (511,000

)

     562,000  

Equipment and leasehold improvements

     (14,000

)

     19,000       5,000  

Intangible assets

     65,000       (12,000 )     53,000  

Operating lease liability

     -       111,000       111,000  
Operating lease right-of -use assets     -       (109,000

)

     (109,000 )

Net operating loss and research credit carryforwards

     13,337,000       1,688,000       15,025,000  

Valuation allowance

     (15,016,000

)

     (700,000

)

     (15,716,000

)

Net deferred tax assets

   $ -     $ -     $ -  

 
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Note U - Earnings Per Share (EPS) (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

Years ended December 31,

  
   

2022

    

2021

  
                 

Stock options

     202,996       212,461  

Warrants

     4,872,025       4,689,387  

Total

     5,075,021       4,901,848  
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 22, 2022
Percentage of Support and Maintenance Revenue to License Cost 18.00%    
Capitalized Contract Cost, Amortization Period (Year) 4 years    
Contract with Customer, Liability, Total $ 515,000 $ 633,000  
Advertising Expense $ 842,000 $ 527,000  
Debt Instrument, Face Amount     $ 2,200,000
Measurement Input, Default Rate [Member]      
Debt Instrument, Measurement Input     0.18
Principal Upon Default [Member]      
Debt Instrument, Measurement Input     0.30
Measurement Input, Discount Rate [Member]      
Debt Instrument, Measurement Input     0.1518
Measurement Input, Likelihood of Default [Member]      
Debt Instrument, Measurement Input     0.50
Minimum [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period 3 years    
Debt Instrument, Interest Rate, Stated Percentage     10.00%
Maximum [Member]      
Debt Instrument, Interest Rate, Stated Percentage     12.00%
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounts receivable $ 2,096,569 $ 1,234,411
Accounts Receivable, Allowance for Credit Loss, Current 213,785 1,733,785
Allowance for doubtful accounts, charged to costs and expenses (360,000) (200,000)
Loss on foreign currency transactions 0 (50,000)
Accounts Receivable, Credit Loss Expense (Reversal) 0 (1,720,000)
Accounts Receivable, Allowance for Credit Loss, Current 573,785 213,785
Allowance for doubtful accounts (573,785) (213,785)
Accounts receivable, net of allowances for doubtful accounts $ 1,522,784 $ 970,626
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)
Dec. 31, 2022
Equipment [Member] | Minimum [Member]  
Property, Plant, and Equipment, useful life (Year) 3 years
Equipment [Member] | Maximum [Member]  
Property, Plant, and Equipment, useful life (Year) 5 years
Furniture and Fixtures [Member] | Minimum [Member]  
Property, Plant, and Equipment, useful life (Year) 3 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, Plant, and Equipment, useful life (Year) 5 years
Software Development [Member]  
Property, Plant, and Equipment, useful life (Year) 3 years
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-based compensation expense $ 387,907 $ 314,715
Selling, General and Administrative Expenses [Member]    
Share-based compensation expense 310,017 269,368
Research and Development Expense [Member]    
Share-based compensation expense $ 77,890 $ 45,347
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details) - Convertible Debt [Member]
Dec. 31, 2022
USD ($)
Convertible note at fair value $ 2,596,203
Fair Value, Inputs, Level 1 [Member]  
Convertible note at fair value 0
Fair Value, Inputs, Level 2 [Member]  
Convertible note at fair value 0
Fair Value, Inputs, Level 3 [Member]  
Convertible note at fair value $ 2,596,203
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details) - Convertible Debt [Member]
 12 Months Ended
Dec. 31, 2022
USD ($)
Beginning balance $ 0
Purchases and issuances 2,200,000
Day one loss on value of hybrid instrument 396,203
Ending balance $ 2,596,203
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Revenue From Contracts With Customers (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized $ 489,000 $ 529,000
Contract with Customer, Liability, Total $ 515,000 $ 633,000
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Services $ 7,020,258 $ 5,114,489
North America [Member]    
Services 3,549,156 3,295,269
Africa [Member]    
Services 626,300 1,262,015
EMEA [Member]    
Services 2,580,295 426,228
Asia [Member]    
Services 264,507 130,977
License [Member]    
Services 4,584,052 2,555,809
License [Member] | North America [Member]    
Services 1,856,814 1,854,088
License [Member] | Africa [Member]    
Services 517,161 521,751
License [Member] | EMEA [Member]    
Services 2,124,088 105,314
License [Member] | Asia [Member]    
Services 85,989 74,656
Hardware [Member]    
Services 646,486 1,285,326
Hardware [Member] | North America [Member]    
Services 422,275 278,655
Hardware [Member] | Africa [Member]    
Services 25,833 698,264
Hardware [Member] | EMEA [Member]    
Services 19,914 265,996
Hardware [Member] | Asia [Member]    
Services 178,464 42,411
Service [Member]    
Services 1,789,720 1,273,354
Service [Member] | North America [Member]    
Services 1,270,067 1,162,526
Service [Member] | Africa [Member]    
Services 83,306 42,000
Service [Member] | EMEA [Member]    
Services 436,293 54,918
Service [Member] | Asia [Member]    
Services $ 54 $ 13,910
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Swivel Secure Europe, SA Acquisition (Details Textual) - USD ($)
 10 Months Ended 12 Months Ended 47 Months Ended
Mar. 08, 2022
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Apr. 30, 2026
Dec. 31, 2020
Payments to Acquire Businesses, Gross     $ 623,578 $ (0)    
Share Price   $ 0.59 $ 0.59 $ 2.21   $ 3.52
Forecast [Member] | Government Loan [Member] | BBVA Bank [Member]            
Debt Instrument, Interest Rate, Stated Percentage         1.75%  
Debt Instrument, Periodic Payment, Principal         $ 11,900  
Swivel Secure Europe [Member]            
Business Acquisition, Percentage of Voting Interests Acquired 100.00%          
Business Combination, Base Purchase Price $ 1,750,000          
Business Combination, Contingent Consideration, Liability 500,000          
Business Combination, Contingent Consideration Earnout Payable, Revenue to Trigger Payment 3,000,000          
Business Combination, Contingent Consideration Earnout Payable, Operating Profit to Trigger Payment 1,000,000          
Payments to Acquire Businesses, Gross $ 1,270,000          
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 269,060          
Business Combination, Indemnification Assets, Shares as of Acquisition Date 89,687          
Share Price $ 2.23          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     $ 500,000      
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual   $ 2,351,975        
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   $ 720,691        
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Goodwill $ 0 $ 1,262,526
Deferred tax liability 190,715  
Swivel Secure Europe [Member]    
Total cash paid, including working capital adjustment 1,273,483  
Earnout payable 500,000  
Cash and cash equivalents 729,905  
Accounts receivable 702,886  
Equipment acquired 65,640  
Other assets 20,708  
Intangible assets 762,860  
Goodwill 1,258,087  
Total estimated assets acquired 3,540,086  
Accounts payable and accrued expenses 431,884  
Government loan 544,000  
Total liabilities assumed 1,166,599  
Total estimated fair value of assets acquired and liabilities assumed 2,373,487  
Swivel Secure Europe [Member] | Restricted [Member]    
Common stock issued 600,004  
Total purchase price consideration $ 2,373,487  
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details) - Swivel Secure Europe [Member]
Mar. 08, 2022
USD ($)
Intangible Assets, Amount $ 762,860
Customer Relationships [Member]  
Intangible Assets, Amount $ 762,860
Estimated useful life (Year) 7 years
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Concentration of Risk (Details Textual)
 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Cash, Uninsured Amount $ 2,000,000 $ 7,057,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Concentration Risk, Number of Major Customers 1 1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]    
Concentration Risk, Percentage 10.00% 13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Concentration Risk, Number of Major Customers 0 3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]    
Concentration Risk, Percentage 35.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]    
Concentration Risk, Percentage   87.00%
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Note Receivable (Details Textual) - USD ($)
 3 Months Ended
Feb. 06, 2024
Jul. 06, 2022
Feb. 25, 2022
Sep. 30, 2020
Dec. 31, 2022
Dec. 31, 2021
Note receivable, net of allowance       $ 295,000 $ 0 $ 82,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)       5.00%    
Accounts Receivable, Allowance for Credit Loss         $ 186,000  
Notes Receivable, Periodic Payment   $ 15,000 $ 1,000      
Forecast [Member]            
Notes Receivable, Periodic Payment $ 2,000          
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Note Receivable - Summary of Note Receivable (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2020
Note receivable $ 195,000 $ 295,000  
Repayment of note (9,000) 0  
Allowance for doubtful account (186,000) (100,000)  
Note receivable, net of allowance 0 195,000  
Note receivable, net of allowance 0 82,000 $ 295,000
Noncurrent portion, net of allowance $ 0 $ 113,000  
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Inventory (Details Textual)
Dec. 31, 2022
USD ($)
NIGERIA  
Inventory Valuation Reserves $ 400,000
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Inventory - Components of Inventory (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Finished goods $ 4,764,643 $ 4,798,203
Fabricated assemblies 69,726 142,457
Reserve on finished goods (400,000) 0
Total inventory $ 4,434,369 $ 4,940,660
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Note H - Resalable Software Licenses Rights (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2022
Dec. 31, 2021
Amortization of Intangible Assets   $ 298,113 $ 216,069
Software License Rights [Member]      
Payments to Acquire Software $ 180,000    
Finite-Lived Intangible Asset, Useful Life 10 years    
The 2015 Software License [Member]      
Cumulative Amount of Amortization Expense, Net of Credits   141,190  
Software License Rights   0 48,752
Amortization of Intangible Assets   $ 48,752 $ 10,130
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Note I - Investment in Debt Security (Details Textual) - Debt Security, Corporate, Non-US [Member]
Sep. 30, 2020
USD ($)
Sep. 30, 2020
HKD ($)
Jun. 30, 2020
Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current $ 512,821 $ 4,000,000  
Investment in Held-to-maturity Debt Securities, Interest Rate     500.00%
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Equipment and Leasehold Improvements (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Selling, General and Administrative Expenses [Member]    
Depreciation, Depletion and Amortization, Nonproduction $ 43,794 $ 54,649
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Property, plant, and equipment, gross $ 1,135,082 $ 1,053,043
Less accumulated depreciation and amortization (1,027,669) (983,875)
Total 107,413 69,168
Equipment [Member]    
Property, plant, and equipment, gross 825,058 831,784
Furniture and Fixtures [Member]    
Property, plant, and equipment, gross 225,978 164,079
Software Development [Member]    
Property, plant, and equipment, gross 49,143 32,045
Leasehold Improvements [Member]    
Property, plant, and equipment, gross $ 34,903 $ 25,135
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Note K - Intangible Assets and Goodwill (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Amortization of Intangible Assets $ 298,113 $ 216,069
Research, Development, and Engineering Expense [Member]    
Amortization of Intangible Assets $ 298,000 $ 216,000
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Gross carrying amount $ 2,607,940 $ 1,845,080
Less accumulated amortization (845,115) (547,003)
Total 1,762,825 1,298,077
Trade Names [Member]    
Gross carrying amount 130,000 130,000
Proprietary Software [Member]    
Gross carrying amount 420,000 420,000
Customer Relationships [Member]    
Gross carrying amount 1,692,860 930,000
Patents [Member]    
Gross carrying amount $ 365,080 $ 365,080
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Note K - Intangible Assets and Goodwill - Amortization Expense (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
2023 $ 320,000  
2024 320,000  
2025 280,000  
2026 230,000  
2027 220,000  
Thereafter 392,825  
Total $ 1,762,825 $ 1,298,077
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Compensation $ 377,958 $ 254,433
Compensated absences 378,874 293,297
Accrued legal and accounting fees 110,008 95,738
Franchise taxes 7,000 40,000
Employee expenses reimbursement 114,209 76,000
Sales tax payable 17,594 18,548
Other 3,480 50,981
Total $ 1,009,123 $ 828,997
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.23.1
Note M - Convertible Note Payable (Details Textual) - USD ($)
 12 Months Ended
Dec. 22, 2022
Dec. 31, 2021
Jun. 23, 2023
Dec. 31, 2022
Debt Instrument, Face Amount $ 2,200,000      
Class of Warrant or Right, Issued During Period   0    
Maximum [Member]        
Debt Instrument, Interest Rate, Stated Percentage 12.00%      
Warrants Issued in Connection With Note [Member]        
Class of Warrant or Right, Issued During Period 200,000      
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 3.00      
Warrants and Rights Outstanding $ 94,316      
The Note [Member]        
Debt Instrument, Face Amount       $ 2,200,000
Debt Instrument, Fair Value Disclosure       $ 2,596,203
The Note [Member] | Senior Secured Promissory Note [Member]        
Debt Instrument, Face Amount 2,200,000      
Proceeds from Debt, Net of Issuance Costs $ 2,002,000      
Debt Instrument, Interest Rate, Stated Percentage 10.00%      
Stock Issued During Period, Shares, Commitment Fee 700,000      
Shares Issued, Price Per Share $ 1.00      
Right to Repurchase Shares if Debt Instrument Paid in Full Within Six Months 350,000      
Debt Instrument, Interest Rate, Default 18.00%      
Debt Instrument, Default, Percentage Increase In Principal 30.00%      
The Note [Member] | Senior Secured Promissory Note [Member] | Maximum [Member]        
Debt Instrument, Convertible, Number of Equity Instruments 1,684,576      
Debt Instrument, Convertible, Percentage of Outstanding Stock 19.90%      
The Note [Member] | Senior Secured Promissory Note [Member] | Forecast [Member]        
Debt Instrument, Interest Rate, Stated Percentage     12.00%  
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.23.1
Note N - Leases - Operating Lease Balance Sheet Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating lease cost $ 254,649 $ 255,892
Total lease cost 254,649 255,892
Operating lease right-of-use assets 197,355 254,100
Operating lease liabilities, current portion 159,665 177,188
Operating lease liabilities, non-current portion 37,829 86,974
Total operating lease liabilities $ 197,494 $ 264,162
Weighted average remaining lease term (in years) – operating leases (Year) 11 months 15 days 1 year 5 months 12 days
Weighted average discount rate – operating leases 5.50% 5.50%
Cash paid for amounts included in the measurement of operating lease liabilities $ 259,558 $ 256,977
Lessee, Operating Lease, Liability, to be Paid, Year One 164,596  
Lessee, Operating Lease, Liability, to be Paid, Year Two 38,808  
Total future lease payments 203,404  
Less: imputed interest (5,910)  
Total $ 197,494 $ 264,162
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Note P - Equity (Details Textual) - USD ($)
 12 Months Ended
Mar. 08, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Preferred Stock, Shares Authorized   5,000,000    
Preferred Stock, Par or Stated Value Per Share   $ 0.0001    
Stock Issued During Period, Value, Acquisitions   $ 600,004    
Share-Based Payment Arrangement, Expense   387,907 $ 314,715  
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture   $ 76,043 $ 25,536  
Class of Warrant or Right, Issued During Period     0  
Share Price   $ 0.59 $ 2.21 $ 3.52
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number   194,561    
Common Stock [Member]        
Stock Issued During Period, Value, Acquisitions   $ 27    
Stock Issued During Period, Shares, Employee Stock Purchase Plans   60,549 19,484  
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   278,000 13,125  
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited   10,500 1,250  
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture   39,636 7,828  
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture   $ 4 $ 1  
Director [Member] | Common Stock [Member]        
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture   39,636 7,828  
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture   $ 76,043 $ 25,536  
Restricted Stock [Member]        
Share-Based Payment Arrangement, Expense   $ 218,552 $ 71,819  
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures   278,000 13,125  
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited   10,500 1,250  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period   3 years    
In The Money Options [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number   0 0 0
Swivel Secure Europe [Member]        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 269,060      
Business Combination, Indemnification Assets, Shares as of Acquisition Date 89,687      
Stock Issued During Period, Value, Acquisitions $ 600,004      
Business Acquisition, Share Price   $ 2.23    
Share-Based Payment Arrangement, Expense   $ 18,787 $ 10,680  
Share Price $ 2.23      
Employee Stock Purchase Plan [Member]        
Common Stock, Capital Shares Reserved for Future Issuance   789,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent 85.00%      
Stock Issued During Period, Shares, Employee Stock Purchase Plans   60,549 19,484  
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.23.1
Note P - Equity - Valuation Assumptions for Warrants (Details) - Referral Fee Warrants [Member]
Dec. 31, 2022
Dec. 31, 2021
Measurement Input, Risk Free Interest Rate [Member]    
Weighted average risk-free interest rate 0.0370 0
Measurement Input, Exercise Price [Member]    
Weighted average risk-free interest rate 3.00 0
Measurement Input, Expected Term [Member]    
Weighted average risk-free interest rate 5 0
Measurement Input, Price Volatility [Member]    
Weighted average risk-free interest rate 1.0860 0
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.23.1
Note P - Equity - Summary of Warrant Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Outstanding, warrants (in shares) 4,689,387 4,689,387  
Outstanding, weighted average exercise price, warrants (in dollars per share) $ 6.04 $ 6.04  
Outstanding, weighted average remaining contractual life, warrants (Year) 2 years 7 months 2 days 3 years 5 months 23 days 4 years 5 months 23 days
Granted, warrants (in shares) 200,000    
Granted, weighted average exercise price, warrants (in dollars per share) $ 3.00    
Exercised, warrants (in shares)   0  
Exercised, weighted average exercise price, warrants (in dollars per share) $ 0 $ 0  
Forfeited, warrants (in shares) 0 0  
Forfeited, weighted average exercise price, warrants (in dollars per share) $ 0 $ 0  
Expired, warrants (in shares) (17,362) 0  
Expired, weighted average exercise price, warrants (in dollars per share) $ 28.80 $ 0  
Forfeited, weighted average exercise price, warrants (in dollars per share) $ 0 $ 0  
Outstanding, warrants (in shares) 4,872,025 4,689,387 4,689,387
Outstanding, weighted average exercise price, warrants (in dollars per share) $ 5.83 $ 6.04 $ 6.04
Public Offering Warrants [Member]      
Granted, warrants (in shares)   0  
Granted, weighted average exercise price, warrants (in dollars per share)   $ 0  
Pre-Funded Warrants [Member]      
Exercised, warrants (in shares) 0    
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.23.1
Note Q - Stock Options (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jan. 27, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 2 years 1 month 20 days 3 years 10 days 3 years 10 months 13 days  
Share Price $ 0.59 $ 2.21 $ 3.52  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 194,561      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value $ 0 $ 0 $ 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) 0 0 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value $ 100,668 $ 252,874    
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 17,630      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 7 months 20 days      
In The Money Options [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 0 0 0  
The 2015 Equity Incentive Plan [Member]        
Common Stock, Capital Shares Reserved for Future Issuance   789,000   187,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 10 years      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) (0) (0)    
The 2015 Equity Incentive Plan [Member] | Minimum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent 100.00%      
The 2015 Equity Incentive Plan [Member] | Maximum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent 110.00%      
XML 88 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Note Q - Stock Options - Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Outstanding (in shares) 212,461 227,274  
Outstanding, weighted average exercise price (in dollars per share) $ 16.65 $ 17.61  
Outstanding, weighted average remaining life (Year) 2 years 1 month 20 days 3 years 10 days 3 years 10 months 13 days
Outstanding, aggregate intrinsic value $ 0 $ 0 $ 0
Granted (in shares) 0 0  
Granted, weighted average exercise price (in dollars per share) $ 0 $ 0  
Exercised (in shares) 0 0 0
Exercised, weighted average exercise price (in dollars per share) $ 0 $ 0  
Forfeited (in shares) 0 (3,291)  
Forfeited, weighted average exercise price (in dollars per share) $ 0 $ 3.87  
Expired (in shares) (9,465) (11,522)  
Expired, weighted average exercise price (in dollars per share) $ 17.28 $ 39.13  
Outstanding (in shares) 202,996 212,461 227,274
Outstanding, weighted average exercise price (in dollars per share) $ 16.63 $ 16.65 $ 17.61
Vested or expected to vest (in shares) 201,271    
Vested or expected to vest, weighted average exercise price (in dollars per share) $ 16.72    
Vested or expected to vest, weighted average remaining life (Year) 2 years 1 month 13 days    
Vested or expected to vest, aggregate intrinsic value $ 0    
Exercisable (in shares) 194,561    
Exercisable, weighted average exercise price (in dollars per share) $ 17.12    
Exercisable, weighted average remaining life (Year) 2 years 10 days    
Exercisable, aggregate intrinsic value $ 0    
The 2015 Equity Incentive Plan [Member]      
Outstanding (in shares) 90,808 94,183  
Outstanding, weighted average remaining life (Year) 10 years    
Granted (in shares) 0 0  
Exercised (in shares) 0 0  
Forfeited (in shares) 0 (3,291)  
Expired (in shares) 0 (84)  
Outstanding (in shares) 90,808 90,808 94,183
Non Plan [Member]      
Outstanding (in shares) 121,653 133,091  
Granted (in shares) 0 0  
Exercised (in shares) 0 0  
Forfeited (in shares) 0 0  
Expired (in shares) (9,465) (11,438)  
Outstanding (in shares) 112,188 121,653 133,091
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.23.1
Note Q - Stock Options - Options Outstanding and Exercisable (Details)
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Exercisable, weighted average exercise price (in dollars per share) $ 17.12
Exercise Price Range 1 [Member]  
Range of exercise prices, lower range (in dollars per share) 4.08
Range of exercise prices, upper range (in dollars per share) $ 5.84
Options outstanding (in shares) | shares 25,565
Options outstanding, weighted average exercise price (in dollars per share) $ 5.20
Options outstanding, weighted average remaining remaining life (Year) 4 years 7 months 17 days
Options exercisable (in shares) | shares 17,130
Exercisable, weighted average exercise price (in dollars per share) $ 5.20
Exercise Price Range 2 [Member]  
Range of exercise prices, lower range (in dollars per share) 5.85
Range of exercise prices, upper range (in dollars per share) $ 28.00
Options outstanding (in shares) | shares 177,431
Options outstanding, weighted average exercise price (in dollars per share) $ 18.27
Options outstanding, weighted average remaining remaining life (Year) 1 year 9 months 21 days
Options exercisable (in shares) | shares 177,431
Exercisable, weighted average exercise price (in dollars per share) $ 18.27
Exercise Price Range 3 [Member]  
Range of exercise prices, lower range (in dollars per share) 4.08
Range of exercise prices, upper range (in dollars per share) $ 28.00
Options outstanding (in shares) | shares 202,996
Options exercisable (in shares) | shares 194,561
XML 90 R77.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred Tax Assets, Valuation Allowance $ 17,188,000 $ 15,891,000 $ 15,716,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total 0 $ 0  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]      
Operating Loss Carryforwards 61,300,000    
Operating Loss Carryforwards, Subject to Expiration 43,100,000    
Operating Loss Carryforwards, Not Subject to Expiration $ 18,200,000    
Open Tax Year 2019 2020 2021 2022    
State and Local Jurisdiction [Member] | Internal Revenue Service (IRS) [Member]      
Operating Loss Carryforwards, Subject to Expiration $ 6,870,000    
XML 91 R78.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes - Net Income Loss (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net loss $ (11,909,903) $ (5,065,781)
UNITED STATES    
Net loss (10,416,593) (4,507,071)
HONG KONG    
Net loss (458,839) (439,814)
Africa [Member]    
Net loss (143,499) (118,896)
SPAIN    
Net loss $ (890,972) $ 0
XML 92 R79.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes - Components of Income Tax Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Current – federal, states, and foreign $ 0 $ 0
Deferred- Federal 1,175,000 128,000
Deferred - States 122,000 47,000
Deferred - Foreign (20,000) 0
Total 1,277.000 175,000
Change in valuation allowance (1,297,000) (175,000)
Provision for income tax benefits $ (20,434) $ 0
XML 93 R80.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes - Components of Deferred Taxes (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accrued compensation $ 113,000 $ 110,000 $ 66,000
Allowance for doubtful accounts 169,000 70,000 3,000
Research and development expenses 633,000 0  
Capital loss carry forward 114,000 0  
Stock-based compensation 456,000 486,000 562,000
Equipment and leasehold improvements (19,000)    
Equipment and leasehold improvements   1,000 5,000
Intangible assets 341,000 61,000 53,000
Intangible assets - Foreign (170,000) 0  
Inventory reserve 89,000 0  
Interest expense 44,000 0  
Operating lease liabilities 44,000 59,000 111,000
Reserve on debt security 0 13,000  
Operating lease right-of-use assets (44,000) (57,000) (109,000)
Net operating loss and credit carryforwards 15,248,000 15,148,000 15,025,000
Valuation allowances (17,188,000) (15,891,000) (15,716,000)
Net deferred tax liability $ (170,000)    
Net deferred tax liability   $ 0 $ 0
XML 94 R81.htm IDEA: XBRL DOCUMENT v3.23.1
Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Federal statutory income tax rate 21.00% 21.00%
State taxes, net of federal benefit 0.90% 1.10%
Permanent differences (4.70%) (1.00%)
Expiration of net operating loss and research credit carryforwards (5.70%) (13.80%)
Expiration and forfeiture of stock options (0.30%) (1.50%)
Other (0.50%) (2.40%)
Valuation allowance (10.90%) (3.40%)
Effective tax rate (0.20%) 0.00%
XML 95 R82.htm IDEA: XBRL DOCUMENT v3.23.1
Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
U.S. statutory income tax rate 21.00% 21.00%  
Accrued Compensation $ 113,000 $ 110,000 $ 66,000
State taxes, net of federal benefit 0.90% 1.10%  
Allowance for doubtful accounts $ 169,000 $ 70,000 3,000
Permanent differences (4.70%) (1.00%)  
Stock based compensation $ 456,000 $ 486,000 562,000
Expiration of net operating loss and research credit carryforwards (5.70%) (13.80%)  
Equipment and leashold improvements $ 19,000    
Equipment and leashold improvements   $ 1,000 5,000
Expiration and forfeiture of stock options (0.30%) (1.50%)  
Intangible assets $ 341,000 $ 61,000 53,000
Other (0.50%) (2.40%)  
Operating lease liability $ 44,000 $ 59,000 111,000
Valuation allowance (10.90%) (3.40%)  
Reserve on debt security $ 0 $ 13,000  
Operationg Lease right-of -use assets 44,000 $ 57,000 109,000
Valuation allowance   0.00%  
Net operating loss and research credit carryforwards $ 15,248,000 $ 15,148,000 15,025,000
Effective tax rate (0.20%) 0.00%  
Valuation allowance $ 17,188,000 $ 15,891,000 15,716,000
Net deferred tax asset   $ 0 0
Previously Reported [Member]      
U.S. statutory income tax rate   21.00%  
Accrued Compensation   $ 135,000 81,000
State taxes, net of federal benefit   0.00%  
Allowance for doubtful accounts   $ 75,000 474,000
Permanent differences   0.00%  
Stock based compensation   $ 1,149,000 1,073,000
Expiration of net operating loss and research credit carryforwards   0.00%  
Equipment and leashold improvements   $ 10,000 14,000
Expiration and forfeiture of stock options   0.00%  
Intangible assets   $ 75,000 65,000
Other   0.00%  
Operating lease liability   $ 0 0
Valuation allowance   0.00%  
Reserve on debt security   $ 0  
Operationg Lease right-of -use assets   $ (0) (0)
Valuation allowance   (21.00%)  
Net operating loss and research credit carryforwards   $ 14,467,000 13,337,000
Effective tax rate   0.00%  
Valuation allowance   $ 15,891,000 15,016,000
Net deferred tax asset   $ 0 0
Revision of Prior Period, Adjustment [Member]      
U.S. statutory income tax rate   0.00%  
Accrued Compensation   $ (25,000) (15,000)
State taxes, net of federal benefit   1.10%  
Allowance for doubtful accounts   $ (5,000) (471,000)
Permanent differences   (1.00%)  
Stock based compensation   $ (663,000) (511,000)
Expiration of net operating loss and research credit carryforwards   (13.80%)  
Equipment and leashold improvements   $ (11,000) (19,000)
Expiration and forfeiture of stock options   (1.50%)  
Intangible assets   $ (14,000) (12,000)
Other   (2.40%)  
Operating lease liability   $ 59,000 111,000
Valuation allowance   (3.40%)  
Reserve on debt security   $ 13,000  
Operationg Lease right-of -use assets   $ 57,000 109,000
Valuation allowance   21.00%  
Net operating loss and research credit carryforwards   $ 681,000 1,688,000
Effective tax rate   0.00%  
Valuation allowance   $ (0) 700,000
Net deferred tax asset   $ 0 $ 0
XML 96 R83.htm IDEA: XBRL DOCUMENT v3.23.1
Note T - Profit Sharing Plan (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0 $ 0
XML 97 R84.htm IDEA: XBRL DOCUMENT v3.23.1
Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) - Exercise Price Greater Than Average Market Price Of Common Shares [Member] - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive securities (in shares) 5,075,021 4,901,848
Share-Based Payment Arrangement, Option [Member]    
Antidilutive securities (in shares) 202,996 212,461
Warrant [Member]    
Antidilutive securities (in shares) 4,872,025 4,689,387
XML 98 R85.htm IDEA: XBRL DOCUMENT v3.23.1
Note V - Subsequent Events (Details Textual) - shares
 12 Months Ended
May 11, 2023
May 05, 2023
Mar. 16, 2023
Dec. 31, 2022
Restricted Stock [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period       3 years
Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member] | Forecast [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period   14,375    
Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Fees [Member] | Forecast [Member]        
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture 17,392      
Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Committee Fees [Member] | Forecast [Member]        
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture 2,900 2,858    
Subsequent Event [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period     40,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     3 years  
Subsequent Event [Member] | Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Fees [Member]        
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture     15,388  
XML 99 bkyi20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0001019034 2022-01-01 2022-12-31 0001019034 srt:ScenarioForecastMember srt:DirectorMember us-gaap:CommonStockMember bkyi:StockIssuedInLieuOfBoardCommitteeFeesMember 2023-05-11 2023-05-11 0001019034 srt:ScenarioForecastMember srt:DirectorMember us-gaap:CommonStockMember bkyi:StockIssuedInLieuOfBoardFeesMember 2023-05-11 2023-05-11 0001019034 srt:ScenarioForecastMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-05-05 2023-05-05 0001019034 srt:ScenarioForecastMember srt:DirectorMember us-gaap:CommonStockMember bkyi:StockIssuedInLieuOfBoardCommitteeFeesMember 2023-05-05 2023-05-05 0001019034 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:SubsequentEventMember 2023-03-16 2023-03-16 0001019034 srt:DirectorMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember bkyi:StockIssuedInLieuOfBoardFeesMember 2023-03-16 2023-03-16 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2022-01-01 2022-12-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2022-01-01 2022-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2021-01-01 2021-12-31 0001019034 us-gaap:EmployeeStockOptionMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2022-01-01 2022-12-31 0001019034 2021-01-01 2021-12-31 0001019034 2020-12-31 0001019034 srt:RestatementAdjustmentMember 2020-12-31 0001019034 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001019034 2021-12-31 0001019034 srt:RestatementAdjustmentMember 2021-12-31 0001019034 srt:ScenarioPreviouslyReportedMember 2021-12-31 0001019034 srt:RestatementAdjustmentMember 2021-01-01 2021-12-31 0001019034 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0001019034 2022-12-31 0001019034 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-01-01 2022-12-31 0001019034 us-gaap:StateAndLocalJurisdictionMember us-gaap:InternalRevenueServiceIRSMember 2022-12-31 0001019034 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-12-31 0001019034 country:ES 2021-01-01 2021-12-31 0001019034 country:ES 2022-01-01 2022-12-31 0001019034 srt:AfricaMember 2021-01-01 2021-12-31 0001019034 srt:AfricaMember 2022-01-01 2022-12-31 0001019034 country:HK 2021-01-01 2021-12-31 0001019034 country:HK 2022-01-01 2022-12-31 0001019034 country:US 2021-01-01 2021-12-31 0001019034 country:US 2022-01-01 2022-12-31 0001019034 2020-01-01 2020-12-31 0001019034 bkyi:InTheMoneyOptionsMember 2020-12-31 0001019034 bkyi:InTheMoneyOptionsMember 2022-12-31 0001019034 bkyi:InTheMoneyOptionsMember 2021-12-31 0001019034 bkyi:ExercisePriceRange3Member 2022-12-31 0001019034 bkyi:ExercisePriceRange3Member 2022-01-01 2022-12-31 0001019034 bkyi:ExercisePriceRange2Member 2022-12-31 0001019034 bkyi:ExercisePriceRange2Member 2022-01-01 2022-12-31 0001019034 bkyi:ExercisePriceRange1Member 2022-12-31 0001019034 bkyi:ExercisePriceRange1Member 2022-01-01 2022-12-31 0001019034 bkyi:NonPlanMember 2022-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2022-12-31 0001019034 bkyi:NonPlanMember 2022-01-01 2022-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2022-01-01 2022-12-31 0001019034 bkyi:NonPlanMember 2021-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2021-12-31 0001019034 bkyi:NonPlanMember 2021-01-01 2021-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2021-01-01 2021-12-31 0001019034 bkyi:NonPlanMember 2020-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2020-12-31 0001019034 srt:MaximumMember bkyi:The2015EquityIncentivePlanMember 2022-01-01 2022-12-31 0001019034 srt:MinimumMember bkyi:The2015EquityIncentivePlanMember 2022-01-01 2022-12-31 0001019034 bkyi:The2015EquityIncentivePlanMember 2016-01-27 0001019034 bkyi:PrefundedWarrantsMember 2022-01-01 2022-12-31 0001019034 bkyi:PublicOfferingWarrantsMember 2021-01-01 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001019034 bkyi:ReferralFeeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001019034 srt:DirectorMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001019034 srt:DirectorMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001019034 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001019034 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001019034 bkyi:SwivelSecureEuropeMember 2021-01-01 2021-12-31 0001019034 bkyi:SwivelSecureEuropeMember 2022-01-01 2022-12-31 0001019034 bkyi:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001019034 bkyi:EmployeeStockPurchasePlanMember 2022-01-01 2022-12-31 0001019034 bkyi:EmployeeStockPurchasePlanMember 2022-03-08 2022-03-08 0001019034 bkyi:EmployeeStockPurchasePlanMember 2022-12-31 0001019034 bkyi:SwivelSecureEuropeMember 2022-12-31 0001019034 bkyi:SwivelSecureEuropeMember 2022-03-08 2022-03-08 0001019034 bkyi:SwivelSecureEuropeMember 2022-03-08 0001019034 bkyi:TheNoteMember 2022-12-31 0001019034 srt:MaximumMember bkyi:TheNoteMember bkyi:SeniorSecuredPromissoryNoteMember 2022-12-22 0001019034 srt:MaximumMember bkyi:TheNoteMember bkyi:SeniorSecuredPromissoryNoteMember 2022-12-22 2022-12-22 0001019034 bkyi:TheNoteMember bkyi:SeniorSecuredPromissoryNoteMember 2022-12-22 2022-12-22 0001019034 bkyi:TheNoteMember bkyi:SeniorSecuredPromissoryNoteMember 2022-12-22 0001019034 bkyi:WarrantsIssuedInConnectionWithNoteMember 2022-12-22 0001019034 bkyi:WarrantsIssuedInConnectionWithNoteMember 2022-12-22 2022-12-22 0001019034 srt:ScenarioForecastMember bkyi:TheNoteMember bkyi:SeniorSecuredPromissoryNoteMember 2023-06-23 0001019034 bkyi:ResearchDevelopmentAndEngineeringExpenseMember 2021-01-01 2021-12-31 0001019034 bkyi:ResearchDevelopmentAndEngineeringExpenseMember 2022-01-01 2022-12-31 0001019034 us-gaap:PatentsMember 2021-12-31 0001019034 us-gaap:PatentsMember 2022-12-31 0001019034 us-gaap:CustomerRelationshipsMember 2021-12-31 0001019034 us-gaap:CustomerRelationshipsMember 2022-12-31 0001019034 bkyi:ProprietarySoftwareMember 2021-12-31 0001019034 bkyi:ProprietarySoftwareMember 2022-12-31 0001019034 us-gaap:TradeNamesMember 2021-12-31 0001019034 us-gaap:TradeNamesMember 2022-12-31 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001019034 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001019034 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001019034 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001019034 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001019034 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001019034 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001019034 us-gaap:EquipmentMember 2021-12-31 0001019034 us-gaap:EquipmentMember 2022-12-31 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2020-09-30 0001019034 us-gaap:ForeignCorporateDebtSecuritiesMember 2020-06-30 0001019034 bkyi:The2015SoftwareLicenseMember 2021-01-01 2021-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2022-01-01 2022-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2021-12-31 0001019034 bkyi:The2015SoftwareLicenseMember 2022-12-31 0001019034 bkyi:SoftwareLicenseRightsMember 2015-12-31 0001019034 bkyi:SoftwareLicenseRightsMember 2015-12-31 2015-12-31 0001019034 country:NG 2022-12-31 0001019034 srt:ScenarioForecastMember 2024-02-06 2024-02-06 0001019034 2022-07-06 2022-07-06 0001019034 2022-02-25 2022-02-25 0001019034 2020-07-01 2020-09-30 0001019034 2020-09-30 0001019034 bkyi:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 bkyi:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001019034 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001019034 bkyi:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001019034 bkyi:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001019034 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001019034 bkyi:SwivelSecureEuropeMember 2022-03-08 2022-12-31 0001019034 bkyi:SwivelSecureEuropeMember us-gaap:CustomerRelationshipsMember 2022-03-08 2022-03-08 0001019034 srt:ScenarioForecastMember bkyi:GovernmentLoanMember bkyi:BbvaBankMember 2022-05-22 2026-04-30 0001019034 srt:ScenarioForecastMember bkyi:GovernmentLoanMember bkyi:BbvaBankMember 2026-04-30 0001019034 bkyi:SwivelSecureEuropeMember bkyi:RestrictedMember 2022-01-01 2022-12-31 0001019034 srt:AsiaMember 2021-01-01 2021-12-31 0001019034 us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:AfricaMember 2021-01-01 2021-12-31 0001019034 us-gaap:ServiceMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:AfricaMember 2021-01-01 2021-12-31 0001019034 bkyi:HardwareMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:AsiaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember us-gaap:EMEAMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:AfricaMember 2021-01-01 2021-12-31 0001019034 us-gaap:LicenseMember srt:NorthAmericaMember 2021-01-01 2021-12-31 0001019034 srt:AsiaMember 2022-01-01 2022-12-31 0001019034 us-gaap:EMEAMember 2022-01-01 2022-12-31 0001019034 srt:NorthAmericaMember 2022-01-01 2022-12-31 0001019034 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001019034 us-gaap:ServiceMember srt:AsiaMember 2022-01-01 2022-12-31 0001019034 us-gaap:ServiceMember us-gaap:EMEAMember 2022-01-01 2022-12-31 0001019034 us-gaap:ServiceMember srt:AfricaMember 2022-01-01 2022-12-31 0001019034 us-gaap:ServiceMember srt:NorthAmericaMember 2022-01-01 2022-12-31 0001019034 bkyi:HardwareMember 2022-01-01 2022-12-31 0001019034 bkyi:HardwareMember srt:AsiaMember 2022-01-01 2022-12-31 0001019034 bkyi:HardwareMember us-gaap:EMEAMember 2022-01-01 2022-12-31 0001019034 bkyi:HardwareMember srt:AfricaMember 2022-01-01 2022-12-31 0001019034 bkyi:HardwareMember srt:NorthAmericaMember 2022-01-01 2022-12-31 0001019034 us-gaap:LicenseMember 2022-01-01 2022-12-31 0001019034 us-gaap:LicenseMember srt:AsiaMember 2022-01-01 2022-12-31 0001019034 us-gaap:LicenseMember us-gaap:EMEAMember 2022-01-01 2022-12-31 0001019034 us-gaap:LicenseMember srt:AfricaMember 2022-01-01 2022-12-31 0001019034 us-gaap:LicenseMember srt:NorthAmericaMember 2022-01-01 2022-12-31 0001019034 us-gaap:ConvertibleDebtMember 2022-12-31 0001019034 us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001019034 us-gaap:ConvertibleDebtMember 2021-12-31 0001019034 bkyi:MeasurementInputLikelihoodOfDefaultMember 2022-12-22 0001019034 us-gaap:MeasurementInputDiscountRateMember 2022-12-22 0001019034 bkyi:PrincipalUponDefaultMember 2022-12-22 0001019034 us-gaap:MeasurementInputDefaultRateMember 2022-12-22 0001019034 srt:MaximumMember 2022-12-22 0001019034 srt:MinimumMember 2022-12-22 0001019034 2022-12-22 0001019034 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtMember 2022-12-31 0001019034 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2022-12-31 0001019034 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtMember 2022-12-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001019034 srt:MinimumMember 2022-01-01 2022-12-31 0001019034 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-12-31 0001019034 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-12-31 0001019034 srt:MaximumMember us-gaap:EquipmentMember 2022-12-31 0001019034 srt:MinimumMember us-gaap:EquipmentMember 2022-12-31 0001019034 us-gaap:RetainedEarningsMember 2022-12-31 0001019034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001019034 us-gaap:CommonStockMember 2022-12-31 0001019034 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001019034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001019034 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001019034 us-gaap:RetainedEarningsMember 2021-12-31 0001019034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001019034 us-gaap:CommonStockMember 2021-12-31 0001019034 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001019034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001019034 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001019034 us-gaap:RetainedEarningsMember 2020-12-31 0001019034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001019034 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001019034 us-gaap:CommonStockMember 2020-12-31 0001019034 2023-05-30 0001019034 2022-06-30 0001019034 us-gaap:NotesReceivableMember 2022-01-01 2022-12-31 thunderdome:item shares utr:Y iso4217:USD pure iso4217:USD shares iso4217:HKD 0001019034 false --12-31 2022 FY P3Y 0 0 0 0 2019 2020 2021 2022 0 0 0 0 0 0 0 P10Y 0 0 0 0 P3Y 0.0001 3 0 1 1 1 P3Y P4Y 0.0001 0.0001 10-K true 2022-12-31 false 1-13463 BIO-KEY INTERNATIONAL, INC. DE 41-1741861 3349 HIGHWAY 138, BUILDING A, SUITE E WALL NJ 07719 732 359-1100 Common Stock, $0.0001 par value per share BKYI NASDAQ No No No Yes Non-accelerated Filer true false false false false 13509134 9234833 Marcum LLC. Saddle Brook, NJ 688 Rotenberg Meril Solomon Bertiger & Guttilla, P.C. Saddle Brook, NJ 361 2635522 7754046 1522784 970626 49500 49500 0 82000 4434369 4940660 342706 216041 8984881 14012873 0 48752 0 452821 107413 69168 283069 249012 8712 8712 0 113000 197355 254100 1762825 1298077 0 1262526 2359374 3756168 11344255 17769041 1108279 427772 1009123 828997 2596203 0 120000 0 462418 565355 159665 177188 5455688 1999312 52134 67300 170281 0 326767 0 37829 86974 587011 154274 6042699 2153586 170000000 170000000 9190504 9190504 7853759 7853759 919 786 122028612 120190139 -242602 0 -116485373 -104575470 5301556 15615455 11344255 17769041 1789720 1273354 4584052 2555809 646486 1285326 7020258 5114489 722152 686175 906417 183199 811001 803555 2439570 1672929 4580688 3441560 9364887 6028360 3252236 2355056 500000 -0 2387193 0 14504316 8383416 -9923628 -4941856 233 4075 0 -50000 452821 60000 1147456 -0 396203 -0 10462 18000 -2006709 -123925 -11930337 0 20434 0 -11909903 -5065781 -11909903 -5065781 -242602 0 -12152505 -5065781 -1.47 -0.65 8100785 7791741 7814572 782 119844026 0 -99509689 20335119 7828 1 25535 0 0 25536 13125 1 -1 0 0 0 1250 -0 -0 -0 -0 -0 -0 5228 -0 -0 5228 19484 2 36628 0 0 36630 0 10680 0 0 10680 0 278499 0 0 278499 0 0 0 -5065781 -5065781 7853759 786 120190139 0 -104575470 15615455 39636 4 76039 0 0 76043 278000 27 -27 0 0 0 10500 1 -0 -0 -0 1 269060 27 599977 0 0 600004 700000 70 699930 0 0 700000 0 94316 0 94316 60549 6 56374 0 0 56380 0 18787 0 0 18787 0 -242602 0 -242602 0 293077 0 0 293077 0 0 0 -11909903 -11909903 9190504 919 122028612 -242602 -116485373 5301556 -11909903 -5065781 43794 54649 2387193 0 500000 -0 298113 216069 48752 10130 1147456 0 -0 -50000 -452821 -60000 400000 0 -186000 -100000 -360000 -200000 0 18000 106624 110681 311864 289179 76043 25536 130111 0 396203 0 -20434 0 155353 233225 339383 672577 -0 -10953 140681 194378 -106291 4609713 46655 14534 239144 183614 167614 320510 -120078 -69681 -165276 -234310 -6229034 -8978428 729905 623578 -0 9000 0 82040 42024 -696618 -42024 2002000 0 155140 -0 56380 36630 -0 250000 -0 5228 1903240 -218598 -96112 0 -5118524 -9239050 7754046 16993096 2635522 7754046 25682 0 10462 0 702886 0 65640 0 20708 0 762860 0 1258087 0 431884 0 544000 0 190715 0 600004 0 700000 0 94316 0 105893 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE A </b>—<b>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Nature of Business</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Going Concern and Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company has historically financed our operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered our expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and therefore is looking into other markets and opportunities to sell or return the product to generate additional cash.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Foreign Currency</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for foreign currency transactions pursuant to ASC 830, <i>Foreign Currency Matters</i> ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Summary of Significant Accounting Policies</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">A summary of the significant accounting policies consistently applied in the preparation of the accompanying consolidated financial statements follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1. <i>Principles</i> <i>of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2. <i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) as set forth in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) and consider the various staff accounting bulletins and other applicable guidance issued by the U.S. Securities and Exchange Commission (SEC). These accounting principles require us to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions upon which it relies are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to accounts receivable, inventory, intangible assets and goodwill, fair value of convertible note payable, and income taxes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">3. <i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the contract with a customer</p> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the performance obligations in the contract</p> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Determine the transaction price</p> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Allocate the transaction price to performance obligations in the contract</p> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Recognize revenue when or as the Company satisfies a performance obligation</p> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Software licenses</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Software license revenue consists of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Hardware</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Support and Maintenance</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the term of the contract begins. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Professional Services</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Contracts with Multiple Performance Obligations</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Costs to Obtain and Fulfill a Contract</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be <span style="-sec-ix-hidden:c479">four</span> years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Deferred Revenue</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Deferred revenue includes customer advances and amounts that have been paid by customers for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2022 and 2021, amounts in deferred revenue were approximately $515,000 and $633,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">4. <i>Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">In accordance with ASC 805, <i>Business Combinations</i> (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">5.<i> Goodwill and acquired intangible assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31st of each year. Refer Note K for more information regarding the impairment of goodwill in 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">6. <i>Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2022 and 2021, cash equivalents consisted of a money market account.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">7. <i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accounts receivable at December 31, 2022 and 2021 consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,096,569</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Loss on foreign currency</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,522,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Bad debt expenses (if any) are recorded in selling, general, and administrative expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The allowance for doubtful accounts for the years ended December 31, 2022 and 2021 is as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beginning of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to Costs and Expenses</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deductions from Reserves</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at End of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2022 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">360,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2021 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,733,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,720,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">8. <i>Equipment and Leasehold Improvements,</i> <i>Intangible Assets and</i> <i>Depreciation and Amortization</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Equipment and leasehold improvements are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td> <td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Equipment and leasehold improvements</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">life or lease term</p> </td> <td rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships. Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">9. <i>Impairment or Disposal of Long Lived Assets, including Intangible Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. There were no impairments in 2022 and 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">10. <i>Advertising Expense </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company expenses the costs of advertising as incurred. Advertising expenses for 2022 and 2021 were approximately $842,000 and $527,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">11. <i>Research and Development Expenditures</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">12. <i>Earnings Per Share of Common Stock (</i>“<i>EPS</i>”<i>)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company’s EPS is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">13. <i>Accounting for Stock-Based Compensation </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over a <span style="-sec-ix-hidden:c539">three</span> year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of certain assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">310,017</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research, development and engineering</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77,890</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">387,907</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">14. <i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company accounts for uncertain tax provisions in accordance with ASC 740. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">15<i>. Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In accordance with ASC 842, <i>Leases </i>(ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">16. <i>The Fair Value Measurement Option</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC 825, <i>Financial Instruments</i>. As a result, the convertible promissory note was recorded at fair value upon issuance and will subsequently be remeasured at each reporting date until settled or converted. The Company recognized the note initially at fair value, which exceeded the proceeds received resulting in a day one loss that has been recognized in net loss. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">17. <i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The following table summarizes our financial instruments measured at fair value at December 31, 2022:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 1</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 2</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 3</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Convertible note at fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company issued a convertible note to which included an original issue discount, conversion features and a detachable warrant, as further discussed in Note M. The detachable warrant represents a freestanding, separable equity-linked financial instrument recorded at fair value. The fair value of the detachable warrant was calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt which was determined based on significant unobservable inputs including the likelihood of default, the estimated date at which the default could take place, and the present value discount rate, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The fair value option requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as change in fair value of convertible note in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible note were expensed and not deferred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at December 22, 2022:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">1. Face amount - $2,200,000</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">2. Nominal interest rate – 10% - 12%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">3. Default interest rate – 18%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">4. Increase in principal upon a default – 30%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">5. Present value discount rate – 15.18%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">6. Likelihood of default – estimated to be 50% at the extended maturity date</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the year ended December 31, 2022:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 224pt;text-indent:36pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beginning balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Purchases and issuances</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,200,000</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Day one loss on value of hybrid instrument</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">396,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ending balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 224pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">18. <i>Recent Accounting Pronouncements</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016- 13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct writedown of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for the Company for annual periods, including interim periods within those annual periods, beginning on January 1, 2023. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</p> <i>Going Concern and Basis of Presentation</i>The Company has historically financed our operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered our expenses through decreasing spending in marketing, and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and therefore is looking into other markets and opportunities to sell or return the product to generate additional cash.The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. <i>Foreign Currency</i>The Company accounts for foreign currency transactions pursuant to ASC 830, <i>Foreign Currency Matters</i> ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss. 1. <i>Principles</i> <i>of Consolidation</i>The accompanying consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Intercompany accounts and transactions have been eliminated in consolidation. 2. <i>Use of Estimates</i> 3. <i>Revenue Recognition</i>In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle, the Company applies the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the contract with a customer</p> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Identify the performance obligations in the contract</p> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Determine the transaction price</p> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Allocate the transaction price to performance obligations in the contract</p> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Recognize revenue when or as the Company satisfies a performance obligation</p> </td> </tr> </tbody></table> All of the Company's performance obligations, and associated revenues, are generally transferred to customers at a point in time, with the exception of support and maintenance, and professional services, which are generally transferred to the customer over time.<i>Software licenses</i>Software license revenue consists of fees for perpetual and subscription licenses for one or more of the Company’s biometric fingerprint solutions or identity access management solutions. Revenue is recognized at a point in time once the software is available to the customer for download. Software license contracts are generally invoiced in full on execution of the arrangement.<i>Hardware</i>Hardware revenue consists of fees for associated equipment sold with or without a software license arrangement, such as servers, locks and fingerprint readers. Customers are not obligated to buy third party hardware from the Company, and may procure these items from a number of suppliers. Revenue is recognized at a point in time once the hardware is shipped to the customer. Hardware items are generally invoiced in full on execution of the arrangement.<i>Support and Maintenance</i>Support and maintenance revenue consists of fees for unspecified upgrades, telephone assistance and bug fixes. The Company satisfies its support and maintenance performance obligation by providing “stand-ready” assistance as required over the contract period. The Company records deferred revenue (contract liability) at time of prepayment until the term of the contract begins. Revenue is recognized over time on a ratable basis over the contract term. Support and maintenance contracts are one to five years in length and are generally invoiced in advance at the beginning of the term. Support and Maintenance revenue for subscription licenses is carved out of the total license cost at 18% and recognized on a ratable basis over the license term.<i>Professional Services</i>Professional services revenues consist primarily of fees for deployment and optimization services, as well as training. The majority of the Company’s consulting contracts are billed on a time and materials basis, and revenue is recognized based on the amount billable to the customer in accordance with practical expedient ASC 606-10-55-18. For other professional services contracts, the Company utilizes an input method and recognizes revenue based on labor hours expended to date relative to the total labor hours expected to be required to satisfy its performance obligation.<i>Contracts with Multiple Performance Obligations</i>Some contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The standalone selling prices are determined based on overall pricing objectives, taking into consideration market conditions and other factors, including the value of the contracts, the cloud applications sold, customer demographics, geographic locations, and the number and types of users within the contracts.The Company considered several factors in determining that control transfers to the customer upon shipment of hardware and availability of download of software. These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership.Accounts receivable from customers are typically due within 30 days of invoicing. The Company does not record a reserve for product returns or warranties as amounts are deemed immaterial based on historical experience.<i>Costs to Obtain and Fulfill a Contract</i>Costs to obtain and fulfill a contract are predominantly sales commissions earned by the sales force and are considered incremental and recoverable costs of obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit determined to be <span style="-sec-ix-hidden:c479">four</span> years. These costs are included as capitalized contract costs on the balance sheet. The period of benefit was determined by taking into consideration customer contracts, technology, and other factors based on historical evidence. Amortization expense is included in selling, general and administrative expenses in the accompanying consolidated statements of operations.<i>Deferred Revenue</i>Deferred revenue includes customer advances and amounts that have been paid by customers for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At December 31, 2022 and 2021, amounts in deferred revenue were approximately $515,000 and $633,000, respectively. 0.18 515000 633000 4. <i>Business Combinations</i>In accordance with ASC 805, <i>Business Combinations</i> (ASC 805), the Company recognizes the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. Determining these fair values requires management to make significant estimates and assumptions, especially with respect to intangible assets.The Company recognizes identifiable assets acquired and liabilities assumed at their acquisition date fair value. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net acquisition date fair value of the assets acquired and the liabilities assumed and represents the expected future economic benefits arising from other assets acquired that are not individually identified and separately recognized. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, its estimates are inherently uncertain and subject to refinement. Assumptions may be incomplete or inaccurate, and unanticipated events or circumstances may occur, which may affect the accuracy or validity of such assumptions, estimates or actual results. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill to the extent that it identifies adjustments to the preliminary purchase price allocation. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations. 5.<i> Goodwill and acquired intangible assets</i>Goodwill is not amortized, but is evaluated for impairment annually, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The Company has determined that there is a single reporting unit for the purpose of conducting this goodwill impairment assessment. For purposes of assessing potential impairment, the Company estimates the fair value of the reporting unit, based on the Company’s market capitalization, and compares this amount to the carrying value of the reporting unit. If the Company determines that the carrying value of the reporting unit exceeds its fair value, an impairment charge would be required. The annual goodwill impairment test will be performed as of December 31st of each year. Refer Note K for more information regarding the impairment of goodwill in 2022.Intangible assets acquired in a business combination are recorded at their estimated fair values at the date of acquisition. The Company amortizes acquired definite-lived intangible assets over their estimated useful lives based on the pattern of consumption of the economic benefits or, if that pattern cannot be readily determined, on a straight-line basis. 6. <i>Cash Equivalents</i>Cash equivalents consist of liquid investments with original maturities of three months or less. At December 31, 2022 and 2021, cash equivalents consisted of a money market account. <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">7. <i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accounts receivable are carried at original amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful receivables by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Accounts receivable are written off when deemed uncollectible.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accounts receivable at December 31, 2022 and 2021 consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,096,569</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Loss on foreign currency</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,522,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Bad debt expenses (if any) are recorded in selling, general, and administrative expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The allowance for doubtful accounts for the years ended December 31, 2022 and 2021 is as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beginning of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to Costs and Expenses</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deductions from Reserves</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at End of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2022 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">360,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2021 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,733,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,720,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,096,569</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Loss on foreign currency</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(50,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net of allowances for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,522,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">970,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beginning of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to Costs and Expenses</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deductions from Reserves</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at End of Year</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2022 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">360,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">573,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Year ended December 31, 2021 Allowance for Doubtful Accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,733,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,720,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">213,785</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 2096569 1234411 0 -50000 573785 213785 1522784 970626 213785 -360000 0 573785 1733785 -200000 -1720000 213785 8. <i>Equipment and Leasehold Improvements,</i> <i>Intangible Assets and</i> <i>Depreciation and Amortization</i>Equipment and leasehold improvements are stated at cost. Depreciation is provided for in amounts sufficient to relate the cost of depreciable assets to operations over the estimated service lives, principally using straight-line methods. Leasehold improvements are amortized over the shorter of the life of the improvement or the lease term, using the straight-line method.The estimated useful lives used to compute depreciation and amortization for financial reporting purposes are as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td> <td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Equipment and leasehold improvements</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">life or lease term</p> </td> <td rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> </tr> </tbody></table> Intangible assets other than goodwill consist of patents, trade name, proprietary software, and customer relationships. Patent costs are capitalized until patents are awarded. Upon award, such costs are amortized using the straight-line method over their respective economic lives. If a patent is denied, all costs are charged to operations in that year. Trade names, proprietary software, and customer relationships are amortized over the economic useful life. <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td> <td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Equipment and leasehold improvements</i></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"><i> </i></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="1" rowspan="1" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td> <td colspan="1" rowspan="1" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td rowspan="1" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6%;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> </td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">life or lease term</p> </td> <td rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> </tr> </tbody></table> P3Y P5Y P3Y P5Y P3Y 9. <i>Impairment or Disposal of Long Lived Assets, including Intangible Assets</i>The Company reviews long-lived assets, including intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of such an asset may not be recoverable. Recoverability of these assets is measured by comparison of their carrying amount to the future undiscounted cash flows the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is equal to the amount by which the carrying value of the assets exceeds their fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique. In assessing recoverability, the Company must make assumptions regarding estimated future cash flows and discount factors. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. Intangible assets with determinable lives are amortized over their estimated useful lives, based upon the pattern in which the expected benefits will be realized, or on a straight-line basis, whichever is greater. There were no impairments in 2022 and 2021. 10. <i>Advertising Expense </i>The Company expenses the costs of advertising as incurred. Advertising expenses for 2022 and 2021 were approximately $842,000 and $527,000, respectively. 842000 527000 11. <i>Research and Development Expenditures</i>Research and development expenses include costs directly attributable to the conduct of research and development programs primarily related to the development of our software products and improving the efficiency and capabilities of our existing software. Such costs include salaries, payroll taxes, employee benefit costs, materials, supplies, depreciation on research equipment, services provided by outside contractors, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and general support services. All costs associated with research and development are expensed as incurred. 12. <i>Earnings Per Share of Common Stock (</i>“<i>EPS</i>”<i>)</i>The Company’s EPS is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants, when the effect of their inclusion is dilutive. 13. <i>Accounting for Stock-Based Compensation </i>The Company accounts for share based compensation in accordance with the provisions of ASC 718-10, “Compensation — Stock Compensation,” which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The majority of its share-based compensation arrangements vest over a <span style="-sec-ix-hidden:c539">three</span> year vesting schedule. The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant. The fair value of stock options is determined using the Black-Scholes valuation model and requires the input of certain assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (the “expected option term”), the estimated volatility of its common stock price over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected annual dividend yield. Changes in these subjective assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized as an expense in the consolidated statements of operations. As required under the accounting rules, the Company reviews its valuation assumptions at each grant date and, as a result, the Company is likely to change its valuation assumptions used to value employee stock-based awards granted in future periods. The values derived from using the Black-Scholes model are recognized as expense over the service period, net of estimated forfeitures (the number of individuals that will ultimately not complete their vesting requirements). The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. Actual results, and future changes in estimates, may differ substantially from current estimates. Options and warrants to outsiders are accounted for under ASC 718.The following table presents share-based compensation expenses included in the Company’s consolidated statements of operations: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">310,017</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research, development and engineering</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77,890</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">387,907</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">310,017</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,368</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research, development and engineering</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77,890</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">387,907</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 310017 269368 77890 45347 387907 314715 14. <i>Income Taxes</i>The provision for, or benefit from, income taxes includes deferred taxes resulting from the temporary differences in income for financial and tax purposes using the liability method. Such temporary differences result primarily from the differences in the carrying value of assets and liabilities. Future realization of deferred income tax assets requires sufficient taxable income within the carryback, carryforward period available under tax law. The Company evaluates, on a quarterly basis whether, based on all available evidence, if it is probable that the deferred income tax assets are realizable. Valuation allowances are established when it is more likely than not that the tax benefit of the deferred tax asset will not be realized. The evaluation, as prescribed by ASC 740-10, “Income Taxes,” includes the consideration of all available evidence, both positive and negative, regarding historical operating results including recent years with reported losses, the estimated timing of future reversals of existing taxable temporary differences, estimated future taxable income exclusive of reversing temporary differences and carryforwards, and potential tax planning strategies which may be employed to prevent an operating loss or tax credit carryforward from expiring unused. Because of the Company’s historical performance and estimated future taxable income, a full valuation allowance has been established.The Company accounts for uncertain tax provisions in accordance with ASC 740. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. 15<i>. Leases</i>In accordance with ASC 842, <i>Leases </i>(ASC 842), the Company records a right-of-use (ROU) asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classifies them as either operating or finance leases.At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration, and to account for the lease and non-lease components as a single lease component.Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate, adjusted for various factors including level of collateralization, term and currency to align with the terms of the lease. The operating lease ROU asset also includes any lease prepayments, offset by lease incentives.An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain we will not exercise the option. <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">16. <i>The Fair Value Measurement Option</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC 825, <i>Financial Instruments</i>. As a result, the convertible promissory note was recorded at fair value upon issuance and will subsequently be remeasured at each reporting date until settled or converted. The Company recognized the note initially at fair value, which exceeded the proceeds received resulting in a day one loss that has been recognized in net loss. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying consolidated statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">17. <i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The following table summarizes our financial instruments measured at fair value at December 31, 2022:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 1</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 2</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 3</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Convertible note at fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company issued a convertible note to which included an original issue discount, conversion features and a detachable warrant, as further discussed in Note M. The detachable warrant represents a freestanding, separable equity-linked financial instrument recorded at fair value. The fair value of the detachable warrant was calculated using a Black-Scholes valuation model. The Company elected the fair value option for the convertible debt which was determined based on significant unobservable inputs including the likelihood of default, the estimated date at which the default could take place, and the present value discount rate, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The fair value option requires recognition at fair value upon issuance and on each balance sheet date thereafter. Changes in the estimated fair value are recognized as change in fair value of convertible note in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the issuance of the convertible note were expensed and not deferred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at December 22, 2022:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">1. Face amount - $2,200,000</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">2. Nominal interest rate – 10% - 12%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">3. Default interest rate – 18%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">4. Increase in principal upon a default – 30%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">5. Present value discount rate – 15.18%</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">6. Likelihood of default – estimated to be 50% at the extended maturity date</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the year ended December 31, 2022:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 224pt;text-indent:36pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beginning balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Purchases and issuances</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,200,000</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Day one loss on value of hybrid instrument</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">396,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ending balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 1</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 2</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 3</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Convertible note at fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table> 2596203 0 0 2596203 2200000 0.10 0.12 0.18 0.30 0.1518 0.50 <table cellpadding="0" cellspacing="0" class="finTable" style="width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beginning balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Purchases and issuances</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,200,000</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Day one loss on value of hybrid instrument</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">396,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ending balance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">2,596,203</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 0 2200000 -396203 2596203 18. <i>Recent Accounting Pronouncements</i>In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016- 13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct writedown of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. ASU 2016-13 is effective for the Company for annual periods, including interim periods within those annual periods, beginning on January 1, 2023. The Company is currently assessing the impact ASU 2016-13 will have on its consolidated financial statements.Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE B</b>—<b>REVENUE FROM CONTRACTS WITH CUSTOMERS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Disaggregation of Revenue</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes revenue from contracts with customers for the years ended December 31, 2022 and 2021:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,856,814</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">517,161</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,124,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">85,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,584,052</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">422,275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,833</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,914</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">178,464</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">646,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,270,067</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">83,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">436,293</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,789,720</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,549,156</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">626,300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,580,295</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,507</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,020,258</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,854,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">521,751</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">105,314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">74,656</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,555,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">278,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">698,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">265,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,285,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,162,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,273,354</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,295,269</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,262,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,114,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">* EMESA – Europe, Middle East, South America</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Revenue recognized during the year ended December 31, 2022 from amounts included in deferred revenue at the beginning of the year was approximately $489,000. Revenue recognized during the year ended December 31, 2021 from amounts included in deferred revenue at the beginning of the year was approximately $529,000. Total deferred revenue (contract liability) was approximately $515,000 and $633,000 at December 31, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Transaction Price Allocated to the Remaining Performance Obligations</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied. The guidance provides certain practical expedients that limit this requirement, which the Company’s contracts meet as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 9pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The performance obligation is part of a contract that has an original expected duration of one year or less, in accordance with ASC 606-10-50-14.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Deferred revenue represents the Company’s remaining performance obligations related to prepaid support and maintenance, all of which is expected to be recognized from one to five years.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,856,814</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">517,161</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,124,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">85,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,584,052</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">422,275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,833</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,914</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">178,464</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">646,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,270,067</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">83,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">436,293</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,789,720</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,549,156</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">626,300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,580,295</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,507</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,020,258</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>North </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>America</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Africa</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>EMESA*</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Asia</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">License fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,854,088</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">521,751</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">105,314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">74,656</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,555,809</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hardware</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">278,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">698,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">265,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,285,326</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,162,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">54,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,273,354</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,295,269</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,262,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,114,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 1856814 517161 2124088 85989 4584052 422275 25833 19914 178464 646486 1270067 83306 436293 54 1789720 3549156 626300 2580295 264507 7020258 1854088 521751 105314 74656 2555809 278655 698264 265996 42411 1285326 1162526 42000 54918 13910 1273354 3295269 1262015 426228 130977 5114489 489000 529000 515000 633000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE C</b>—<b>SWIVEL SECURE EUROPE, SA ACQUISITION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On March 8, 2022, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Swivel Secure based in Madrid, Spain, pursuant to the terms of a stock purchase agreement. The aggregate purchase price consisted of a base purchase price of $1.75 million, subject to closing adjustments based on the closing date working capital, indebtedness and unpaid transaction expenses, and an earn-out of $500,000. The earn-out was payable based on Swivel Secure generating $3,000,000 of revenue and $1,000,000 of operating profit during an earn-out period commencing on the closing date and ending on January 31, 2023, which was not attained. At the closing, the Company made a cash payment of $1.27 million and issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the stock purchase agreement. The shares of Company common stock were priced at $2.23, the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The business combination has been accounted for as an acquisition and, in accordance with ASC 805. The Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following table summarizes the purchase price allocation, with no earnout payment:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 27pt;"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 84%;">Purchase consideration:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash paid, including working capital adjustment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,273,483</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Earnout payable</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">500,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock issued</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600,004</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total purchase price consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,373,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Fair value of assets acquired and liabilities assumed:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">729,905</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">702,886</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment acquired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,640</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20,708</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,258,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total estimated assets acquired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,540,086</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">431,884</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Government loan</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">544,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Deferred tax liability</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total liabilities assumed</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,166,599</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total estimated fair value of assets acquired and liabilities assumed</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,373,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">The fair value of the assets acquired and liabilities assumed was less than the purchase price, resulting in the recognition of goodwill. The goodwill reflected the value of the synergies the Company expected to realize and the assembled workforce. Refer to Note K for more information regarding the impairment of goodwill.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The significant intangible asset identified in the purchase price allocation discussed above was Customer Relationships. To value the Customer Relationships, the Company utilized the Excess Earnings Method, which isolates the value of the specific intangible asset by discounting its income stream to present value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The government loan was issued through BBVA Bank during the COVID-19 pandemic. The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through April 2026. The installment payments have been paid monthly as per the schedule, as of the date of this report.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The following table presents the final fair values and useful lives of the identifiable intangible assets acquired:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 9pt;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">As discussed above, the earnout payable was not achieved. As such, the Company reversed the earnout payable of $500,000 and recognized the income on the reversal of the earnout payable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">For the period from March 8, 2022 to December 31, 2022, revenue from Swivel Secure amounted to $2,351,975 and net loss amounted to $720,691.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1 1750000 500000 3000000 1000000 1270000 269060 89687 2.23 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 27pt;"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 84%;">Purchase consideration:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash paid, including working capital adjustment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,273,483</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Earnout payable</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">500,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock issued</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600,004</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total purchase price consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,373,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Fair value of assets acquired and liabilities assumed:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">729,905</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">702,886</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment acquired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,640</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20,708</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,258,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total estimated assets acquired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,540,086</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable and accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">431,884</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Government loan</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">544,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Deferred tax liability</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190,715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total liabilities assumed</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,166,599</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total estimated fair value of assets acquired and liabilities assumed</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,373,487</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1273483 500000 600004 2373487 729905 702886 65640 20708 762860 1258087 3540086 431884 544000 190715 1166599 2373487 0.0175 11900 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 9pt;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total identifiable intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">762,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 762860 P7Y 762860 -500000 2351975 720691 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE D</b>—<b>FAIR VALUES OF FINANCIAL INSTRUMENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE E</b>—<b>CONCENTRATION OF RISK</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Financial instruments which potentially subject the Company to risk primarily consist of cash, and cash equivalents, investment in debt security, and accounts receivables.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company maintains its cash and cash equivalents with various financial institutions, which, at times may exceed insured limits. The exposure to the Company is solely dependent upon daily bank balances and the respective strength of the financial institutions. The Company was in excess of coverage of approximately $2,000,000 and $7,057,000 at December 31, 2022 and 2021, respectively. The Company has not incurred any losses on these accounts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company extends credit to customers on an unsecured basis in the normal course of business. The Company’s policy is to perform an analysis of the recoverability of its receivables at the end of each reporting period and to establish allowances where appropriate. The Company analyzes historical bad debts and contract losses, customer concentrations, and customer credit-worthiness when evaluating the adequacy of the allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">For the year ended December 31, 2022 <span style="-sec-ix-hidden:c903"><span style="-sec-ix-hidden:c904">no</span></span> customer accounted for 10% of total revenue. For the year ended December 2021, <span style="-sec-ix-hidden:c906">one</span> customer accounted for 13% of total revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">At December 31, 2022, <span style="-sec-ix-hidden:c908">one</span> customer accounted for 35% of the total accounts receivable. At December 31, 2021, <span style="-sec-ix-hidden:c910">three</span> customers accounted for 87% of total accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2000000 7057000 0.10 0.13 0.35 0.87 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE F</b>—<b>NOTE RECEIVABLE</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">During the third quarter of 2020, the Company loaned $295,000 as an advance to Technology Transfer Institute (“TTI”) to aid in fulfilling the African contracts. The note did not bear any interest if paid within the nine (9) monthly installments beginning December 31, 2020. The note bore a default rate of 5%. Due to the ongoing delays in payment, the Company reserved $186,000 of the note as an allowance. On February 17, 2022, the Company amended the note to modify the payment terms to provide for lower monthly payments, with an updated maturity date on or before December 6, 2023. On May 5, 2022, the Company amended the note to modify the payment terms to eight biweekly installments of $1,000 beginning February 25, 2022, nineteen consecutive monthly installments of $15,000 beginning on July 6, 2022, and $2,000 on or before February 6, 2024. Currently, the payments are several months behind schedule. Due to the delay in payments, the Company has increased the allowance for the remainder of the balance owed under the note. We are continuing to pursue payment and expect that we will start to receive funds in the second quarter of 2023. A member of our board of directors served as Chief Executive Officer of TTI until August 12, 2020.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Note receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Repayment of note</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful account</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Note receivable, net of allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Current portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Noncurrent portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 295000 0.05 186000 1000 15000 2000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Note receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">295,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Repayment of note</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(9,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful account</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Note receivable, net of allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">195,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Current portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Noncurrent portion, net of allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 195000 295000 9000 -0 186000 100000 0 195000 0 82000 0 113000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE G</b>—<b>INVENTORY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Inventory is comprised of the following as of December 31:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,764,643</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,798,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Fabricated assemblies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">69,726</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">142,457</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reserve on finished goods</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(400,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventory</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,434,369</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,940,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 400000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,764,643</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,798,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Fabricated assemblies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">69,726</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">142,457</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reserve on finished goods</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(400,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventory</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,434,369</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,940,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 4764643 4798203 69726 142457 400000 -0 4434369 4940660 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE H</b>—<b>RESALABLE SOFTWARE LICENSES</b> <b>RIGHTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On December 31, 2015, the Company purchased third-party software licenses in the amount of $180,000 in anticipation of a large pending deployment that has yet to materialize. The Company was amortizing the total cost at the greater of the actual unit cost per license sold or straight-line amortization over 10 years. Since the license purchase, the actual per unit cost (actual usage) of such license rights in the cumulative amount of $141,190 has been charged to cost of sales. Since we have not received any sales for the license within the last two years, we accelerated the amortization for the balance of the license in 2022, leaving a carrying balance of $0 and $48,752 as of December 31, 2022 and 2021, respectively. A total of $48,752 and $10,130 was charged to cost of sales during the years ended December 31, 2022 and 2021, respectively.</p> 180000 P10Y 141190 0 48752 48752 10130 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE I</b>—<b>INVESTMENT IN DEBT SECURITY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company purchased a 4,000,000 Hong Kong dollar denominated Bond Certificate with a financial institution in Hong Kong in September 2020 bearing interest at 5% per annum. The Bond Certificate translated to $512,821 U.S. Dollars, based on the exchange rate at the purchase date.  The investment was originally recorded at amortized cost and was scheduled to mature in June 2021. The Company never received the proceeds and accrued interest from the investment and as such, wrote off the investment during 2022 as the bond issuer defaulted on repayment, and the Company had no recourse.</p> 4000000 5 512821 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE J</b>—<b>EQUIPMENT AND LEASEHOLD IMPROVEMENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Equipment and leasehold improvements consisted of the following as of December 31:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">825,058</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">831,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">225,978</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,143</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,903</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,135,082</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,053,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,027,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(983,875</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,413</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,168</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Depreciation was $43,794 and $54,649 for 2022 and 2021, respectively. Amounts are recorded in selling, general, and administrative expense as well as in cost of services.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">825,058</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">831,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">225,978</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,079</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,143</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,903</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,135</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,135,082</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,053,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,027,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(983,875</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,413</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,168</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 825058 831784 225978 164079 49143 32045 34903 25135 1135082 1053043 1027669 983875 107413 69168 43794 54649 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE K</b>—<b>INTANGIBLE ASSETS AND GOODWILL</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intangible assets consisted of the following as of December 31:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Trade name</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Proprietary software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,692,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Patents and patents pending</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,607,940</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(845,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(547,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,762,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Aggregate amortization expense for 2022 and 2021 was approximately $298,000 and $216,000, respectively. Estimated minimum amortization expense based on straight line amortization of the software license rights for each of the next five years and thereafter approximates the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">320,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">320,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">280,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">230,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">220,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">392,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,762,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Goodwill</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company conducted its annual impairment analysis of its goodwill balances as at December 31, 2022. The Company noted the noted the cyclical downturn in technology stock values over the 2022 period, since our previous annual impairment assessment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The analysis showed the carrying value of the Company’s reporting segment was in excess of the Company’s market valuation as at December 31, 2022 based on a fair valuation measure as the quoted market price for the Company’s publicly traded stock as of that date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Accordingly, the Company concluded the amounts in goodwill had been fully impaired and accordingly wrote-off the entire balance in full as at December 31, 2022.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Trade name</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Proprietary software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">420,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer relationships</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,692,860</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">930,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Patents and patents pending</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">365,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,607,940</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,845,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(845,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(547,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,762,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,298,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 130000 130000 420000 420000 1692860 930000 365080 365080 2607940 1845080 845115 547003 1762825 1298077 298000 216000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Years ending December 31</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">320,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">320,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">280,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">230,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">220,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">392,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,762,825</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 320000 320000 280000 230000 220000 392825 1762825 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE L</b>—<b>ACCRUED LIABILITIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accrued liabilities consisted of the following as of December 31:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">377,958</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,433</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensated absences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">378,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">293,297</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued legal and accounting fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,008</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">95,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Franchise taxes</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee expenses reimbursement</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,209</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales tax payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,480</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,009,123</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">828,997</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">377,958</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,433</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensated absences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">378,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">293,297</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued legal and accounting fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,008</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">95,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Franchise taxes</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee expenses reimbursement</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,209</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales tax payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,480</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,009,123</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">828,997</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 377958 254433 378874 293297 110008 95738 7000 40000 114209 76000 17594 18548 3480 50981 1009123 828997 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE M</b>—<b>CONVERTIBLE NOTE PAYABLE</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Securities Purchase Agreement dated December 22, 2022</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) which issued a $2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $2,002,000 was funded, with the proceeds to be used for general working capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension by the Company. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">In connection with the issuance of the Note, the Company issued to the investor 700,000 shares of Common Stock (the “Commitment Shares”) valued at $1.00 per share and a warrant (the “Warrant”) to purchase 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $3.00 per share, exercisable commencing on the date of issuance with a term of five years. The warrant was valued at $94,316 (see Note P. #3). In the event the Note is paid in full within six months after the date of issuance, the Company will exercise its right to repurchase 350,000 of the Commitment Shares for aggregate payment to the Investor of $1.00.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Upon issuance, the Note is not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at 1,684,576 which is 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">During April 2023, we were in default under the Note due to our failure to timely file this annual report and timely file a registration statement covering the public resale of the shares issued to the holder of the Note in connection with the financing. We have obtained a waiver and, therefore, as of the date of this report we are not in default.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">As of December 31, 2022, the Note with principal balance of $2,200,000, at fair value, was recorded at $2,596,203.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2200000 2002000 0.10 0.12 700000 1.00 200000 3.00 94316 350000 0.18 0.30 1684576 0.199 2200000 2596203 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE N</b>—<b>LEASES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"><b>Lease cost</b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,649</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">254,649</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Balance sheet information</b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating right-of-use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">197,355</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities, current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159,665</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177,188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities, non-current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,829</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,974</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">197,494</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average remaining lease term (in years) – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.96</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.45</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average discount rate – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Supplemental cash flow information related to leases were as follows:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">259,558</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">256,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Maturities of operating lease liabilities were as follows as of December 31, 2022:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,808</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total future lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">203,404</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">197,494</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"><b>Lease cost</b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,649</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">254,649</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Balance sheet information</b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating right-of-use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">197,355</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">254,100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities, current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159,665</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177,188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities, non-current portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,829</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,974</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">197,494</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">264,162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average remaining lease term (in years) – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.96</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.45</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average discount rate – operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Supplemental cash flow information related to leases were as follows:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">259,558</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">256,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Maturities of operating lease liabilities were as follows as of December 31, 2022:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,808</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total future lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">203,404</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,910</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">197,494</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 254649 255892 254649 255892 197355 254100 159665 177188 37829 86974 197494 264162 P0Y11M15D P1Y5M12D 0.0550 0.0550 259558 256977 164596 38808 203404 5910 197494 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE O</b>—<b>COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><span style="text-decoration: underline; ">Distribution Agreement</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 9pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 9pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 9pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><span style="text-decoration: underline; ">Litigation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">From time to time, the Company may be involved in litigation relating to claims arising out of its operations in the normal course of business. As of December 31, 2022, the Company was not a party to any pending lawsuits.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE P</b>—<b> EQUITY</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">1. Preferred Stock</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Within the limits and restrictions provided in the Company’s Certificate of Incorporation, the Board of Directors has the authority, without further action by the shareholders, to issue up to 5,000,000 shares of preferred stock, $<span style="-sec-ix-hidden:c1260">.0001</span> par value per share, in one or more series, and to fix, as to any such series, any dividend rate, redemption price, preference on liquidation or dissolution, sinking fund terms, conversion rights, voting rights, and any other preference or special rights and qualifications.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">2. Common Stock</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Holders of common stock have equal rights to receive dividends when, as and if declared by the Board of Directors, out of funds legally available therefor. Holders of common stock have one vote for each share held of record and do not have cumulative voting rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Holders of common stock are entitled, upon liquidation of the Company, to share ratably in the net assets available for distribution, subject to the rights, if any, of holders of any preferred stock then outstanding. Shares of common stock are not redeemable and have no preemptive or similar rights. All outstanding shares of common stock are fully paid and nonassessable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan (“ESPP”). Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><span style="text-decoration: underline; ">Issuances of Common Stock</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">On December 22, 2022, the Company issued the Commitment Shares. See Note M - Convertible Note Payable for more information.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On March 8, 2022, the Company issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $600,004, priced at $2.23, based on the contractual 20-day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">On June 18, 2021, the stockholders approved the 2021 Employee Stock Purchase Plan. Under the terms of this plan, 789,000 shares of common stock are reserved for issuance to employees and officers of the Company at 85% of the lower of the closing price of the common stock as reported on the Nasdaq Capital Market at the first day or the last day of the offering period. Eligible employees are granted an option to purchase shares under the plan funded by payroll deductions. The Board may suspend or terminate the plan at any time, otherwise the plan expires June 17, 2031. During 2022 and 2021, 60,549, and 19,484 shares respectively were issued under the ESPP to employees, which resulted in a $18,787, and $10,680 non-cash compensation expense respectively for the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Issuances of Restricted Stock</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The Company issued 278,000 shares of restricted common stock to certain employees of the Company and 10,500 of shares of restricted common stock were forfeited during fiscal year 2022. The Company issued 13,125 shares of restricted common stock to certain employees of the Company and 1,250 of shares of restricted common stock were forfeited during fiscal year 2021. These shares vest in equal annual installments over a <span style="-sec-ix-hidden:c1297">three-year</span> period from the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Restricted stock compensation for the years ended December 31, 2022 and 2021 was $218,552 and $71,819, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><span style="text-decoration: underline; ">Issuances to Directors, Executive Officers &amp; Consultants</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">During the 2022 and 2021 years, the Company issued 39,636 and 7,828 shares of common stock respectively to its directors in lieu of payment of board fees, valued at $76,043 and $25,536 respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">3. Warrants</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">There were <span style="-sec-ix-hidden:c1309">no</span> warrants issued during 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Warrants Issued with Convertible Note:</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">See Note M - Convertible Note Payable for the warrant issued with a convertible note in 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Valuation Assumptions for Warrants:</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company records the warrants at their fair value which is determined using the Black-Scholes valuation model on the date of the grant. The fair value of the warrant issued in 2022 was estimated with the following assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average exercise price</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average exercise period</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average Volatility of stock price</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">108.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The volatility for each issuance is determined based on the review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected exercise period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the years to maturity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">A summary of warrant activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Warrants</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.48</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,362</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">28.80</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,872,025</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.83</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.59</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the warrant holders had all warrant holders exercised their options as of that date. There were <span style="-sec-ix-hidden:c1355"><span style="-sec-ix-hidden:c1356"><span style="-sec-ix-hidden:c1357">no</span></span></span> in-the-money warrants exercisable as of December 31, 2022, 2021 and 2020.</p> 5000000 789000 0.85 269060 89687 600004 2.23 789000 0.85 60549 19484 18787 10680 278000 10500 13125 1250 218552 71819 39636 7828 76043 25536 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average exercise price</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average exercise period</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average Volatility of stock price</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">108.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> 0.0370 0 3.00 0 5 0 1.0860 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Warrants</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.48</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,362</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">28.80</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,872,025</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.83</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.59</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 4689387 6.04 P4Y5M23D 0 0 -0 0 -0 0 -0 0 4689387 6.04 P3Y5M23D 200000 3.00 -0 0 -0 0 17362 28.80 4872025 5.83 P2Y7M2D 0.59 2.21 3.52 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE Q</b>—<b>STOCK OPTIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">2015<i> Stock Option Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. The term of stock options granted under the 2015 Plan, may not exceed <span style="-sec-ix-hidden:c1415">ten</span> years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Non-Plan Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Periodically, the Company has granted options outside of the 2015 Plan to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Stock Option Activity</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Information summarizing option activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Number of Options</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>remaining</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Aggregate</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2015 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Non </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>life</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(in years)</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>intrinsic</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>value</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2020</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">133,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">227,274</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17.61</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.87</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,438</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,522</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39.13</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2021</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>90,808</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>121,653</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>212,461</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>16.65</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3.03</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>0</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17.28</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2022</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>90,808</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>112,188</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>202,996</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.63</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.14</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Vested or expected to vest at December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">201,271</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16.72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Exercisable at December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">194,561</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.03</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The options outstanding and exercisable at December 31, 2022 were in the following exercise price ranges:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Options Outstanding</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Options Exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 15%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Range of exercise prices</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercise</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>remaining </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>life (in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercise</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.08</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.84</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,565</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.63</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.85</td> <td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">177,431</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.81</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">177,431</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.08</td> <td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">202,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">194,561</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were <span style="-sec-ix-hidden:c1510"><span style="-sec-ix-hidden:c1511"><span style="-sec-ix-hidden:c1512">no</span></span></span> in-the-money options exercisable as of December 31, 2022, 2021 and 2020.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The weighted average fair value of options granted during the years ended December 31, 2022 and 2021 was $0 as <span style="-sec-ix-hidden:c1522"><span style="-sec-ix-hidden:c1523">no</span></span> options were granted in either year. The total intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $0 as <span style="-sec-ix-hidden:c1529"><span style="-sec-ix-hidden:c1530">no</span></span> options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2022 and 2021 was $100,668 and $252,874, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of December 31, 2022, future forfeiture adjusted compensation cost related to nonvested stock options is $17,630 and will be recognized over an estimated weighted average period of 0.64 years.</p> 187500 187500 789000 1 1.10 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Number of Options</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>average</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>remaining</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Aggregate</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2015 </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Non </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Plan</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>life</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(in years)</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>intrinsic</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>value</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2020</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">133,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">227,274</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17.61</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,291</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.87</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(84</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,438</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,522</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39.13</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2021</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>90,808</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>121,653</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>212,461</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>16.65</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>3.03</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>0</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">—</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17.28</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outstanding, as of December 31, 2022</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>90,808</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>112,188</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>202,996</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>16.63</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>2.14</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>0</b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Vested or expected to vest at December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">201,271</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16.72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Exercisable at December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"><b> </b></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">194,561</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b> </b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.03</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 94183 133091 227274 17.61 P3Y10M13D 0 0 0 0 0 -0 -0 -0 0 3291 -0 3291 3.87 84 11438 11522 39.13 90808 121653 212461 16.65 P3Y10D 0 0 0 0 0 -0 -0 -0 0 -0 -0 -0 0 -0 9465 9465 17.28 90808 112188 202996 16.63 P2Y1M20D 0 201271 16.72 P2Y1M13D 0 194561 17.12 P2Y10D 0 <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b> </b></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Options Outstanding</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Options Exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 15%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Range of exercise prices</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercise</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>remaining </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>life (in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>exercise</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.08</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.84</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,565</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.63</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.85</td> <td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">177,431</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.81</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">177,431</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.08</td> <td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">202,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">194,561</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> </tr> </tbody></table> 4.08 5.84 25565 5.20 P4Y7M17D 17130 5.20 5.85 28.00 177431 18.27 P1Y9M21D 177431 18.27 4.08 28.00 202996 194561 0.59 2.21 3.52 0 0 0 0 100668 252874 17630 P0Y7M20D <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE R</b>—<b>INCOME TAXES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The components of net loss consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,416,593</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,507,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hong Kong</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(458,839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(439,814</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Nigeria</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(143,499</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(118,896</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Spain</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(890,972</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11,909,903</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">There was no provision for current federal, foreign or state taxes for both of the years ended December 31, 2022 and 2021 as a result of taxable losses incurred in these jurisdictions. The provision for income tax benefits consist of the following (in thousands):</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current – federal, states, and foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred- Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">128,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred - States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">47,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred - Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,277.000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,297,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income tax benefits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20,434</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Significant components of deferred tax assets and liabilities are as follows at December 31, 2022 and 2021 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">169,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Research and development expenses</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">633,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Capital loss carry forward</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">456,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">486,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(19,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets - US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">341,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Intangible assets - Foreign</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(170,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Inventory reserve</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">89,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Interest expense</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease liabilities</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reserve on debt security</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease right-of-use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research and credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,248,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,148,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,188,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Net deferred tax liability</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(170,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">During the year ended December 31, 2022, the Company determined that certain attributes of deferred tax assets and liabilities were incorrect for December 31, 2021 and 2020. See Note S for further information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has a valuation allowance against the full amount of its net deferred taxes due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. With a full valuation allowance, any change in the deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. At December 31, 2022 and 2021, the Company provided a valuation allowance on its net deferred tax assets of $17,188,000 and $15,891,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of December 31, 2022, the Company has U.S. federal net operating loss carryforwards of approximately $61.3 million. Approximately $43.1 million are subject to expiration between 2023 and 2037, and $18.2 million net operating loss carryforwards have no expiration date. These net operating loss carryforwards could be subject to the limitations under Section 382 of the Internal Revenue Code due to changes in the equity ownership of the Company. In addition, the Company has net operating loss carry forwards from various states of approximately $6.87 million which expire from 2026 through 2042.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">A reconciliation of the effective income tax rate on operations reflected in the statements of operations to the US federal statutory income tax rate is presented below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year ended</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31,</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2022</b></b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year ended </b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31,</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2021</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>As Revised</b></b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration of net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration and forfeiture of stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has not been audited by the Internal Revenue Service (“IRS”) or any states in connection with income taxes. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The periods from <span style="-sec-ix-hidden:c1728">2019</span> through 2022 remain open to examination by the IRS and state jurisdictions.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our subsidiary in Nigeria has not filed its required returns since inception. Management believes that when the returns are filed, no taxes will be owed due to the losses incurred during those periods. We are also not subject to minimum tax during the first four years of operations. As a result, management could not calculate the amount of net operating loss carryforwards that are available to offset future taxable income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our subsidiary in Hong Kong has not filed its required returns in several years. Management believes that when the returns are filed, no taxes will be owed due to losses incurred during those periods. As a result, management could not calculate the amount of net operating loss carryforwards are available to offset future taxable income.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company believes it is not subject to any tax audit risk beyond those periods. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does <span style="-sec-ix-hidden:c1732"><span style="-sec-ix-hidden:c1733">not</span></span> have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended December 31, 2022 and 2021.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In August 2022, the Inflation Reduction Act of 2022 was signed into law which includes a stock buyback excise tax of 1% on share repurchases, which will apply to net stock buybacks after December 31, 2022. We do not expect this to have a material impact if and when share repurchases occur.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,416,593</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,507,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Hong Kong</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(458,839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(439,814</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Nigeria</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(143,499</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(118,896</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Spain</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(890,972</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11,909,903</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,065,781</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> -10416593 -4507071 -458839 -439814 -143499 -118896 -890972 0 -11909903 -5065781 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current – federal, states, and foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred- Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">128,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred - States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">47,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred - Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,277.000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,297,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(175,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income tax benefits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20,434</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 0 1175000 128000 122000 47000 -20000 0 1277.000 175000 1297000 175000 20434 -0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">113,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">169,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Research and development expenses</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">633,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Capital loss carry forward</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">456,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">486,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(19,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets - US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">341,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Intangible assets - Foreign</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(170,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Inventory reserve</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">89,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Interest expense</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease liabilities</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Reserve on debt security</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease right-of-use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research and credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,248,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,148,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,188,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Net deferred tax liability</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(170,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> 113000 110000 169000 70000 633000 0 114000 0 456000 486000 19000 1000 341000 61000 170000 -0 89000 0 44000 0 44000 59000 0 13000 44000 57000 15248000 15148000 17188000 15891000 170000 0 17188000 15891000 61300000 43100000 18200000 6870000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year ended</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31,</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2022</b></b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year ended </b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31,</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2021</b></b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>As Revised</b></b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration of net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5.7</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration and forfeiture of stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> 0.210 0.210 0.009 0.011 -0.047 -0.010 -0.057 -0.138 -0.003 -0.015 -0.005 -0.024 -0.109 -0.034 -0.002 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>NOTE S</b>—<b>REVISION OF PREVIOUSLY ISSUED CONSOLDATED FINANCIAL STATEMENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Due to errors discovered in the Company’s 2020 and 2021 tax provisions, the Company revised certain previously issued disclosures related to the components of its deferred tax assets and liabilities and valuation allowance as of December 31, 2021 and 2020. Additionally, the Company has revised the reconciliation of its income tax rate computed using the federal statutory rate for the year ended December 31, 2021. The errors related primarily to the calculation of available net operating loss carryforwards and to stock based compensation. Since the Company provided a full valuation allowance on its net deferred tax assets, there was no impact to the Consolidated Balance Sheet as of December 31, 2021 and the consolidated statements of operations, stockholders’ equity and cash flows as of and for the year ended December 31, 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The Company further reviewed its disclosure of the rate reconciliation and deferred tax calculation along with the valuation allowance of its net deferred tax assets. Other items that were corrected in the disclosure included allowance for doubtful accounts, equipment and leasehold improvements and operating lease liability along with the associated operating lease ROU assets.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The below table summarizes the revisions to the reconciliation of our income tax rate computed using the federal statutory rate to our actual income tax rate for the year ended December 31, 2021:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As Reported</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Adjustments</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As Revised</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. statutory income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration of net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration and forfeiture of stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Valuation allowance</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of net operating loss</p> </td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.0</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;">)%</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">21.0</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2021 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Reported</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Adjustments</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(25,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(663,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">486,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve on debt security</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease right-of -use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research credit carryforwards</p> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">14,467,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">681,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">15,148,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The table below summarizes the revisions to the attributes of the deferred tax assets and liabilities as of December 31, 2020 (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Reported</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Adjustments</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;">Accrued compensation</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">81,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(15,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">474,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(471,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,073,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(511,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">562,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">111,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">111,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease right-of -use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,337,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,688,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,025,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,016,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(700,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,716,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As Reported</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Adjustments</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As Revised</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. statutory income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration of net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expiration and forfeiture of stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Valuation allowance</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of net operating loss</p> </td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.0</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;">)%</td> <td style="width: 1%;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">21.0</td> <td style="width: 1%; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Reported</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Adjustments</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(25,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">110,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(663,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">486,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">75,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">59,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve on debt security</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease right-of -use assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research credit carryforwards</p> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">14,467,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">681,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;">15,148,000</td> <td style="width: 1%; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,891,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Reported</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Adjustments</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As Revised</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;">Accrued compensation</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">81,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(15,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Allowance for doubtful accounts</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">474,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(471,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,073,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(511,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">562,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment and leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">65,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(12,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">111,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">111,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Operating lease right-of -use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss and research credit carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,337,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,688,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,025,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,016,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(700,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,716,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> 0.210 0 0.210 0 0.011 0.011 0 -0.010 -0.010 0 -0.138 -0.138 0 -0.015 -0.015 0 -0.024 -0.024 0 -0.034 -0.034 -0.210 0.210 0 0 0 0 135000 -25000 110000 75000 -5000 70000 1149000 -663000 486000 10000 -11000 1000 75000 -14000 61000 0 59000 59000 0 13000 13000 -0 57000 57000 14467000 681000 15148000 15891000 -0 15891000 0 0 0 81000 -15000 66000 474000 -471000 3000 1073000 -511000 562000 14000 -19000 5000 65000 -12000 53000 0 111000 111000 -0 109000 109000 13337000 1688000 15025000 15016000 700000 15716000 0 0 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE T</b>—<b>PROFIT SHARING PLAN</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has established a savings plan under section 401(k) of the Internal Revenue Code. All employees of the Company, after completing one day of service, are eligible to enroll in the 401(k) plan. Participating employees may elect to defer a portion of their salary on a pre-tax basis up to the limits as provided by the IRS Code. The Company is not required to match employee contributions but may do so at its discretion. The Company made <span style="-sec-ix-hidden:c2027"><span style="-sec-ix-hidden:c2028">no</span></span> matching contributions during the years ended December 31, 2022 and 2021.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE U</b>—<b>EARNINGS PER SHARE (EPS)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Items excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">202,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,872,025</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,075,021</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,901,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">202,996</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">212,461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,872,025</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,689,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,075,021</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,901,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 202996 212461 4872025 4689387 5075021 4901848 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOTE V</b>—<b>SUBSEQUENT EVENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On March 16, 2023, the Company issued 15,388 shares of common stock to its directors in payment of board fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On March 16, 2023, the Company issued an aggregate of 40,000 shares of restricted common stock to new employees which vest in equal annual installments over a <span style="-sec-ix-hidden:c2056">three-year</span> period from the date of grant.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On May 5, 2023, the Company issued 2,858 shares of common stock to its directors in payment of board committee fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On May 5, 2023, the Company received 14,375 shares of restricted common stock from employees who left the Company before the vesting period was completed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On May 11, 2023, the Company issued 17,392 shares of common stock to its directors in payment of board fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">On May 11, 2023, the Company issued 2,900 shares of common stock to its directors in payment of board committee fees.</p> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> 15388 40000 2858 14375 17392 2900 EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

!%NB+15&'G'O35A=K:4E;B08/9 M;C9-_1EP4W8JS*+[*PZ\M^VH="+/FVM%.U^RA:?V*'EZO2^%_8 M-6NCK _YUEBU:8V1P496S9,_M3H<&*3!"P:L-6">=[.19_F!6WYUH=4.M%N- M:&[@7?762$Y6+B@SJ_&K1#M[=:>L@&LX@:EX%-56P(U6&QBKRFH4S, 7:=

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end XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 214 433 1 false 81 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://bio-key.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://bio-key.com/20221231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows (Parentheticals) Sheet http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals Consolidated Statements of Cash Flows (Parentheticals) Statements 7 false false R8.htm 007 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies Note A - The Company and Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note B - Revenue From Contracts With Customers Sheet http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers Note B - Revenue From Contracts With Customers Notes 9 false false R10.htm 009 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition Sheet http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition Note C - Swivel Secure Europe, SA Acquisition Notes 10 false false R11.htm 010 - Disclosure - Note D - Fair Values of Financial Instruments Sheet http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments Note D - Fair Values of Financial Instruments Notes 11 false false R12.htm 011 - Disclosure - Note E - Concentration of Risk Sheet http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk Note E - Concentration of Risk Notes 12 false false R13.htm 012 - Disclosure - Note F - Note Receivable Sheet http://bio-key.com/20221231/role/statement-note-f-note-receivable Note F - Note Receivable Notes 13 false false R14.htm 013 - Disclosure - Note G - Inventory Sheet http://bio-key.com/20221231/role/statement-note-g-inventory- Note G - Inventory Notes 14 false false R15.htm 014 - Disclosure - Note H - Resalable Software Licenses Rights Sheet http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights Note H - Resalable Software Licenses Rights Notes 15 false false R16.htm 015 - Disclosure - Note I - Investment in Debt Security Sheet http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security- Note I - Investment in Debt Security Notes 16 false false R17.htm 016 - Disclosure - Note J - Equipment and Leasehold Improvements Sheet http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements Note J - Equipment and Leasehold Improvements Notes 17 false false R18.htm 017 - Disclosure - Note K - Intangible Assets and Goodwill Sheet http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill Note K - Intangible Assets and Goodwill Notes 18 false false R19.htm 018 - Disclosure - Note L - Accrued Liabilities Sheet http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities Note L - Accrued Liabilities Notes 19 false false R20.htm 019 - Disclosure - Note M - Convertible Note Payable Sheet http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable Note M - Convertible Note Payable Notes 20 false false R21.htm 020 - Disclosure - Note N - Leases Sheet http://bio-key.com/20221231/role/statement-note-n-leases Note N - Leases Notes 21 false false R22.htm 021 - Disclosure - Note O - Commitments and Contingencies Sheet http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies- Note O - Commitments and Contingencies Notes 22 false false R23.htm 022 - Disclosure - Note P - Equity Sheet http://bio-key.com/20221231/role/statement-note-p-equity Note P - Equity Notes 23 false false R24.htm 023 - Disclosure - Note Q - Stock Options Sheet http://bio-key.com/20221231/role/statement-note-q-stock-options Note Q - Stock Options Notes 24 false false R25.htm 024 - Disclosure - Note R - Income Taxes Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes Note R - Income Taxes Notes 25 false false R26.htm 025 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements Sheet http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements Note S - Revision of Previously Issued Consolidated Financial Statements Notes 26 false false R27.htm 026 - Disclosure - Note T - Profit Sharing Plan Sheet http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan Note T - Profit Sharing Plan Notes 27 false false R28.htm 027 - Disclosure - Note U - Earnings Per Share (EPS) Sheet http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps Note U - Earnings Per Share (EPS) Notes 28 false false R29.htm 028 - Disclosure - Note V - Subsequent Events Sheet http://bio-key.com/20221231/role/statement-note-v-subsequent-events Note V - Subsequent Events Notes 29 false false R30.htm 029 - Disclosure - Significant Accounting Policies (Policies) Sheet http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies 30 false false R31.htm 030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables Note A - The Company and Summary of Significant Accounting Policies (Tables) Tables http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies 31 false false R32.htm 031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables) Sheet http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables Note B - Revenue From Contracts With Customers (Tables) Tables http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers 32 false false R33.htm 032 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Tables) Sheet http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables Note C - Swivel Secure Europe, SA Acquisition (Tables) Tables http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition 33 false false R34.htm 033 - Disclosure - Note F - Note Receivable (Tables) Sheet http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables Note F - Note Receivable (Tables) Tables http://bio-key.com/20221231/role/statement-note-f-note-receivable 34 false false R35.htm 034 - Disclosure - Note G - Inventory (Tables) Sheet http://bio-key.com/20221231/role/statement-note-g-inventory-tables Note G - Inventory (Tables) Tables http://bio-key.com/20221231/role/statement-note-g-inventory- 35 false false R36.htm 035 - Disclosure - Note J - Equipment and Leasehold Improvements (Tables) Sheet http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables Note J - Equipment and Leasehold Improvements (Tables) Tables http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements 36 false false R37.htm 036 - Disclosure - Note K - Intangible Assets and Goodwill (Tables) Sheet http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables Note K - Intangible Assets and Goodwill (Tables) Tables http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill 37 false false R38.htm 037 - Disclosure - Note L - Accrued Liabilities (Tables) Sheet http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables Note L - Accrued Liabilities (Tables) Tables http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities 38 false false R39.htm 038 - Disclosure - Note N - Leases (Tables) Sheet http://bio-key.com/20221231/role/statement-note-n-leases-tables Note N - Leases (Tables) Tables http://bio-key.com/20221231/role/statement-note-n-leases 39 false false R40.htm 039 - Disclosure - Note P - Equity (Tables) Sheet http://bio-key.com/20221231/role/statement-note-p-equity-tables Note P - Equity (Tables) Tables http://bio-key.com/20221231/role/statement-note-p-equity 40 false false R41.htm 040 - Disclosure - Note Q - Stock Options (Tables) Sheet http://bio-key.com/20221231/role/statement-note-q-stock-options-tables Note Q - Stock Options (Tables) Tables http://bio-key.com/20221231/role/statement-note-q-stock-options 41 false false R42.htm 041 - Disclosure - Note R - Income Taxes (Tables) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables Note R - Income Taxes (Tables) Tables http://bio-key.com/20221231/role/statement-note-r-income-taxes 42 false false R43.htm 042 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements (Tables) Sheet http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables Note S - Revision of Previously Issued Consolidated Financial Statements (Tables) Tables http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements 43 false false R44.htm 043 - Disclosure - Note U - Earnings Per Share (EPS) (Tables) Sheet http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables Note U - Earnings Per Share (EPS) (Tables) Tables http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps 44 false false R45.htm 044 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual Note A - The Company and Summary of Significant Accounting Policies (Details Textual) Details http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables 45 false false R46.htm 045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details) Details 46 false false R47.htm 046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details) Details 47 false false R48.htm 047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details) Details 48 false false R49.htm 048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details) Details http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables 49 false false R50.htm 049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details) Sheet http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details) Details 50 false false R51.htm 050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual Note B - Revenue From Contracts With Customers (Details Textual) Details http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables 51 false false R52.htm 051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Sheet http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) Details 52 false false R53.htm 052 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual Note C - Swivel Secure Europe, SA Acquisition (Details Textual) Details http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables 53 false false R54.htm 053 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details) Sheet http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details) Details 54 false false R55.htm 054 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details) Sheet http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details) Details 55 false false R56.htm 055 - Disclosure - Note E - Concentration of Risk (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual Note E - Concentration of Risk (Details Textual) Details http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk 56 false false R57.htm 056 - Disclosure - Note F - Note Receivable (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual Note F - Note Receivable (Details Textual) Details http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables 57 false false R58.htm 057 - Disclosure - Note F - Note Receivable - Summary of Note Receivable (Details) Sheet http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details Note F - Note Receivable - Summary of Note Receivable (Details) Details 58 false false R59.htm 058 - Disclosure - Note G - Inventory (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual Note G - Inventory (Details Textual) Details http://bio-key.com/20221231/role/statement-note-g-inventory-tables 59 false false R60.htm 059 - Disclosure - Note G - Inventory - Components of Inventory (Details) Sheet http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details Note G - Inventory - Components of Inventory (Details) Details 60 false false R61.htm 060 - Disclosure - Note H - Resalable Software Licenses Rights (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual Note H - Resalable Software Licenses Rights (Details Textual) Details http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights 61 false false R62.htm 061 - Disclosure - Note I - Investment in Debt Security (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual Note I - Investment in Debt Security (Details Textual) Details http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security- 62 false false R63.htm 062 - Disclosure - Note J - Equipment and Leasehold Improvements (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual Note J - Equipment and Leasehold Improvements (Details Textual) Details http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables 63 false false R64.htm 063 - Disclosure - Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) Sheet http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details) Details 64 false false R65.htm 064 - Disclosure - Note K - Intangible Assets and Goodwill (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual Note K - Intangible Assets and Goodwill (Details Textual) Details http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables 65 false false R66.htm 065 - Disclosure - Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) Sheet http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) Details 66 false false R67.htm 066 - Disclosure - Note K - Intangible Assets and Goodwill - Amortization Expense (Details) Sheet http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details Note K - Intangible Assets and Goodwill - Amortization Expense (Details) Details 67 false false R68.htm 067 - Disclosure - Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details) Sheet http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details) Details 68 false false R69.htm 068 - Disclosure - Note M - Convertible Note Payable (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual Note M - Convertible Note Payable (Details Textual) Details http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable 69 false false R70.htm 069 - Disclosure - Note N - Leases - Operating Lease Balance Sheet Information (Details) Sheet http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details Note N - Leases - Operating Lease Balance Sheet Information (Details) Details 70 false false R71.htm 070 - Disclosure - Note P - Equity (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-p-equity-details-textual Note P - Equity (Details Textual) Details http://bio-key.com/20221231/role/statement-note-p-equity-tables 71 false false R72.htm 071 - Disclosure - Note P - Equity - Valuation Assumptions for Warrants (Details) Sheet http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details Note P - Equity - Valuation Assumptions for Warrants (Details) Details 72 false false R73.htm 072 - Disclosure - Note P - Equity - Summary of Warrant Activity (Details) Sheet http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details Note P - Equity - Summary of Warrant Activity (Details) Details 73 false false R74.htm 073 - Disclosure - Note Q - Stock Options (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual Note Q - Stock Options (Details Textual) Details http://bio-key.com/20221231/role/statement-note-q-stock-options-tables 74 false false R75.htm 074 - Disclosure - Note Q - Stock Options - Option Activity (Details) Sheet http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details Note Q - Stock Options - Option Activity (Details) Details 75 false false R76.htm 075 - Disclosure - Note Q - Stock Options - Options Outstanding and Exercisable (Details) Sheet http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details Note Q - Stock Options - Options Outstanding and Exercisable (Details) Details 76 false false R77.htm 076 - Disclosure - Note R - Income Taxes (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual Note R - Income Taxes (Details Textual) Details http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables 77 false false R78.htm 077 - Disclosure - Note R - Income Taxes - Net Income Loss (Details) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details Note R - Income Taxes - Net Income Loss (Details) Details 78 false false R79.htm 078 - Disclosure - Note R - Income Taxes - Components of Income Tax Expense (Details) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details Note R - Income Taxes - Components of Income Tax Expense (Details) Details 79 false false R80.htm 079 - Disclosure - Note R - Income Taxes - Components of Deferred Taxes (Details) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details Note R - Income Taxes - Components of Deferred Taxes (Details) Details 80 false false R81.htm 080 - Disclosure - Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) Sheet http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details) Details 81 false false R82.htm 081 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details) Sheet http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details) Details 82 false false R83.htm 082 - Disclosure - Note T - Profit Sharing Plan (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual Note T - Profit Sharing Plan (Details Textual) Details http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan 83 false false R84.htm 083 - Disclosure - Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) Sheet http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) Details http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables 84 false false R85.htm 084 - Disclosure - Note V - Subsequent Events (Details Textual) Sheet http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual Note V - Subsequent Events (Details Textual) Details http://bio-key.com/20221231/role/statement-note-v-subsequent-events 85 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 29 fact(s) appearing in ix:hidden were eligible for transformation: bkyi:ClassOfWarrantOrRightIssuedDuringPeriod, bkyi:ConcentrationRiskNumberOfMajorCustomers, dei:CurrentFiscalYearEndDate, us-gaap:CapitalizedContractCostAmortizationPeriod, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2, us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued - bkyi20221231_10k.htm 10, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 [dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorFirmId must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorFirmId fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. bkyi20221231_10k.htm 7017 [dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorLocation must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorLocation fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. bkyi20221231_10k.htm 7017 [dqc-0033-Document-Period-End-Date-Context] The ending date of 2021-12-31 used for AuditorName must be the same as the Document Period End Date, 2022-12-31. The properties of this AuditorName fact are Context: d_2021-01-01_2021-12-31, Unit: (none), Rule Element Id: 2. bkyi20221231_10k.htm 7017 bkyi20221231_10k.htm bkyi-20221231.xsd bkyi-20221231_cal.xml bkyi-20221231_def.xml bkyi-20221231_lab.xml bkyi-20221231_pre.xml ex_493138.htm ex_493139.htm ex_493140.htm ex_493141.htm ex_493142.htm ex_493143.htm ex_523736.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bkyi20221231_10k.htm": { "axisCustom": 0, "axisStandard": 33, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 917, "http://xbrl.sec.gov/dei/2023": 40 }, "contextCount": 214, "dts": { "calculationLink": { "local": [ "bkyi-20221231_cal.xml" ] }, "definitionLink": { "local": [ "bkyi-20221231_def.xml" ] }, "inline": { "local": [ "bkyi20221231_10k.htm" ] }, "labelLink": { "local": [ "bkyi-20221231_lab.xml" ] }, "presentationLink": { "local": [ "bkyi-20221231_pre.xml" ] }, "schema": { "local": [ "bkyi-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 652, "entityCount": 1, "hidden": { "http://bio-key.com/20221231": 6, "http://fasb.org/us-gaap/2023": 23, "http://xbrl.sec.gov/dei/2023": 5, "total": 34 }, "keyCustom": 72, "keyStandard": 361, "memberCustom": 29, "memberStandard": 52, "nsprefix": "bkyi", "nsuri": "http://bio-key.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://bio-key.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition", "menuCat": "Notes", "order": "10", "role": "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "shortName": "Note C - Swivel Secure Europe, SA Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note D - Fair Values of Financial Instruments", "menuCat": "Notes", "order": "11", "role": "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "shortName": "Note D - Fair Values of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note E - Concentration of Risk", "menuCat": "Notes", "order": "12", "role": "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "shortName": "Note E - Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note F - Note Receivable", "menuCat": "Notes", "order": "13", "role": "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "shortName": "Note F - Note Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note G - Inventory", "menuCat": "Notes", "order": "14", "role": "http://bio-key.com/20221231/role/statement-note-g-inventory-", "shortName": "Note G - Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note H - Resalable Software Licenses Rights", "menuCat": "Notes", "order": "15", "role": "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "shortName": "Note H - Resalable Software Licenses Rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note I - Investment in Debt Security", "menuCat": "Notes", "order": "16", "role": "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "shortName": "Note I - Investment in Debt Security", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note J - Equipment and Leasehold Improvements", "menuCat": "Notes", "order": "17", "role": "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "shortName": "Note J - Equipment and Leasehold Improvements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note K - Intangible Assets and Goodwill", "menuCat": "Notes", "order": "18", "role": "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "shortName": "Note K - Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note L - Accrued Liabilities", "menuCat": "Notes", "order": "19", "role": "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "shortName": "Note L - Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note M - Convertible Note Payable", "menuCat": "Notes", "order": "20", "role": "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "shortName": "Note M - Convertible Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note N - Leases", "menuCat": "Notes", "order": "21", "role": "http://bio-key.com/20221231/role/statement-note-n-leases", "shortName": "Note N - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note O - Commitments and Contingencies", "menuCat": "Notes", "order": "22", "role": "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "shortName": "Note O - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note P - Equity", "menuCat": "Notes", "order": "23", "role": "http://bio-key.com/20221231/role/statement-note-p-equity", "shortName": "Note P - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note Q - Stock Options", "menuCat": "Notes", "order": "24", "role": "http://bio-key.com/20221231/role/statement-note-q-stock-options", "shortName": "Note Q - Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note R - Income Taxes", "menuCat": "Notes", "order": "25", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "shortName": "Note R - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements", "menuCat": "Notes", "order": "26", "role": "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "shortName": "Note S - Revision of Previously Issued Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note T - Profit Sharing Plan", "menuCat": "Notes", "order": "27", "role": "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "shortName": "Note T - Profit Sharing Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note U - Earnings Per Share (EPS)", "menuCat": "Notes", "order": "28", "role": "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "shortName": "Note U - Earnings Per Share (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note V - Subsequent Events", "menuCat": "Notes", "order": "29", "role": "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "shortName": "Note V - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "30", "role": "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "31", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "shortName": "Note A - The Company and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "lang": "en-US", "name": "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note B - Revenue From Contracts With Customers (Tables)", "menuCat": "Tables", "order": "32", "role": "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "shortName": "Note B - Revenue From Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Tables)", "menuCat": "Tables", "order": "33", "role": "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "shortName": "Note C - Swivel Secure Europe, SA Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note F - Note Receivable (Tables)", "menuCat": "Tables", "order": "34", "role": "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "shortName": "Note F - Note Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-NotesReceivableMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note G - Inventory (Tables)", "menuCat": "Tables", "order": "35", "role": "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "shortName": "Note G - Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note J - Equipment and Leasehold Improvements (Tables)", "menuCat": "Tables", "order": "36", "role": "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "shortName": "Note J - Equipment and Leasehold Improvements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note K - Intangible Assets and Goodwill (Tables)", "menuCat": "Tables", "order": "37", "role": "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "shortName": "Note K - Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note L - Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "38", "role": "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "shortName": "Note L - Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note N - Leases (Tables)", "menuCat": "Tables", "order": "39", "role": "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "shortName": "Note N - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note P - Equity (Tables)", "menuCat": "Tables", "order": "40", "role": "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "shortName": "Note P - Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note Q - Stock Options (Tables)", "menuCat": "Tables", "order": "41", "role": "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "shortName": "Note Q - Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NetIncomeLossByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note R - Income Taxes (Tables)", "menuCat": "Tables", "order": "42", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "shortName": "Note R - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "bkyi:NetIncomeLossByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements (Tables)", "menuCat": "Tables", "order": "43", "role": "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "shortName": "Note S - Revision of Previously Issued Consolidated Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note U - Earnings Per Share (EPS) (Tables)", "menuCat": "Tables", "order": "44", "role": "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables", "shortName": "Note U - Earnings Per Share (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "bkyi:PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "45", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note A - The Company and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "bkyi:PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)", "menuCat": "Details", "order": "46", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)", "menuCat": "Details", "order": "47", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "bkyi:UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)", "menuCat": "Details", "order": "48", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details)", "menuCat": "Details", "order": "49", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details)", "menuCat": "Details", "order": "50", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "shortName": "Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note B - Revenue From Contracts With Customers (Details Textual)", "menuCat": "Details", "order": "51", "role": "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "shortName": "Note B - Revenue From Contracts With Customers (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "52", "role": "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-NorthAmericaMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition (Details Textual)", "menuCat": "Details", "order": "53", "role": "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "shortName": "Note C - Swivel Secure Europe, SA Acquisition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2026-04-30_DebtInstrumentAxis-GovernmentLoanMember_LineOfCreditFacilityAxis-BbvaBankMember_StatementScenarioAxis-ScenarioForecastMember", "decimals": "4", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details)", "menuCat": "Details", "order": "54", "role": "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "shortName": "Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-03-08_2022-03-08_BusinessAcquisitionAxis-SwivelSecureEuropeMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details)", "menuCat": "Details", "order": "55", "role": "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "shortName": "Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-03-08_2022-03-08_BusinessAcquisitionAxis-SwivelSecureEuropeMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note E - Concentration of Risk (Details Textual)", "menuCat": "Details", "order": "56", "role": "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual", "shortName": "Note E - Concentration of Risk (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note F - Note Receivable (Details Textual)", "menuCat": "Details", "order": "57", "role": "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "shortName": "Note F - Note Receivable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "2", "lang": null, "name": "us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note F - Note Receivable - Summary of Note Receivable (Details)", "menuCat": "Details", "order": "58", "role": "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details", "shortName": "Note F - Note Receivable - Summary of Note Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bkyi:NotesReceivableTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_StatementGeographicalAxis-NG", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note G - Inventory (Details Textual)", "menuCat": "Details", "order": "59", "role": "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "shortName": "Note G - Inventory (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_StatementGeographicalAxis-NG", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note G - Inventory - Components of Inventory (Details)", "menuCat": "Details", "order": "60", "role": "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details", "shortName": "Note G - Inventory - Components of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note H - Resalable Software Licenses Rights (Details Textual)", "menuCat": "Details", "order": "61", "role": "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "shortName": "Note H - Resalable Software Licenses Rights (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2015-12-31_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-SoftwareLicenseRightsMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsToAcquireSoftware", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2020-09-30_FinancialInstrumentAxis-ForeignCorporateDebtSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note I - Investment in Debt Security (Details Textual)", "menuCat": "Details", "order": "62", "role": "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual", "shortName": "Note I - Investment in Debt Security (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2020-09-30_FinancialInstrumentAxis-ForeignCorporateDebtSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note J - Equipment and Leasehold Improvements (Details Textual)", "menuCat": "Details", "order": "63", "role": "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "shortName": "Note J - Equipment and Leasehold Improvements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)", "menuCat": "Details", "order": "64", "role": "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "shortName": "Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note K - Intangible Assets and Goodwill (Details Textual)", "menuCat": "Details", "order": "65", "role": "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual", "shortName": "Note K - Intangible Assets and Goodwill (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchDevelopmentAndEngineeringExpenseMember", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)", "menuCat": "Details", "order": "66", "role": "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "shortName": "Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note K - Intangible Assets and Goodwill - Amortization Expense (Details)", "menuCat": "Details", "order": "67", "role": "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "shortName": "Note K - Intangible Assets and Goodwill - Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "menuCat": "Details", "order": "68", "role": "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "shortName": "Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-22", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note M - Convertible Note Payable (Details Textual)", "menuCat": "Details", "order": "69", "role": "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "shortName": "Note M - Convertible Note Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-12-22_2022-12-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithNoteMember", "decimals": "INF", "lang": null, "name": "bkyi:ClassOfWarrantOrRightIssuedDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows (Parentheticals)", "menuCat": "Statements", "order": "7", "role": "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "shortName": "Consolidated Statements of Cash Flows (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_BusinessAcquisitionAxis-SwivelSecureEuropeMember", "decimals": "0", "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note N - Leases - Operating Lease Balance Sheet Information (Details)", "menuCat": "Details", "order": "70", "role": "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details", "shortName": "Note N - Leases - Operating Lease Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note P - Equity (Details Textual)", "menuCat": "Details", "order": "71", "role": "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "shortName": "Note P - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_ClassOfWarrantOrRightAxis-ReferralFeeWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note P - Equity - Valuation Assumptions for Warrants (Details)", "menuCat": "Details", "order": "72", "role": "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details", "shortName": "Note P - Equity - Valuation Assumptions for Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_ClassOfWarrantOrRightAxis-ReferralFeeWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note P - Equity - Summary of Warrant Activity (Details)", "menuCat": "Details", "order": "73", "role": "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "shortName": "Note P - Equity - Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "lang": "en-US", "name": "bkyi:WarrantsOutstandingWeightedAverageRemainingLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note Q - Stock Options (Details Textual)", "menuCat": "Details", "order": "74", "role": "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "shortName": "Note Q - Stock Options (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note Q - Stock Options - Option Activity (Details)", "menuCat": "Details", "order": "75", "role": "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "shortName": "Note Q - Stock Options - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note Q - Stock Options - Options Outstanding and Exercisable (Details)", "menuCat": "Details", "order": "76", "role": "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "shortName": "Note Q - Stock Options - Options Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note R - Income Taxes (Details Textual)", "menuCat": "Details", "order": "77", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "shortName": "Note R - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note R - Income Taxes - Net Income Loss (Details)", "menuCat": "Details", "order": "78", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details", "shortName": "Note R - Income Taxes - Net Income Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "bkyi:NetIncomeLossByGeographicAreasTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-US", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note R - Income Taxes - Components of Income Tax Expense (Details)", "menuCat": "Details", "order": "79", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details", "shortName": "Note R - Income Taxes - Components of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note A - The Company and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "shortName": "Note A - The Company and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note R - Income Taxes - Components of Deferred Taxes (Details)", "menuCat": "Details", "order": "80", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "shortName": "Note R - Income Taxes - Components of Deferred Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "0", "lang": null, "name": "bkyi:DeferredTaxAssetsResarchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)", "menuCat": "Details", "order": "81", "role": "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "shortName": "Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details)", "menuCat": "Details", "order": "82", "role": "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "shortName": "Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "0", "lang": null, "name": "bkyi:EffectiveIncomeTaxRateReconciliationEffectOfNetOperatingLossPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R83": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Note T - Profit Sharing Plan (Details Textual)", "menuCat": "Details", "order": "83", "role": "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual", "shortName": "Note T - Profit Sharing Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details)", "menuCat": "Details", "order": "84", "role": "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "shortName": "Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2023-05-05_2023-05-05_AwardTypeAxis-RestrictedStockMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementScenarioAxis-ScenarioForecastMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "084 - Disclosure - Note V - Subsequent Events (Details Textual)", "menuCat": "Details", "order": "85", "role": "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual", "shortName": "Note V - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2023-05-05_2023-05-05_AwardTypeAxis-RestrictedStockMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementScenarioAxis-ScenarioForecastMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note B - Revenue From Contracts With Customers", "menuCat": "Notes", "order": "9", "role": "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "shortName": "Note B - Revenue From Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bkyi20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 81, "tag": { "bkyi_AccruedEmployeeExpensesReimbursementCurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued employee expenses reimbursement, current.", "label": "Employee expenses reimbursement" } } }, "localname": "AccruedEmployeeExpensesReimbursementCurrent", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AccruedFranchiseTaxesCurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current portion of accrued franchise taxes.", "label": "Franchise taxes" } } }, "localname": "AccruedFranchiseTaxesCurrent", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of decrease to additional paid in capital during the period resulting from legal fees.", "label": "bkyi_AdjustmentsToAdditionalPaidInCapitalLegalFees", "negatedLabel": "Legal fees" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalLegalFees", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "bkyi_AllowanceForDoubtfulAccounts": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "bkyi_AllowanceForDoubtfulAccounts", "negatedLabel": "Allowance for doubtful account", "verboseLabel": "Allowance for doubtful accounts, charged to costs and expenses" } } }, "localname": "AllowanceForDoubtfulAccounts", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "bkyi_AmortizationOfNoteDiscount": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expenses to amortize note discount.", "label": "Amortization of note discount" } } }, "localname": "AmortizationOfNoteDiscount", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_AmortizationOfSoftwareLicenseRights": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of amortization charged against earnings during the period for software license rights.", "label": "Amortization of resalable software license rights" } } }, "localname": "AmortizationOfSoftwareLicenseRights", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BbvaBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to BBVA bank.", "label": "BBVA Bank [Member]" } } }, "localname": "BbvaBankMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_BusinessCombinationAccountsReceivableAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accounts receivable acquired.", "label": "Accounts receivable acquired from Swivel Secure" } } }, "localname": "BusinessCombinationAccountsReceivableAcquired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationBasePurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of base purchase price under business combination.", "label": "bkyi_BusinessCombinationBasePurchasePrice", "terseLabel": "Business Combination, Base Purchase Price" } } }, "localname": "BusinessCombinationBasePurchasePrice", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationConsiderationTransferredLiabilitiesIncurredFairValue": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination, fair value.", "label": "Earnout payable" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurredFairValue", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationContingentConsiderationEarnoutPayableOperatingProfitToTriggerPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of operating profit to trigger payment of earnout payable under contingent consideration.", "label": "bkyi_BusinessCombinationContingentConsiderationEarnoutPayableOperatingProfitToTriggerPayment", "terseLabel": "Business Combination, Contingent Consideration Earnout Payable, Operating Profit to Trigger Payment" } } }, "localname": "BusinessCombinationContingentConsiderationEarnoutPayableOperatingProfitToTriggerPayment", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationContingentConsiderationEarnoutPayableRevenueToTriggerPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue required to trigger earnout payable payment under contingent consideration.", "label": "bkyi_BusinessCombinationContingentConsiderationEarnoutPayableRevenueToTriggerPayment", "terseLabel": "Business Combination, Contingent Consideration Earnout Payable, Revenue to Trigger Payment" } } }, "localname": "BusinessCombinationContingentConsiderationEarnoutPayableRevenueToTriggerPayment", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationEquipmentAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of equipment acquired.", "label": "Equipment acquired from Swivel Secure" } } }, "localname": "BusinessCombinationEquipmentAcquired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationIndemnificationAssetsSharesAsOfAcquisitionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares held for indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination.", "label": "bkyi_BusinessCombinationIndemnificationAssetsSharesAsOfAcquisitionDate", "terseLabel": "Business Combination, Indemnification Assets, Shares as of Acquisition Date" } } }, "localname": "BusinessCombinationIndemnificationAssetsSharesAsOfAcquisitionDate", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_BusinessCombinationIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents intangible assets acquired.", "label": "Intangible assets acquired from Swivel Secure" } } }, "localname": "BusinessCombinationIntangibleAssetsAcquired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets including goodwill acquired at the acquisition date.", "label": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "totalLabel": "Total estimated assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued liabilities, assumed at the acquisition date.", "label": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebt": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt assumed at the acquisition date.", "label": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebt", "verboseLabel": "Government loan" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDebt", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "bkyi_BusinessCombinationReversalOfEarnoutPayable": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of earnout payable reversal incurred as part of a business combination.", "label": "bkyi_BusinessCombinationReversalOfEarnoutPayable", "negatedLabel": "Reversal of earnout payable \u2013 Swivel acquisition" } } }, "localname": "BusinessCombinationReversalOfEarnoutPayable", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "bkyi_ClassOfWarrantOrRightGrantsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of warrants granted during the period.", "label": "Granted, warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightGrantsInPeriod", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_ClassOfWarrantOrRightIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The class of warrant or right issued during the period.", "label": "bkyi_ClassOfWarrantOrRightIssuedDuringPeriod", "terseLabel": "Class of Warrant or Right, Issued During Period" } } }, "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_ConcentrationRiskNumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of external customers that accounts for 10 percent or more of an entity's revenues or accounts receivable.", "label": "bkyi_ConcentrationRiskNumberOfMajorCustomers", "terseLabel": "Concentration Risk, Number of Major Customers" } } }, "localname": "ConcentrationRiskNumberOfMajorCustomers", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "integerItemType" }, "bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents cumulative amount of amortization expense net of credit expense.", "label": "bkyi_CumulativeAmountOfAmortizationExpenseNetOfCredits", "terseLabel": "Cumulative Amount of Amortization Expense, Net of Credits" } } }, "localname": "CumulativeAmountOfAmortizationExpenseNetOfCredits", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_DebtInstrumentConvertiblePercentageOfOutstandingStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of of outstanding stock for shares issued upon conversion of debt instrument.", "label": "bkyi_DebtInstrumentConvertiblePercentageOfOutstandingStock", "terseLabel": "Debt Instrument, Convertible, Percentage of Outstanding Stock" } } }, "localname": "DebtInstrumentConvertiblePercentageOfOutstandingStock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_DebtInstrumentDefaultPercentageIncreaseInPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in principal outstanding in the event of default on the debt instrument.", "label": "bkyi_DebtInstrumentDefaultPercentageIncreaseInPrincipal", "terseLabel": "Debt Instrument, Default, Percentage Increase In Principal" } } }, "localname": "DebtInstrumentDefaultPercentageIncreaseInPrincipal", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_DebtInstrumentInterestRateDefault": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of interest rate in the event of default on the debt instrument.", "label": "bkyi_DebtInstrumentInterestRateDefault", "terseLabel": "Debt Instrument, Interest Rate, Default" } } }, "localname": "DebtInstrumentInterestRateDefault", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.", "label": "bkyi_DeferredTaxAssetsOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "bkyi_DeferredTaxAssetsResarchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.", "label": "bkyi_DeferredTaxAssetsResarchAndDevelopmentExpenses", "terseLabel": "Research and development expenses" } } }, "localname": "DeferredTaxAssetsResarchAndDevelopmentExpenses", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "bkyi_EffectiveIncomeTaxRateReconciliationEffectOfNetOperatingLossPercent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to effect of net operating loss.", "label": "bkyi_EffectiveIncomeTaxRateReconciliationEffectOfNetOperatingLossPercent", "verboseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationEffectOfNetOperatingLossPercent", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "bkyi_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAndResearchCreditCarryforwardsPercent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating loss and research credit carryforwards.", "label": "bkyi_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAndResearchCreditCarryforwardsPercent", "verboseLabel": "Expiration of net operating loss and research credit carryforwards" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAndResearchCreditCarryforwardsPercent", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "bkyi_EffectiveIncomeTaxReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax reconciliation permanent differences.", "label": "bkyi_EffectiveIncomeTaxReconciliationPermanentDifferences", "verboseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxReconciliationPermanentDifferences", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "bkyi_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information regarding employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price greater than average market price of common shares member.", "label": "Exercise Price Greater Than Average Market Price Of Common Shares [Member]" } } }, "localname": "ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The first exercise price range.", "label": "Exercise Price Range 1 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The second exercise price range.", "label": "Exercise Price Range 2 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The third exercise price range.", "label": "Exercise Price Range 3 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "domainItemType" }, "bkyi_FairValueAdjustmentOfConvertibleNote": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents fair value adjustment of convertible note.", "label": "Change in fair value of convertible note", "negatedLabel": "Change in fair value of convertible note" } } }, "localname": "FairValueAdjustmentOfConvertibleNote", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "bkyi_GovernmentLoanAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents government loan acquired.", "label": "Government loan acquired from Swivel Secure" } } }, "localname": "GovernmentLoanAcquired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_GovernmentLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to government loan.", "label": "Government Loan [Member]" } } }, "localname": "GovernmentLoanMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_HardwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to hardware.", "label": "Hardware [Member]" } } }, "localname": "HardwareMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "bkyi_InTheMoneyOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents in-the-money options exercisable.", "label": "In The Money Options [Member]" } } }, "localname": "InTheMoneyOptionsMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_IncomeTaxExpenseBenefitGross": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations before valuation allowance.", "label": "bkyi_IncomeTaxExpenseBenefitGross", "totalLabel": "Total" } } }, "localname": "IncomeTaxExpenseBenefitGross", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "bkyi_IncomeTaxExpenseBenefitValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation allowance for income tax expense (benefit).", "label": "bkyi_IncomeTaxExpenseBenefitValuationAllowance", "negatedLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxExpenseBenefitValuationAllowance", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "bkyi_IncreaseDecreaseInCapitalizedContractCosts": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in capitalized contract costs.", "label": "bkyi_IncreaseDecreaseInCapitalizedContractCosts", "negatedLabel": "Capitalized contract costs" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCosts", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_InventoryFinishedGoodsReserves": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "bkyi_InventoryFinishedGoodsReserves", "negatedLabel": "Reserve on finished goods" } } }, "localname": "InventoryFinishedGoodsReserves", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate of an investment in held-to-maturity debt securities.", "label": "bkyi_InvestmentInHeldtomaturityDebtSecuritiesInterestRate", "terseLabel": "Investment in Held-to-maturity Debt Securities, Interest Rate" } } }, "localname": "InvestmentInHeldtomaturityDebtSecuritiesInterestRate", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_InvestmentIncomeDebtSecurityReserveExpense": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to debt security reserve.", "label": "bkyi_InvestmentIncomeDebtSecurityReserveExpense", "negatedLabel": "Investment-debt security reserve" } } }, "localname": "InvestmentIncomeDebtSecurityReserveExpense", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "bkyi_LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of costs, assets, and liabilities subject to operating lease by lessee.", "label": "Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseCostsAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_LoanTransactionCosts": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents transaction costs for loan.", "label": "bkyi_LoanTransactionCosts", "negatedLabel": "Loan transaction costs" } } }, "localname": "LoanTransactionCosts", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "bkyi_MeasurementInputLikelihoodOfDefaultMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents likelihood of default for measurement input.", "label": "Measurement Input, Likelihood of Default [Member]" } } }, "localname": "MeasurementInputLikelihoodOfDefaultMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_NetIncomeLossByGeographicAreasTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of net income (loss) by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Net Income (Loss) by Geographic Areas [Table Text Block]" } } }, "localname": "NetIncomeLossByGeographicAreasTableTextBlock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_NonPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non plan member.", "label": "Non Plan [Member]" } } }, "localname": "NonPlanMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_NoncashOrPartNoncashAcquisitionAccruedExpensesAndOtherLiabilitiesAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accounts payable and accrued expenses, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.", "label": "Accounts payable and accrued expenses acquired from Swivel Secure" } } }, "localname": "NoncashOrPartNoncashAcquisitionAccruedExpensesAndOtherLiabilitiesAssumed", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_NoncashOrPartNoncashAcquisitionDeferredTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents noncash or part noncash acquisition for deferred tax liability.", "label": "Deferred tax liability from the acquisition of Swivel Secure" } } }, "localname": "NoncashOrPartNoncashAcquisitionDeferredTaxLiability", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_NoncashOrPartNoncashAcquisitionStockIssuedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents stock issued related to noncash or part noncash acquisition.", "label": "Common stock issued for acquisition of Swivel Secure" } } }, "localname": "NoncashOrPartNoncashAcquisitionStockIssuedAmount", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_NotesReceivablePeriodicPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of periodic payment of notes receivable.", "label": "bkyi_NotesReceivablePeriodicPayment", "terseLabel": "Notes Receivable, Periodic Payment" } } }, "localname": "NotesReceivablePeriodicPayment", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_NotesReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes receivable.", "label": "Notes Receivable [Text Block]" } } }, "localname": "NotesReceivableTextBlock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable" ], "xbrltype": "textBlockItemType" }, "bkyi_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to one customer.", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "bkyi_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "bkyi_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_PaymentsForLegalFees": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for legal fees.", "label": "bkyi_PaymentsForLegalFees", "negatedLabel": "Legal fees" } } }, "localname": "PaymentsForLegalFees", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of support and maintenance revenue for SaaS license to total license cost.", "label": "bkyi_PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "terseLabel": "Percentage of Support and Maintenance Revenue to License Cost" } } }, "localname": "PercentageOfSupportAndMaintenanceRevenueToLicenseCost", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "bkyi_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pre-funded warrants.", "label": "Pre-Funded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_PrincipalUponDefaultMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents increase in principal upon a default.", "label": "Principal Upon Default [Member]" } } }, "localname": "PrincipalUponDefaultMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ProceedsFromEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents proceeds from employee stock purchase plan.", "label": "Proceeds from Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromEmployeeStockPurchasePlan", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_ProprietarySoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to proprietary software.", "label": "Proprietary Software [Member]" } } }, "localname": "ProprietarySoftwareMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "bkyi_PublicOfferingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the public offering warrants.", "label": "Public Offering Warrants [Member]" } } }, "localname": "PublicOfferingWarrantsMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_ReferralFeeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to referral fee warrants.", "label": "Referral Fee Warrants [Member]" } } }, "localname": "ReferralFeeWarrantsMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "bkyi_ResearchDevelopmentAndEngineeringExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research, development and engineering expense have been included.", "label": "Research, Development, and Engineering Expense [Member]" } } }, "localname": "ResearchDevelopmentAndEngineeringExpenseMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ReserveForInvestmentSecurity": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reserve for investment security.", "label": "bkyi_ReserveForInvestmentSecurity", "negatedLabel": "Reserve for investment security" } } }, "localname": "ReserveForInvestmentSecurity", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_ReserveForNoteReceivable": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reserve for note receivable.", "label": "bkyi_ReserveForNoteReceivable", "negatedLabel": "Reserve for note receivable" } } }, "localname": "ReserveForNoteReceivable", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_RestrictedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents restricted classification.", "label": "Restricted [Member]" } } }, "localname": "RestrictedMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "bkyi_RightToRepurchaseSharesIfDebtInstrumentPaidInFullWithinSixMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares that can be repurchased if the debt instrument is paid in full within six months.", "label": "bkyi_RightToRepurchaseSharesIfDebtInstrumentPaidInFullWithinSixMonths", "terseLabel": "Right to Repurchase Shares if Debt Instrument Paid in Full Within Six Months" } } }, "localname": "RightToRepurchaseSharesIfDebtInstrumentPaidInFullWithinSixMonths", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_ScheduleOfWarrantsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants.", "label": "Schedule of Warrants Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfWarrantsValuationAssumptionsTableTextBlock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_SeniorSecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the senior secured promissory note.", "label": "Senior Secured Promissory Note [Member]" } } }, "localname": "SeniorSecuredPromissoryNoteMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ShareBasedCompensationExcludingDirectorsFees": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement, excluding directors fees.", "label": "Share based and warrant compensation for employees and consultants" } } }, "localname": "ShareBasedCompensationExcludingDirectorsFees", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_SoftwareLicenseRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of current and noncurrent software license rights as of the balance sheet date.", "label": "bkyi_SoftwareLicenseRights", "terseLabel": "Software License Rights" } } }, "localname": "SoftwareLicenseRights", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "bkyi_SoftwareLicenseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The software license rights, generally of limited duration, for internal use.", "label": "Software License Rights [Member]" } } }, "localname": "SoftwareLicenseRightsMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_SoftwareLicenseRightsNoncurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amounts as of the balance sheet date of software license rights classified as non-current.", "label": "Resalable software license rights" } } }, "localname": "SoftwareLicenseRightsNoncurrent", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "bkyi_StockBasedFeesToDirectorsAndConsultants": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs and payments related to stock-based fees to directors and consultants.", "label": "Stock based fees to directors" } } }, "localname": "StockBasedFeesToDirectorsAndConsultants", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_StockIssuedDuringPeriodSharesCommitmentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number fo shares issued during the period for commitment fee.", "label": "bkyi_StockIssuedDuringPeriodSharesCommitmentFee", "terseLabel": "Stock Issued During Period, Shares, Commitment Fee" } } }, "localname": "StockIssuedDuringPeriodSharesCommitmentFee", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "sharesItemType" }, "bkyi_StockIssuedInLieuOfBoardCommitteeFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "refers to stock issued in lieu of board committee fees.", "label": "Stock Issued in Lieu of Board Committee Fees [Member]" } } }, "localname": "StockIssuedInLieuOfBoardCommitteeFeesMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_StockIssuedInLieuOfBoardFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to stock issued in lieu of board fees.", "label": "Stock Issued in Lieu of Board Fees [Member]" } } }, "localname": "StockIssuedInLieuOfBoardFeesMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_StockIssuedWithNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock issued with note payable.", "label": "Common stock issued for acquisition of note payable" } } }, "localname": "StockIssuedWithNotePayable", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_SwivelSecureEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information regarding the business acquisition of Swivel Secure Europe.", "label": "Swivel Secure Europe [Member]" } } }, "localname": "SwivelSecureEuropeMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_The2015EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding the 2015 Equity Incentive plan.", "label": "The 2015 Equity Incentive Plan [Member]" } } }, "localname": "The2015EquityIncentivePlanMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "bkyi_The2015SoftwareLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about the 2015 Software License.", "label": "The 2015 Software License [Member]" } } }, "localname": "The2015SoftwareLicenseMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_TheNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to The Note.", "label": "The Note [Member]" } } }, "localname": "TheNoteMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to three customers.", "label": "Three Customers [Member]" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_TotalWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised during period.", "label": "bkyi_TotalWarrantsExercised", "negatedLabel": "Exercised, warrants (in shares)" } } }, "localname": "TotalWarrantsExercised", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_TotalWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants expired during period.", "label": "bkyi_TotalWarrantsExpired", "negatedLabel": "Expired, warrants (in shares)" } } }, "localname": "TotalWarrantsExpired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_TotalWarrantsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants forfeited during period.", "label": "bkyi_TotalWarrantsForfeited", "negatedLabel": "Forfeited, warrants (in shares)" } } }, "localname": "TotalWarrantsForfeited", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "bkyi_UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Useful Lives of Property Plan and Equipment [Table Text Block]" } } }, "localname": "UsefulLivesOfPropertyPlanAndEquipmentTableTextBlock", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "bkyi_WarrantsIssuedInConnectionWithNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in connection with note.", "label": "Warrants Issued in Connection With Note [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithNoteMember", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "domainItemType" }, "bkyi_WarrantsIssuedWithLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of warrants issued with loan in noncash financing activities.", "label": "bkyi_WarrantsIssuedWithLoan", "terseLabel": "Issuance of warrant in conjunction with note payable" } } }, "localname": "WarrantsIssuedWithLoan", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "bkyi_WarrantsOutstandingExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding exercise price.", "label": "bkyi_WarrantsOutstandingExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price, warrants (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WarrantsOutstandingExercisePrice", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WarrantsOutstandingWeightedAverageRemainingLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants outstanding weighted average remaining life.", "label": "bkyi_WarrantsOutstandingWeightedAverageRemainingLife", "verboseLabel": "Outstanding, weighted average remaining contractual life, warrants (Year)" } } }, "localname": "WarrantsOutstandingWeightedAverageRemainingLife", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "durationItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants exercised in the period.", "label": "Exercised, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsExercised", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants expired during period.", "label": "Expired, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsExpired", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of the warrants forfeited.", "label": "Forfeited, weighted average exercise price, warrants (in dollars per share)", "verboseLabel": "Forfeited, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsForfeited", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_WeightedAverageExercisePriceWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants granted during period.", "label": "Granted, weighted average exercise price, warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceWarrantsGranted", "nsuri": "http://bio-key.com/20221231", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Estimated Useful Lives for Depreciation and Amortization (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Fair Value (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Share-based Compensation Expenses for Continuing Operations (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Significant Unobservable Inputs (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies - Summary of Accounts Receivable (Details)" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - The Company and Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-b-revenue-from-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Revenue From Contracts With Customers" } } }, "localname": "statement-statement-note-b-revenue-from-contracts-with-customers-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Swivel Secure Europe, SA Acquisition - Assets Acquired and Liabilities Assumed (Details)" } } }, "localname": "statement-statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Swivel Secure Europe, SA Acquisition - Identifiable Intangible Assets Acquired (Details)" } } }, "localname": "statement-statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-c-swivel-secure-europe-sa-acquisition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Swivel Secure Europe, SA Acquisition" } } }, "localname": "statement-statement-note-c-swivel-secure-europe-sa-acquisition-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-f-note-receivable-summary-of-note-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note F - Note Receivable - Summary of Note Receivable (Details)" } } }, "localname": "statement-statement-note-f-note-receivable-summary-of-note-receivable-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-f-note-receivable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note F - Note Receivable" } } }, "localname": "statement-statement-note-f-note-receivable-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-g-inventory-components-of-inventory-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Inventory - Components of Inventory (Details)" } } }, "localname": "statement-statement-note-g-inventory-components-of-inventory-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-g-inventory-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Inventory" } } }, "localname": "statement-statement-note-g-inventory-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note J - Equipment and Leasehold Improvements - Summary of Equipment and Leasehold Improvements (Details)" } } }, "localname": "statement-statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-j-equipment-and-leasehold-improvements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note J - Equipment and Leasehold Improvements" } } }, "localname": "statement-statement-note-j-equipment-and-leasehold-improvements-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note K - Intangible Assets and Goodwill - Amortization Expense (Details)" } } }, "localname": "statement-statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note K - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)" } } }, "localname": "statement-statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-k-intangible-assets-and-goodwill-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note K - Intangible Assets and Goodwill" } } }, "localname": "statement-statement-note-k-intangible-assets-and-goodwill-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note L - Accrued Liabilities - Summary of Accrued Liabilities (Details)" } } }, "localname": "statement-statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-l-accrued-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note L - Accrued Liabilities" } } }, "localname": "statement-statement-note-l-accrued-liabilities-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-n-leases-operating-lease-balance-sheet-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note N - Leases - Operating Lease Balance Sheet Information (Details)" } } }, "localname": "statement-statement-note-n-leases-operating-lease-balance-sheet-information-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-n-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note N - Leases" } } }, "localname": "statement-statement-note-n-leases-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-p-equity-summary-of-warrant-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note P - Equity - Summary of Warrant Activity (Details)" } } }, "localname": "statement-statement-note-p-equity-summary-of-warrant-activity-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-p-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note P - Equity" } } }, "localname": "statement-statement-note-p-equity-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-p-equity-valuation-assumptions-for-warrants-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note P - Equity - Valuation Assumptions for Warrants (Details)" } } }, "localname": "statement-statement-note-p-equity-valuation-assumptions-for-warrants-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-q-stock-options-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Q - Stock Options - Option Activity (Details)" } } }, "localname": "statement-statement-note-q-stock-options-option-activity-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-q-stock-options-options-outstanding-and-exercisable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Q - Stock Options - Options Outstanding and Exercisable (Details)" } } }, "localname": "statement-statement-note-q-stock-options-options-outstanding-and-exercisable-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-q-stock-options-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Q - Stock Options" } } }, "localname": "statement-statement-note-q-stock-options-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-income-taxes-components-of-deferred-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Income Taxes - Components of Deferred Taxes (Details)" } } }, "localname": "statement-statement-note-r-income-taxes-components-of-deferred-taxes-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-income-taxes-components-of-income-tax-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Income Taxes - Components of Income Tax Expense (Details)" } } }, "localname": "statement-statement-note-r-income-taxes-components-of-income-tax-expense-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-income-taxes-net-income-loss-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Income Taxes - Net Income Loss (Details)" } } }, "localname": "statement-statement-note-r-income-taxes-net-income-loss-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Income Taxes - Reconciliation of the Effective Income Tax Rate to US Federal Statutory Income Tax Rate (Details)" } } }, "localname": "statement-statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-r-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note R - Income Taxes" } } }, "localname": "statement-statement-note-r-income-taxes-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note S - Revision of Previously Issued Consolidated Financial Statements - Summary of Revisions (Details)" } } }, "localname": "statement-statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note S - Revision of Previously Issued Consolidated Financial Statements" } } }, "localname": "statement-statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note U - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details)" } } }, "localname": "statement-statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-note-u-earnings-per-share-eps-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note U - Earnings Per Share (EPS)" } } }, "localname": "statement-statement-note-u-earnings-per-share-eps-tables", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "bkyi_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://bio-key.com/20221231", "xbrltype": "stringItemType" }, "country_ES": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SPAIN" } } }, "localname": "ES", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "domainItemType" }, "country_NG": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NIGERIA" } } }, "localname": "NG", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "dei_CityAreaCode", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFinStmtErrorCorrectionFlag": { "auth_ref": [ "r821", "r822", "r823", "r825" ], "lang": { "en-us": { "role": { "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.", "label": "dei_DocumentFinStmtErrorCorrectionFlag", "terseLabel": "Document Financial Statement Error Correction [Flag]" } } }, "localname": "DocumentFinStmtErrorCorrectionFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "dei_DocumentType", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-document-and-entity-information", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-n-leases", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual", "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "dei_EntityPublicFloat", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "dei_EntityVoluntaryFilers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r827" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "dei_EntityWellKnownSeasonedIssuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "label": "dei_IcfrAuditorAttestationFlag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-document-and-entity-information", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-n-leases", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual", "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_AfricaMember": { "auth_ref": [ "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "label": "Africa [Member]" } } }, "localname": "AfricaMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "domainItemType" }, "srt_AsiaMember": { "auth_ref": [ "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r869", "r952" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r293", "r795", "r893", "r949", "r950" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r364", "r365", "r366", "r367", "r462", "r634", "r666", "r689", "r690", "r745", "r747", "r749", "r750", "r752", "r767", "r768", "r782", "r792", "r801", "r806", "r892", "r939", "r940", "r941", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r364", "r365", "r366", "r367", "r462", "r634", "r666", "r689", "r690", "r745", "r747", "r749", "r750", "r752", "r767", "r768", "r782", "r792", "r801", "r806", "r892", "r939", "r940", "r941", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r293", "r795", "r893", "r949", "r950" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [ "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "label": "North America [Member]" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r290", "r635", "r660", "r661", "r662", "r663", "r664", "r665", "r771", "r793", "r805", "r840", "r888", "r889", "r893", "r949" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r290", "r635", "r660", "r661", "r662", "r663", "r664", "r665", "r771", "r793", "r805", "r840", "r888", "r889", "r893", "r949" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r364", "r365", "r366", "r367", "r445", "r462", "r494", "r495", "r496", "r610", "r634", "r666", "r689", "r690", "r745", "r747", "r749", "r750", "r752", "r767", "r768", "r782", "r792", "r801", "r806", "r809", "r887", "r892", "r940", "r941", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r364", "r365", "r366", "r367", "r445", "r462", "r494", "r495", "r496", "r610", "r634", "r666", "r689", "r690", "r745", "r747", "r749", "r750", "r752", "r767", "r768", "r782", "r792", "r801", "r806", "r809", "r887", "r892", "r940", "r941", "r942", "r943", "r944" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r248", "r249", "r250", "r259", "r260", "r274", "r560", "r561", "r831", "r832", "r833", "r834", "r838", "r843", "r844" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r205", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r274", "r332", "r333", "r533", "r559", "r560", "r561", "r562", "r586", "r599", "r600", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r678" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r205", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r274", "r332", "r333", "r533", "r559", "r560", "r561", "r562", "r586", "r599", "r600", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r678" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r463", "r868" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r205", "r248", "r250", "r251", "r252", "r253", "r254", "r262", "r274", "r533", "r559", "r560", "r561", "r586", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r678", "r838", "r841", "r842", "r843", "r867", "r882", "r883", "r930", "r934", "r935" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r263", "r463", "r828", "r868" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r291", "r292", "r686", "r687", "r688", "r746", "r748", "r751", "r753", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r772", "r794", "r809", "r893", "r949" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r291", "r292", "r686", "r687", "r688", "r746", "r748", "r751", "r753", "r756", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r772", "r794", "r809", "r893", "r949" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r263", "r463", "r828", "r829", "r868" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r869", "r936" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r217", "r294", "r295", "r775" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "us-gaap_AccountsReceivableGrossCurrent", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r757" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r294", "r295" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowances for doubtful accounts", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued legal and accounting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r28", "r776" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Compensation" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r72", "r211", "r652" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r37", "r38", "r134", "r219", "r648", "r672", "r676" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r5", "r15", "r38", "r552", "r555", "r600", "r667", "r668", "r856", "r857", "r858", "r864", "r865", "r866" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful life (Year)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r126", "r804", "r953" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r503", "r504", "r505", "r684", "r864", "r865", "r866", "r929", "r955" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Share based compensation for employee stock purchase plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r86", "r87", "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r16", "r74", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrant in conjunction with note payable" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used for operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r498", "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based compensation expense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r220", "r296", "r335", "r338", "r341", "r948" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r220", "r296", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent", "negatedLabel": "Allowance for doubtful accounts", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Current", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r340" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Bad debt expense" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r8", "r111", "r142", "r399" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r8", "r66", "r70" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets and write-off", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r176", "r214", "r244", "r276", "r284", "r288", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r547", "r549", "r571", "r644", "r712", "r804", "r817", "r890", "r891", "r937" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r207", "r223", "r244", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r547", "r549", "r571", "r804", "r890", "r891", "r937" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r244", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r547", "r549", "r571", "r890", "r891", "r937" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r542", "r799", "r800" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r92", "r95", "r542", "r799", "r800" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "us-gaap_BusinessAcquisitionSharePrice", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r1", "r2", "r11" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "totalLabel": "Total purchase price consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Common stock issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r546", "r859" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "negatedLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r3", "r100", "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r169", "r543" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "verboseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 3.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment", "verboseLabel": "Equipment acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r96", "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 5.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r96", "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "totalLabel": "Total estimated fair value of assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r97" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 4.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "verboseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r351" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Amortization of capitalized contract costs" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r837" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r41" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Receipt of cash from note receivable" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r46", "r209", "r773" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r46", "r144", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r4", "r144" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodEndLabel": "Outstanding, warrants (in shares)", "periodStartLabel": "Outstanding, warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r115", "r646", "r698" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r807", "r808", "r809", "r811", "r812", "r813", "r814", "r864", "r865", "r929", "r951", "r955" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r125", "r699" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r125", "r699", "r718", "r955", "r956" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r125", "r647", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock \u2014 authorized, 170,000,000 shares; issued and outstanding; 9,190,504 and 7,853,759 of $.0001 par value at December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatedAbsencesLiability": { "auth_ref": [ "r76" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.", "label": "Compensated absences" } } }, "localname": "CompensatedAbsencesLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r39", "r225", "r227", "r233", "r640", "r657" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r57", "r59", "r109", "r110", "r293", "r757" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r57", "r59", "r109", "r110", "r293", "r677", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r57", "r59", "r109", "r110", "r293", "r757", "r836" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r57", "r59", "r109", "r110", "r293" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r57", "r59", "r109", "r110", "r293", "r757" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r101", "r778" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r420", "r422", "r441" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Capitalized contract costs, net" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r420", "r421", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r420", "r421", "r441" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue - current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r420", "r421", "r441" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r159", "r378", "r379", "r389", "r390", "r391", "r395", "r396", "r397", "r398", "r399", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r138", "r635" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "us-gaap_CostOfGoodsAndServicesSold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and other expenses" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r168", "r531", "r537", "r863" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details": { "order": 2.0, "parentTag": "bkyi_IncomeTaxExpenseBenefitGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current \u2013 federal, states, and foreign" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r58", "r293" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r158", "r242", "r377", "r383", "r384", "r385", "r386", "r387", "r388", "r393", "r400", "r401", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r121", "r122", "r177", "r178", "r247", "r378", "r379", "r380", "r381", "r382", "r384", "r389", "r390", "r391", "r392", "r394", "r395", "r396", "r397", "r398", "r399", "r585", "r787", "r788", "r789", "r790", "r791", "r861" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r31", "r75", "r161", "r162", "r380" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments", "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r112", "r114", "r378", "r585", "r788", "r789" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r391", "r570", "r788", "r789" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Convertible note at fair value", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r30", "r379" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMeasurementInput": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.", "label": "us-gaap_DebtInstrumentMeasurementInput", "terseLabel": "Debt Instrument, Measurement Input" } } }, "localname": "DebtInstrumentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "decimalItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r32", "r247", "r378", "r379", "r380", "r381", "r382", "r384", "r389", "r390", "r391", "r392", "r394", "r395", "r396", "r397", "r398", "r399", "r585", "r787", "r788", "r789", "r790", "r791", "r861" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "us-gaap_DebtInstrumentPeriodicPaymentPrincipal", "terseLabel": "Debt Instrument, Periodic Payment, Principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r863", "r926", "r927" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details": { "order": 3.0, "parentTag": "bkyi_IncomeTaxExpenseBenefitGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred- Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r168", "r863", "r926" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details": { "order": 1.0, "parentTag": "bkyi_IncomeTaxExpenseBenefitGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred - Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r8", "r168", "r196", "r536", "r537", "r863" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r518", "r519", "r645" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r863", "r926", "r927" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details": { "order": 0.0, "parentTag": "bkyi_IncomeTaxExpenseBenefitGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred - States" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "auth_ref": [ "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 14.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.", "label": "Interest expense" } } }, "localname": "DeferredTaxAssetInterestCarryforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Capital loss carry forward" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets", "verboseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 13.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory reserve" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInvestments": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "us-gaap_DeferredTaxAssetsInvestments", "terseLabel": "Reserve on debt security", "verboseLabel": "Reserve on debt security" } } }, "localname": "DeferredTaxAssetsInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r924" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax liability", "verboseLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss and credit carryforwards", "verboseLabel": "Net operating loss and research credit carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment", "terseLabel": "Equipment and leasehold improvements", "verboseLabel": "Equipment and leashold improvements" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Accrued compensation", "verboseLabel": "Accrued Compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation", "verboseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Allowance for doubtful accounts", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r527" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowances", "terseLabel": "Deferred Tax Assets, Valuation Allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r88", "r924" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "negatedLabel": "Intangible assets - Foreign" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedTerseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operationg Lease right-of -use assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r90", "r925" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedTerseLabel": "Equipment and leasehold improvements", "verboseLabel": "Equipment and leashold improvements" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r853" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits and other assets" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r8", "r71" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r8", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r17", "r102", "r103", "r104", "r105", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r464", "r468", "r499", "r500", "r502", "r802" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-n-leases", "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [ "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r234", "r253", "r254", "r256", "r257", "r259", "r265", "r266", "r268", "r269", "r270", "r274", "r561", "r562", "r641", "r658", "r779" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and Diluted Loss per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r264", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r933" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r521" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r245", "r521", "r538" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory income tax rate", "verboseLabel": "U.S. statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r923", "r928" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r923", "r928" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "verboseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r830", "r923" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "verboseLabel": "Expiration and forfeiture of stock options" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r923", "r928" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "verboseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r922" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r16", "r204", "r229", "r230", "r231", "r248", "r249", "r250", "r252", "r260", "r262", "r275", "r331", "r334", "r419", "r503", "r504", "r505", "r532", "r533", "r551", "r552", "r553", "r554", "r555", "r556", "r560", "r577", "r578", "r579", "r580", "r581", "r582", "r600", "r667", "r668", "r669", "r684", "r740" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "Error Correction [Text Block]" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r391", "r447", "r448", "r449", "r450", "r451", "r452", "r564", "r607", "r608", "r609", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r391", "r447", "r452", "r564", "r607", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r391", "r447", "r452", "r564", "r608", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r391", "r447", "r448", "r449", "r450", "r451", "r452", "r564", "r609", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r106", "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r18", "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Day one loss on value of hybrid instrument" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Purchases and issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r391", "r447", "r448", "r449", "r450", "r451", "r452", "r607", "r608", "r609", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r336", "r337", "r342", "r343", "r344", "r346", "r347", "r348", "r402", "r416", "r557", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r656", "r785", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r877", "r878", "r879", "r880" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r12", "r200", "r202", "r203", "r220", "r335", "r338", "r341", "r946" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "us-gaap_FinancingReceivableAllowanceForCreditLosses", "negatedLabel": "Allowance for doubtful account" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r213", "r360" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r154" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r154" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r154" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r154" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r154" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r357", "r359", "r360", "r361", "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r153", "r637" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r153", "r636" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Intangible Assets, Amount" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r874", "r875", "r895" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r573", "r574", "r575", "r576", "r737" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.", "label": "Loss on foreign currency transactions", "negatedLabel": "Loss on foreign currency" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r212", "r352", "r638", "r786", "r804", "r885", "r886" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "bkyi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodWillTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r354", "r786" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill resulting from the acquisition from Swivel Secure" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r10", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r8", "r353", "r355", "r356", "r786" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r465", "r467", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r465", "r467", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r137", "r244", "r276", "r283", "r287", "r289", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r571", "r781", "r890" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r298", "r876", "r884" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "us-gaap_HeldToMaturitySecuritiesCurrent", "terseLabel": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesNoncurrent": { "auth_ref": [ "r298", "r876", "r884" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Investment \u2013 debt security, net" } } }, "localname": "HeldToMaturitySecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r135", "r180", "r276", "r283", "r287", "r289", "r642", "r654", "r781" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before provision for income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r362", "r363", "r723" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r363", "r723" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r245", "r515", "r522", "r525", "r529", "r534", "r539", "r540", "r541", "r683" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r186", "r197", "r261", "r262", "r281", "r520", "r535", "r659" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income tax benefit", "negatedTerseLabel": "Provision for income tax benefits" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r228", "r516", "r517", "r525", "r526", "r528", "r530", "r680" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r769" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInDeferredRevenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r839", "r859" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherReceivables", "negatedLabel": "Due from factor" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r7" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r65", "r68" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r113", "r182", "r232", "r280", "r584", "r724", "r815", "r954" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for:" } } }, "localname": "InterestPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r237", "r239", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r150", "r777" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r221", "r774", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net of reserve", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r150", "r854" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Fabricated assemblies" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r63", "r854" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r350" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "us-gaap_InventoryWriteDown", "terseLabel": "Reserve for inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r140", "r279" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r175", "r183", "r184", "r199", "r297", "r299", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r592", "r803" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r598" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r598" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r598" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r244", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r548", "r549", "r550", "r571", "r697", "r780", "r817", "r890", "r937", "r938" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r130", "r179", "r650", "r804", "r862", "r881", "r932" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r208", "r244", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r548", "r549", "r550", "r571", "r804", "r890", "r937", "r938" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r21", "r117", "r118", "r119", "r123", "r244", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r548", "r549", "r550", "r571", "r890", "r937", "r938" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r894" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r25", "r861" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r25", "r861" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r215" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Government loan \u2013 BBVA Bank, current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r216" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Government loan \u2013 BBVA Bank, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r32", "r73" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDefaultRateMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using likelihood loan will not be repaid as proportion of outstanding loan.", "label": "Measurement Input, Default Rate [Member]" } } }, "localname": "MeasurementInputDefaultRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r238" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r238" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r144", "r145", "r146" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used for operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOW FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r136", "r146", "r181", "r206", "r224", "r226", "r231", "r244", "r251", "r253", "r254", "r256", "r257", "r261", "r262", "r267", "r276", "r283", "r287", "r289", "r330", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r562", "r571", "r655", "r720", "r738", "r739", "r781", "r815", "r890" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": { "auth_ref": [ "r49", "r50", "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, classified as other, acquired in a noncash or part noncash acquisition.", "label": "Other assets acquired from Swivel Secure" } } }, "localname": "NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r141" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r294", "r295", "r639" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "us-gaap_NotesAndLoansReceivableNetCurrent", "terseLabel": "Note receivable, net of allowance" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Note receivable, net of allowance", "terseLabel": "Noncurrent portion, net of allowance" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r195", "r200", "r201", "r218", "r342", "r345", "r783", "r784", "r852", "r884" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Note receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Notes Receivable [Member]" } } }, "localname": "NotesReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r294", "r345", "r707" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "us-gaap_NotesReceivableNet", "terseLabel": "Note receivable, net of allowance" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r276", "r283", "r287", "r289", "r781" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r593", "r803" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r589" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r589" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, current portion", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r589" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, net of current portion", "terseLabel": "Operating lease liabilities, non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r590", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r588" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r860" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r597", "r803" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate \u2013 operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r596", "r803" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (in years) \u2013 operating leases (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r222", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "us-gaap_OtherAssetsCurrent", "terseLabel": "Due from factor" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r6", "r14", "r173" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other comprehensive loss- Foreign translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r45" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Costs incurred for issuance of convertible note" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r42", "r544" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "us-gaap_PaymentsToAcquireBusinessesGross", "negatedLabel": "Purchase of Swivel Secure, net of cash acquired of $729,905", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r42" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "verboseLabel": "Total cash paid, including working capital adjustment" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r143" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "us-gaap_PaymentsToAcquireSoftware", "terseLabel": "Payments to Acquire Software" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r444", "r445", "r446", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r798" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r124", "r405" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "us-gaap_PreferredStockParOrStatedValuePerShare", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r124", "r699" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "us-gaap_PreferredStockSharesAuthorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r855" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_ProceedsFromCollectionOfNotesReceivable", "negatedTerseLabel": "Repayment of note" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r43" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible notes, net of OID" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "us-gaap_ProceedsFromDebtNetOfIssuanceCosts", "terseLabel": "Proceeds from Debt, Net of Issuance Costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r155", "r190", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r156", "r210", "r653" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant, and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r643", "r653", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 8.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment and leasehold improvements, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r9", "r190", "r193", "r651" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant, and Equipment, useful life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r235", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r112", "r585" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate", "terseLabel": "Receivable with Imputed Interest, Effective Yield (Interest Rate)" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r870", "r871", "r872", "r873" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Repayment of note payable - PistolStar" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r116", "r513", "r945" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research, development and engineering" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r185", "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r127", "r163", "r649", "r671", "r676", "r682", "r700", "r804" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r204", "r248", "r249", "r250", "r252", "r260", "r262", "r331", "r334", "r503", "r504", "r505", "r532", "r533", "r551", "r553", "r554", "r556", "r560", "r667", "r669", "r684", "r955" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r277", "r278", "r282", "r285", "r286", "r290", "r291", "r293", "r439", "r440", "r635" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax", "terseLabel": "Services" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r198", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r770" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r198", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r595", "r803" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Operating lease right-of-use asset and liability for new lease" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r293", "r835" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r52", "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-g-inventory-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r19", "r20", "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r139" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "us-gaap_SellingGeneralAndAdministrativeExpense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r793" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r802" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r464", "r472", "r491", "r492", "r493", "r494", "r497", "r506", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, lower range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, upper range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r467", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining life (Year)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested or expected to vest, weighted average remaining life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Options outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options outstanding, weighted average remaining remaining life (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance as of December 31, 2021 (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r120", "r177", "r804", "r947" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Convertible note payable, net of debt discount" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r35", "r204", "r229", "r230", "r231", "r248", "r249", "r250", "r252", "r260", "r262", "r275", "r331", "r334", "r419", "r503", "r504", "r505", "r532", "r533", "r551", "r552", "r553", "r554", "r555", "r556", "r560", "r577", "r578", "r579", "r580", "r581", "r582", "r600", "r667", "r668", "r669", "r684", "r740" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r248", "r249", "r250", "r275", "r635", "r679", "r685", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r702", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717", "r719", "r721", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r740", "r810" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-n-leases", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual", "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r248", "r249", "r250", "r275", "r635", "r679", "r685", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r702", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717", "r719", "r721", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r740", "r810" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-details-textual", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-estimated-useful-lives-for-depreciation-and-amortization-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-fair-value-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-sharebased-compensation-expenses-for-continuing-operations-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-significant-unobservable-inputs-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-summary-of-accounts-receivable-details", "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-details-textual", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-disaggregation-of-revenue-details", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-assets-acquired-and-liabilities-assumed-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-details-textual", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-identifiable-intangible-assets-acquired-details", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "http://bio-key.com/20221231/role/statement-note-d-fair-values-of-financial-instruments", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk", "http://bio-key.com/20221231/role/statement-note-e-concentration-of-risk-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-details-textual", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-summary-of-note-receivable-details", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "http://bio-key.com/20221231/role/statement-note-g-inventory-", "http://bio-key.com/20221231/role/statement-note-g-inventory-components-of-inventory-details", "http://bio-key.com/20221231/role/statement-note-g-inventory-details-textual", "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights", "http://bio-key.com/20221231/role/statement-note-h-resalable-software-licenses-rights-details-textual", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-details-textual", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-summary-of-equipment-and-leasehold-improvements-details", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-amortization-expense-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-details-textual", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-summary-of-accrued-liabilities-details", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable", "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual", "http://bio-key.com/20221231/role/statement-note-n-leases", "http://bio-key.com/20221231/role/statement-note-n-leases-operating-lease-balance-sheet-information-details", "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "http://bio-key.com/20221231/role/statement-note-o-commitments-and-contingencies-", "http://bio-key.com/20221231/role/statement-note-p-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual", "http://bio-key.com/20221231/role/statement-note-p-equity-summary-of-warrant-activity-details", "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options", "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-options-outstanding-and-exercisable-details", "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "http://bio-key.com/20221231/role/statement-note-r-income-taxes", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-deferred-taxes-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-components-of-income-tax-expense-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-net-income-loss-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-reconciliation-of-the-effective-income-tax-rate-to-us-federal-statutory-income-tax-rate-details", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-summary-of-revisions-details", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan", "http://bio-key.com/20221231/role/statement-note-t-profit-sharing-plan-details-textual", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual", "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r124", "r125", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Issuance of common stock pursuant to Swivel purchase agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Issuance of common stock for Employee stock purchase plan (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r124", "r125", "r163", "r681", "r740", "r754" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock for note issuance fees (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "negatedLabel": "Forfeiture of restricted stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Issuance of restricted common stock to employees (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock for directors\u2019 fees (in shares)", "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross", "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r124", "r125", "r163", "r478" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-q-stock-options-details-textual", "http://bio-key.com/20221231/role/statement-note-q-stock-options-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r16", "r35", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Issuance of common stock pursuant to Swivel purchase agreement", "terseLabel": "Stock Issued During Period, Value, Acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of common stock for Employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r124", "r125", "r163", "r684", "r740", "r754", "r816" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock for note issuance fees" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r16", "r124", "r125", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "negatedLabel": "Forfeiture of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Issuance of restricted common stock to employees" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r82", "r124", "r125", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock for directors\u2019 fees", "terseLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://bio-key.com/20221231/role/statement-note-p-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r125", "r128", "r129", "r149", "r701", "r718", "r741", "r742", "r804", "r817", "r862", "r881", "r932", "r955" ], "calculation": { "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance as of December 31, 2021", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets", "http://bio-key.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r160", "r243", "r404", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r419", "r558", "r743", "r744", "r755" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r583", "r602" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r583", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r583", "r602" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r601", "r603" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-v-subsequent-events", "http://bio-key.com/20221231/role/statement-note-v-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-a-the-company-and-summary-of-significant-accounting-policies-tables", "http://bio-key.com/20221231/role/statement-note-b-revenue-from-contracts-with-customers-tables", "http://bio-key.com/20221231/role/statement-note-c-swivel-secure-europe-sa-acquisition-tables", "http://bio-key.com/20221231/role/statement-note-f-note-receivable-tables", "http://bio-key.com/20221231/role/statement-note-g-inventory-tables", "http://bio-key.com/20221231/role/statement-note-j-equipment-and-leasehold-improvements-tables", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-tables", "http://bio-key.com/20221231/role/statement-note-l-accrued-liabilities-tables", "http://bio-key.com/20221231/role/statement-note-n-leases-tables", "http://bio-key.com/20221231/role/statement-note-p-equity-tables", "http://bio-key.com/20221231/role/statement-note-q-stock-options-tables", "http://bio-key.com/20221231/role/statement-note-r-income-taxes-tables", "http://bio-key.com/20221231/role/statement-note-s-revision-of-previously-issued-consolidated-financial-statements-tables", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill", "http://bio-key.com/20221231/role/statement-note-k-intangible-assets-and-goodwill-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r402", "r416", "r557", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r656", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r877", "r878", "r879", "r880" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-", "http://bio-key.com/20221231/role/statement-note-i-investment-in-debt-security-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-r-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r60", "r61", "r62", "r188", "r189", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r807", "r808", "r811", "r812", "r813", "r814" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps", "http://bio-key.com/20221231/role/statement-note-u-earnings-per-share-eps-securities-excluded-from-the-diluted-per-share-calculation-2-details" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-m-convertible-note-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Weighted average risk-free interest rate" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-note-p-equity-valuation-assumptions-for-warrants-details" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Shares Outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r265", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bio-key.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org//985-730/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org//715/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r818": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r819": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r821": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r822": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 107 0001437749-23-016374-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-016374-xbrl.zip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b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